id	sid	tid	token	lemma	pos
ajcp-4886	1	1	pa	pa	PROPN
ajcp-4886	1	2	ge	ge	PROPN
ajcp-4886	1	3	1	1	NUM
ajcp-4886	1	4	pa	pa	PROPN
ajcp-4886	1	5	ge	ge	PROPN
ajcp-4886	1	6	16	16	NUM
ajcp-4886	1	7	american	american	PROPN
ajcp-4886	1	8	journal	journal	PROPN
ajcp-4886	1	9	of	of	ADP
ajcp-4886	1	10	chemistry	chemistry	NOUN
ajcp-4886	1	11	and	and	CCONJ
ajcp-4886	1	12	pharmacy	pharmacy	NOUN
ajcp-4886	1	13	(	(	PUNCT
ajcp-4886	1	14	ajcp	ajcp	NOUN
ajcp-4886	1	15	)	)	PUNCT
ajcp-4886	1	16	chemical	chemical	NOUN
ajcp-4886	1	17	modulation	modulation	NOUN
ajcp-4886	1	18	of	of	ADP
ajcp-4886	1	19	amyloid	amyloid	NOUN
ajcp-4886	1	20	beta	beta	PROPN
ajcp-4886	1	21	oligomer	oligomer	NOUN
ajcp-4886	1	22	’s	’s	PART
ajcp-4886	1	23	in	in	ADP
ajcp-4886	1	24	alzheimer	alzheimer	PROPN
ajcp-4886	1	25	’s	’s	PART
ajcp-4886	1	26	disease	disease	NOUN
ajcp-4886	1	27	muhammad	muhammad	PROPN
ajcp-4886	1	28	jehangir1	jehangir1	PROPN
ajcp-4886	1	29	*	*	PROPN
ajcp-4886	1	30	,	,	PUNCT
ajcp-4886	1	31	sayyad	sayyad	PROPN
ajcp-4886	1	32	muhammad2	muhammad2	PROPN
ajcp-4886	1	33	,	,	PUNCT
ajcp-4886	1	34	muhammad	muhammad	PROPN
ajcp-4886	1	35	tayyab3	tayyab3	PROPN
ajcp-4886	1	36	,	,	PUNCT
ajcp-4886	1	37	wajid	wajid	PROPN
ajcp-4886	1	38	ali3	ali3	PROPN
ajcp-4886	1	39	,	,	PUNCT
ajcp-4886	1	40	ali	ali	PROPN
ajcp-4886	1	41	danish	danish	PROPN
ajcp-4886	1	42	alvi3	alvi3	PROPN
ajcp-4886	1	43	,	,	PUNCT
ajcp-4886	1	44	.	.	PUNCT
ajcp-4886	2	1	muhammad	muhammad	PROPN
ajcp-4886	2	2	naveed4	naveed4	PROPN
ajcp-4886	2	3	volume	volume	NOUN
ajcp-4886	2	4	4	4	NUM
ajcp-4886	2	5	issue	issue	NOUN
ajcp-4886	2	6	1	1	NUM
ajcp-4886	2	7	,	,	PUNCT
ajcp-4886	2	8	year	year	NOUN
ajcp-4886	2	9	2024	2024	NUM
ajcp-4886	2	10	issn	issn	X
ajcp-4886	2	11	:	:	PUNCT
ajcp-4886	2	12	2834	2834	NUM
ajcp-4886	2	13	-	-	SYM
ajcp-4886	2	14	0116	0116	NUM
ajcp-4886	2	15	(	(	PUNCT
ajcp-4886	2	16	online	online	ADJ
ajcp-4886	2	17	)	)	PUNCT
ajcp-4886	2	18	doi	doi	NOUN
ajcp-4886	2	19	:	:	PUNCT
ajcp-4886	2	20	https://doi.org/10.54536/ajcp.v4i1.4886	https://doi.org/10.54536/ajcp.v4i1.4886	PROPN
ajcp-4886	2	21	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-4886	2	22	article	article	NOUN
ajcp-4886	2	23	information	information	NOUN
ajcp-4886	2	24	abstract	abstract	ADV
ajcp-4886	2	25	received	receive	VERB
ajcp-4886	2	26	:	:	PUNCT
ajcp-4886	2	27	april	april	PROPN
ajcp-4886	2	28	01	01	NUM
ajcp-4886	2	29	,	,	PUNCT
ajcp-4886	2	30	2025	2025	NUM
ajcp-4886	2	31	accepted	accept	VERB
ajcp-4886	2	32	:	:	PUNCT
ajcp-4886	2	33	may	may	AUX
ajcp-4886	2	34	03	03	NUM
ajcp-4886	2	35	,	,	PUNCT
ajcp-4886	2	36	2025	2025	NUM
ajcp-4886	2	37	published	publish	VERB
ajcp-4886	2	38	:	:	PUNCT
ajcp-4886	2	39	june	june	PROPN
ajcp-4886	2	40	15	15	NUM
ajcp-4886	2	41	,	,	PUNCT
ajcp-4886	2	42	2025	2025	NUM
ajcp-4886	2	43	amyloid	amyloid	NOUN
ajcp-4886	2	44	beta	beta	NOUN
ajcp-4886	2	45	oligomers	oligomer	NOUN
ajcp-4886	2	46	play	play	VERB
ajcp-4886	2	47	a	a	DET
ajcp-4886	2	48	key	key	ADJ
ajcp-4886	2	49	role	role	NOUN
ajcp-4886	2	50	in	in	ADP
ajcp-4886	2	51	the	the	DET
ajcp-4886	2	52	pathophysiology	pathophysiology	NOUN
ajcp-4886	2	53	of	of	ADP
ajcp-4886	2	54	alzheimer	alzheimer	PROPN
ajcp-4886	2	55	’s	’s	PART
ajcp-4886	2	56	disease	disease	NOUN
ajcp-4886	2	57	.	.	PUNCT
ajcp-4886	3	1	since	since	SCONJ
ajcp-4886	3	2	it	it	PRON
ajcp-4886	3	3	contributes	contribute	VERB
ajcp-4886	3	4	to	to	ADP
ajcp-4886	3	5	memory	memory	NOUN
ajcp-4886	3	6	and	and	CCONJ
ajcp-4886	3	7	neuronal	neuronal	ADJ
ajcp-4886	3	8	loss	loss	NOUN
ajcp-4886	3	9	,	,	PUNCT
ajcp-4886	3	10	cognitive	cognitive	ADJ
ajcp-4886	3	11	decline	decline	NOUN
ajcp-4886	3	12	,	,	PUNCT
ajcp-4886	3	13	degradation	degradation	NOUN
ajcp-4886	3	14	of	of	ADP
ajcp-4886	3	15	neurons	neuron	NOUN
ajcp-4886	3	16	as	as	ADV
ajcp-4886	3	17	well	well	ADV
ajcp-4886	3	18	as	as	ADP
ajcp-4886	3	19	diseases	disease	NOUN
ajcp-4886	3	20	progression	progression	NOUN
ajcp-4886	3	21	.	.	PUNCT
ajcp-4886	4	1	as	as	SCONJ
ajcp-4886	4	2	aβ	aβ	PRON
ajcp-4886	4	3	oligomer	oligomer	ADJ
ajcp-4886	4	4	is	be	AUX
ajcp-4886	4	5	very	very	ADV
ajcp-4886	4	6	small	small	ADJ
ajcp-4886	4	7	and	and	CCONJ
ajcp-4886	4	8	heterogeneous	heterogeneous	ADJ
ajcp-4886	4	9	and	and	CCONJ
ajcp-4886	4	10	it	it	PRON
ajcp-4886	4	11	can	can	AUX
ajcp-4886	4	12	change	change	VERB
ajcp-4886	4	13	from	from	ADP
ajcp-4886	4	14	one	one	NUM
ajcp-4886	4	15	shape	shape	NOUN
ajcp-4886	4	16	to	to	ADP
ajcp-4886	4	17	another	another	DET
ajcp-4886	4	18	shape	shape	NOUN
ajcp-4886	4	19	therefore	therefore	ADV
ajcp-4886	4	20	it	it	PRON
ajcp-4886	4	21	has	have	VERB
ajcp-4886	4	22	various	various	ADJ
ajcp-4886	4	23	kinds	kind	NOUN
ajcp-4886	4	24	of	of	ADP
ajcp-4886	4	25	morphologies	morphology	NOUN
ajcp-4886	4	26	including	include	VERB
ajcp-4886	4	27	monomers	monomer	NOUN
ajcp-4886	4	28	,	,	PUNCT
ajcp-4886	4	29	oligomers	oligomer	NOUN
ajcp-4886	4	30	and	and	CCONJ
ajcp-4886	4	31	fibrils	fibril	NOUN
ajcp-4886	4	32	.	.	PUNCT
ajcp-4886	5	1	due	due	ADP
ajcp-4886	5	2	to	to	ADP
ajcp-4886	5	3	instable	instable	ADJ
ajcp-4886	5	4	behavior	behavior	NOUN
ajcp-4886	5	5	of	of	ADP
ajcp-4886	5	6	these	these	DET
ajcp-4886	5	7	proteins	protein	NOUN
ajcp-4886	5	8	,	,	PUNCT
ajcp-4886	5	9	it	it	PRON
ajcp-4886	5	10	’s	’	VERB
ajcp-4886	5	11	very	very	ADV
ajcp-4886	5	12	difficult	difficult	ADJ
ajcp-4886	5	13	to	to	PART
ajcp-4886	5	14	understand	understand	VERB
ajcp-4886	5	15	its	its	PRON
ajcp-4886	5	16	exact	exact	ADJ
ajcp-4886	5	17	mechanism	mechanism	NOUN
ajcp-4886	5	18	.	.	PUNCT
ajcp-4886	6	1	in	in	ADP
ajcp-4886	6	2	this	this	DET
ajcp-4886	6	3	concise	concise	ADJ
ajcp-4886	6	4	review	review	NOUN
ajcp-4886	6	5	,	,	PUNCT
ajcp-4886	6	6	information	information	NOUN
ajcp-4886	6	7	over	over	ADP
ajcp-4886	6	8	the	the	DET
ajcp-4886	6	9	past	past	ADJ
ajcp-4886	6	10	seven	seven	NUM
ajcp-4886	6	11	years	year	NOUN
ajcp-4886	6	12	concentrated	concentrate	VERB
ajcp-4886	6	13	on	on	ADP
ajcp-4886	6	14	the	the	DET
ajcp-4886	6	15	molecular	molecular	ADJ
ajcp-4886	6	16	characteristics	characteristic	NOUN
ajcp-4886	6	17	of	of	ADP
ajcp-4886	6	18	amyloid	amyloid	NOUN
ajcp-4886	6	19	-	-	PUNCT
ajcp-4886	6	20	β	β	NOUN
ajcp-4886	6	21	oligomers	oligomer	NOUN
ajcp-4886	6	22	has	have	AUX
ajcp-4886	6	23	been	be	AUX
ajcp-4886	6	24	summarized	summarize	VERB
ajcp-4886	6	25	along	along	ADP
ajcp-4886	6	26	with	with	ADP
ajcp-4886	6	27	two	two	NUM
ajcp-4886	6	28	pathways	pathway	NOUN
ajcp-4886	6	29	involving	involve	VERB
ajcp-4886	6	30	protein	protein	NOUN
ajcp-4886	6	31	aggregation	aggregation	NOUN
ajcp-4886	6	32	and	and	CCONJ
ajcp-4886	6	33	condensation	condensation	NOUN
ajcp-4886	6	34	.	.	PUNCT
ajcp-4886	7	1	furthermore	furthermore	ADV
ajcp-4886	7	2	,	,	PUNCT
ajcp-4886	7	3	metal	metal	NOUN
ajcp-4886	7	4	complexes	complex	NOUN
ajcp-4886	7	5	,	,	PUNCT
ajcp-4886	7	6	immunotherapies	immunotherapy	NOUN
ajcp-4886	7	7	,	,	PUNCT
ajcp-4886	7	8	and	and	CCONJ
ajcp-4886	7	9	anti	anti	ADJ
ajcp-4886	7	10	-	-	ADJ
ajcp-4886	7	11	aβ	aβ	ADJ
ajcp-4886	7	12	antibodies	antibody	NOUN
ajcp-4886	7	13	are	be	AUX
ajcp-4886	7	14	reported	report	VERB
ajcp-4886	7	15	here	here	ADV
ajcp-4886	7	16	,	,	PUNCT
ajcp-4886	7	17	which	which	PRON
ajcp-4886	7	18	can	can	AUX
ajcp-4886	7	19	modulate	modulate	VERB
ajcp-4886	7	20	aggregation	aggregation	NOUN
ajcp-4886	7	21	,	,	PUNCT
ajcp-4886	7	22	stabilize	stabilize	VERB
ajcp-4886	7	23	non	non	ADJ
ajcp-4886	7	24	-	-	ADJ
ajcp-4886	7	25	toxic	toxic	ADJ
ajcp-4886	7	26	forms	form	NOUN
ajcp-4886	7	27	,	,	PUNCT
ajcp-4886	7	28	and	and	CCONJ
ajcp-4886	7	29	enhance	enhance	VERB
ajcp-4886	7	30	degradation	degradation	NOUN
ajcp-4886	7	31	.	.	PUNCT
ajcp-4886	8	1	finally	finally	ADV
ajcp-4886	8	2	,	,	PUNCT
ajcp-4886	8	3	new	new	ADJ
ajcp-4886	8	4	discoveries	discovery	NOUN
ajcp-4886	8	5	on	on	ADP
ajcp-4886	8	6	small	small	ADJ
ajcp-4886	8	7	molecules	molecule	NOUN
ajcp-4886	8	8	that	that	PRON
ajcp-4886	8	9	control	control	VERB
ajcp-4886	8	10	,	,	PUNCT
ajcp-4886	8	11	modify	modify	VERB
ajcp-4886	8	12	and	and	CCONJ
ajcp-4886	8	13	inhibit	inhibit	VERB
ajcp-4886	8	14	the	the	DET
ajcp-4886	8	15	progression	progression	NOUN
ajcp-4886	8	16	of	of	ADP
ajcp-4886	8	17	amyloid	amyloid	NOUN
ajcp-4886	8	18	-	-	PUNCT
ajcp-4886	8	19	β	β	NOUN
ajcp-4886	8	20	oligomers	oligomer	NOUN
ajcp-4886	8	21	are	be	AUX
ajcp-4886	8	22	integrated	integrate	VERB
ajcp-4886	8	23	,	,	PUNCT
ajcp-4886	8	24	as	as	SCONJ
ajcp-4886	8	25	these	these	PRON
ajcp-4886	8	26	are	be	AUX
ajcp-4886	8	27	key	key	ADJ
ajcp-4886	8	28	characteristics	characteristic	NOUN
ajcp-4886	8	29	of	of	ADP
ajcp-4886	8	30	alzheimer	alzheimer	PROPN
ajcp-4886	8	31	’s	’s	PART
ajcp-4886	8	32	disease	disease	NOUN
ajcp-4886	8	33	.	.	PUNCT
ajcp-4886	9	1	keywords	keyword	NOUN
ajcp-4886	9	2	alzheimer	alzheimer	PROPN
ajcp-4886	9	3	’s	’s	PART
ajcp-4886	9	4	diseases	disease	NOUN
ajcp-4886	9	5	,	,	PUNCT
ajcp-4886	9	6	aβ	aβ	PROPN
ajcp-4886	9	7	oligomer	oligomer	NOUN
ajcp-4886	9	8	’s	’s	PART
ajcp-4886	9	9	,	,	PUNCT
ajcp-4886	9	10	degradation	degradation	NOUN
ajcp-4886	9	11	,	,	PUNCT
ajcp-4886	9	12	protein	protein	NOUN
ajcp-4886	9	13	aggregation	aggregation	NOUN
ajcp-4886	9	14	and	and	CCONJ
ajcp-4886	9	15	condensation	condensation	NOUN
ajcp-4886	9	16	,	,	PUNCT
ajcp-4886	9	17	stabilization	stabilization	NOUN
ajcp-4886	9	18	1	1	NUM
ajcp-4886	9	19	school	school	NOUN
ajcp-4886	9	20	of	of	ADP
ajcp-4886	9	21	chemistry	chemistry	NOUN
ajcp-4886	9	22	and	and	CCONJ
ajcp-4886	9	23	molecular	molecular	ADJ
ajcp-4886	9	24	engineering	engineering	NOUN
ajcp-4886	9	25	,	,	PUNCT
ajcp-4886	9	26	nanjing	nanjing	PROPN
ajcp-4886	9	27	tech	tech	PROPN
ajcp-4886	9	28	university	university	PROPN
ajcp-4886	9	29	,	,	PUNCT
ajcp-4886	9	30	nanjing	nanjing	PROPN
ajcp-4886	9	31	211816	211816	NUM
ajcp-4886	9	32	,	,	PUNCT
ajcp-4886	9	33	p.	p.	PROPN
ajcp-4886	9	34	r.	r.	PROPN
ajcp-4886	10	1	china	china	PROPN
ajcp-4886	10	2	2	2	NUM
ajcp-4886	10	3	department	department	PROPN
ajcp-4886	10	4	of	of	ADP
ajcp-4886	10	5	chemical	chemical	PROPN
ajcp-4886	10	6	engineering	engineering	PROPN
ajcp-4886	10	7	,	,	PUNCT
ajcp-4886	10	8	nanjing	nanjing	PROPN
ajcp-4886	10	9	tech	tech	PROPN
ajcp-4886	10	10	university	university	PROPN
ajcp-4886	10	11	,	,	PUNCT
ajcp-4886	10	12	nanjing	nanjing	PROPN
ajcp-4886	10	13	211816	211816	NUM
ajcp-4886	10	14	,	,	PUNCT
ajcp-4886	10	15	p.	p.	PROPN
ajcp-4886	10	16	r.	r.	PROPN
ajcp-4886	11	1	china	china	PROPN
ajcp-4886	11	2	3	3	NUM
ajcp-4886	11	3	school	school	NOUN
ajcp-4886	11	4	of	of	ADP
ajcp-4886	11	5	pharmaceutical	pharmaceutical	NOUN
ajcp-4886	11	6	science	science	NOUN
ajcp-4886	11	7	,	,	PUNCT
ajcp-4886	11	8	nanjing	nanjing	PROPN
ajcp-4886	11	9	tech	tech	PROPN
ajcp-4886	11	10	university	university	PROPN
ajcp-4886	11	11	,	,	PUNCT
ajcp-4886	11	12	nanjing	nanjing	PROPN
ajcp-4886	11	13	211816	211816	NUM
ajcp-4886	11	14	,	,	PUNCT
ajcp-4886	11	15	china	china	PROPN
ajcp-4886	11	16	4	4	NUM
ajcp-4886	11	17	school	school	NOUN
ajcp-4886	11	18	of	of	ADP
ajcp-4886	11	19	biological	biological	ADJ
ajcp-4886	11	20	and	and	CCONJ
ajcp-4886	11	21	pharmaceutical	pharmaceutical	NOUN
ajcp-4886	11	22	engineering	engineering	NOUN
ajcp-4886	11	23	,	,	PUNCT
ajcp-4886	11	24	nanjing	nanjing	PROPN
ajcp-4886	11	25	tech	tech	PROPN
ajcp-4886	11	26	university	university	PROPN
ajcp-4886	11	27	,	,	PUNCT
ajcp-4886	11	28	p.r	p.r	PROPN
ajcp-4886	11	29	.	.	PROPN
ajcp-4886	11	30	china	china	PROPN
ajcp-4886	11	31	*	*	PUNCT
ajcp-4886	11	32	corresponding	correspond	VERB
ajcp-4886	11	33	author	author	NOUN
ajcp-4886	11	34	’s	’s	PART
ajcp-4886	11	35	e	e	NOUN
ajcp-4886	11	36	-	-	NOUN
ajcp-4886	11	37	mail	mail	NOUN
ajcp-4886	11	38	:	:	PUNCT
ajcp-4886	11	39	jehangirm62@gmail.com	jehangirm62@gmail.com	X
ajcp-4886	11	40	introduction	introduction	NOUN
ajcp-4886	11	41	according	accord	VERB
ajcp-4886	11	42	to	to	ADP
ajcp-4886	11	43	recent	recent	ADJ
ajcp-4886	11	44	projections	projection	NOUN
ajcp-4886	11	45	,	,	PUNCT
ajcp-4886	11	46	the	the	DET
ajcp-4886	11	47	number	number	NOUN
ajcp-4886	11	48	of	of	ADP
ajcp-4886	11	49	people	people	NOUN
ajcp-4886	11	50	living	live	VERB
ajcp-4886	11	51	with	with	ADP
ajcp-4886	11	52	alzheimer	alzheimer	PROPN
ajcp-4886	11	53	disease	disease	NOUN
ajcp-4886	11	54	(	(	PUNCT
ajcp-4886	11	55	ad	ad	NOUN
ajcp-4886	11	56	)	)	PUNCT
ajcp-4886	11	57	,	,	PUNCT
ajcp-4886	11	58	the	the	DET
ajcp-4886	11	59	most	most	ADV
ajcp-4886	11	60	prevalent	prevalent	ADJ
ajcp-4886	11	61	form	form	NOUN
ajcp-4886	11	62	of	of	ADP
ajcp-4886	11	63	dementia	dementia	NOUN
ajcp-4886	11	64	,	,	PUNCT
ajcp-4886	11	65	is	be	AUX
ajcp-4886	11	66	expected	expect	VERB
ajcp-4886	11	67	to	to	PART
ajcp-4886	11	68	reach	reach	VERB
ajcp-4886	11	69	87	87	NUM
ajcp-4886	11	70	million	million	NUM
ajcp-4886	11	71	by	by	ADP
ajcp-4886	11	72	2050	2050	NUM
ajcp-4886	11	73	.	.	PUNCT
ajcp-4886	12	1	age	age	NOUN
ajcp-4886	12	2	is	be	AUX
ajcp-4886	12	3	the	the	DET
ajcp-4886	12	4	primary	primary	ADJ
ajcp-4886	12	5	risk	risk	NOUN
ajcp-4886	12	6	factor	factor	NOUN
ajcp-4886	12	7	for	for	ADP
ajcp-4886	12	8	ad	ad	NOUN
ajcp-4886	12	9	,	,	PUNCT
ajcp-4886	12	10	which	which	PRON
ajcp-4886	12	11	currently	currently	ADV
ajcp-4886	12	12	affects	affect	VERB
ajcp-4886	12	13	more	more	ADJ
ajcp-4886	12	14	than	than	ADP
ajcp-4886	12	15	35	35	NUM
ajcp-4886	12	16	million	million	NUM
ajcp-4886	12	17	people	people	NOUN
ajcp-4886	12	18	worldwide	worldwide	ADV
ajcp-4886	12	19	(	(	PUNCT
ajcp-4886	12	20	hwang	hwang	PROPN
ajcp-4886	12	21	et	et	PROPN
ajcp-4886	12	22	al	al	PROPN
ajcp-4886	12	23	.	.	PROPN
ajcp-4886	12	24	,	,	PUNCT
ajcp-4886	12	25	2019	2019	NUM
ajcp-4886	12	26	;	;	PUNCT
ajcp-4886	12	27	tzioras	tzioras	PROPN
ajcp-4886	12	28	et	et	PROPN
ajcp-4886	12	29	al	al	PROPN
ajcp-4886	12	30	.	.	PROPN
ajcp-4886	12	31	,	,	PUNCT
ajcp-4886	12	32	2022	2022	NUM
ajcp-4886	12	33	)	)	PUNCT
ajcp-4886	12	34	.	.	PUNCT
ajcp-4886	13	1	given	give	VERB
ajcp-4886	13	2	that	that	PRON
ajcp-4886	13	3	50–80	50–80	NUM
ajcp-4886	13	4	%	%	NOUN
ajcp-4886	13	5	of	of	ADP
ajcp-4886	13	6	all	all	DET
ajcp-4886	13	7	cases	case	NOUN
ajcp-4886	13	8	among	among	ADP
ajcp-4886	13	9	the	the	DET
ajcp-4886	13	10	elderly	elderly	ADJ
ajcp-4886	13	11	population	population	NOUN
ajcp-4886	13	12	are	be	AUX
ajcp-4886	13	13	estimated	estimate	VERB
ajcp-4886	13	14	to	to	PART
ajcp-4886	13	15	be	be	AUX
ajcp-4886	13	16	related	relate	VERB
ajcp-4886	13	17	to	to	ADP
ajcp-4886	13	18	this	this	DET
ajcp-4886	13	19	rapidly	rapidly	ADV
ajcp-4886	13	20	ageing	age	VERB
ajcp-4886	13	21	population	population	NOUN
ajcp-4886	13	22	,	,	PUNCT
ajcp-4886	13	23	it	it	PRON
ajcp-4886	13	24	has	have	AUX
ajcp-4886	13	25	emerged	emerge	VERB
ajcp-4886	13	26	as	as	ADP
ajcp-4886	13	27	a	a	DET
ajcp-4886	13	28	significant	significant	ADJ
ajcp-4886	13	29	social	social	ADJ
ajcp-4886	13	30	issue	issue	NOUN
ajcp-4886	13	31	(	(	PUNCT
ajcp-4886	13	32	peng	peng	PROPN
ajcp-4886	13	33	et	et	PROPN
ajcp-4886	13	34	al	al	PROPN
ajcp-4886	13	35	.	.	PROPN
ajcp-4886	13	36	,	,	PUNCT
ajcp-4886	13	37	2019	2019	NUM
ajcp-4886	13	38	)	)	PUNCT
ajcp-4886	13	39	.	.	PUNCT
ajcp-4886	14	1	aberrant	aberrant	ADJ
ajcp-4886	14	2	protein	protein	NOUN
ajcp-4886	14	3	aggregation	aggregation	NOUN
ajcp-4886	14	4	,	,	PUNCT
ajcp-4886	14	5	which	which	PRON
ajcp-4886	14	6	affects	affect	VERB
ajcp-4886	14	7	synaptic	synaptic	ADJ
ajcp-4886	14	8	signaling	signal	VERB
ajcp-4886	14	9	,	,	PUNCT
ajcp-4886	14	10	mitochondrial	mitochondrial	ADJ
ajcp-4886	14	11	function	function	NOUN
ajcp-4886	14	12	,	,	PUNCT
ajcp-4886	14	13	neuroinflammation	neuroinflammation	NOUN
ajcp-4886	14	14	,	,	PUNCT
ajcp-4886	14	15	and	and	CCONJ
ajcp-4886	14	16	neuronal	neuronal	ADJ
ajcp-4886	14	17	loss	loss	NOUN
ajcp-4886	14	18	,	,	PUNCT
ajcp-4886	14	19	is	be	AUX
ajcp-4886	14	20	indicative	indicative	ADJ
ajcp-4886	14	21	of	of	ADP
ajcp-4886	14	22	ad	ad	NOUN
ajcp-4886	14	23	and	and	CCONJ
ajcp-4886	14	24	leads	lead	VERB
ajcp-4886	14	25	to	to	ADP
ajcp-4886	14	26	multifactorial	multifactorial	ADJ
ajcp-4886	14	27	neuronal	neuronal	ADJ
ajcp-4886	14	28	dysfunction	dysfunction	NOUN
ajcp-4886	14	29	(	(	PUNCT
ajcp-4886	14	30	limbocker	limbocker	NOUN
ajcp-4886	14	31	et	et	PROPN
ajcp-4886	14	32	al	al	PROPN
ajcp-4886	14	33	.	.	PROPN
ajcp-4886	14	34	,	,	PUNCT
ajcp-4886	14	35	2019	2019	NUM
ajcp-4886	14	36	)	)	PUNCT
ajcp-4886	14	37	.	.	PUNCT
ajcp-4886	15	1	alzheimer	alzheimer	PROPN
ajcp-4886	15	2	’s	’s	PART
ajcp-4886	15	3	disease	disease	NOUN
ajcp-4886	15	4	(	(	PUNCT
ajcp-4886	15	5	ad	ad	NOUN
ajcp-4886	15	6	)	)	PUNCT
ajcp-4886	15	7	is	be	AUX
ajcp-4886	15	8	caused	cause	VERB
ajcp-4886	15	9	by	by	ADP
ajcp-4886	15	10	misfolded	misfolde	VERB
ajcp-4886	15	11	tau	tau	PROPN
ajcp-4886	15	12	and	and	CCONJ
ajcp-4886	15	13	amyloid	amyloid	NOUN
ajcp-4886	15	14	-	-	PUNCT
ajcp-4886	15	15	beta	beta	NOUN
ajcp-4886	15	16	(	(	PUNCT
ajcp-4886	15	17	aβ	aβ	NOUN
ajcp-4886	15	18	)	)	PUNCT
ajcp-4886	15	19	proteins	protein	NOUN
ajcp-4886	15	20	that	that	PRON
ajcp-4886	15	21	build	build	VERB
ajcp-4886	15	22	up	up	ADP
ajcp-4886	15	23	in	in	ADP
ajcp-4886	15	24	the	the	DET
ajcp-4886	15	25	brain	brain	NOUN
ajcp-4886	15	26	along	along	ADP
ajcp-4886	15	27	harmful	harmful	ADJ
ajcp-4886	15	28	pathways	pathway	NOUN
ajcp-4886	15	29	that	that	PRON
ajcp-4886	15	30	cause	cause	VERB
ajcp-4886	15	31	selective	selective	ADJ
ajcp-4886	15	32	neuronal	neuronal	ADJ
ajcp-4886	15	33	death	death	NOUN
ajcp-4886	15	34	and	and	CCONJ
ajcp-4886	15	35	synaptic	synaptic	ADJ
ajcp-4886	15	36	loss	loss	NOUN
ajcp-4886	15	37	(	(	PUNCT
ajcp-4886	15	38	figure	figure	NOUN
ajcp-4886	15	39	1	1	NUM
ajcp-4886	15	40	)	)	PUNCT
ajcp-4886	15	41	(	(	PUNCT
ajcp-4886	15	42	senapati	senapati	PROPN
ajcp-4886	15	43	et	et	PROPN
ajcp-4886	15	44	al	al	PROPN
ajcp-4886	15	45	.	.	PROPN
ajcp-4886	15	46	,	,	PUNCT
ajcp-4886	15	47	2023	2023	NUM
ajcp-4886	15	48	)	)	PUNCT
ajcp-4886	15	49	.	.	PUNCT
ajcp-4886	16	1	the	the	DET
ajcp-4886	16	2	primary	primary	ADJ
ajcp-4886	16	3	neurotoxic	neurotoxic	ADJ
ajcp-4886	16	4	species	specie	NOUN
ajcp-4886	16	5	responsible	responsible	ADJ
ajcp-4886	16	6	for	for	ADP
ajcp-4886	16	7	the	the	DET
ajcp-4886	16	8	onset	onset	NOUN
ajcp-4886	16	9	of	of	ADP
ajcp-4886	16	10	alzheimer	alzheimer	PROPN
ajcp-4886	16	11	’s	’s	PART
ajcp-4886	16	12	disease	disease	NOUN
ajcp-4886	16	13	(	(	PUNCT
ajcp-4886	16	14	ad	ad	NOUN
ajcp-4886	16	15	)	)	PUNCT
ajcp-4886	16	16	are	be	AUX
ajcp-4886	16	17	oligomeric	oligomeric	ADJ
ajcp-4886	16	18	aggregates	aggregate	NOUN
ajcp-4886	16	19	of	of	ADP
ajcp-4886	16	20	amyloid	amyloid	NOUN
ajcp-4886	16	21	-	-	PUNCT
ajcp-4886	16	22	β	β	NOUN
ajcp-4886	16	23	peptides	peptide	NOUN
ajcp-4886	16	24	(	(	PUNCT
ajcp-4886	16	25	aβ	aβ	NOUN
ajcp-4886	16	26	)	)	PUNCT
ajcp-4886	16	27	.	.	PUNCT
ajcp-4886	17	1	aβ	aβ	PRON
ajcp-4886	17	2	oligomers	oligomer	NOUN
ajcp-4886	17	3	stimulate	stimulate	VERB
ajcp-4886	17	4	additional	additional	ADJ
ajcp-4886	17	5	pathological	pathological	ADJ
ajcp-4886	17	6	processes	process	NOUN
ajcp-4886	17	7	of	of	ADP
ajcp-4886	17	8	ad	ad	NOUN
ajcp-4886	17	9	,	,	PUNCT
ajcp-4886	17	10	including	include	VERB
ajcp-4886	17	11	tau	tau	PROPN
ajcp-4886	17	12	hyperphosphorylation	hyperphosphorylation	NOUN
ajcp-4886	17	13	,	,	PUNCT
ajcp-4886	17	14	oxidative	oxidative	ADJ
ajcp-4886	17	15	stress	stress	NOUN
ajcp-4886	17	16	,	,	PUNCT
ajcp-4886	17	17	and	and	CCONJ
ajcp-4886	17	18	mitochondrial	mitochondrial	ADJ
ajcp-4886	17	19	dysfunction	dysfunction	NOUN
ajcp-4886	17	20	,	,	PUNCT
ajcp-4886	17	21	in	in	ADP
ajcp-4886	17	22	addition	addition	NOUN
ajcp-4886	17	23	to	to	ADP
ajcp-4886	17	24	causing	cause	VERB
ajcp-4886	17	25	various	various	ADJ
ajcp-4886	17	26	neuronal	neuronal	ADJ
ajcp-4886	17	27	dysfunctions	dysfunction	NOUN
ajcp-4886	17	28	like	like	ADP
ajcp-4886	17	29	loss	loss	NOUN
ajcp-4886	17	30	of	of	ADP
ajcp-4886	17	31	memory	memory	NOUN
ajcp-4886	17	32	and	and	CCONJ
ajcp-4886	17	33	learning	learning	NOUN
ajcp-4886	17	34	.	.	PUNCT
ajcp-4886	18	1	thus	thus	ADV
ajcp-4886	18	2	,	,	PUNCT
ajcp-4886	18	3	it	it	PRON
ajcp-4886	18	4	is	be	AUX
ajcp-4886	18	5	acknowledged	acknowledge	VERB
ajcp-4886	18	6	that	that	SCONJ
ajcp-4886	18	7	aβ	aβ	PRON
ajcp-4886	18	8	oligomers	oligomer	NOUN
ajcp-4886	18	9	are	be	AUX
ajcp-4886	18	10	suitable	suitable	ADJ
ajcp-4886	18	11	targets	target	NOUN
ajcp-4886	18	12	for	for	ADP
ajcp-4886	18	13	ad	ad	NOUN
ajcp-4886	18	14	diagnosis	diagnosis	NOUN
ajcp-4886	18	15	and	and	CCONJ
ajcp-4886	18	16	treatment	treatment	NOUN
ajcp-4886	18	17	(	(	PUNCT
ajcp-4886	18	18	sehar	sehar	NOUN
ajcp-4886	18	19	et	et	PROPN
ajcp-4886	18	20	al	al	PROPN
ajcp-4886	18	21	.	.	PROPN
ajcp-4886	18	22	,	,	PUNCT
ajcp-4886	18	23	2022	2022	NUM
ajcp-4886	18	24	)	)	PUNCT
ajcp-4886	18	25	.	.	PUNCT
ajcp-4886	19	1	in	in	ADP
ajcp-4886	19	2	the	the	DET
ajcp-4886	19	3	pathophysiology	pathophysiology	NOUN
ajcp-4886	19	4	of	of	ADP
ajcp-4886	19	5	ad	ad	NOUN
ajcp-4886	19	6	and	and	CCONJ
ajcp-4886	19	7	other	other	ADJ
ajcp-4886	19	8	tauopathies	tauopathie	NOUN
ajcp-4886	19	9	,	,	PUNCT
ajcp-4886	19	10	tauos	tauos	NOUN
ajcp-4886	19	11	and	and	CCONJ
ajcp-4886	19	12	tau	tau	PROPN
ajcp-4886	19	13	filaments	filament	NOUN
ajcp-4886	19	14	may	may	AUX
ajcp-4886	19	15	be	be	AUX
ajcp-4886	19	16	crucial	crucial	ADJ
ajcp-4886	19	17	players	player	NOUN
ajcp-4886	19	18	.	.	PUNCT
ajcp-4886	20	1	the	the	DET
ajcp-4886	20	2	general	general	ADJ
ajcp-4886	20	3	consensus	consensus	NOUN
ajcp-4886	20	4	is	be	AUX
ajcp-4886	20	5	that	that	SCONJ
ajcp-4886	20	6	smaller	small	ADJ
ajcp-4886	20	7	,	,	PUNCT
ajcp-4886	20	8	diffusible	diffusible	ADJ
ajcp-4886	20	9	oligomers	oligomer	NOUN
ajcp-4886	20	10	are	be	AUX
ajcp-4886	20	11	more	more	ADV
ajcp-4886	20	12	likely	likely	ADJ
ajcp-4886	20	13	to	to	PART
ajcp-4886	20	14	be	be	AUX
ajcp-4886	20	15	involved	involve	VERB
ajcp-4886	20	16	in	in	ADP
ajcp-4886	20	17	ad	ad	NOUN
ajcp-4886	20	18	pathogenesis	pathogenesis	NOUN
ajcp-4886	20	19	than	than	ADP
ajcp-4886	20	20	the	the	DET
ajcp-4886	20	21	larger	large	ADJ
ajcp-4886	20	22	tau	tau	PROPN
ajcp-4886	20	23	assemblies	assembly	NOUN
ajcp-4886	20	24	,	,	PUNCT
ajcp-4886	20	25	which	which	PRON
ajcp-4886	20	26	include	include	VERB
ajcp-4886	20	27	straight	straight	ADJ
ajcp-4886	20	28	filaments	filament	NOUN
ajcp-4886	20	29	,	,	PUNCT
ajcp-4886	20	30	phf	phf	NOUN
ajcp-4886	20	31	,	,	PUNCT
ajcp-4886	20	32	nft	nft	PROPN
ajcp-4886	20	33	,	,	PUNCT
ajcp-4886	20	34	and	and	CCONJ
ajcp-4886	20	35	ghost	ghost	NOUN
ajcp-4886	20	36	tangles	tangle	NOUN
ajcp-4886	20	37	,	,	PUNCT
ajcp-4886	20	38	which	which	PRON
ajcp-4886	20	39	are	be	AUX
ajcp-4886	20	40	thought	think	VERB
ajcp-4886	20	41	to	to	PART
ajcp-4886	20	42	be	be	AUX
ajcp-4886	20	43	less	less	ADV
ajcp-4886	20	44	toxic	toxic	ADJ
ajcp-4886	20	45	(	(	PUNCT
ajcp-4886	20	46	penke	penke	VERB
ajcp-4886	20	47	et	et	PROPN
ajcp-4886	20	48	al	al	PROPN
ajcp-4886	20	49	.	.	PROPN
ajcp-4886	20	50	,	,	PUNCT
ajcp-4886	20	51	2020	2020	NUM
ajcp-4886	20	52	)	)	PUNCT
ajcp-4886	20	53	.	.	PUNCT
ajcp-4886	21	1	compared	compare	VERB
ajcp-4886	21	2	to	to	ADP
ajcp-4886	21	3	amyloid	amyloid	NOUN
ajcp-4886	21	4	fibrils	fibril	NOUN
ajcp-4886	21	5	,	,	PUNCT
ajcp-4886	21	6	soluble	soluble	ADJ
ajcp-4886	21	7	aβ	aβ	NOUN
ajcp-4886	21	8	oligomers	oligomer	NOUN
ajcp-4886	21	9	have	have	VERB
ajcp-4886	21	10	a	a	DET
ajcp-4886	21	11	stronger	strong	ADJ
ajcp-4886	21	12	correlation	correlation	NOUN
ajcp-4886	21	13	with	with	ADP
ajcp-4886	21	14	the	the	DET
ajcp-4886	21	15	advancement	advancement	NOUN
ajcp-4886	21	16	of	of	ADP
ajcp-4886	21	17	disease	disease	NOUN
ajcp-4886	21	18	.	.	PUNCT
ajcp-4886	22	1	for	for	ADP
ajcp-4886	22	2	this	this	DET
ajcp-4886	22	3	reason	reason	NOUN
ajcp-4886	22	4	,	,	PUNCT
ajcp-4886	22	5	focusing	focus	VERB
ajcp-4886	22	6	on	on	ADP
ajcp-4886	22	7	these	these	DET
ajcp-4886	22	8	oligomers	oligomer	NOUN
ajcp-4886	22	9	may	may	AUX
ajcp-4886	22	10	prove	prove	VERB
ajcp-4886	22	11	to	to	PART
ajcp-4886	22	12	be	be	AUX
ajcp-4886	22	13	a	a	DET
ajcp-4886	22	14	useful	useful	ADJ
ajcp-4886	22	15	therapeutic	therapeutic	ADJ
ajcp-4886	22	16	approach	approach	NOUN
ajcp-4886	22	17	in	in	ADP
ajcp-4886	22	18	the	the	DET
ajcp-4886	22	19	management	management	NOUN
ajcp-4886	22	20	and	and	CCONJ
ajcp-4886	22	21	prevention	prevention	NOUN
ajcp-4886	22	22	of	of	ADP
ajcp-4886	22	23	alzheimer	alzheimer	PROPN
ajcp-4886	22	24	’s	’s	PART
ajcp-4886	22	25	(	(	PUNCT
ajcp-4886	22	26	jehangir	jehangir	PROPN
ajcp-4886	22	27	et	et	PROPN
ajcp-4886	22	28	al	al	PROPN
ajcp-4886	22	29	.	.	PROPN
ajcp-4886	22	30	,	,	PUNCT
ajcp-4886	22	31	2024	2024	NUM
ajcp-4886	22	32	)	)	PUNCT
ajcp-4886	22	33	.	.	PUNCT
ajcp-4886	23	1	finding	find	VERB
ajcp-4886	23	2	aβo	aβo	VERB
ajcp-4886	23	3	in	in	ADP
ajcp-4886	23	4	biological	biological	ADJ
ajcp-4886	23	5	samples	sample	NOUN
ajcp-4886	23	6	,	,	PUNCT
ajcp-4886	23	7	like	like	ADP
ajcp-4886	23	8	blood	blood	NOUN
ajcp-4886	23	9	or	or	CCONJ
ajcp-4886	23	10	cerebrospinal	cerebrospinal	ADJ
ajcp-4886	23	11	fluid	fluid	NOUN
ajcp-4886	23	12	,	,	PUNCT
ajcp-4886	23	13	has	have	VERB
ajcp-4886	23	14	enormous	enormous	ADJ
ajcp-4886	23	15	potential	potential	NOUN
ajcp-4886	23	16	for	for	ADP
ajcp-4886	23	17	tracking	track	VERB
ajcp-4886	23	18	the	the	DET
ajcp-4886	23	19	development	development	NOUN
ajcp-4886	23	20	of	of	ADP
ajcp-4886	23	21	ad	ad	NOUN
ajcp-4886	23	22	and	and	CCONJ
ajcp-4886	23	23	providing	provide	VERB
ajcp-4886	23	24	an	an	DET
ajcp-4886	23	25	early	early	ADJ
ajcp-4886	23	26	diagnosis	diagnosis	NOUN
ajcp-4886	23	27	.	.	PUNCT
ajcp-4886	24	1	but	but	CCONJ
ajcp-4886	24	2	because	because	SCONJ
ajcp-4886	24	3	aβo	aβo	NOUN
ajcp-4886	24	4	are	be	AUX
ajcp-4886	24	5	dynamic	dynamic	ADJ
ajcp-4886	24	6	,	,	PUNCT
ajcp-4886	24	7	structurally	structurally	ADV
ajcp-4886	24	8	complex	complex	ADJ
ajcp-4886	24	9	,	,	PUNCT
ajcp-4886	24	10	and	and	CCONJ
ajcp-4886	24	11	rare	rare	ADJ
ajcp-4886	24	12	,	,	PUNCT
ajcp-4886	24	13	it	it	PRON
ajcp-4886	24	14	’s	’	VERB
ajcp-4886	24	15	still	still	ADV
ajcp-4886	24	16	very	very	ADV
ajcp-4886	24	17	difficult	difficult	ADJ
ajcp-4886	24	18	to	to	PART
ajcp-4886	24	19	detect	detect	VERB
ajcp-4886	24	20	them	they	PRON
ajcp-4886	24	21	accurately	accurately	ADV
ajcp-4886	24	22	(	(	PUNCT
ajcp-4886	24	23	penke	penke	VERB
ajcp-4886	24	24	et	et	PROPN
ajcp-4886	24	25	al	al	PROPN
ajcp-4886	24	26	.	.	PROPN
ajcp-4886	24	27	,	,	PUNCT
ajcp-4886	24	28	2020	2020	NUM
ajcp-4886	24	29	)	)	PUNCT
ajcp-4886	24	30	.	.	PUNCT
ajcp-4886	25	1	many	many	ADJ
ajcp-4886	25	2	of	of	ADP
ajcp-4886	25	3	these	these	DET
ajcp-4886	25	4	diseaseassociated	diseaseassociate	VERB
ajcp-4886	25	5	proteins	protein	NOUN
ajcp-4886	25	6	not	not	PART
ajcp-4886	25	7	only	only	ADV
ajcp-4886	25	8	misfold	misfold	ADJ
ajcp-4886	25	9	and	and	CCONJ
ajcp-4886	25	10	aggregate	aggregate	ADJ
ajcp-4886	25	11	,	,	PUNCT
ajcp-4886	25	12	but	but	CCONJ
ajcp-4886	25	13	also	also	ADV
ajcp-4886	25	14	go	go	VERB
ajcp-4886	25	15	through	through	ADP
ajcp-4886	25	16	liquid	liquid	NOUN
ajcp-4886	25	17	-	-	PUNCT
ajcp-4886	25	18	liquid	liquid	NOUN
ajcp-4886	25	19	phase	phase	NOUN
ajcp-4886	25	20	separation	separation	NOUN
ajcp-4886	25	21	(	(	PUNCT
ajcp-4886	25	22	llps	llps	PROPN
ajcp-4886	25	23	)	)	PUNCT
ajcp-4886	25	24	to	to	PART
ajcp-4886	25	25	create	create	VERB
ajcp-4886	25	26	dynamic	dynamic	ADJ
ajcp-4886	25	27	condensates	condensate	NOUN
ajcp-4886	25	28	,	,	PUNCT
ajcp-4886	25	29	which	which	PRON
ajcp-4886	25	30	are	be	AUX
ajcp-4886	25	31	essential	essential	ADJ
ajcp-4886	25	32	for	for	ADP
ajcp-4886	25	33	regular	regular	ADJ
ajcp-4886	25	34	cellular	cellular	ADJ
ajcp-4886	25	35	processing	processing	NOUN
ajcp-4886	25	36	(	(	PUNCT
ajcp-4886	25	37	muhammad	muhammad	PROPN
ajcp-4886	25	38	et	et	PROPN
ajcp-4886	25	39	al	al	PROPN
ajcp-4886	25	40	.	.	PROPN
ajcp-4886	25	41	,	,	PUNCT
ajcp-4886	25	42	2024	2024	NUM
ajcp-4886	25	43	)	)	PUNCT
ajcp-4886	25	44	.	.	PUNCT
ajcp-4886	26	1	many	many	ADJ
ajcp-4886	26	2	studies	study	NOUN
ajcp-4886	26	3	suggest	suggest	VERB
ajcp-4886	26	4	that	that	SCONJ
ajcp-4886	26	5	llps	llp	NOUN
ajcp-4886	26	6	plays	play	VERB
ajcp-4886	26	7	a	a	DET
ajcp-4886	26	8	significant	significant	ADJ
ajcp-4886	26	9	role	role	NOUN
ajcp-4886	26	10	in	in	ADP
ajcp-4886	26	11	the	the	DET
ajcp-4886	26	12	deposition	deposition	NOUN
ajcp-4886	26	13	and	and	CCONJ
ajcp-4886	26	14	aggregation	aggregation	NOUN
ajcp-4886	26	15	of	of	ADP
ajcp-4886	26	16	tau	tau	PROPN
ajcp-4886	26	17	and	and	CCONJ
ajcp-4886	26	18	amyloid	amyloid	NOUN
ajcp-4886	26	19	-	-	PUNCT
ajcp-4886	26	20	β	β	X
ajcp-4886	26	21	and	and	CCONJ
ajcp-4886	26	22	is	be	AUX
ajcp-4886	26	23	closely	closely	ADV
ajcp-4886	26	24	linked	link	VERB
ajcp-4886	26	25	to	to	ADP
ajcp-4886	26	26	the	the	DET
ajcp-4886	26	27	pathophysiology	pathophysiology	NOUN
ajcp-4886	26	28	of	of	ADP
ajcp-4886	26	29	ad	ad	NOUN
ajcp-4886	26	30	.	.	PUNCT
ajcp-4886	27	1	investigating	investigate	VERB
ajcp-4886	27	2	the	the	DET
ajcp-4886	27	3	fundamental	fundamental	ADJ
ajcp-4886	27	4	mechanism	mechanism	NOUN
ajcp-4886	27	5	in	in	ADP
ajcp-4886	27	6	greater	great	ADJ
ajcp-4886	27	7	detail	detail	NOUN
ajcp-4886	27	8	will	will	AUX
ajcp-4886	27	9	help	help	VERB
ajcp-4886	27	10	increase	increase	VERB
ajcp-4886	27	11	the	the	DET
ajcp-4886	27	12	rate	rate	NOUN
ajcp-4886	27	13	of	of	ADP
ajcp-4886	27	14	early	early	ADJ
ajcp-4886	27	15	ad	ad	NOUN
ajcp-4886	27	16	detection	detection	NOUN
ajcp-4886	27	17	,	,	PUNCT
ajcp-4886	27	18	which	which	PRON
ajcp-4886	27	19	will	will	AUX
ajcp-4886	27	20	lead	lead	VERB
ajcp-4886	27	21	to	to	ADP
ajcp-4886	27	22	the	the	DET
ajcp-4886	27	23	development	development	NOUN
ajcp-4886	27	24	of	of	ADP
ajcp-4886	27	25	anti	anti	ADJ
ajcp-4886	27	26	-	-	ADJ
ajcp-4886	27	27	ad	ad	ADJ
ajcp-4886	27	28	medications	medication	NOUN
ajcp-4886	27	29	and	and	CCONJ
ajcp-4886	27	30	better	well	ADJ
ajcp-4886	27	31	outcomes	outcome	NOUN
ajcp-4886	27	32	for	for	ADP
ajcp-4886	27	33	ad	ad	NOUN
ajcp-4886	27	34	patients	patient	NOUN
ajcp-4886	27	35	(	(	PUNCT
ajcp-4886	27	36	muhammad	muhammad	PROPN
ajcp-4886	27	37	et	et	PROPN
ajcp-4886	27	38	al	al	PROPN
ajcp-4886	27	39	.	.	PROPN
ajcp-4886	27	40	,	,	PUNCT
ajcp-4886	27	41	2024	2024	NUM
ajcp-4886	27	42	)	)	PUNCT
ajcp-4886	27	43	.	.	PUNCT
ajcp-4886	28	1	in	in	ADP
ajcp-4886	28	2	this	this	DET
ajcp-4886	28	3	concise	concise	ADJ
ajcp-4886	28	4	review	review	NOUN
ajcp-4886	28	5	,	,	PUNCT
ajcp-4886	28	6	we	we	PRON
ajcp-4886	28	7	gathered	gather	VERB
ajcp-4886	28	8	information	information	NOUN
ajcp-4886	28	9	over	over	ADP
ajcp-4886	28	10	the	the	DET
ajcp-4886	28	11	past	past	ADJ
ajcp-4886	28	12	seven	seven	NUM
ajcp-4886	28	13	years	year	NOUN
ajcp-4886	28	14	and	and	CCONJ
ajcp-4886	28	15	concentrated	concentrate	VERB
ajcp-4886	28	16	on	on	ADP
ajcp-4886	28	17	the	the	DET
ajcp-4886	28	18	molecular	molecular	ADJ
ajcp-4886	28	19	characteristics	characteristic	NOUN
ajcp-4886	28	20	of	of	ADP
ajcp-4886	28	21	amyloid	amyloid	NOUN
ajcp-4886	28	22	-	-	PUNCT
ajcp-4886	28	23	β	β	NOUN
ajcp-4886	28	24	oligomers	oligomer	NOUN
ajcp-4886	28	25	,	,	PUNCT
ajcp-4886	28	26	along	along	ADP
ajcp-4886	28	27	with	with	ADP
ajcp-4886	28	28	two	two	NUM
ajcp-4886	28	29	pathways	pathway	NOUN
ajcp-4886	28	30	involving	involve	VERB
ajcp-4886	28	31	protein	protein	NOUN
ajcp-4886	28	32	aggregation	aggregation	NOUN
ajcp-4886	28	33	and	and	CCONJ
ajcp-4886	28	34	condensation	condensation	NOUN
ajcp-4886	28	35	.	.	PUNCT
ajcp-4886	29	1	we	we	PRON
ajcp-4886	29	2	also	also	ADV
ajcp-4886	29	3	integrated	integrate	VERB
ajcp-4886	29	4	new	new	ADJ
ajcp-4886	29	5	discoveries	discovery	NOUN
ajcp-4886	29	6	on	on	ADP
ajcp-4886	29	7	small	small	ADJ
ajcp-4886	29	8	molecules	molecule	NOUN
ajcp-4886	29	9	that	that	PRON
ajcp-4886	29	10	control	control	NOUN
ajcp-4886	29	11	,	,	PUNCT
ajcp-4886	29	12	modify	modify	VERB
ajcp-4886	29	13	,	,	PUNCT
ajcp-4886	29	14	and	and	CCONJ
ajcp-4886	29	15	break	break	VERB
ajcp-4886	29	16	down	down	ADP
ajcp-4886	29	17	amyloid	amyloid	NOUN
ajcp-4886	29	18	-	-	PUNCT
ajcp-4886	29	19	β	β	NOUN
ajcp-4886	29	20	oligomers	oligomer	NOUN
ajcp-4886	29	21	,	,	PUNCT
ajcp-4886	29	22	which	which	PRON
ajcp-4886	29	23	are	be	AUX
ajcp-4886	29	24	key	key	ADJ
ajcp-4886	29	25	characteristics	characteristic	NOUN
ajcp-4886	29	26	of	of	ADP
ajcp-4886	29	27	alzheimer	alzheimer	PROPN
ajcp-4886	29	28	’s	’s	PART
ajcp-4886	29	29	disease	disease	NOUN
ajcp-4886	29	30	.	.	PUNCT
ajcp-4886	30	1	finally	finally	ADV
ajcp-4886	30	2	,	,	PUNCT
ajcp-4886	30	3	we	we	PRON
ajcp-4886	30	4	touched	touch	VERB
ajcp-4886	30	5	on	on	ADP
ajcp-4886	30	6	their	their	PRON
ajcp-4886	30	7	roles	role	NOUN
ajcp-4886	30	8	in	in	ADP
ajcp-4886	30	9	the	the	DET
ajcp-4886	30	10	pathophysiology	pathophysiology	NOUN
ajcp-4886	30	11	of	of	ADP
ajcp-4886	30	12	the	the	DET
ajcp-4886	30	13	disease	disease	NOUN
ajcp-4886	30	14	.	.	PUNCT
ajcp-4886	31	1	it	it	PRON
ajcp-4886	31	2	is	be	AUX
ajcp-4886	31	3	known	know	VERB
ajcp-4886	31	4	that	that	SCONJ
ajcp-4886	31	5	aβ	aβ	PRON
ajcp-4886	31	6	oligomers	oligomer	NOUN
ajcp-4886	31	7	are	be	AUX
ajcp-4886	31	8	the	the	DET
ajcp-4886	31	9	target	target	NOUN
ajcp-4886	31	10	of	of	ADP
ajcp-4886	31	11	studies	study	NOUN
ajcp-4886	31	12	on	on	ADP
ajcp-4886	31	13	chemical	chemical	ADJ
ajcp-4886	31	14	regulatory	regulatory	ADJ
ajcp-4886	31	15	mechanisms	mechanism	NOUN
ajcp-4886	31	16	,	,	PUNCT
ajcp-4886	31	17	stabilization	stabilization	NOUN
ajcp-4886	31	18	,	,	PUNCT
ajcp-4886	31	19	and	and	CCONJ
ajcp-4886	31	20	degradation	degradation	NOUN
ajcp-4886	31	21	processes	process	NOUN
ajcp-4886	31	22	,	,	PUNCT
ajcp-4886	31	23	as	as	ADV
ajcp-4886	31	24	well	well	ADV
ajcp-4886	31	25	as	as	ADP
ajcp-4886	31	26	the	the	DET
ajcp-4886	31	27	role	role	NOUN
ajcp-4886	31	28	of	of	ADP
ajcp-4886	31	29	phase	phase	NOUN
ajcp-4886	31	30	separation	separation	NOUN
ajcp-4886	31	31	in	in	ADP
ajcp-4886	31	32	alzheimer	alzheimer	PROPN
ajcp-4886	31	33	’s	’s	PART
ajcp-4886	31	34	disease	disease	NOUN
ajcp-4886	31	35	.	.	PUNCT
ajcp-4886	32	1	pa	pa	PROPN
ajcp-4886	32	2	ge	ge	PROPN
ajcp-4886	32	3	17	17	NUM
ajcp-4886	32	4	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-4886	32	5	am	be	AUX
ajcp-4886	32	6	.	.	PUNCT
ajcp-4886	33	1	j.	j.	PROPN
ajcp-4886	33	2	chem	chem	PROPN
ajcp-4886	33	3	.	.	PUNCT
ajcp-4886	34	1	pharm	pharm	PROPN
ajcp-4886	34	2	.	.	PUNCT
ajcp-4886	35	1	4(1	4(1	NOUN
ajcp-4886	35	2	)	)	PUNCT
ajcp-4886	36	1	16	16	NUM
ajcp-4886	36	2	-	-	SYM
ajcp-4886	36	3	28	28	NUM
ajcp-4886	36	4	,	,	PUNCT
ajcp-4886	36	5	2025	2025	NUM
ajcp-4886	36	6	literature	literature	NOUN
ajcp-4886	36	7	review	review	NOUN
ajcp-4886	36	8	amyloid	amyloid	NOUN
ajcp-4886	36	9	-	-	PUNCT
ajcp-4886	36	10	β	β	X
ajcp-4886	36	11	oligomers	oligomer	NOUN
ajcp-4886	36	12	,	,	PUNCT
ajcp-4886	36	13	protein	protein	NOUN
ajcp-4886	36	14	aggregation	aggregation	NOUN
ajcp-4886	36	15	and	and	CCONJ
ajcp-4886	36	16	condensation	condensation	NOUN
ajcp-4886	36	17	soluble	soluble	ADJ
ajcp-4886	36	18	aβo	aβo	NOUN
ajcp-4886	36	19	can	can	AUX
ajcp-4886	36	20	start	start	VERB
ajcp-4886	36	21	to	to	PART
ajcp-4886	36	22	accumulate	accumulate	VERB
ajcp-4886	36	23	in	in	ADP
ajcp-4886	36	24	the	the	DET
ajcp-4886	36	25	brain	brain	NOUN
ajcp-4886	36	26	up	up	ADP
ajcp-4886	36	27	to	to	PART
ajcp-4886	36	28	two	two	NUM
ajcp-4886	36	29	decades	decade	NOUN
ajcp-4886	36	30	before	before	SCONJ
ajcp-4886	36	31	clinical	clinical	ADJ
ajcp-4886	36	32	symptoms	symptom	NOUN
ajcp-4886	36	33	appear	appear	VERB
ajcp-4886	36	34	(	(	PUNCT
ajcp-4886	36	35	hector	hector	NOUN
ajcp-4886	36	36	&	&	CCONJ
ajcp-4886	36	37	brouillette	brouillette	NOUN
ajcp-4886	36	38	,	,	PUNCT
ajcp-4886	36	39	2021	2021	NUM
ajcp-4886	36	40	)	)	PUNCT
ajcp-4886	36	41	.	.	PUNCT
ajcp-4886	37	1	aβ	aβ	PRON
ajcp-4886	37	2	is	be	AUX
ajcp-4886	37	3	produced	produce	VERB
ajcp-4886	37	4	as	as	ADP
ajcp-4886	37	5	a	a	DET
ajcp-4886	37	6	result	result	NOUN
ajcp-4886	37	7	of	of	ADP
ajcp-4886	37	8	the	the	DET
ajcp-4886	37	9	amyloid	amyloid	NOUN
ajcp-4886	37	10	precursor	precursor	NOUN
ajcp-4886	37	11	protein	protein	NOUN
ajcp-4886	37	12	’s	’s	PART
ajcp-4886	37	13	proteolytic	proteolytic	ADJ
ajcp-4886	37	14	cleavage	cleavage	NOUN
ajcp-4886	37	15	by	by	ADP
ajcp-4886	37	16	β	β	NOUN
ajcp-4886	37	17	and	and	CCONJ
ajcp-4886	37	18	γ	γ	NOUN
ajcp-4886	37	19	-	-	PUNCT
ajcp-4886	37	20	secretases	secretase	NOUN
ajcp-4886	37	21	.	.	PUNCT
ajcp-4886	38	1	the	the	DET
ajcp-4886	38	2	two	two	NUM
ajcp-4886	38	3	most	most	ADV
ajcp-4886	38	4	prevalent	prevalent	ADJ
ajcp-4886	38	5	forms	form	NOUN
ajcp-4886	38	6	of	of	ADP
ajcp-4886	38	7	aβ	aβ	PRON
ajcp-4886	38	8	in	in	ADP
ajcp-4886	38	9	human	human	ADJ
ajcp-4886	38	10	bodies	body	NOUN
ajcp-4886	38	11	are	be	AUX
ajcp-4886	38	12	aβ40	aβ40	PROPN
ajcp-4886	38	13	and	and	CCONJ
ajcp-4886	38	14	aβ42	aβ42	PROPN
ajcp-4886	38	15	.	.	PUNCT
ajcp-4886	39	1	aβ42	aβ42	PROPN
ajcp-4886	39	2	was	be	AUX
ajcp-4886	39	3	found	find	VERB
ajcp-4886	39	4	to	to	PART
ajcp-4886	39	5	be	be	AUX
ajcp-4886	39	6	more	more	ADV
ajcp-4886	39	7	likely	likely	ADJ
ajcp-4886	39	8	to	to	PART
ajcp-4886	39	9	aggregate	aggregate	VERB
ajcp-4886	39	10	,	,	PUNCT
ajcp-4886	39	11	despite	despite	SCONJ
ajcp-4886	39	12	the	the	DET
ajcp-4886	39	13	fact	fact	NOUN
ajcp-4886	39	14	that	that	SCONJ
ajcp-4886	39	15	aβ40	aβ40	PROPN
ajcp-4886	39	16	and	and	CCONJ
ajcp-4886	39	17	aβ42	aβ42	PROPN
ajcp-4886	39	18	only	only	ADV
ajcp-4886	39	19	differ	differ	VERB
ajcp-4886	39	20	by	by	ADP
ajcp-4886	39	21	two	two	NUM
ajcp-4886	39	22	amino	amino	NOUN
ajcp-4886	39	23	acid	acid	NOUN
ajcp-4886	39	24	residues	residue	NOUN
ajcp-4886	39	25	.	.	PUNCT
ajcp-4886	40	1	aβ	aβ	PRON
ajcp-4886	40	2	has	have	VERB
ajcp-4886	40	3	a	a	DET
ajcp-4886	40	4	tendency	tendency	NOUN
ajcp-4886	40	5	to	to	PART
ajcp-4886	40	6	form	form	VERB
ajcp-4886	40	7	a	a	DET
ajcp-4886	40	8	variety	variety	NOUN
ajcp-4886	40	9	of	of	ADP
ajcp-4886	40	10	self	self	NOUN
ajcp-4886	40	11	-	-	PUNCT
ajcp-4886	40	12	assembly	assembly	NOUN
ajcp-4886	40	13	structures	structure	NOUN
ajcp-4886	40	14	,	,	PUNCT
ajcp-4886	40	15	from	from	ADP
ajcp-4886	40	16	mature	mature	ADJ
ajcp-4886	40	17	fibrils	fibril	NOUN
ajcp-4886	40	18	to	to	ADP
ajcp-4886	40	19	oligomers	oligomer	NOUN
ajcp-4886	40	20	and	and	CCONJ
ajcp-4886	40	21	as	as	ADV
ajcp-4886	40	22	well	well	ADV
ajcp-4886	40	23	as	as	ADP
ajcp-4886	40	24	monomer	monomer	NOUN
ajcp-4886	40	25	’s	’s	PART
ajcp-4886	40	26	(	(	PUNCT
ajcp-4886	40	27	volynsky	volynsky	PROPN
ajcp-4886	40	28	et	et	PROPN
ajcp-4886	40	29	al	al	PROPN
ajcp-4886	40	30	.	.	PROPN
ajcp-4886	40	31	,	,	PUNCT
ajcp-4886	40	32	2025	2025	NUM
ajcp-4886	40	33	)	)	PUNCT
ajcp-4886	40	34	.	.	PUNCT
ajcp-4886	41	1	aβ	aβ	NOUN
ajcp-4886	41	2	toxicity	toxicity	NOUN
ajcp-4886	41	3	has	have	AUX
ajcp-4886	41	4	been	be	AUX
ajcp-4886	41	5	shown	show	VERB
ajcp-4886	41	6	to	to	PART
ajcp-4886	41	7	be	be	AUX
ajcp-4886	41	8	primarily	primarily	ADV
ajcp-4886	41	9	caused	cause	VERB
ajcp-4886	41	10	by	by	ADP
ajcp-4886	41	11	aβ1~42	aβ1~42	ADJ
ajcp-4886	41	12	oligomers	oligomer	NOUN
ajcp-4886	41	13	,	,	PUNCT
ajcp-4886	41	14	both	both	CCONJ
ajcp-4886	41	15	in	in	ADP
ajcp-4886	41	16	vitro	vitro	X
ajcp-4886	41	17	and	and	CCONJ
ajcp-4886	41	18	in	in	ADP
ajcp-4886	41	19	vivo	vivo	NOUN
ajcp-4886	41	20	(	(	PUNCT
ajcp-4886	41	21	han	han	PROPN
ajcp-4886	41	22	et	et	PROPN
ajcp-4886	41	23	al	al	PROPN
ajcp-4886	41	24	.	.	PROPN
ajcp-4886	41	25	,	,	PUNCT
ajcp-4886	41	26	2025	2025	NUM
ajcp-4886	41	27	)	)	PUNCT
ajcp-4886	41	28	.	.	PUNCT
ajcp-4886	42	1	experimentally	experimentally	ADV
ajcp-4886	42	2	and	and	CCONJ
ajcp-4886	42	3	computationally	computationally	ADV
ajcp-4886	42	4	characterizing	characterize	VERB
ajcp-4886	42	5	the	the	DET
ajcp-4886	42	6	early	early	ADJ
ajcp-4886	42	7	aβ	aβ	NOUN
ajcp-4886	42	8	oligomers	oligomer	NOUN
ajcp-4886	42	9	is	be	AUX
ajcp-4886	42	10	a	a	DET
ajcp-4886	42	11	difficult	difficult	ADJ
ajcp-4886	42	12	task	task	NOUN
ajcp-4886	42	13	.	.	PUNCT
ajcp-4886	43	1	since	since	SCONJ
ajcp-4886	43	2	most	most	ADJ
ajcp-4886	43	3	experimental	experimental	ADJ
ajcp-4886	43	4	observations	observation	NOUN
ajcp-4886	43	5	provide	provide	VERB
ajcp-4886	43	6	timeand	timeand	NOUN
ajcp-4886	43	7	space	space	NOUN
ajcp-4886	43	8	-	-	PUNCT
ajcp-4886	43	9	averaged	average	VERB
ajcp-4886	43	10	properties	property	NOUN
ajcp-4886	43	11	,	,	PUNCT
ajcp-4886	43	12	the	the	DET
ajcp-4886	43	13	transient	transient	ADJ
ajcp-4886	43	14	and	and	CCONJ
ajcp-4886	43	15	heterogeneous	heterogeneous	ADJ
ajcp-4886	43	16	ensemble	ensemble	ADJ
ajcp-4886	43	17	of	of	ADP
ajcp-4886	43	18	oligomer	oligomer	ADJ
ajcp-4886	43	19	structures	structure	NOUN
ajcp-4886	43	20	presents	present	VERB
ajcp-4886	43	21	an	an	DET
ajcp-4886	43	22	experimental	experimental	ADJ
ajcp-4886	43	23	challenge	challenge	NOUN
ajcp-4886	43	24	(	(	PUNCT
ajcp-4886	43	25	derreumaux	derreumaux	VERB
ajcp-4886	43	26	et	et	PROPN
ajcp-4886	43	27	al	al	PROPN
ajcp-4886	43	28	.	.	PROPN
ajcp-4886	43	29	,	,	PUNCT
ajcp-4886	43	30	2022	2022	NUM
ajcp-4886	43	31	)	)	PUNCT
ajcp-4886	43	32	.	.	PUNCT
ajcp-4886	44	1	at	at	ADP
ajcp-4886	44	2	physiological	physiological	ADJ
ajcp-4886	44	3	concentrations	concentration	NOUN
ajcp-4886	44	4	of	of	ADP
ajcp-4886	44	5	1–20	1–20	PROPN
ajcp-4886	44	6	nm	nm	NOUN
ajcp-4886	44	7	,	,	PUNCT
ajcp-4886	44	8	aβ42	aβ42	PROPN
ajcp-4886	44	9	synthesis	synthesis	NOUN
ajcp-4886	44	10	easily	easily	ADV
ajcp-4886	44	11	forms	form	VERB
ajcp-4886	44	12	oligomeric	oligomeric	ADJ
ajcp-4886	44	13	structures	structure	NOUN
ajcp-4886	44	14	,	,	PUNCT
ajcp-4886	44	15	and	and	CCONJ
ajcp-4886	44	16	the	the	DET
ajcp-4886	44	17	rate	rate	NOUN
ajcp-4886	44	18	of	of	ADP
ajcp-4886	44	19	oligomer	oligomer	ADJ
ajcp-4886	44	20	formation	formation	NOUN
ajcp-4886	44	21	is	be	AUX
ajcp-4886	44	22	temperature	temperature	NOUN
ajcp-4886	44	23	-	-	PUNCT
ajcp-4886	44	24	dependent	dependent	ADJ
ajcp-4886	44	25	.	.	PUNCT
ajcp-4886	45	1	at	at	ADP
ajcp-4886	45	2	physiological	physiological	ADJ
ajcp-4886	45	3	concentrations	concentration	NOUN
ajcp-4886	45	4	,	,	PUNCT
ajcp-4886	45	5	the	the	DET
ajcp-4886	45	6	formation	formation	NOUN
ajcp-4886	45	7	of	of	ADP
ajcp-4886	45	8	aβ42	aβ42	PROPN
ajcp-4886	45	9	oligomers	oligomer	NOUN
ajcp-4886	45	10	is	be	AUX
ajcp-4886	45	11	a	a	DET
ajcp-4886	45	12	kinetically	kinetically	ADV
ajcp-4886	45	13	analyzed	analyze	VERB
ajcp-4886	45	14	and	and	CCONJ
ajcp-4886	45	15	inhibitable	inhibitable	ADJ
ajcp-4886	45	16	process	process	NOUN
ajcp-4886	45	17	that	that	PRON
ajcp-4886	45	18	is	be	AUX
ajcp-4886	45	19	repeatable	repeatable	ADJ
ajcp-4886	45	20	(	(	PUNCT
ajcp-4886	45	21	li	li	PROPN
ajcp-4886	45	22	et	et	PROPN
ajcp-4886	45	23	al	al	PROPN
ajcp-4886	45	24	.	.	PROPN
ajcp-4886	45	25	,	,	PUNCT
ajcp-4886	45	26	2023	2023	NUM
ajcp-4886	45	27	)	)	PUNCT
ajcp-4886	45	28	.	.	PUNCT
ajcp-4886	46	1	the	the	DET
ajcp-4886	46	2	most	most	ADV
ajcp-4886	46	3	neurotoxic	neurotoxic	ADJ
ajcp-4886	46	4	agents	agent	NOUN
ajcp-4886	46	5	are	be	AUX
ajcp-4886	46	6	thought	think	VERB
ajcp-4886	46	7	to	to	PART
ajcp-4886	46	8	be	be	AUX
ajcp-4886	46	9	aβ42	aβ42	PROPN
ajcp-4886	46	10	oligomers	oligomer	NOUN
ajcp-4886	46	11	.	.	PUNCT
ajcp-4886	47	1	the	the	DET
ajcp-4886	47	2	morphologies	morphology	NOUN
ajcp-4886	47	3	of	of	ADP
ajcp-4886	47	4	these	these	DET
ajcp-4886	47	5	oligomeric	oligomeric	ADJ
ajcp-4886	47	6	intermediates	intermediate	NOUN
ajcp-4886	47	7	are	be	AUX
ajcp-4886	47	8	diverse	diverse	ADJ
ajcp-4886	47	9	,	,	PUNCT
ajcp-4886	47	10	encompassing	encompass	VERB
ajcp-4886	47	11	spherical	spherical	ADJ
ajcp-4886	47	12	,	,	PUNCT
ajcp-4886	47	13	annular	annular	ADJ
ajcp-4886	47	14	,	,	PUNCT
ajcp-4886	47	15	β	β	NOUN
ajcp-4886	47	16	-	-	NOUN
ajcp-4886	47	17	barrel	barrel	NOUN
ajcp-4886	47	18	,	,	PUNCT
ajcp-4886	47	19	and	and	CCONJ
ajcp-4886	47	20	protofibrillar	protofibrillar	ADJ
ajcp-4886	47	21	forms	form	NOUN
ajcp-4886	47	22	,	,	PUNCT
ajcp-4886	47	23	all	all	PRON
ajcp-4886	47	24	of	of	ADP
ajcp-4886	47	25	which	which	PRON
ajcp-4886	47	26	have	have	VERB
ajcp-4886	47	27	the	the	DET
ajcp-4886	47	28	potential	potential	NOUN
ajcp-4886	47	29	to	to	PART
ajcp-4886	47	30	contribute	contribute	VERB
ajcp-4886	47	31	differently	differently	ADV
ajcp-4886	47	32	to	to	ADP
ajcp-4886	47	33	the	the	DET
ajcp-4886	47	34	toxicity	toxicity	NOUN
ajcp-4886	47	35	of	of	ADP
ajcp-4886	47	36	aβ	aβ	PROPN
ajcp-4886	47	37	(	(	PUNCT
ajcp-4886	47	38	foley	foley	PROPN
ajcp-4886	47	39	et	et	PROPN
ajcp-4886	47	40	al	al	PROPN
ajcp-4886	47	41	.	.	PROPN
ajcp-4886	47	42	,	,	PUNCT
ajcp-4886	47	43	2019	2019	NUM
ajcp-4886	47	44	)	)	PUNCT
ajcp-4886	47	45	.	.	PUNCT
ajcp-4886	48	1	in	in	ADP
ajcp-4886	48	2	order	order	NOUN
ajcp-4886	48	3	to	to	PART
ajcp-4886	48	4	diagnose	diagnose	VERB
ajcp-4886	48	5	and	and	CCONJ
ajcp-4886	48	6	treat	treat	VERB
ajcp-4886	48	7	ad	ad	NOUN
ajcp-4886	48	8	,	,	PUNCT
ajcp-4886	48	9	aβ	aβ	DET
ajcp-4886	48	10	oligomers	oligomer	NOUN
ajcp-4886	48	11	are	be	AUX
ajcp-4886	48	12	accepted	accept	VERB
ajcp-4886	48	13	as	as	ADP
ajcp-4886	48	14	valid	valid	ADJ
ajcp-4886	48	15	targets	target	NOUN
ajcp-4886	48	16	.	.	PUNCT
ajcp-4886	49	1	however	however	ADV
ajcp-4886	49	2	,	,	PUNCT
ajcp-4886	49	3	because	because	SCONJ
ajcp-4886	49	4	the	the	DET
ajcp-4886	49	5	term	term	NOUN
ajcp-4886	49	6	“	"	PUNCT
ajcp-4886	49	7	aβ	aβ	NOUN
ajcp-4886	49	8	oligomer	oligomer	ADJ
ajcp-4886	49	9	”	"	PUNCT
ajcp-4886	49	10	can	can	AUX
ajcp-4886	49	11	refer	refer	VERB
ajcp-4886	49	12	to	to	ADP
ajcp-4886	49	13	a	a	DET
ajcp-4886	49	14	variety	variety	NOUN
ajcp-4886	49	15	of	of	ADP
ajcp-4886	49	16	soluble	soluble	ADJ
ajcp-4886	49	17	aβ	aβ	NOUN
ajcp-4886	49	18	species	specie	NOUN
ajcp-4886	49	19	or	or	CCONJ
ajcp-4886	49	20	a	a	DET
ajcp-4886	49	21	mixture	mixture	NOUN
ajcp-4886	49	22	of	of	ADP
ajcp-4886	49	23	different	different	ADJ
ajcp-4886	49	24	types	type	NOUN
ajcp-4886	49	25	of	of	ADP
ajcp-4886	49	26	metastable	metastable	ADJ
ajcp-4886	49	27	oligomeric	oligomeric	ADJ
ajcp-4886	49	28	species	specie	NOUN
ajcp-4886	49	29	with	with	ADP
ajcp-4886	49	30	different	different	ADJ
ajcp-4886	49	31	sizes	size	NOUN
ajcp-4886	49	32	,	,	PUNCT
ajcp-4886	49	33	shapes	shape	NOUN
ajcp-4886	49	34	,	,	PUNCT
ajcp-4886	49	35	and	and	CCONJ
ajcp-4886	49	36	conformations	conformation	NOUN
ajcp-4886	49	37	as	as	ADP
ajcp-4886	49	38	a	a	DET
ajcp-4886	49	39	result	result	NOUN
ajcp-4886	49	40	of	of	ADP
ajcp-4886	49	41	aβ	aβ	NOUN
ajcp-4886	49	42	’s	’s	PART
ajcp-4886	49	43	dynamic	dynamic	ADJ
ajcp-4886	49	44	assembly	assembly	NOUN
ajcp-4886	49	45	,	,	PUNCT
ajcp-4886	49	46	it	it	PRON
ajcp-4886	49	47	can	can	AUX
ajcp-4886	49	48	be	be	AUX
ajcp-4886	49	49	somewhat	somewhat	ADV
ajcp-4886	49	50	ambiguous	ambiguous	ADJ
ajcp-4886	49	51	(	(	PUNCT
ajcp-4886	49	52	viola	viola	PROPN
ajcp-4886	49	53	&	&	CCONJ
ajcp-4886	49	54	klein	klein	PROPN
ajcp-4886	49	55	,	,	PUNCT
ajcp-4886	49	56	2015	2015	NUM
ajcp-4886	49	57	)	)	PUNCT
ajcp-4886	49	58	.	.	PUNCT
ajcp-4886	50	1	various	various	ADJ
ajcp-4886	50	2	experiments	experiment	NOUN
ajcp-4886	50	3	have	have	AUX
ajcp-4886	50	4	contributed	contribute	VERB
ajcp-4886	50	5	to	to	ADP
ajcp-4886	50	6	our	our	PRON
ajcp-4886	50	7	current	current	ADJ
ajcp-4886	50	8	understanding	understanding	NOUN
ajcp-4886	50	9	of	of	ADP
ajcp-4886	50	10	the	the	DET
ajcp-4886	50	11	structures	structure	NOUN
ajcp-4886	50	12	and	and	CCONJ
ajcp-4886	50	13	biology	biology	NOUN
ajcp-4886	50	14	of	of	ADP
ajcp-4886	50	15	aβ	aβ	DET
ajcp-4886	50	16	oligomers	oligomer	NOUN
ajcp-4886	50	17	,	,	PUNCT
ajcp-4886	50	18	even	even	ADV
ajcp-4886	50	19	though	though	SCONJ
ajcp-4886	50	20	a	a	DET
ajcp-4886	50	21	unified	unified	ADJ
ajcp-4886	50	22	model	model	NOUN
ajcp-4886	50	23	for	for	ADP
ajcp-4886	50	24	their	their	PRON
ajcp-4886	50	25	role	role	NOUN
ajcp-4886	50	26	in	in	ADP
ajcp-4886	50	27	alzheimer	alzheimer	PROPN
ajcp-4886	50	28	’s	’s	PART
ajcp-4886	50	29	disease	disease	NOUN
ajcp-4886	50	30	has	have	AUX
ajcp-4886	50	31	not	not	PART
ajcp-4886	50	32	yet	yet	ADV
ajcp-4886	50	33	been	be	AUX
ajcp-4886	50	34	developed	develop	VERB
ajcp-4886	50	35	.	.	PUNCT
ajcp-4886	51	1	studies	study	NOUN
ajcp-4886	51	2	using	use	VERB
ajcp-4886	51	3	solid	solid	ADJ
ajcp-4886	51	4	-	-	PUNCT
ajcp-4886	51	5	state	state	NOUN
ajcp-4886	51	6	nuclear	nuclear	ADJ
ajcp-4886	51	7	magnetic	magnetic	ADJ
ajcp-4886	51	8	resonance	resonance	NOUN
ajcp-4886	51	9	(	(	PUNCT
ajcp-4886	51	10	nmr	nmr	NOUN
ajcp-4886	51	11	)	)	PUNCT
ajcp-4886	51	12	conducted	conduct	VERB
ajcp-4886	51	13	by	by	ADP
ajcp-4886	51	14	paravastu	paravastu	NOUN
ajcp-4886	51	15	and	and	CCONJ
ajcp-4886	51	16	colleagues	colleague	NOUN
ajcp-4886	51	17	revealed	reveal	VERB
ajcp-4886	51	18	that	that	SCONJ
ajcp-4886	51	19	antiparallel	antiparallel	ADJ
ajcp-4886	51	20	β	β	NOUN
ajcp-4886	51	21	-	-	NOUN
ajcp-4886	51	22	sheets	sheet	NOUN
ajcp-4886	51	23	make	make	VERB
ajcp-4886	51	24	up	up	ADP
ajcp-4886	51	25	the	the	DET
ajcp-4886	51	26	oligomers	oligomer	NOUN
ajcp-4886	51	27	of	of	ADP
ajcp-4886	51	28	aβ	aβ	PROPN
ajcp-4886	51	29	(	(	PUNCT
ajcp-4886	51	30	haerianardakani	haerianardakani	X
ajcp-4886	51	31	et	et	PROPN
ajcp-4886	51	32	al	al	PROPN
ajcp-4886	51	33	.	.	PROPN
ajcp-4886	51	34	,	,	PUNCT
ajcp-4886	51	35	2020	2020	NUM
ajcp-4886	51	36	)	)	PUNCT
ajcp-4886	51	37	.	.	PUNCT
ajcp-4886	52	1	protein	protein	NOUN
ajcp-4886	52	2	aggregation	aggregation	NOUN
ajcp-4886	52	3	and	and	CCONJ
ajcp-4886	52	4	condensation	condensation	NOUN
ajcp-4886	52	5	the	the	DET
ajcp-4886	52	6	word	word	NOUN
ajcp-4886	52	7	“	"	PUNCT
ajcp-4886	52	8	aggregation	aggregation	NOUN
ajcp-4886	52	9	”	"	PUNCT
ajcp-4886	52	10	is	be	AUX
ajcp-4886	52	11	frequently	frequently	ADV
ajcp-4886	52	12	used	use	VERB
ajcp-4886	52	13	in	in	ADP
ajcp-4886	52	14	biology	biology	NOUN
ajcp-4886	52	15	to	to	PART
ajcp-4886	52	16	refer	refer	VERB
ajcp-4886	52	17	to	to	ADP
ajcp-4886	52	18	assemblies	assembly	NOUN
ajcp-4886	52	19	that	that	PRON
ajcp-4886	52	20	are	be	AUX
ajcp-4886	52	21	created	create	VERB
ajcp-4886	52	22	under	under	ADP
ajcp-4886	52	23	pathological	pathological	ADJ
ajcp-4886	52	24	circumstances	circumstance	NOUN
ajcp-4886	52	25	,	,	PUNCT
ajcp-4886	52	26	where	where	SCONJ
ajcp-4886	52	27	the	the	DET
ajcp-4886	52	28	molecules	molecule	NOUN
ajcp-4886	52	29	within	within	ADP
ajcp-4886	52	30	the	the	DET
ajcp-4886	52	31	aggregate	aggregate	NOUN
ajcp-4886	52	32	are	be	AUX
ajcp-4886	52	33	irreversibly	irreversibly	ADV
ajcp-4886	52	34	disrupted	disrupt	VERB
ajcp-4886	52	35	and	and	CCONJ
ajcp-4886	52	36	frequently	frequently	ADV
ajcp-4886	52	37	regarded	regard	VERB
ajcp-4886	52	38	as	as	ADP
ajcp-4886	52	39	pathogenic	pathogenic	ADJ
ajcp-4886	52	40	factors	factor	NOUN
ajcp-4886	52	41	.	.	PUNCT
ajcp-4886	53	1	one	one	NUM
ajcp-4886	53	2	important	important	ADJ
ajcp-4886	53	3	feature	feature	NOUN
ajcp-4886	53	4	of	of	ADP
ajcp-4886	53	5	biological	biological	ADJ
ajcp-4886	53	6	processes	process	NOUN
ajcp-4886	53	7	that	that	PRON
ajcp-4886	53	8	are	be	AUX
ajcp-4886	53	9	irreversible	irreversible	ADJ
ajcp-4886	53	10	is	be	AUX
ajcp-4886	53	11	aggregation	aggregation	NOUN
ajcp-4886	53	12	.	.	PUNCT
ajcp-4886	54	1	in	in	ADP
ajcp-4886	54	2	contrast	contrast	NOUN
ajcp-4886	54	3	,	,	PUNCT
ajcp-4886	54	4	the	the	DET
ajcp-4886	54	5	word	word	NOUN
ajcp-4886	54	6	“	"	PUNCT
ajcp-4886	54	7	condensation	condensation	NOUN
ajcp-4886	54	8	”	"	PUNCT
ajcp-4886	54	9	describes	describe	VERB
ajcp-4886	54	10	dynamic	dynamic	ADJ
ajcp-4886	54	11	,	,	PUNCT
ajcp-4886	54	12	reversible	reversible	ADJ
ajcp-4886	54	13	molecules	molecule	NOUN
ajcp-4886	54	14	that	that	PRON
ajcp-4886	54	15	can	can	AUX
ajcp-4886	54	16	be	be	AUX
ajcp-4886	54	17	redissolved	redissolve	VERB
ajcp-4886	54	18	to	to	PART
ajcp-4886	54	19	carry	carry	VERB
ajcp-4886	54	20	out	out	ADP
ajcp-4886	54	21	their	their	PRON
ajcp-4886	54	22	specific	specific	ADJ
ajcp-4886	54	23	tasks	task	NOUN
ajcp-4886	54	24	;	;	PUNCT
ajcp-4886	54	25	the	the	DET
ajcp-4886	54	26	intracellular	intracellular	ADJ
ajcp-4886	54	27	environment	environment	NOUN
ajcp-4886	54	28	is	be	AUX
ajcp-4886	54	29	closely	closely	ADV
ajcp-4886	54	30	monitored	monitor	VERB
ajcp-4886	54	31	during	during	ADP
ajcp-4886	54	32	their	their	PRON
ajcp-4886	54	33	assembly	assembly	NOUN
ajcp-4886	54	34	(	(	PUNCT
ajcp-4886	54	35	alberti	alberti	PROPN
ajcp-4886	54	36	&	&	CCONJ
ajcp-4886	54	37	hyman	hyman	PROPN
ajcp-4886	54	38	,	,	PUNCT
ajcp-4886	54	39	2021	2021	NUM
ajcp-4886	54	40	)	)	PUNCT
ajcp-4886	54	41	.	.	PUNCT
ajcp-4886	55	1	but	but	CCONJ
ajcp-4886	55	2	there	there	PRON
ajcp-4886	55	3	is	be	VERB
ajcp-4886	55	4	some	some	DET
ajcp-4886	55	5	degree	degree	NOUN
ajcp-4886	55	6	of	of	ADP
ajcp-4886	55	7	interdependence	interdependence	NOUN
ajcp-4886	55	8	between	between	ADP
ajcp-4886	55	9	these	these	DET
ajcp-4886	55	10	two	two	NUM
ajcp-4886	55	11	categories	category	NOUN
ajcp-4886	55	12	of	of	ADP
ajcp-4886	55	13	higher	high	ADJ
ajcp-4886	55	14	-	-	PUNCT
ajcp-4886	55	15	order	order	NOUN
ajcp-4886	55	16	protein	protein	NOUN
ajcp-4886	55	17	assemblers	assembler	NOUN
ajcp-4886	55	18	.	.	PUNCT
ajcp-4886	56	1	protein	protein	NOUN
ajcp-4886	56	2	components	component	NOUN
ajcp-4886	56	3	can	can	AUX
ajcp-4886	56	4	misfold	misfold	VERB
ajcp-4886	56	5	and	and	CCONJ
ajcp-4886	56	6	irreversibly	irreversibly	ADV
ajcp-4886	56	7	aggregate	aggregate	ADJ
ajcp-4886	56	8	when	when	SCONJ
ajcp-4886	56	9	protein	protein	NOUN
ajcp-4886	56	10	homeostasis	homeostasis	NOUN
ajcp-4886	56	11	is	be	AUX
ajcp-4886	56	12	disrupted	disrupt	VERB
ajcp-4886	56	13	under	under	ADP
ajcp-4886	56	14	pathological	pathological	ADJ
ajcp-4886	56	15	or	or	CCONJ
ajcp-4886	56	16	pressure	pressure	NOUN
ajcp-4886	56	17	conditions	condition	NOUN
ajcp-4886	56	18	,	,	PUNCT
ajcp-4886	56	19	which	which	PRON
ajcp-4886	56	20	can	can	AUX
ajcp-4886	56	21	lead	lead	VERB
ajcp-4886	56	22	to	to	ADP
ajcp-4886	56	23	an	an	DET
ajcp-4886	56	24	imbalance	imbalance	NOUN
ajcp-4886	56	25	in	in	ADP
ajcp-4886	56	26	biomolecular	biomolecular	ADJ
ajcp-4886	56	27	condensation	condensation	NOUN
ajcp-4886	56	28	and	and	CCONJ
ajcp-4886	56	29	the	the	DET
ajcp-4886	56	30	uncontrollable	uncontrollable	ADJ
ajcp-4886	56	31	collapse	collapse	NOUN
ajcp-4886	56	32	of	of	ADP
ajcp-4886	56	33	these	these	DET
ajcp-4886	56	34	structures	structure	NOUN
ajcp-4886	56	35	.	.	PUNCT
ajcp-4886	57	1	aging	age	VERB
ajcp-4886	57	2	or	or	CCONJ
ajcp-4886	57	3	solidified	solidify	VERB
ajcp-4886	57	4	condensates	condensate	NOUN
ajcp-4886	57	5	can	can	AUX
ajcp-4886	57	6	then	then	ADV
ajcp-4886	57	7	frequently	frequently	ADV
ajcp-4886	57	8	transform	transform	VERB
ajcp-4886	57	9	into	into	ADP
ajcp-4886	57	10	aggregates	aggregate	NOUN
ajcp-4886	57	11	(	(	PUNCT
ajcp-4886	57	12	amzallag	amzallag	NOUN
ajcp-4886	57	13	&	&	CCONJ
ajcp-4886	57	14	hornstein	hornstein	PROPN
ajcp-4886	57	15	,	,	PUNCT
ajcp-4886	57	16	2022	2022	NUM
ajcp-4886	57	17	;	;	PUNCT
ajcp-4886	57	18	savastano	savastano	NOUN
ajcp-4886	57	19	et	et	PROPN
ajcp-4886	57	20	al	al	PROPN
ajcp-4886	57	21	.	.	PROPN
ajcp-4886	57	22	,	,	PUNCT
ajcp-4886	57	23	2020	2020	NUM
ajcp-4886	57	24	)	)	PUNCT
ajcp-4886	57	25	.	.	PUNCT
ajcp-4886	58	1	protein	protein	NOUN
ajcp-4886	58	2	condensates	condensate	NOUN
ajcp-4886	58	3	or	or	CCONJ
ajcp-4886	58	4	aggregates	aggregate	NOUN
ajcp-4886	58	5	may	may	AUX
ajcp-4886	58	6	arise	arise	VERB
ajcp-4886	58	7	from	from	ADP
ajcp-4886	58	8	intermediate	intermediate	ADJ
ajcp-4886	58	9	clusters	cluster	NOUN
ajcp-4886	58	10	as	as	ADP
ajcp-4886	58	11	precursors	precursor	NOUN
ajcp-4886	58	12	of	of	ADP
ajcp-4886	58	13	droplets	droplet	NOUN
ajcp-4886	58	14	or	or	CCONJ
ajcp-4886	58	15	aggregates	aggregate	NOUN
ajcp-4886	58	16	under	under	ADP
ajcp-4886	58	17	certain	certain	ADJ
ajcp-4886	58	18	circumstances	circumstance	NOUN
ajcp-4886	58	19	.	.	PUNCT
ajcp-4886	59	1	a	a	DET
ajcp-4886	59	2	droplet	droplet	NOUN
ajcp-4886	59	3	that	that	SCONJ
ajcp-4886	59	4	forms	form	NOUN
ajcp-4886	59	5	as	as	ADP
ajcp-4886	59	6	an	an	DET
ajcp-4886	59	7	intermediate	intermediate	ADJ
ajcp-4886	59	8	aggregate	aggregate	NOUN
ajcp-4886	59	9	and	and	CCONJ
ajcp-4886	59	10	then	then	ADV
ajcp-4886	59	11	transforms	transform	VERB
ajcp-4886	59	12	into	into	ADP
ajcp-4886	59	13	a	a	DET
ajcp-4886	59	14	solid	solid	ADJ
ajcp-4886	59	15	state	state	NOUN
ajcp-4886	59	16	is	be	AUX
ajcp-4886	59	17	one	one	NUM
ajcp-4886	59	18	more	more	ADV
ajcp-4886	59	19	potential	potential	ADJ
ajcp-4886	59	20	mechanism	mechanism	NOUN
ajcp-4886	59	21	for	for	ADP
ajcp-4886	59	22	protein	protein	NOUN
ajcp-4886	59	23	aggregation	aggregation	NOUN
ajcp-4886	59	24	(	(	PUNCT
ajcp-4886	59	25	wegmann	wegmann	PROPN
ajcp-4886	59	26	et	et	PROPN
ajcp-4886	59	27	al	al	PROPN
ajcp-4886	59	28	.	.	PROPN
ajcp-4886	59	29	,	,	PUNCT
ajcp-4886	59	30	2018	2018	NUM
ajcp-4886	59	31	)	)	PUNCT
ajcp-4886	59	32	.	.	PUNCT
ajcp-4886	60	1	nonetheless	nonetheless	ADV
ajcp-4886	60	2	,	,	PUNCT
ajcp-4886	60	3	a	a	DET
ajcp-4886	60	4	number	number	NOUN
ajcp-4886	60	5	of	of	ADP
ajcp-4886	60	6	investigations	investigation	NOUN
ajcp-4886	60	7	have	have	AUX
ajcp-4886	60	8	indicated	indicate	VERB
ajcp-4886	60	9	that	that	SCONJ
ajcp-4886	60	10	amyloid	amyloid	NOUN
ajcp-4886	60	11	(	(	PUNCT
ajcp-4886	60	12	or	or	CCONJ
ajcp-4886	60	13	cross	cross	NOUN
ajcp-4886	60	14	-	-	ADJ
ajcp-4886	60	15	β	β	ADJ
ajcp-4886	60	16	)	)	PUNCT
ajcp-4886	60	17	interactions	interaction	NOUN
ajcp-4886	60	18	play	play	VERB
ajcp-4886	60	19	a	a	DET
ajcp-4886	60	20	role	role	NOUN
ajcp-4886	60	21	in	in	ADP
ajcp-4886	60	22	the	the	DET
ajcp-4886	60	23	development	development	NOUN
ajcp-4886	60	24	of	of	ADP
ajcp-4886	60	25	protein	protein	NOUN
ajcp-4886	60	26	aggregates	aggregate	NOUN
ajcp-4886	60	27	,	,	PUNCT
ajcp-4886	60	28	and	and	CCONJ
ajcp-4886	60	29	the	the	DET
ajcp-4886	60	30	in	in	ADV
ajcp-4886	60	31	vitro	vitro	X
ajcp-4886	60	32	production	production	NOUN
ajcp-4886	60	33	of	of	ADP
ajcp-4886	60	34	amyloid	amyloid	NOUN
ajcp-4886	60	35	fibrils	fibril	NOUN
ajcp-4886	60	36	is	be	AUX
ajcp-4886	60	37	commonly	commonly	ADV
ajcp-4886	60	38	observed	observe	VERB
ajcp-4886	60	39	in	in	ADP
ajcp-4886	60	40	phase	phase	NOUN
ajcp-4886	60	41	-	-	PUNCT
ajcp-4886	60	42	separated	separate	VERB
ajcp-4886	60	43	proteins	protein	NOUN
ajcp-4886	60	44	(	(	PUNCT
ajcp-4886	60	45	hughes	hughe	NOUN
ajcp-4886	60	46	et	et	PROPN
ajcp-4886	60	47	al	al	PROPN
ajcp-4886	60	48	.	.	PROPN
ajcp-4886	60	49	,	,	PUNCT
ajcp-4886	60	50	2018	2018	NUM
ajcp-4886	60	51	;	;	PUNCT
ajcp-4886	60	52	luo	luo	PROPN
ajcp-4886	60	53	et	et	PROPN
ajcp-4886	60	54	al	al	PROPN
ajcp-4886	60	55	.	.	PROPN
ajcp-4886	60	56	,	,	PUNCT
ajcp-4886	60	57	2018	2018	NUM
ajcp-4886	60	58	)	)	PUNCT
ajcp-4886	60	59	.	.	PUNCT
ajcp-4886	61	1	aside	aside	ADV
ajcp-4886	61	2	from	from	ADP
ajcp-4886	61	3	nervous	nervous	ADJ
ajcp-4886	61	4	system	system	NOUN
ajcp-4886	61	5	conditions	condition	NOUN
ajcp-4886	61	6	like	like	ADP
ajcp-4886	61	7	schizophrenia	schizophrenia	NOUN
ajcp-4886	61	8	,	,	PUNCT
ajcp-4886	61	9	bipolar	bipolar	ADJ
ajcp-4886	61	10	,	,	PUNCT
ajcp-4886	61	11	and	and	CCONJ
ajcp-4886	61	12	autism	autism	NOUN
ajcp-4886	61	13	disorders	disorder	NOUN
ajcp-4886	61	14	,	,	PUNCT
ajcp-4886	61	15	depression	depression	NOUN
ajcp-4886	61	16	,	,	PUNCT
ajcp-4886	61	17	epilepsy	epilepsy	NOUN
ajcp-4886	61	18	,	,	PUNCT
ajcp-4886	61	19	and	and	CCONJ
ajcp-4886	61	20	figure	figure	VERB
ajcp-4886	61	21	1	1	NUM
ajcp-4886	61	22	:	:	PUNCT
ajcp-4886	61	23	amyloid	amyloid	NOUN
ajcp-4886	61	24	-	-	PUNCT
ajcp-4886	61	25	β	β	X
ajcp-4886	61	26	(	(	PUNCT
ajcp-4886	61	27	aβ	aβ	PROPN
ajcp-4886	61	28	)	)	PUNCT
ajcp-4886	61	29	misfolds	misfold	NOUN
ajcp-4886	61	30	and	and	CCONJ
ajcp-4886	61	31	forms	form	VERB
ajcp-4886	61	32	soluble	soluble	ADJ
ajcp-4886	61	33	toxic	toxic	ADJ
ajcp-4886	61	34	oligomers	oligomer	NOUN
ajcp-4886	61	35	and	and	CCONJ
ajcp-4886	61	36	fibrils	fibril	NOUN
ajcp-4886	61	37	that	that	PRON
ajcp-4886	61	38	accumulate	accumulate	VERB
ajcp-4886	61	39	in	in	ADP
ajcp-4886	61	40	the	the	DET
ajcp-4886	61	41	brain	brain	NOUN
ajcp-4886	61	42	leading	lead	VERB
ajcp-4886	61	43	to	to	ADP
ajcp-4886	61	44	synaptic	synaptic	ADJ
ajcp-4886	61	45	loss	loss	NOUN
ajcp-4886	61	46	and	and	CCONJ
ajcp-4886	61	47	selective	selective	ADJ
ajcp-4886	61	48	neuronal	neuronal	ADJ
ajcp-4886	61	49	death	death	NOUN
ajcp-4886	61	50	pa	pa	PROPN
ajcp-4886	61	51	ge	ge	PROPN
ajcp-4886	61	52	18	18	NUM
ajcp-4886	61	53	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-4886	61	54	am	be	AUX
ajcp-4886	61	55	.	.	PUNCT
ajcp-4886	62	1	j.	j.	PROPN
ajcp-4886	62	2	chem	chem	PROPN
ajcp-4886	62	3	.	.	PUNCT
ajcp-4886	63	1	pharm	pharm	PROPN
ajcp-4886	63	2	.	.	PUNCT
ajcp-4886	64	1	4(1	4(1	NOUN
ajcp-4886	64	2	)	)	PUNCT
ajcp-4886	65	1	16	16	NUM
ajcp-4886	65	2	-	-	SYM
ajcp-4886	65	3	28	28	NUM
ajcp-4886	65	4	,	,	PUNCT
ajcp-4886	65	5	2025	2025	NUM
ajcp-4886	65	6	alzheimer	alzheimer	X
ajcp-4886	65	7	’s	’s	PART
ajcp-4886	65	8	and	and	CCONJ
ajcp-4886	65	9	parkinson	parkinson	NOUN
ajcp-4886	65	10	’s	’s	PART
ajcp-4886	65	11	diseases	disease	NOUN
ajcp-4886	66	1	,	,	PUNCT
ajcp-4886	66	2	the	the	DET
ajcp-4886	66	3	top	top	ADV
ajcp-4886	66	4	-	-	PUNCT
ajcp-4886	66	5	ranking	rank	VERB
ajcp-4886	66	6	protein	protein	NOUN
ajcp-4886	66	7	condensation	condensation	NOUN
ajcp-4886	66	8	diseases	disease	NOUN
ajcp-4886	66	9	also	also	ADV
ajcp-4886	66	10	include	include	VERB
ajcp-4886	66	11	depression	depression	NOUN
ajcp-4886	66	12	.	.	PUNCT
ajcp-4886	67	1	synaptic	synaptic	ADJ
ajcp-4886	67	2	condensate	condensate	NOUN
ajcp-4886	67	3	-	-	PUNCT
ajcp-4886	67	4	forming	form	VERB
ajcp-4886	67	5	proteins	protein	NOUN
ajcp-4886	67	6	’	'	PUNCT
ajcp-4886	67	7	genes	gene	NOUN
ajcp-4886	67	8	are	be	AUX
ajcp-4886	67	9	linked	link	VERB
ajcp-4886	67	10	to	to	ADP
ajcp-4886	67	11	the	the	DET
ajcp-4886	67	12	majority	majority	NOUN
ajcp-4886	67	13	of	of	ADP
ajcp-4886	67	14	these	these	DET
ajcp-4886	67	15	neurological	neurological	ADJ
ajcp-4886	67	16	disorders	disorder	NOUN
ajcp-4886	67	17	(	(	PUNCT
ajcp-4886	67	18	zeng	zeng	PROPN
ajcp-4886	67	19	et	et	PROPN
ajcp-4886	67	20	al	al	PROPN
ajcp-4886	67	21	.	.	PROPN
ajcp-4886	67	22	,	,	PUNCT
ajcp-4886	67	23	2016	2016	NUM
ajcp-4886	67	24	)	)	PUNCT
ajcp-4886	67	25	.	.	PUNCT
ajcp-4886	68	1	the	the	DET
ajcp-4886	68	2	growing	grow	VERB
ajcp-4886	68	3	body	body	NOUN
ajcp-4886	68	4	of	of	ADP
ajcp-4886	68	5	evidence	evidence	NOUN
ajcp-4886	68	6	indicates	indicate	VERB
ajcp-4886	68	7	that	that	SCONJ
ajcp-4886	68	8	a	a	DET
ajcp-4886	68	9	variety	variety	NOUN
ajcp-4886	68	10	of	of	ADP
ajcp-4886	68	11	human	human	ADJ
ajcp-4886	68	12	diseases	disease	NOUN
ajcp-4886	68	13	are	be	AUX
ajcp-4886	68	14	probably	probably	ADV
ajcp-4886	68	15	caused	cause	VERB
ajcp-4886	68	16	by	by	ADP
ajcp-4886	68	17	aberrant	aberrant	ADJ
ajcp-4886	68	18	protein	protein	NOUN
ajcp-4886	68	19	condensation	condensation	NOUN
ajcp-4886	68	20	.	.	PUNCT
ajcp-4886	69	1	changes	change	NOUN
ajcp-4886	69	2	in	in	ADP
ajcp-4886	69	3	the	the	DET
ajcp-4886	69	4	physiological	physiological	ADJ
ajcp-4886	69	5	states	state	NOUN
ajcp-4886	69	6	of	of	ADP
ajcp-4886	69	7	proteins	protein	NOUN
ajcp-4886	69	8	are	be	AUX
ajcp-4886	69	9	the	the	DET
ajcp-4886	69	10	root	root	NOUN
ajcp-4886	69	11	cause	cause	NOUN
ajcp-4886	69	12	of	of	ADP
ajcp-4886	69	13	these	these	DET
ajcp-4886	69	14	pathologies	pathology	NOUN
ajcp-4886	69	15	,	,	PUNCT
ajcp-4886	69	16	which	which	PRON
ajcp-4886	69	17	are	be	AUX
ajcp-4886	69	18	collectively	collectively	ADV
ajcp-4886	69	19	known	know	VERB
ajcp-4886	69	20	as	as	ADP
ajcp-4886	69	21	protein	protein	NOUN
ajcp-4886	69	22	condensation	condensation	NOUN
ajcp-4886	69	23	diseases	disease	NOUN
ajcp-4886	69	24	(	(	PUNCT
ajcp-4886	69	25	li	li	PROPN
ajcp-4886	69	26	et	et	PROPN
ajcp-4886	69	27	al	al	PROPN
ajcp-4886	69	28	.	.	PROPN
ajcp-4886	69	29	,	,	PUNCT
ajcp-4886	69	30	2020	2020	NUM
ajcp-4886	69	31	)	)	PUNCT
ajcp-4886	69	32	.	.	PUNCT
ajcp-4886	70	1	yet	yet	ADV
ajcp-4886	70	2	,	,	PUNCT
ajcp-4886	70	3	nucleation	nucleation	NOUN
ajcp-4886	70	4	and	and	CCONJ
ajcp-4886	70	5	off	off	ADP
ajcp-4886	70	6	-	-	PUNCT
ajcp-4886	70	7	pathway	pathway	NOUN
ajcp-4886	70	8	aggregation	aggregation	NOUN
ajcp-4886	70	9	are	be	AUX
ajcp-4886	70	10	frequently	frequently	ADV
ajcp-4886	70	11	involved	involve	VERB
ajcp-4886	70	12	in	in	ADP
ajcp-4886	70	13	the	the	DET
ajcp-4886	70	14	formation	formation	NOUN
ajcp-4886	70	15	of	of	ADP
ajcp-4886	70	16	amyloid	amyloid	NOUN
ajcp-4886	70	17	fibrils	fibril	NOUN
ajcp-4886	70	18	,	,	PUNCT
ajcp-4886	70	19	which	which	PRON
ajcp-4886	70	20	is	be	AUX
ajcp-4886	70	21	not	not	PART
ajcp-4886	70	22	just	just	ADV
ajcp-4886	70	23	a	a	DET
ajcp-4886	70	24	straightforward	straightforward	ADJ
ajcp-4886	70	25	polymerization	polymerization	NOUN
ajcp-4886	70	26	process	process	NOUN
ajcp-4886	70	27	.	.	PUNCT
ajcp-4886	71	1	delays	delay	NOUN
ajcp-4886	71	2	cause	cause	VERB
ajcp-4886	71	3	disordered	disordered	ADJ
ajcp-4886	71	4	intermediates	intermediate	NOUN
ajcp-4886	71	5	to	to	PART
ajcp-4886	71	6	refold	refold	VERB
ajcp-4886	71	7	into	into	ADP
ajcp-4886	71	8	non	non	ADJ
ajcp-4886	71	9	-	-	ADJ
ajcp-4886	71	10	native	native	ADJ
ajcp-4886	71	11	secondary	secondary	ADJ
ajcp-4886	71	12	structures	structure	NOUN
ajcp-4886	71	13	(	(	PUNCT
ajcp-4886	71	14	β	β	NOUN
ajcp-4886	71	15	-	-	NOUN
ajcp-4886	71	16	strands	strand	NOUN
ajcp-4886	71	17	)	)	PUNCT
ajcp-4886	71	18	,	,	PUNCT
ajcp-4886	71	19	which	which	PRON
ajcp-4886	71	20	are	be	AUX
ajcp-4886	71	21	linked	link	VERB
ajcp-4886	71	22	to	to	ADP
ajcp-4886	71	23	the	the	DET
ajcp-4886	71	24	creation	creation	NOUN
ajcp-4886	71	25	of	of	ADP
ajcp-4886	71	26	oligomers	oligomer	NOUN
ajcp-4886	71	27	,	,	PUNCT
ajcp-4886	71	28	during	during	ADP
ajcp-4886	71	29	a	a	DET
ajcp-4886	71	30	lag	lag	NOUN
ajcp-4886	71	31	phase	phase	NOUN
ajcp-4886	71	32	.	.	PUNCT
ajcp-4886	72	1	in	in	ADP
ajcp-4886	72	2	certain	certain	ADJ
ajcp-4886	72	3	cases	case	NOUN
ajcp-4886	72	4	,	,	PUNCT
ajcp-4886	72	5	during	during	ADP
ajcp-4886	72	6	the	the	DET
ajcp-4886	72	7	α	α	NOUN
ajcp-4886	72	8	-	-	PUNCT
ajcp-4886	72	9	β	β	ADJ
ajcp-4886	72	10	structure	structure	NOUN
ajcp-4886	72	11	transition	transition	NOUN
ajcp-4886	72	12	,	,	PUNCT
ajcp-4886	72	13	folding	fold	VERB
ajcp-4886	72	14	intermediates	intermediate	NOUN
ajcp-4886	72	15	with	with	ADP
ajcp-4886	72	16	extended	extended	ADJ
ajcp-4886	72	17	(	(	PUNCT
ajcp-4886	72	18	non	non	ADJ
ajcp-4886	72	19	-	-	ADJ
ajcp-4886	72	20	native	native	ADJ
ajcp-4886	72	21	)	)	PUNCT
ajcp-4886	72	22	α	α	NOUN
ajcp-4886	72	23	-	-	PUNCT
ajcp-4886	72	24	helices	helix	NOUN
ajcp-4886	72	25	can	can	AUX
ajcp-4886	72	26	form	form	VERB
ajcp-4886	72	27	native	native	ADJ
ajcp-4886	72	28	or	or	CCONJ
ajcp-4886	72	29	amyloid	amyloid	NOUN
ajcp-4886	72	30	states	state	NOUN
ajcp-4886	72	31	(	(	PUNCT
ajcp-4886	72	32	žerovnik	žerovnik	X
ajcp-4886	72	33	&	&	CCONJ
ajcp-4886	72	34	venko	venko	PROPN
ajcp-4886	72	35	,	,	PUNCT
ajcp-4886	72	36	2023	2023	NUM
ajcp-4886	72	37	)	)	PUNCT
ajcp-4886	72	38	.	.	PUNCT
ajcp-4886	73	1	because	because	SCONJ
ajcp-4886	73	2	of	of	ADP
ajcp-4886	73	3	the	the	DET
ajcp-4886	73	4	stacking	stacking	NOUN
ajcp-4886	73	5	of	of	ADP
ajcp-4886	73	6	aromatic	aromatic	ADJ
ajcp-4886	73	7	rings	ring	NOUN
ajcp-4886	73	8	and	and	CCONJ
ajcp-4886	73	9	a	a	DET
ajcp-4886	73	10	network	network	NOUN
ajcp-4886	73	11	of	of	ADP
ajcp-4886	73	12	backbone	backbone	NOUN
ajcp-4886	73	13	hydrogen	hydrogen	NOUN
ajcp-4886	73	14	bonds	bond	NOUN
ajcp-4886	73	15	,	,	PUNCT
ajcp-4886	73	16	amyloid	amyloid	NOUN
ajcp-4886	73	17	fibrils	fibril	NOUN
ajcp-4886	73	18	,	,	PUNCT
ajcp-4886	73	19	which	which	PRON
ajcp-4886	73	20	are	be	AUX
ajcp-4886	73	21	highly	highly	ADV
ajcp-4886	73	22	ordered	order	VERB
ajcp-4886	73	23	and	and	CCONJ
ajcp-4886	73	24	rigid	rigid	ADJ
ajcp-4886	73	25	protein	protein	NOUN
ajcp-4886	73	26	states	state	NOUN
ajcp-4886	73	27	,	,	PUNCT
ajcp-4886	73	28	can	can	AUX
ajcp-4886	73	29	have	have	VERB
ajcp-4886	73	30	a	a	DET
ajcp-4886	73	31	variety	variety	NOUN
ajcp-4886	73	32	of	of	ADP
ajcp-4886	73	33	morphologies	morphology	NOUN
ajcp-4886	73	34	(	(	PUNCT
ajcp-4886	73	35	stanković	stanković	NOUN
ajcp-4886	73	36	et	et	NOUN
ajcp-4886	73	37	al	al	PROPN
ajcp-4886	73	38	.	.	PROPN
ajcp-4886	73	39	,	,	PUNCT
ajcp-4886	73	40	2020	2020	NUM
ajcp-4886	73	41	;	;	PUNCT
ajcp-4886	73	42	taylor	taylor	PROPN
ajcp-4886	73	43	&	&	CCONJ
ajcp-4886	73	44	staniforth	staniforth	PROPN
ajcp-4886	73	45	,	,	PUNCT
ajcp-4886	73	46	2022	2022	NUM
ajcp-4886	73	47	)	)	PUNCT
ajcp-4886	73	48	.	.	PUNCT
ajcp-4886	74	1	reversibility	reversibility	NOUN
ajcp-4886	74	2	is	be	AUX
ajcp-4886	74	3	one	one	NUM
ajcp-4886	74	4	of	of	ADP
ajcp-4886	74	5	the	the	DET
ajcp-4886	74	6	main	main	ADJ
ajcp-4886	74	7	distinctions	distinction	NOUN
ajcp-4886	74	8	between	between	ADP
ajcp-4886	74	9	protein	protein	NOUN
ajcp-4886	74	10	condensates	condensate	NOUN
ajcp-4886	74	11	and	and	CCONJ
ajcp-4886	74	12	aggregates	aggregate	NOUN
ajcp-4886	74	13	.	.	PUNCT
ajcp-4886	75	1	protein	protein	NOUN
ajcp-4886	75	2	condensates	condensate	NOUN
ajcp-4886	75	3	are	be	AUX
ajcp-4886	75	4	at	at	ADP
ajcp-4886	75	5	least	least	ADJ
ajcp-4886	75	6	initially	initially	ADV
ajcp-4886	75	7	reversible	reversible	ADJ
ajcp-4886	75	8	,	,	PUNCT
ajcp-4886	75	9	in	in	ADP
ajcp-4886	75	10	contrast	contrast	NOUN
ajcp-4886	75	11	to	to	ADP
ajcp-4886	75	12	more	more	ADV
ajcp-4886	75	13	toxic	toxic	ADJ
ajcp-4886	75	14	forms	form	NOUN
ajcp-4886	75	15	of	of	ADP
ajcp-4886	75	16	protein	protein	NOUN
ajcp-4886	75	17	aggregates	aggregate	NOUN
ajcp-4886	75	18	(	(	PUNCT
ajcp-4886	75	19	shin	shin	NOUN
ajcp-4886	75	20	et	et	PROPN
ajcp-4886	75	21	al	al	PROPN
ajcp-4886	75	22	.	.	PROPN
ajcp-4886	75	23	,	,	PUNCT
ajcp-4886	75	24	2017	2017	NUM
ajcp-4886	75	25	)	)	PUNCT
ajcp-4886	75	26	.	.	PUNCT
ajcp-4886	76	1	a	a	DET
ajcp-4886	76	2	characteristic	characteristic	NOUN
ajcp-4886	76	3	of	of	ADP
ajcp-4886	76	4	diseases	disease	NOUN
ajcp-4886	76	5	like	like	ADP
ajcp-4886	76	6	transmissible	transmissible	ADJ
ajcp-4886	76	7	spongiform	spongiform	NOUN
ajcp-4886	76	8	encephalopathies	encephalopathy	NOUN
ajcp-4886	76	9	,	,	PUNCT
ajcp-4886	76	10	prion	prion	NOUN
ajcp-4886	76	11	diseases	disease	NOUN
ajcp-4886	76	12	,	,	PUNCT
ajcp-4886	76	13	alzheimer	alzheimer	PROPN
ajcp-4886	76	14	’s	’s	PART
ajcp-4886	76	15	disease	disease	NOUN
ajcp-4886	76	16	,	,	PUNCT
ajcp-4886	76	17	and	and	CCONJ
ajcp-4886	76	18	parkinson	parkinson	NOUN
ajcp-4886	76	19	’s	’s	PART
ajcp-4886	76	20	disease	disease	NOUN
ajcp-4886	76	21	is	be	AUX
ajcp-4886	76	22	protein	protein	NOUN
ajcp-4886	76	23	aggregation	aggregation	NOUN
ajcp-4886	76	24	.	.	PUNCT
ajcp-4886	77	1	there	there	PRON
ajcp-4886	77	2	is	be	VERB
ajcp-4886	77	3	ongoing	ongoing	ADJ
ajcp-4886	77	4	debate	debate	NOUN
ajcp-4886	77	5	as	as	ADP
ajcp-4886	77	6	to	to	ADP
ajcp-4886	77	7	whether	whether	SCONJ
ajcp-4886	77	8	the	the	DET
ajcp-4886	77	9	aggregated	aggregate	VERB
ajcp-4886	77	10	proteins	protein	NOUN
ajcp-4886	77	11	are	be	AUX
ajcp-4886	77	12	involved	involve	VERB
ajcp-4886	77	13	in	in	ADP
ajcp-4886	77	14	the	the	DET
ajcp-4886	77	15	pathological	pathological	ADJ
ajcp-4886	77	16	process	process	NOUN
ajcp-4886	77	17	directly	directly	ADV
ajcp-4886	77	18	or	or	CCONJ
ajcp-4886	77	19	are	be	AUX
ajcp-4886	77	20	merely	merely	ADV
ajcp-4886	77	21	bystanders	bystander	NOUN
ajcp-4886	77	22	.	.	PUNCT
ajcp-4886	78	1	consequently	consequently	ADV
ajcp-4886	78	2	,	,	PUNCT
ajcp-4886	78	3	it	it	PRON
ajcp-4886	78	4	is	be	AUX
ajcp-4886	78	5	crucial	crucial	ADJ
ajcp-4886	78	6	to	to	PART
ajcp-4886	78	7	comprehend	comprehend	VERB
ajcp-4886	78	8	ps	ps	NOUN
ajcp-4886	78	9	and	and	CCONJ
ajcp-4886	78	10	aggregation	aggregation	NOUN
ajcp-4886	78	11	.	.	PUNCT
ajcp-4886	79	1	it	it	PRON
ajcp-4886	79	2	is	be	AUX
ajcp-4886	79	3	becoming	become	VERB
ajcp-4886	79	4	evident	evident	ADJ
ajcp-4886	79	5	that	that	SCONJ
ajcp-4886	79	6	the	the	DET
ajcp-4886	79	7	pathogenesis	pathogenesis	NOUN
ajcp-4886	79	8	of	of	ADP
ajcp-4886	79	9	neurodegenerative	neurodegenerative	ADJ
ajcp-4886	79	10	disorders	disorder	NOUN
ajcp-4886	79	11	may	may	AUX
ajcp-4886	79	12	involve	involve	VERB
ajcp-4886	79	13	proteins	protein	NOUN
ajcp-4886	79	14	with	with	ADP
ajcp-4886	79	15	liquid	liquid	NOUN
ajcp-4886	79	16	-	-	PUNCT
ajcp-4886	79	17	to	to	ADP
ajcp-4886	79	18	-	-	PUNCT
ajcp-4886	79	19	solid	solid	ADJ
ajcp-4886	79	20	transitions	transition	NOUN
ajcp-4886	79	21	,	,	PUNCT
ajcp-4886	79	22	such	such	ADJ
ajcp-4886	79	23	as	as	ADP
ajcp-4886	79	24	tau	tau	PROPN
ajcp-4886	79	25	,	,	PUNCT
ajcp-4886	79	26	α	α	NOUN
ajcp-4886	79	27	-	-	PUNCT
ajcp-4886	79	28	synuclein	synuclein	NOUN
ajcp-4886	79	29	,	,	PUNCT
ajcp-4886	79	30	and	and	CCONJ
ajcp-4886	79	31	tdp-43	tdp-43	NOUN
ajcp-4886	79	32	,	,	PUNCT
ajcp-4886	79	33	which	which	PRON
ajcp-4886	79	34	bind	bind	VERB
ajcp-4886	79	35	to	to	ADP
ajcp-4886	79	36	rna	rna	NOUN
ajcp-4886	79	37	and	and	CCONJ
ajcp-4886	79	38	are	be	AUX
ajcp-4886	79	39	fused	fuse	VERB
ajcp-4886	79	40	in	in	ADP
ajcp-4886	79	41	sarcoma	sarcoma	NOUN
ajcp-4886	79	42	(	(	PUNCT
ajcp-4886	79	43	fus	fus	PROPN
ajcp-4886	79	44	)	)	PUNCT
ajcp-4886	79	45	(	(	PUNCT
ajcp-4886	79	46	zbinden	zbinden	NOUN
ajcp-4886	79	47	et	et	PROPN
ajcp-4886	79	48	al	al	PROPN
ajcp-4886	79	49	.	.	PROPN
ajcp-4886	79	50	,	,	PUNCT
ajcp-4886	79	51	2020	2020	NUM
ajcp-4886	79	52	)	)	PUNCT
ajcp-4886	79	53	.	.	PUNCT
ajcp-4886	80	1	the	the	DET
ajcp-4886	80	2	discovery	discovery	NOUN
ajcp-4886	80	3	of	of	ADP
ajcp-4886	80	4	liquid	liquid	NOUN
ajcp-4886	80	5	-	-	PUNCT
ajcp-4886	80	6	like	like	ADJ
ajcp-4886	80	7	condensates	condensate	NOUN
ajcp-4886	80	8	raises	raise	VERB
ajcp-4886	80	9	the	the	DET
ajcp-4886	80	10	prospect	prospect	NOUN
ajcp-4886	80	11	of	of	ADP
ajcp-4886	80	12	a	a	DET
ajcp-4886	80	13	different	different	ADJ
ajcp-4886	80	14	route	route	NOUN
ajcp-4886	80	15	for	for	ADP
ajcp-4886	80	16	amyloid	amyloid	NOUN
ajcp-4886	80	17	aggregation	aggregation	NOUN
ajcp-4886	80	18	.	.	PUNCT
ajcp-4886	81	1	this	this	DET
ajcp-4886	81	2	“	"	PUNCT
ajcp-4886	81	3	condensation	condensation	NOUN
ajcp-4886	81	4	pathway	pathway	NOUN
ajcp-4886	81	5	”	"	PUNCT
ajcp-4886	81	6	is	be	AUX
ajcp-4886	81	7	different	different	ADJ
ajcp-4886	81	8	from	from	ADP
ajcp-4886	81	9	the	the	DET
ajcp-4886	81	10	“	"	PUNCT
ajcp-4886	81	11	deposition	deposition	NOUN
ajcp-4886	81	12	pathway	pathway	NOUN
ajcp-4886	81	13	,	,	PUNCT
ajcp-4886	81	14	”	"	PUNCT
ajcp-4886	81	15	which	which	PRON
ajcp-4886	81	16	is	be	AUX
ajcp-4886	81	17	the	the	DET
ajcp-4886	81	18	direct	direct	ADJ
ajcp-4886	81	19	formation	formation	NOUN
ajcp-4886	81	20	of	of	ADP
ajcp-4886	81	21	amyloid	amyloid	NOUN
ajcp-4886	81	22	aggregates	aggregate	NOUN
ajcp-4886	81	23	from	from	ADP
ajcp-4886	81	24	their	their	PRON
ajcp-4886	81	25	native	native	ADJ
ajcp-4886	81	26	state	state	NOUN
ajcp-4886	81	27	via	via	ADP
ajcp-4886	81	28	oligomeric	oligomeric	ADJ
ajcp-4886	81	29	species	specie	NOUN
ajcp-4886	81	30	.	.	PUNCT
ajcp-4886	82	1	even	even	ADV
ajcp-4886	82	2	within	within	ADP
ajcp-4886	82	3	the	the	DET
ajcp-4886	82	4	same	same	ADJ
ajcp-4886	82	5	cell	cell	NOUN
ajcp-4886	82	6	and	and	CCONJ
ajcp-4886	82	7	protein	protein	NOUN
ajcp-4886	82	8	system	system	NOUN
ajcp-4886	82	9	going	go	VERB
ajcp-4886	82	10	through	through	ADP
ajcp-4886	82	11	self	self	NOUN
ajcp-4886	82	12	-	-	PUNCT
ajcp-4886	82	13	assembly	assembly	NOUN
ajcp-4886	82	14	,	,	PUNCT
ajcp-4886	82	15	solid	solid	ADJ
ajcp-4886	82	16	deposits	deposit	NOUN
ajcp-4886	82	17	have	have	AUX
ajcp-4886	82	18	been	be	AUX
ajcp-4886	82	19	seen	see	VERB
ajcp-4886	82	20	to	to	PART
ajcp-4886	82	21	form	form	VERB
ajcp-4886	82	22	either	either	CCONJ
ajcp-4886	82	23	directly	directly	ADV
ajcp-4886	82	24	through	through	ADP
ajcp-4886	82	25	the	the	DET
ajcp-4886	82	26	deposition	deposition	NOUN
ajcp-4886	82	27	pathway	pathway	NOUN
ajcp-4886	82	28	or	or	CCONJ
ajcp-4886	82	29	from	from	ADP
ajcp-4886	82	30	liquid	liquid	ADJ
ajcp-4886	82	31	droplets	droplet	NOUN
ajcp-4886	82	32	through	through	ADP
ajcp-4886	82	33	the	the	DET
ajcp-4886	82	34	condensation	condensation	NOUN
ajcp-4886	82	35	pathway	pathway	NOUN
ajcp-4886	82	36	(	(	PUNCT
ajcp-4886	82	37	cascella	cascella	NOUN
ajcp-4886	82	38	et	et	PROPN
ajcp-4886	82	39	al	al	PROPN
ajcp-4886	82	40	.	.	PROPN
ajcp-4886	82	41	,	,	PUNCT
ajcp-4886	82	42	2022	2022	NUM
ajcp-4886	82	43	;	;	PUNCT
ajcp-4886	82	44	hardenberg	hardenberg	ADV
ajcp-4886	82	45	et	et	PROPN
ajcp-4886	82	46	al	al	PROPN
ajcp-4886	82	47	.	.	PROPN
ajcp-4886	82	48	,	,	PUNCT
ajcp-4886	82	49	2020	2020	NUM
ajcp-4886	82	50	)	)	PUNCT
ajcp-4886	82	51	.	.	PUNCT
ajcp-4886	83	1	however	however	ADV
ajcp-4886	83	2	,	,	PUNCT
ajcp-4886	83	3	when	when	SCONJ
ajcp-4886	83	4	amyloid	amyloid	NOUN
ajcp-4886	83	5	aggregation	aggregation	NOUN
ajcp-4886	83	6	occurs	occur	VERB
ajcp-4886	83	7	within	within	ADP
ajcp-4886	83	8	condensates	condensate	NOUN
ajcp-4886	83	9	,	,	PUNCT
ajcp-4886	83	10	the	the	DET
ajcp-4886	83	11	role	role	NOUN
ajcp-4886	83	12	of	of	ADP
ajcp-4886	83	13	oligomers	oligomer	NOUN
ajcp-4886	83	14	is	be	AUX
ajcp-4886	83	15	still	still	ADV
ajcp-4886	83	16	unclear	unclear	ADJ
ajcp-4886	83	17	.	.	PUNCT
ajcp-4886	84	1	within	within	ADP
ajcp-4886	84	2	a	a	DET
ajcp-4886	84	3	condensed	condense	VERB
ajcp-4886	84	4	gel	gel	NOUN
ajcp-4886	84	5	-	-	PUNCT
ajcp-4886	84	6	like	like	ADJ
ajcp-4886	84	7	phase	phase	NOUN
ajcp-4886	84	8	,	,	PUNCT
ajcp-4886	84	9	it	it	PRON
ajcp-4886	84	10	was	be	AUX
ajcp-4886	84	11	discovered	discover	VERB
ajcp-4886	84	12	that	that	SCONJ
ajcp-4886	84	13	tdp-43	tdp-43	NOUN
ajcp-4886	84	14	oligomers	oligomer	NOUN
ajcp-4886	84	15	form	form	VERB
ajcp-4886	84	16	in	in	ADP
ajcp-4886	84	17	both	both	CCONJ
ajcp-4886	84	18	the	the	DET
ajcp-4886	84	19	deposition	deposition	NOUN
ajcp-4886	84	20	and	and	CCONJ
ajcp-4886	84	21	condensation	condensation	NOUN
ajcp-4886	84	22	pathways	pathway	NOUN
ajcp-4886	84	23	and	and	CCONJ
ajcp-4886	84	24	before	before	SCONJ
ajcp-4886	84	25	solid	solid	ADJ
ajcp-4886	84	26	aggregates	aggregate	NOUN
ajcp-4886	84	27	emerge	emerge	VERB
ajcp-4886	84	28	(	(	PUNCT
ajcp-4886	84	29	french	french	PROPN
ajcp-4886	84	30	et	et	PROPN
ajcp-4886	84	31	al	al	PROPN
ajcp-4886	84	32	.	.	PROPN
ajcp-4886	84	33	,	,	PUNCT
ajcp-4886	84	34	2019	2019	NUM
ajcp-4886	84	35	)	)	PUNCT
ajcp-4886	84	36	.	.	PUNCT
ajcp-4886	85	1	furthermore	furthermore	ADV
ajcp-4886	85	2	,	,	PUNCT
ajcp-4886	85	3	it	it	PRON
ajcp-4886	85	4	has	have	AUX
ajcp-4886	85	5	been	be	AUX
ajcp-4886	85	6	documented	document	VERB
ajcp-4886	85	7	that	that	SCONJ
ajcp-4886	85	8	⍺	⍺	ADJ
ajcp-4886	85	9	-synuclein	-synuclein	ADJ
ajcp-4886	85	10	oligomers	oligomer	NOUN
ajcp-4886	85	11	were	be	AUX
ajcp-4886	85	12	formed	form	VERB
ajcp-4886	85	13	right	right	ADV
ajcp-4886	85	14	after	after	ADP
ajcp-4886	85	15	the	the	DET
ajcp-4886	85	16	monomeric	monomeric	ADJ
ajcp-4886	85	17	protein	protein	NOUN
ajcp-4886	85	18	underwent	underwent	NOUN
ajcp-4886	85	19	phase	phase	NOUN
ajcp-4886	85	20	separation	separation	NOUN
ajcp-4886	85	21	into	into	ADP
ajcp-4886	85	22	a	a	DET
ajcp-4886	85	23	hydrogel	hydrogel	NOUN
ajcp-4886	85	24	.	.	PUNCT
ajcp-4886	86	1	in	in	ADP
ajcp-4886	86	2	this	this	DET
ajcp-4886	86	3	environment	environment	NOUN
ajcp-4886	86	4	,	,	PUNCT
ajcp-4886	86	5	monomers	monomer	NOUN
ajcp-4886	86	6	,	,	PUNCT
ajcp-4886	86	7	oligomers	oligomer	NOUN
ajcp-4886	86	8	,	,	PUNCT
ajcp-4886	86	9	and	and	CCONJ
ajcp-4886	86	10	fbrils	fbril	NOUN
ajcp-4886	86	11	coexist	coexist	VERB
ajcp-4886	86	12	,	,	PUNCT
ajcp-4886	86	13	and	and	CCONJ
ajcp-4886	86	14	the	the	DET
ajcp-4886	86	15	hydrogels	hydrogel	NOUN
ajcp-4886	86	16	trap	trap	VERB
ajcp-4886	86	17	⍺	⍺	NOUN
ajcp-4886	86	18	-synuclein	-synuclein	ADJ
ajcp-4886	86	19	in	in	ADP
ajcp-4886	86	20	a	a	DET
ajcp-4886	86	21	highly	highly	ADV
ajcp-4886	86	22	cytotoxic	cytotoxic	ADJ
ajcp-4886	86	23	state	state	NOUN
ajcp-4886	86	24	rather	rather	ADV
ajcp-4886	86	25	than	than	ADP
ajcp-4886	86	26	releasing	release	VERB
ajcp-4886	86	27	it	it	PRON
ajcp-4886	86	28	(	(	PUNCT
ajcp-4886	86	29	kumar	kumar	PROPN
ajcp-4886	86	30	et	et	PROPN
ajcp-4886	86	31	al	al	PROPN
ajcp-4886	86	32	.	.	PROPN
ajcp-4886	86	33	,	,	PUNCT
ajcp-4886	86	34	2018	2018	NUM
ajcp-4886	86	35	)	)	PUNCT
ajcp-4886	86	36	.	.	PUNCT
ajcp-4886	87	1	similarly	similarly	ADV
ajcp-4886	87	2	,	,	PUNCT
ajcp-4886	87	3	it	it	PRON
ajcp-4886	87	4	was	be	AUX
ajcp-4886	87	5	discovered	discover	VERB
ajcp-4886	87	6	that	that	SCONJ
ajcp-4886	87	7	liquid	liquid	NOUN
ajcp-4886	87	8	–	–	PUNCT
ajcp-4886	87	9	liquid	liquid	ADJ
ajcp-4886	87	10	phase	phase	NOUN
ajcp-4886	87	11	separation	separation	NOUN
ajcp-4886	87	12	causes	cause	VERB
ajcp-4886	87	13	a	a	DET
ajcp-4886	87	14	pathogenic	pathogenic	ADJ
ajcp-4886	87	15	conformation	conformation	NOUN
ajcp-4886	87	16	and	and	CCONJ
ajcp-4886	87	17	oligomerization	oligomerization	NOUN
ajcp-4886	87	18	in	in	ADP
ajcp-4886	87	19	tau	tau	PROPN
ajcp-4886	87	20	and	and	CCONJ
ajcp-4886	87	21	comes	come	VERB
ajcp-4886	87	22	before	before	ADP
ajcp-4886	87	23	gel	gel	NOUN
ajcp-4886	87	24	formation	formation	NOUN
ajcp-4886	87	25	and	and	CCONJ
ajcp-4886	87	26	subsequently	subsequently	ADV
ajcp-4886	87	27	aggregation	aggregation	NOUN
ajcp-4886	87	28	in	in	ADP
ajcp-4886	87	29	vitro	vitro	X
ajcp-4886	87	30	(	(	PUNCT
ajcp-4886	87	31	kanaan	kanaan	PROPN
ajcp-4886	87	32	et	et	PROPN
ajcp-4886	87	33	al	al	PROPN
ajcp-4886	87	34	.	.	PROPN
ajcp-4886	87	35	,	,	PUNCT
ajcp-4886	87	36	2020	2020	NUM
ajcp-4886	87	37	;	;	PUNCT
ajcp-4886	87	38	wegmann	wegmann	PROPN
ajcp-4886	87	39	et	et	PROPN
ajcp-4886	87	40	al	al	PROPN
ajcp-4886	87	41	.	.	PROPN
ajcp-4886	87	42	,	,	PUNCT
ajcp-4886	87	43	2018	2018	NUM
ajcp-4886	87	44	)	)	PUNCT
ajcp-4886	87	45	.	.	PUNCT
ajcp-4886	88	1	figure	figure	VERB
ajcp-4886	88	2	2	2	NUM
ajcp-4886	88	3	:	:	PUNCT
ajcp-4886	88	4	a	a	DET
ajcp-4886	88	5	synopsis	synopsis	NOUN
ajcp-4886	88	6	of	of	ADP
ajcp-4886	88	7	condensation	condensation	NOUN
ajcp-4886	88	8	and	and	CCONJ
ajcp-4886	88	9	the	the	DET
ajcp-4886	88	10	amyloid	amyloid	NOUN
ajcp-4886	88	11	formation	formation	NOUN
ajcp-4886	88	12	deposition	deposition	NOUN
ajcp-4886	88	13	pathway	pathway	NOUN
ajcp-4886	88	14	.	.	PUNCT
ajcp-4886	89	1	source	source	NOUN
ajcp-4886	89	2	:	:	PUNCT
ajcp-4886	89	3	biorender	biorender	VERB
ajcp-4886	89	4	structural	structural	ADJ
ajcp-4886	89	5	features	feature	NOUN
ajcp-4886	89	6	understanding	understand	VERB
ajcp-4886	89	7	the	the	DET
ajcp-4886	89	8	intricate	intricate	ADJ
ajcp-4886	89	9	structure	structure	NOUN
ajcp-4886	89	10	of	of	ADP
ajcp-4886	89	11	aβ(1	aβ(1	PROPN
ajcp-4886	89	12	-	-	PUNCT
ajcp-4886	89	13	42	42	NUM
ajcp-4886	89	14	)	)	PUNCT
ajcp-4886	89	15	oligomer	oligomer	NOUN
ajcp-4886	89	16	’s	’s	PART
ajcp-4886	89	17	is	be	AUX
ajcp-4886	89	18	crucial	crucial	ADJ
ajcp-4886	89	19	,	,	PUNCT
ajcp-4886	89	20	and	and	CCONJ
ajcp-4886	89	21	in	in	ADP
ajcp-4886	89	22	recent	recent	ADJ
ajcp-4886	89	23	times	time	NOUN
ajcp-4886	89	24	,	,	PUNCT
ajcp-4886	89	25	solid	solid	ADJ
ajcp-4886	89	26	-	-	PUNCT
ajcp-4886	89	27	state	state	NOUN
ajcp-4886	89	28	nmr	nmr	NOUN
ajcp-4886	89	29	-	-	PUNCT
ajcp-4886	89	30	spectroscopy	spectroscopy	NOUN
ajcp-4886	89	31	has	have	AUX
ajcp-4886	89	32	been	be	AUX
ajcp-4886	89	33	used	use	VERB
ajcp-4886	89	34	to	to	PART
ajcp-4886	89	35	perform	perform	VERB
ajcp-4886	89	36	structural	structural	ADJ
ajcp-4886	89	37	analyses	analysis	NOUN
ajcp-4886	89	38	on	on	ADP
ajcp-4886	89	39	various	various	ADJ
ajcp-4886	89	40	oligomer	oligomer	ADJ
ajcp-4886	89	41	preparations	preparation	NOUN
ajcp-4886	89	42	of	of	ADP
ajcp-4886	89	43	aβ(1	aβ(1	ADJ
ajcp-4886	89	44	-	-	PUNCT
ajcp-4886	89	45	42	42	NUM
ajcp-4886	89	46	)	)	PUNCT
ajcp-4886	89	47	oligomer	oligomer	NOUN
ajcp-4886	89	48	’s	’s	PART
ajcp-4886	89	49	and	and	CCONJ
ajcp-4886	89	50	aβ(1	aβ(1	ADJ
ajcp-4886	89	51	-	-	PUNCT
ajcp-4886	89	52	40)oligomer	40)oligomer	NUM
ajcp-4886	89	53	’s	’s	PART
ajcp-4886	89	54	(	(	PUNCT
ajcp-4886	89	55	also	also	ADV
ajcp-4886	89	56	known	know	VERB
ajcp-4886	89	57	as	as	ADP
ajcp-4886	89	58	pyroglu	pyroglu	NOUN
ajcp-4886	89	59	-	-	PUNCT
ajcp-4886	89	60	aβ(3/11–40	aβ(3/11–40	NOUN
ajcp-4886	89	61	)	)	PUNCT
ajcp-4886	90	1	oligomers)(könig	oligomers)(könig	NOUN
ajcp-4886	90	2	et	et	PROPN
ajcp-4886	90	3	al	al	PROPN
ajcp-4886	90	4	.	.	PROPN
ajcp-4886	90	5	,	,	PUNCT
ajcp-4886	90	6	2021	2021	NUM
ajcp-4886	90	7	)	)	PUNCT
ajcp-4886	90	8	.	.	PUNCT
ajcp-4886	91	1	both	both	PRON
ajcp-4886	91	2	on	on	ADP
ajcp-4886	91	3	-	-	PUNCT
ajcp-4886	91	4	pathway	pathway	NOUN
ajcp-4886	91	5	precursor	precursor	NOUN
ajcp-4886	91	6	and	and	CCONJ
ajcp-4886	91	7	off	off	ADP
ajcp-4886	91	8	-	-	PUNCT
ajcp-4886	91	9	pathway	pathway	NOUN
ajcp-4886	91	10	competitors	competitor	NOUN
ajcp-4886	91	11	can	can	AUX
ajcp-4886	91	12	be	be	AUX
ajcp-4886	91	13	acted	act	VERB
ajcp-4886	91	14	upon	upon	SCONJ
ajcp-4886	91	15	by	by	ADP
ajcp-4886	91	16	the	the	DET
ajcp-4886	91	17	oligomers	oligomer	NOUN
ajcp-4886	91	18	during	during	ADP
ajcp-4886	91	19	the	the	DET
ajcp-4886	91	20	oligomer	oligomer	NOUN
ajcp-4886	91	21	to	to	PART
ajcp-4886	91	22	mature	mature	VERB
ajcp-4886	91	23	fibril	fibril	ADJ
ajcp-4886	91	24	conversion	conversion	NOUN
ajcp-4886	91	25	for	for	ADP
ajcp-4886	91	26	aβ42	aβ42	PROPN
ajcp-4886	91	27	.	.	PUNCT
ajcp-4886	92	1	mostly	mostly	ADV
ajcp-4886	92	2	composed	compose	VERB
ajcp-4886	92	3	of	of	ADP
ajcp-4886	92	4	residue	residue	NOUN
ajcp-4886	92	5	aβ	aβ	PRON
ajcp-4886	92	6	peptide	peptide	NOUN
ajcp-4886	92	7	species	specie	NOUN
ajcp-4886	92	8	,	,	PUNCT
ajcp-4886	92	9	these	these	DET
ajcp-4886	92	10	fibrils	fibril	NOUN
ajcp-4886	92	11	have	have	VERB
ajcp-4886	92	12	wellknown	wellknown	ADJ
ajcp-4886	92	13	structures	structure	NOUN
ajcp-4886	92	14	.	.	PUNCT
ajcp-4886	93	1	the	the	DET
ajcp-4886	93	2	β	β	NOUN
ajcp-4886	93	3	-	-	NOUN
ajcp-4886	93	4	strands	strand	NOUN
ajcp-4886	93	5	of	of	ADP
ajcp-4886	93	6	these	these	DET
ajcp-4886	93	7	firbils	firbil	NOUN
ajcp-4886	93	8	are	be	AUX
ajcp-4886	93	9	oriented	orient	VERB
ajcp-4886	93	10	perpendicularly	perpendicularly	ADV
ajcp-4886	93	11	to	to	ADP
ajcp-4886	93	12	the	the	DET
ajcp-4886	93	13	fibril	fibril	ADJ
ajcp-4886	93	14	axis	axis	NOUN
ajcp-4886	93	15	,	,	PUNCT
ajcp-4886	93	16	giving	give	VERB
ajcp-4886	93	17	them	they	PRON
ajcp-4886	93	18	a	a	DET
ajcp-4886	93	19	general	general	ADJ
ajcp-4886	93	20	appearance	appearance	NOUN
ajcp-4886	93	21	of	of	ADP
ajcp-4886	93	22	cross	cross	ADJ
ajcp-4886	93	23	-	-	ADJ
ajcp-4886	93	24	shaped	shaped	ADJ
ajcp-4886	93	25	β	β	NOUN
ajcp-4886	93	26	structure	structure	NOUN
ajcp-4886	93	27	.	.	PUNCT
ajcp-4886	94	1	two	two	NUM
ajcp-4886	94	2	pa	pa	PROPN
ajcp-4886	94	3	ge	ge	PROPN
ajcp-4886	94	4	19	19	NUM
ajcp-4886	94	5	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-4886	94	6	am	be	AUX
ajcp-4886	94	7	.	.	PUNCT
ajcp-4886	95	1	j.	j.	PROPN
ajcp-4886	95	2	chem	chem	PROPN
ajcp-4886	95	3	.	.	PUNCT
ajcp-4886	96	1	pharm	pharm	PROPN
ajcp-4886	96	2	.	.	PUNCT
ajcp-4886	97	1	4(1	4(1	NOUN
ajcp-4886	97	2	)	)	PUNCT
ajcp-4886	98	1	16	16	NUM
ajcp-4886	98	2	-	-	SYM
ajcp-4886	98	3	28	28	NUM
ajcp-4886	98	4	,	,	PUNCT
ajcp-4886	98	5	2025	2025	NUM
ajcp-4886	98	6	hydrophobic	hydrophobic	NOUN
ajcp-4886	98	7	β	β	NOUN
ajcp-4886	98	8	-	-	ADJ
ajcp-4886	98	9	sheet	sheet	NOUN
ajcp-4886	98	10	segments	segment	NOUN
ajcp-4886	98	11	with	with	ADP
ajcp-4886	98	12	an	an	DET
ajcp-4886	98	13	in	in	ADP
ajcp-4886	98	14	-	-	PUNCT
ajcp-4886	98	15	register	register	NOUN
ajcp-4886	98	16	orientation	orientation	NOUN
ajcp-4886	98	17	and	and	CCONJ
ajcp-4886	98	18	parallel	parallel	ADJ
ajcp-4886	98	19	orientation	orientation	NOUN
ajcp-4886	98	20	are	be	AUX
ajcp-4886	98	21	present	present	ADJ
ajcp-4886	98	22	in	in	ADP
ajcp-4886	98	23	these	these	DET
ajcp-4886	98	24	fibrils	fibril	NOUN
ajcp-4886	98	25	,	,	PUNCT
ajcp-4886	98	26	despite	despite	SCONJ
ajcp-4886	98	27	their	their	PRON
ajcp-4886	98	28	unstructured	unstructured	ADJ
ajcp-4886	98	29	n	n	CCONJ
ajcp-4886	98	30	-	-	PUNCT
ajcp-4886	98	31	terminus	terminus	NOUN
ajcp-4886	98	32	(	(	PUNCT
ajcp-4886	98	33	saha	saha	PROPN
ajcp-4886	98	34	&	&	CCONJ
ajcp-4886	98	35	jana	jana	PROPN
ajcp-4886	98	36	,	,	PUNCT
ajcp-4886	98	37	2022	2022	NUM
ajcp-4886	98	38	)	)	PUNCT
ajcp-4886	98	39	.	.	PUNCT
ajcp-4886	99	1	in	in	ADP
ajcp-4886	99	2	order	order	NOUN
ajcp-4886	99	3	to	to	PART
ajcp-4886	99	4	examine	examine	VERB
ajcp-4886	99	5	the	the	DET
ajcp-4886	99	6	biological	biological	ADJ
ajcp-4886	99	7	activities	activity	NOUN
ajcp-4886	99	8	of	of	ADP
ajcp-4886	99	9	aβ	aβ	NOUN
ajcp-4886	99	10	oligomers	oligomer	NOUN
ajcp-4886	99	11	and	and	CCONJ
ajcp-4886	99	12	evaluate	evaluate	VERB
ajcp-4886	99	13	their	their	PRON
ajcp-4886	99	14	physicochemical	physicochemical	ADJ
ajcp-4886	99	15	and	and	CCONJ
ajcp-4886	99	16	structural	structural	ADJ
ajcp-4886	99	17	characteristics	characteristic	NOUN
ajcp-4886	99	18	,	,	PUNCT
ajcp-4886	99	19	various	various	ADJ
ajcp-4886	99	20	techniques	technique	NOUN
ajcp-4886	99	21	have	have	AUX
ajcp-4886	99	22	been	be	AUX
ajcp-4886	99	23	devised	devise	VERB
ajcp-4886	99	24	to	to	PART
ajcp-4886	99	25	produce	produce	VERB
ajcp-4886	99	26	oligomers	oligomer	NOUN
ajcp-4886	99	27	that	that	PRON
ajcp-4886	99	28	are	be	AUX
ajcp-4886	99	29	relatively	relatively	ADV
ajcp-4886	99	30	stable	stable	ADJ
ajcp-4886	99	31	and	and	CCONJ
ajcp-4886	99	32	do	do	AUX
ajcp-4886	99	33	not	not	PART
ajcp-4886	99	34	easily	easily	ADV
ajcp-4886	99	35	transform	transform	VERB
ajcp-4886	99	36	into	into	ADP
ajcp-4886	99	37	amyloid	amyloid	NOUN
ajcp-4886	99	38	fibrils	fibril	NOUN
ajcp-4886	99	39	.	.	PUNCT
ajcp-4886	100	1	aβ	aβ	PRON
ajcp-4886	100	2	oligomers	oligomer	NOUN
ajcp-4886	100	3	that	that	PRON
ajcp-4886	100	4	are	be	AUX
ajcp-4886	100	5	frequently	frequently	ADV
ajcp-4886	100	6	employed	employ	VERB
ajcp-4886	100	7	in	in	ADP
ajcp-4886	100	8	the	the	DET
ajcp-4886	100	9	examination	examination	NOUN
ajcp-4886	100	10	of	of	ADP
ajcp-4886	100	11	animal	animal	NOUN
ajcp-4886	100	12	and	and	CCONJ
ajcp-4886	100	13	cellular	cellular	ADJ
ajcp-4886	100	14	models	model	NOUN
ajcp-4886	100	15	of	of	ADP
ajcp-4886	100	16	alzheimer	alzheimer	PROPN
ajcp-4886	100	17	’s	’s	PART
ajcp-4886	100	18	disease	disease	NOUN
ajcp-4886	100	19	are	be	AUX
ajcp-4886	100	20	aβ	aβ	PRON
ajcp-4886	100	21	-	-	PUNCT
ajcp-4886	100	22	derived	derive	VERB
ajcp-4886	100	23	diffusible	diffusible	ADJ
ajcp-4886	100	24	ligands	ligand	NOUN
ajcp-4886	100	25	,	,	PUNCT
ajcp-4886	100	26	or	or	CCONJ
ajcp-4886	100	27	addls	addls	PROPN
ajcp-4886	100	28	(	(	PUNCT
ajcp-4886	100	29	jang	jang	PROPN
ajcp-4886	100	30	et	et	PROPN
ajcp-4886	100	31	al	al	PROPN
ajcp-4886	100	32	.	.	PROPN
ajcp-4886	100	33	,	,	PUNCT
ajcp-4886	100	34	2023	2023	NUM
ajcp-4886	100	35	)	)	PUNCT
ajcp-4886	100	36	.	.	PUNCT
ajcp-4886	101	1	the	the	DET
ajcp-4886	101	2	toxic	toxic	ADJ
ajcp-4886	101	3	conformer	conformer	NOUN
ajcp-4886	101	4	of	of	ADP
ajcp-4886	101	5	aβ42	aβ42	PROPN
ajcp-4886	101	6	,	,	PUNCT
ajcp-4886	101	7	with	with	ADP
ajcp-4886	101	8	a	a	DET
ajcp-4886	101	9	turn	turn	NOUN
ajcp-4886	101	10	at	at	ADP
ajcp-4886	101	11	positions	position	NOUN
ajcp-4886	101	12	22/23	22/23	NUM
ajcp-4886	101	13	,	,	PUNCT
ajcp-4886	101	14	and	and	CCONJ
ajcp-4886	101	15	the	the	DET
ajcp-4886	101	16	less	less	ADV
ajcp-4886	101	17	toxic	toxic	ADJ
ajcp-4886	101	18	conformer	conformer	NOUN
ajcp-4886	101	19	,	,	PUNCT
ajcp-4886	101	20	with	with	ADP
ajcp-4886	101	21	a	a	DET
ajcp-4886	101	22	turn	turn	NOUN
ajcp-4886	101	23	at	at	ADP
ajcp-4886	101	24	positions	position	NOUN
ajcp-4886	101	25	25/26	25/26	NUM
ajcp-4886	101	26	,	,	PUNCT
ajcp-4886	101	27	were	be	AUX
ajcp-4886	101	28	identified	identify	VERB
ajcp-4886	101	29	(	(	PUNCT
ajcp-4886	101	30	figure	figure	NOUN
ajcp-4886	101	31	3a	3a	NUM
ajcp-4886	101	32	)	)	PUNCT
ajcp-4886	101	33	through	through	ADP
ajcp-4886	101	34	systematic	systematic	ADJ
ajcp-4886	101	35	proline	proline	NOUN
ajcp-4886	101	36	replacement	replacement	NOUN
ajcp-4886	101	37	and	and	CCONJ
ajcp-4886	101	38	analyses	analysis	NOUN
ajcp-4886	101	39	using	use	VERB
ajcp-4886	101	40	solid	solid	ADJ
ajcp-4886	101	41	-	-	PUNCT
ajcp-4886	101	42	state	state	NOUN
ajcp-4886	101	43	nuclear	nuclear	ADJ
ajcp-4886	101	44	magnetic	magnetic	ADJ
ajcp-4886	101	45	resonance	resonance	NOUN
ajcp-4886	101	46	(	(	PUNCT
ajcp-4886	101	47	nmr	nmr	NOUN
ajcp-4886	101	48	)	)	PUNCT
ajcp-4886	101	49	spectroscopy	spectroscopy	NOUN
ajcp-4886	101	50	and	and	CCONJ
ajcp-4886	101	51	electron	electron	NOUN
ajcp-4886	101	52	spin	spin	NOUN
ajcp-4886	101	53	resonance	resonance	NOUN
ajcp-4886	101	54	(	(	PUNCT
ajcp-4886	101	55	esr	esr	PROPN
ajcp-4886	101	56	)	)	PUNCT
ajcp-4886	101	57	to	to	PART
ajcp-4886	101	58	gather	gather	VERB
ajcp-4886	101	59	information	information	NOUN
ajcp-4886	101	60	on	on	ADP
ajcp-4886	101	61	the	the	DET
ajcp-4886	101	62	secondary	secondary	ADJ
ajcp-4886	101	63	structure	structure	NOUN
ajcp-4886	101	64	of	of	ADP
ajcp-4886	101	65	aβ42	aβ42	PROPN
ajcp-4886	101	66	oligomers	oligomer	NOUN
ajcp-4886	101	67	and	and	CCONJ
ajcp-4886	101	68	fibrils	fibril	NOUN
ajcp-4886	101	69	.	.	PUNCT
ajcp-4886	102	1	the	the	DET
ajcp-4886	102	2	turn	turn	NOUN
ajcp-4886	102	3	at	at	ADP
ajcp-4886	102	4	positions	position	NOUN
ajcp-4886	102	5	22/23	22/23	NUM
ajcp-4886	102	6	is	be	AUX
ajcp-4886	102	7	one	one	NUM
ajcp-4886	102	8	of	of	ADP
ajcp-4886	102	9	the	the	DET
ajcp-4886	102	10	important	important	ADJ
ajcp-4886	102	11	secondary	secondary	ADJ
ajcp-4886	102	12	structures	structure	NOUN
ajcp-4886	102	13	of	of	ADP
ajcp-4886	102	14	aβ42	aβ42	PROPN
ajcp-4886	102	15	for	for	ADP
ajcp-4886	102	16	cytotoxicity	cytotoxicity	NOUN
ajcp-4886	102	17	and	and	CCONJ
ajcp-4886	102	18	aggregative	aggregative	ADJ
ajcp-4886	102	19	ability	ability	NOUN
ajcp-4886	102	20	,	,	PUNCT
ajcp-4886	102	21	as	as	SCONJ
ajcp-4886	102	22	was	be	AUX
ajcp-4886	102	23	previously	previously	ADV
ajcp-4886	102	24	mentioned	mention	VERB
ajcp-4886	102	25	.	.	PUNCT
ajcp-4886	103	1	we	we	PRON
ajcp-4886	103	2	performed	perform	VERB
ajcp-4886	103	3	cross	cross	ADJ
ajcp-4886	103	4	-	-	ADJ
ajcp-4886	103	5	linking	linking	NOUN
ajcp-4886	103	6	of	of	ADP
ajcp-4886	103	7	the	the	DET
ajcp-4886	103	8	residues	residue	NOUN
ajcp-4886	103	9	located	locate	VERB
ajcp-4886	103	10	at	at	ADP
ajcp-4886	103	11	aβ42	aβ42	PROPN
ajcp-4886	103	12	positions	position	NOUN
ajcp-4886	103	13	21/24	21/24	NUM
ajcp-4886	103	14	,	,	PUNCT
ajcp-4886	103	15	19/26	19/26	NUM
ajcp-4886	103	16	,	,	PUNCT
ajcp-4886	103	17	17/28	17/28	NUM
ajcp-4886	103	18	,	,	PUNCT
ajcp-4886	103	19	15/30	15/30	NUM
ajcp-4886	103	20	,	,	PUNCT
ajcp-4886	103	21	and	and	CCONJ
ajcp-4886	103	22	13/32	13/32	NUM
ajcp-4886	103	23	.	.	PUNCT
ajcp-4886	104	1	an	an	DET
ajcp-4886	104	2	intramolecular	intramolecular	ADJ
ajcp-4886	104	3	disulfide	disulfide	NOUN
ajcp-4886	104	4	bond	bond	NOUN
ajcp-4886	104	5	at	at	ADP
ajcp-4886	104	6	positions	position	NOUN
ajcp-4886	104	7	17/28	17/28	NUM
ajcp-4886	104	8	is	be	AUX
ajcp-4886	104	9	present	present	ADJ
ajcp-4886	104	10	in	in	ADP
ajcp-4886	104	11	the	the	DET
ajcp-4886	104	12	aβ42	aβ42	PROPN
ajcp-4886	104	13	analogue	analogue	NOUN
ajcp-4886	104	14	(	(	PUNCT
ajcp-4886	104	15	figure	figure	NOUN
ajcp-4886	104	16	3	3	NUM
ajcp-4886	104	17	)	)	PUNCT
ajcp-4886	104	18	(	(	PUNCT
ajcp-4886	104	19	matsushima	matsushima	PROPN
ajcp-4886	104	20	et	et	PROPN
ajcp-4886	104	21	al	al	PROPN
ajcp-4886	104	22	.	.	PROPN
ajcp-4886	104	23	,	,	PUNCT
ajcp-4886	104	24	2022	2022	NUM
ajcp-4886	104	25	)	)	PUNCT
ajcp-4886	104	26	.	.	PUNCT
ajcp-4886	105	1	mixtures	mixture	NOUN
ajcp-4886	105	2	of	of	ADP
ajcp-4886	105	3	diverse	diverse	ADJ
ajcp-4886	105	4	species	specie	NOUN
ajcp-4886	105	5	,	,	PUNCT
ajcp-4886	105	6	varying	vary	VERB
ajcp-4886	105	7	in	in	ADP
ajcp-4886	105	8	size	size	NOUN
ajcp-4886	105	9	from	from	ADP
ajcp-4886	105	10	tiny	tiny	ADJ
ajcp-4886	105	11	to	to	ADP
ajcp-4886	105	12	large	large	ADJ
ajcp-4886	105	13	,	,	PUNCT
ajcp-4886	105	14	make	make	VERB
ajcp-4886	105	15	up	up	ADP
ajcp-4886	105	16	aβos	aβos	NOUN
ajcp-4886	105	17	;	;	PUNCT
ajcp-4886	105	18	however	however	ADV
ajcp-4886	105	19	,	,	PUNCT
ajcp-4886	105	20	it	it	PRON
ajcp-4886	105	21	is	be	AUX
ajcp-4886	105	22	still	still	ADV
ajcp-4886	105	23	unclear	unclear	ADJ
ajcp-4886	105	24	which	which	PRON
ajcp-4886	105	25	species	specie	NOUN
ajcp-4886	105	26	are	be	AUX
ajcp-4886	105	27	the	the	DET
ajcp-4886	105	28	most	most	ADV
ajcp-4886	105	29	toxic	toxic	ADJ
ajcp-4886	105	30	(	(	PUNCT
ajcp-4886	105	31	araki	araki	PROPN
ajcp-4886	105	32	,	,	PUNCT
ajcp-4886	105	33	2023	2023	NUM
ajcp-4886	105	34	)	)	PUNCT
ajcp-4886	105	35	.	.	PUNCT
ajcp-4886	106	1	our	our	PRON
ajcp-4886	106	2	findings	finding	NOUN
ajcp-4886	106	3	,	,	PUNCT
ajcp-4886	106	4	along	along	ADP
ajcp-4886	106	5	with	with	ADP
ajcp-4886	106	6	numerous	numerous	ADJ
ajcp-4886	106	7	other	other	ADJ
ajcp-4886	106	8	in	in	ADP
ajcp-4886	106	9	vitro	vitro	X
ajcp-4886	106	10	and	and	CCONJ
ajcp-4886	106	11	in	in	ADP
ajcp-4886	106	12	vivo	vivo	ADJ
ajcp-4886	106	13	investigations	investigation	NOUN
ajcp-4886	106	14	,	,	PUNCT
ajcp-4886	106	15	corroborate	corroborate	VERB
ajcp-4886	106	16	the	the	DET
ajcp-4886	106	17	notion	notion	NOUN
ajcp-4886	106	18	that	that	SCONJ
ajcp-4886	106	19	aβos	aβos	PROPN
ajcp-4886	106	20	cause	cause	VERB
ajcp-4886	106	21	a	a	DET
ajcp-4886	106	22	range	range	NOUN
ajcp-4886	106	23	of	of	ADP
ajcp-4886	106	24	pathological	pathological	ADJ
ajcp-4886	106	25	changes	change	NOUN
ajcp-4886	106	26	,	,	PUNCT
ajcp-4886	106	27	such	such	ADJ
ajcp-4886	106	28	as	as	ADP
ajcp-4886	106	29	oxidative	oxidative	ADJ
ajcp-4886	106	30	stress	stress	NOUN
ajcp-4886	106	31	,	,	PUNCT
ajcp-4886	106	32	mitochondrial	mitochondrial	ADJ
ajcp-4886	106	33	dysfunction	dysfunction	NOUN
ajcp-4886	106	34	,	,	PUNCT
ajcp-4886	106	35	synaptic	synaptic	ADJ
ajcp-4886	106	36	deficits	deficit	NOUN
ajcp-4886	106	37	,	,	PUNCT
ajcp-4886	106	38	apoptosis	apoptosis	NOUN
ajcp-4886	106	39	,	,	PUNCT
ajcp-4886	106	40	aberrant	aberrant	ADJ
ajcp-4886	106	41	tau	tau	PROPN
ajcp-4886	106	42	alterations	alteration	NOUN
ajcp-4886	106	43	,	,	PUNCT
ajcp-4886	106	44	and	and	CCONJ
ajcp-4886	106	45	cognitive	cognitive	ADJ
ajcp-4886	106	46	impairments	impairment	NOUN
ajcp-4886	106	47	(	(	PUNCT
ajcp-4886	106	48	araki	araki	PROPN
ajcp-4886	106	49	&	&	CCONJ
ajcp-4886	106	50	kametani	kametani	PROPN
ajcp-4886	106	51	,	,	PUNCT
ajcp-4886	106	52	2022	2022	NUM
ajcp-4886	106	53	)	)	PUNCT
ajcp-4886	107	1	aβ	aβ	PRON
ajcp-4886	107	2	oligomers	oligomer	NOUN
ajcp-4886	107	3	may	may	AUX
ajcp-4886	107	4	be	be	AUX
ajcp-4886	107	5	involved	involve	VERB
ajcp-4886	107	6	in	in	ADP
ajcp-4886	107	7	ad	ad	NOUN
ajcp-4886	107	8	pathology	pathology	NOUN
ajcp-4886	107	9	in	in	ADP
ajcp-4886	107	10	a	a	DET
ajcp-4886	107	11	number	number	NOUN
ajcp-4886	107	12	of	of	ADP
ajcp-4886	107	13	ways	way	NOUN
ajcp-4886	107	14	,	,	PUNCT
ajcp-4886	107	15	such	such	ADJ
ajcp-4886	107	16	as	as	ADP
ajcp-4886	107	17	neuronal	neuronal	ADJ
ajcp-4886	107	18	toxicity	toxicity	NOUN
ajcp-4886	107	19	and	and	CCONJ
ajcp-4886	107	20	excitotoxicity	excitotoxicity	NOUN
ajcp-4886	107	21	caused	cause	VERB
ajcp-4886	107	22	by	by	ADP
ajcp-4886	107	23	constriction	constriction	NOUN
ajcp-4886	107	24	of	of	ADP
ajcp-4886	107	25	brain	brain	NOUN
ajcp-4886	107	26	blood	blood	NOUN
ajcp-4886	107	27	vessels	vessel	NOUN
ajcp-4886	107	28	due	due	ADJ
ajcp-4886	107	29	to	to	ADP
ajcp-4886	107	30	increased	increase	VERB
ajcp-4886	107	31	calcium	calcium	NOUN
ajcp-4886	107	32	levels	level	NOUN
ajcp-4886	107	33	.	.	PUNCT
ajcp-4886	108	1	ad	ad	NOUN
ajcp-4886	108	2	can	can	AUX
ajcp-4886	108	3	start	start	VERB
ajcp-4886	108	4	in	in	ADP
ajcp-4886	108	5	vivo	vivo	NOUN
ajcp-4886	108	6	and	and	CCONJ
ajcp-4886	108	7	in	in	ADP
ajcp-4886	108	8	vitro	vitro	X
ajcp-4886	108	9	when	when	SCONJ
ajcp-4886	108	10	small	small	ADJ
ajcp-4886	108	11	soluble	soluble	ADJ
ajcp-4886	108	12	aβ1	aβ1	NOUN
ajcp-4886	108	13	-	-	PUNCT
ajcp-4886	108	14	42	42	NUM
ajcp-4886	108	15	oligomers	oligomer	NOUN
ajcp-4886	108	16	cause	cause	VERB
ajcp-4886	108	17	neurotoxicity	neurotoxicity	NOUN
ajcp-4886	108	18	.	.	PUNCT
ajcp-4886	109	1	for	for	ADP
ajcp-4886	109	2	this	this	DET
ajcp-4886	109	3	reason	reason	NOUN
ajcp-4886	109	4	,	,	PUNCT
ajcp-4886	109	5	it	it	PRON
ajcp-4886	109	6	is	be	AUX
ajcp-4886	109	7	currently	currently	ADV
ajcp-4886	109	8	thought	think	VERB
ajcp-4886	109	9	that	that	SCONJ
ajcp-4886	109	10	aβ	aβ	PRON
ajcp-4886	109	11	oligomers	oligomer	NOUN
ajcp-4886	109	12	are	be	AUX
ajcp-4886	109	13	more	more	ADV
ajcp-4886	109	14	neurotoxic	neurotoxic	ADJ
ajcp-4886	109	15	and	and	CCONJ
ajcp-4886	109	16	disease	disease	NOUN
ajcp-4886	109	17	-	-	PUNCT
ajcp-4886	109	18	relevant	relevant	ADJ
ajcp-4886	109	19	than	than	ADP
ajcp-4886	109	20	aβ	aβ	DET
ajcp-4886	109	21	fibrils	fibril	NOUN
ajcp-4886	109	22	(	(	PUNCT
ajcp-4886	109	23	matuszyk	matuszyk	NOUN
ajcp-4886	109	24	et	et	PROPN
ajcp-4886	109	25	al	al	PROPN
ajcp-4886	109	26	.	.	PROPN
ajcp-4886	109	27	,	,	PUNCT
ajcp-4886	109	28	2021	2021	NUM
ajcp-4886	109	29	)	)	PUNCT
ajcp-4886	109	30	.	.	PUNCT
ajcp-4886	110	1	when	when	SCONJ
ajcp-4886	110	2	aβos	aβos	PROPN
ajcp-4886	110	3	binds	bind	VERB
ajcp-4886	110	4	to	to	ADP
ajcp-4886	110	5	different	different	ADJ
ajcp-4886	110	6	receptors	receptor	NOUN
ajcp-4886	110	7	on	on	ADP
ajcp-4886	110	8	the	the	DET
ajcp-4886	110	9	surface	surface	NOUN
ajcp-4886	110	10	of	of	ADP
ajcp-4886	110	11	neurons	neuron	NOUN
ajcp-4886	110	12	,	,	PUNCT
ajcp-4886	110	13	it	it	PRON
ajcp-4886	110	14	can	can	AUX
ajcp-4886	110	15	interfere	interfere	VERB
ajcp-4886	110	16	with	with	ADP
ajcp-4886	110	17	signaling	signal	VERB
ajcp-4886	110	18	pathways	pathway	NOUN
ajcp-4886	110	19	and	and	CCONJ
ajcp-4886	110	20	cause	cause	VERB
ajcp-4886	110	21	cells	cell	NOUN
ajcp-4886	110	22	to	to	PART
ajcp-4886	110	23	die	die	VERB
ajcp-4886	110	24	.	.	PUNCT
ajcp-4886	111	1	aβos	aβos	PROPN
ajcp-4886	111	2	recognizes	recognize	VERB
ajcp-4886	111	3	more	more	ADJ
ajcp-4886	111	4	than	than	ADP
ajcp-4886	111	5	20	20	NUM
ajcp-4886	111	6	receptors	receptor	NOUN
ajcp-4886	111	7	,	,	PUNCT
ajcp-4886	111	8	such	such	ADJ
ajcp-4886	111	9	as	as	ADP
ajcp-4886	111	10	β7nachr	β7nachr	PROPN
ajcp-4886	111	11	,	,	PUNCT
ajcp-4886	111	12	p75ntr	p75ntr	PROPN
ajcp-4886	111	13	,	,	PUNCT
ajcp-4886	111	14	prpc	prpc	ADJ
ajcp-4886	111	15	,	,	PUNCT
ajcp-4886	111	16	glutamate	glutamate	ADJ
ajcp-4886	111	17	receptors	receptor	NOUN
ajcp-4886	111	18	,	,	PUNCT
ajcp-4886	111	19	and	and	CCONJ
ajcp-4886	111	20	β2	β2	NOUN
ajcp-4886	111	21	-	-	PUNCT
ajcp-4886	111	22	ar	ar	PROPN
ajcp-4886	111	23	.	.	PROPN
ajcp-4886	111	24	app	app	PROPN
ajcp-4886	111	25	intracellular	intracellular	ADJ
ajcp-4886	111	26	domain	domain	NOUN
ajcp-4886	111	27	(	(	PUNCT
ajcp-4886	111	28	aicd	aicd	NOUN
ajcp-4886	111	29	)	)	PUNCT
ajcp-4886	111	30	production	production	NOUN
ajcp-4886	111	31	is	be	AUX
ajcp-4886	111	32	decreased	decrease	VERB
ajcp-4886	111	33	and	and	CCONJ
ajcp-4886	111	34	β	β	NOUN
ajcp-4886	111	35	-	-	ADJ
ajcp-4886	111	36	secretase	secretase	ADJ
ajcp-4886	111	37	activity	activity	NOUN
ajcp-4886	111	38	is	be	AUX
ajcp-4886	111	39	inhibited	inhibit	VERB
ajcp-4886	111	40	by	by	ADP
ajcp-4886	111	41	prpc	prpc	NOUN
ajcp-4886	111	42	,	,	PUNCT
ajcp-4886	111	43	an	an	DET
ajcp-4886	111	44	important	important	ADJ
ajcp-4886	111	45	protein	protein	NOUN
ajcp-4886	111	46	that	that	PRON
ajcp-4886	111	47	regulates	regulate	VERB
ajcp-4886	111	48	aβ	aβ	PRON
ajcp-4886	111	49	metabolism	metabolism	NOUN
ajcp-4886	111	50	in	in	ADP
ajcp-4886	111	51	vivo	vivo	NOUN
ajcp-4886	111	52	under	under	ADP
ajcp-4886	111	53	normal	normal	ADJ
ajcp-4886	111	54	physiological	physiological	ADJ
ajcp-4886	111	55	conditions	condition	NOUN
ajcp-4886	111	56	.	.	PUNCT
ajcp-4886	112	1	aβos	aβos	PROPN
ajcp-4886	112	2	,	,	PUNCT
ajcp-4886	112	3	on	on	ADP
ajcp-4886	112	4	the	the	DET
ajcp-4886	112	5	other	other	ADJ
ajcp-4886	112	6	hand	hand	NOUN
ajcp-4886	112	7	,	,	PUNCT
ajcp-4886	112	8	binds	bind	VERB
ajcp-4886	112	9	to	to	PART
ajcp-4886	112	10	prpc	prpc	NOUN
ajcp-4886	112	11	and	and	CCONJ
ajcp-4886	112	12	interferes	interfere	VERB
ajcp-4886	112	13	with	with	ADP
ajcp-4886	112	14	its	its	PRON
ajcp-4886	112	15	normal	normal	ADJ
ajcp-4886	112	16	physiological	physiological	ADJ
ajcp-4886	112	17	functions	function	NOUN
ajcp-4886	112	18	in	in	ADP
ajcp-4886	112	19	ad	ad	NOUN
ajcp-4886	112	20	brains	brain	NOUN
ajcp-4886	112	21	(	(	PUNCT
ajcp-4886	112	22	huang	huang	PROPN
ajcp-4886	112	23	&	&	CCONJ
ajcp-4886	112	24	liu	liu	PROPN
ajcp-4886	112	25	,	,	PUNCT
ajcp-4886	112	26	2020	2020	NUM
ajcp-4886	112	27	)	)	PUNCT
ajcp-4886	112	28	.	.	PUNCT
ajcp-4886	113	1	the	the	DET
ajcp-4886	113	2	majority	majority	NOUN
ajcp-4886	113	3	of	of	ADP
ajcp-4886	113	4	scientists	scientist	NOUN
ajcp-4886	113	5	believe	believe	VERB
ajcp-4886	113	6	that	that	SCONJ
ajcp-4886	113	7	aβ	aβ	PRON
ajcp-4886	113	8	oligomers	oligomer	NOUN
ajcp-4886	113	9	cause	cause	VERB
ajcp-4886	113	10	synaptotoxicity	synaptotoxicity	NOUN
ajcp-4886	113	11	by	by	ADP
ajcp-4886	113	12	activating	activate	VERB
ajcp-4886	113	13	metabotropic	metabotropic	NOUN
ajcp-4886	113	14	glutamate	glutamate	NOUN
ajcp-4886	113	15	receptor	receptor	NOUN
ajcp-4886	113	16	type	type	NOUN
ajcp-4886	113	17	5	5	NUM
ajcp-4886	113	18	(	(	PUNCT
ajcp-4886	113	19	mglur5	mglur5	NOUN
ajcp-4886	113	20	)	)	PUNCT
ajcp-4886	113	21	and	and	CCONJ
ajcp-4886	113	22	stimulating	stimulate	VERB
ajcp-4886	113	23	three	three	NUM
ajcp-4886	113	24	kinases	kinase	NOUN
ajcp-4886	113	25	that	that	PRON
ajcp-4886	113	26	inhibit	inhibit	VERB
ajcp-4886	113	27	ltp	ltp	PROPN
ajcp-4886	113	28	:	:	PUNCT
ajcp-4886	113	29	c	c	X
ajcp-4886	113	30	-	-	PUNCT
ajcp-4886	113	31	jun	jun	PROPN
ajcp-4886	113	32	n	n	CCONJ
ajcp-4886	113	33	-	-	PUNCT
ajcp-4886	113	34	terminal	terminal	ADJ
ajcp-4886	113	35	protein	protein	NOUN
ajcp-4886	113	36	kinase	kinase	NOUN
ajcp-4886	113	37	1	1	NUM
ajcp-4886	113	38	,	,	PUNCT
ajcp-4886	113	39	jnk1	jnk1	NOUN
ajcp-4886	113	40	;	;	PUNCT
ajcp-4886	113	41	cyclin	cyclin	NOUN
ajcp-4886	113	42	-	-	PUNCT
ajcp-4886	113	43	dependent	dependent	ADJ
ajcp-4886	113	44	kinase	kinase	NOUN
ajcp-4886	113	45	5	5	NUM
ajcp-4886	113	46	,	,	PUNCT
ajcp-4886	113	47	cdk5	cdk5	PROPN
ajcp-4886	113	48	;	;	PUNCT
ajcp-4886	113	49	and	and	CCONJ
ajcp-4886	113	50	p38	p38	NOUN
ajcp-4886	113	51	mitogen	mitogen	NOUN
ajcp-4886	113	52	-	-	PUNCT
ajcp-4886	113	53	activated	activate	VERB
ajcp-4886	113	54	protein	protein	NOUN
ajcp-4886	113	55	kinase	kinase	NOUN
ajcp-4886	113	56	,	,	PUNCT
ajcp-4886	113	57	p38	p38	NOUN
ajcp-4886	113	58	mapk	mapk	NOUN
ajcp-4886	113	59	(	(	PUNCT
ajcp-4886	113	60	diociaiuti	diociaiuti	NOUN
ajcp-4886	113	61	et	et	PROPN
ajcp-4886	113	62	al	al	PROPN
ajcp-4886	113	63	.	.	PROPN
ajcp-4886	113	64	,	,	PUNCT
ajcp-4886	113	65	2021	2021	NUM
ajcp-4886	113	66	)	)	PUNCT
ajcp-4886	113	67	.	.	PUNCT
ajcp-4886	114	1	the	the	DET
ajcp-4886	114	2	species	specie	NOUN
ajcp-4886	114	3	most	most	ADV
ajcp-4886	114	4	closely	closely	ADV
ajcp-4886	114	5	linked	link	VERB
ajcp-4886	114	6	to	to	ADP
ajcp-4886	114	7	the	the	DET
ajcp-4886	114	8	pathophysiology	pathophysiology	NOUN
ajcp-4886	114	9	of	of	ADP
ajcp-4886	114	10	ad	ad	NOUN
ajcp-4886	114	11	are	be	AUX
ajcp-4886	114	12	soluble	soluble	ADJ
ajcp-4886	114	13	aβ	aβ	ADP
ajcp-4886	114	14	oligomers	oligomer	NOUN
ajcp-4886	114	15	,	,	PUNCT
ajcp-4886	114	16	which	which	PRON
ajcp-4886	114	17	can	can	AUX
ajcp-4886	114	18	be	be	AUX
ajcp-4886	114	19	found	find	VERB
ajcp-4886	114	20	in	in	ADP
ajcp-4886	114	21	app	app	NOUN
ajcp-4886	114	22	transgenic	transgenic	NOUN
ajcp-4886	114	23	mice	mouse	NOUN
ajcp-4886	114	24	,	,	PUNCT
ajcp-4886	114	25	ad	ad	NOUN
ajcp-4886	114	26	patients	patient	NOUN
ajcp-4886	114	27	,	,	PUNCT
ajcp-4886	114	28	vitro	vitro	X
ajcp-4886	114	29	,	,	PUNCT
ajcp-4886	114	30	and	and	CCONJ
ajcp-4886	114	31	in	in	ADP
ajcp-4886	114	32	vivo	vivo	NOUN
ajcp-4886	114	33	in	in	ADP
ajcp-4886	114	34	a	a	DET
ajcp-4886	114	35	wide	wide	ADJ
ajcp-4886	114	36	variety	variety	NOUN
ajcp-4886	114	37	of	of	ADP
ajcp-4886	114	38	forms	form	NOUN
ajcp-4886	114	39	.	.	PUNCT
ajcp-4886	115	1	these	these	DET
ajcp-4886	115	2	diverse	diverse	ADJ
ajcp-4886	115	3	aβ	aβ	PRON
ajcp-4886	115	4	oligomer	oligomer	ADJ
ajcp-4886	115	5	types	type	NOUN
ajcp-4886	115	6	show	show	VERB
ajcp-4886	115	7	their	their	PRON
ajcp-4886	115	8	neurotoxic	neurotoxic	ADJ
ajcp-4886	115	9	effects	effect	NOUN
ajcp-4886	115	10	in	in	ADP
ajcp-4886	115	11	ad	ad	NOUN
ajcp-4886	115	12	via	via	ADP
ajcp-4886	115	13	multiple	multiple	ADJ
ajcp-4886	115	14	distinct	distinct	ADJ
ajcp-4886	115	15	mechanisms	mechanism	NOUN
ajcp-4886	115	16	(	(	PUNCT
ajcp-4886	115	17	madhu	madhu	PROPN
ajcp-4886	115	18	&	&	CCONJ
ajcp-4886	115	19	mukhopadhyay	mukhopadhyay	PROPN
ajcp-4886	115	20	,	,	PUNCT
ajcp-4886	115	21	2021	2021	NUM
ajcp-4886	115	22	)	)	PUNCT
ajcp-4886	115	23	.	.	PUNCT
ajcp-4886	116	1	the	the	DET
ajcp-4886	116	2	toxic	toxic	ADJ
ajcp-4886	116	3	influence	influence	NOUN
ajcp-4886	116	4	of	of	ADP
ajcp-4886	116	5	aβos	aβos	PROPN
ajcp-4886	116	6	has	have	AUX
ajcp-4886	116	7	been	be	AUX
ajcp-4886	116	8	extensively	extensively	ADV
ajcp-4886	116	9	studied	study	VERB
ajcp-4886	116	10	in	in	ADP
ajcp-4886	116	11	transgenic	transgenic	NOUN
ajcp-4886	116	12	animal	animal	NOUN
ajcp-4886	116	13	models	model	NOUN
ajcp-4886	116	14	,	,	PUNCT
ajcp-4886	116	15	ad	ad	NOUN
ajcp-4886	116	16	brain	brain	NOUN
ajcp-4886	116	17	tissues	tissue	NOUN
ajcp-4886	116	18	,	,	PUNCT
ajcp-4886	116	19	and	and	CCONJ
ajcp-4886	116	20	cell	cell	NOUN
ajcp-4886	116	21	cultures	culture	NOUN
ajcp-4886	116	22	.	.	PUNCT
ajcp-4886	117	1	numerous	numerous	ADJ
ajcp-4886	117	2	studies	study	NOUN
ajcp-4886	117	3	have	have	AUX
ajcp-4886	117	4	shown	show	VERB
ajcp-4886	117	5	that	that	SCONJ
ajcp-4886	117	6	amyloid	amyloid	NOUN
ajcp-4886	117	7	oligomers	oligomer	NOUN
ajcp-4886	117	8	of	of	ADP
ajcp-4886	117	9	different	different	ADJ
ajcp-4886	117	10	origins	origin	NOUN
ajcp-4886	117	11	can	can	AUX
ajcp-4886	117	12	cause	cause	VERB
ajcp-4886	117	13	alterations	alteration	NOUN
ajcp-4886	117	14	in	in	ADP
ajcp-4886	117	15	neurons	neuron	NOUN
ajcp-4886	117	16	.	.	PUNCT
ajcp-4886	118	1	aβos	aβos	PROPN
ajcp-4886	118	2	isolated	isolate	VERB
ajcp-4886	118	3	from	from	ADP
ajcp-4886	118	4	the	the	DET
ajcp-4886	118	5	brains	brain	NOUN
ajcp-4886	118	6	of	of	ADP
ajcp-4886	118	7	ad	ad	NOUN
ajcp-4886	118	8	patients	patient	NOUN
ajcp-4886	118	9	or	or	CCONJ
ajcp-4886	118	10	animal	animal	NOUN
ajcp-4886	118	11	models	model	NOUN
ajcp-4886	118	12	of	of	ADP
ajcp-4886	118	13	the	the	DET
ajcp-4886	118	14	disease	disease	NOUN
ajcp-4886	118	15	,	,	PUNCT
ajcp-4886	118	16	as	as	ADV
ajcp-4886	118	17	well	well	ADV
ajcp-4886	118	18	as	as	ADP
ajcp-4886	118	19	synthetic	synthetic	ADJ
ajcp-4886	118	20	peptides	peptide	NOUN
ajcp-4886	118	21	or	or	CCONJ
ajcp-4886	118	22	aβ	aβ	DET
ajcp-4886	118	23	species	specie	NOUN
ajcp-4886	118	24	secreted	secrete	VERB
ajcp-4886	118	25	in	in	ADP
ajcp-4886	118	26	cultured	cultured	ADJ
ajcp-4886	118	27	cells	cell	NOUN
ajcp-4886	118	28	(	(	PUNCT
ajcp-4886	118	29	mroczko	mroczko	PROPN
ajcp-4886	118	30	et	et	PROPN
ajcp-4886	118	31	al	al	PROPN
ajcp-4886	118	32	.	.	PROPN
ajcp-4886	118	33	,	,	PUNCT
ajcp-4886	118	34	2017	2017	NUM
ajcp-4886	118	35	)	)	PUNCT
ajcp-4886	118	36	.	.	PUNCT
ajcp-4886	119	1	in	in	ADP
ajcp-4886	119	2	summary	summary	NOUN
ajcp-4886	119	3	,	,	PUNCT
ajcp-4886	119	4	aβos	aβos	PROPN
ajcp-4886	119	5	have	have	AUX
ajcp-4886	119	6	been	be	AUX
ajcp-4886	119	7	observed	observe	VERB
ajcp-4886	119	8	to	to	PART
ajcp-4886	119	9	trigger	trigger	VERB
ajcp-4886	119	10	tau	tau	PROPN
ajcp-4886	119	11	pathology	pathology	NOUN
ajcp-4886	119	12	,	,	PUNCT
ajcp-4886	119	13	axonal	axonal	ADJ
ajcp-4886	119	14	transport	transport	NOUN
ajcp-4886	119	15	impairment	impairment	NOUN
ajcp-4886	119	16	,	,	PUNCT
ajcp-4886	119	17	loss	loss	NOUN
ajcp-4886	119	18	of	of	ADP
ajcp-4886	119	19	neuronal	neuronal	ADJ
ajcp-4886	119	20	polarity	polarity	NOUN
ajcp-4886	119	21	,	,	PUNCT
ajcp-4886	119	22	oxidative	oxidative	ADJ
ajcp-4886	119	23	stress	stress	NOUN
ajcp-4886	119	24	,	,	PUNCT
ajcp-4886	119	25	endoplasmic	endoplasmic	ADJ
ajcp-4886	119	26	reticulum	reticulum	NOUN
ajcp-4886	119	27	(	(	PUNCT
ajcp-4886	119	28	er	er	INTJ
ajcp-4886	119	29	)	)	PUNCT
ajcp-4886	119	30	stress	stress	NOUN
ajcp-4886	119	31	,	,	PUNCT
ajcp-4886	119	32	deterioration	deterioration	NOUN
ajcp-4886	119	33	of	of	ADP
ajcp-4886	119	34	synapses	synapsis	NOUN
ajcp-4886	119	35	,	,	PUNCT
ajcp-4886	119	36	insulin	insulin	NOUN
ajcp-4886	119	37	resistance	resistance	NOUN
ajcp-4886	119	38	,	,	PUNCT
ajcp-4886	119	39	neuroinflammation	neuroinflammation	NOUN
ajcp-4886	119	40	,	,	PUNCT
ajcp-4886	119	41	cholinergic	cholinergic	ADJ
ajcp-4886	119	42	impairment	impairment	NOUN
ajcp-4886	119	43	,	,	PUNCT
ajcp-4886	119	44	loss	loss	NOUN
ajcp-4886	119	45	of	of	ADP
ajcp-4886	119	46	trophic	trophic	ADJ
ajcp-4886	119	47	factors	factor	NOUN
ajcp-4886	119	48	,	,	PUNCT
ajcp-4886	119	49	epigenetic	epigenetic	ADJ
ajcp-4886	119	50	modifications	modification	NOUN
ajcp-4886	119	51	,	,	PUNCT
ajcp-4886	119	52	ectopic	ectopic	NOUN
ajcp-4886	119	53	mitosis	mitosis	NOUN
ajcp-4886	119	54	,	,	PUNCT
ajcp-4886	119	55	and	and	CCONJ
ajcp-4886	119	56	selective	selective	ADJ
ajcp-4886	119	57	death	death	NOUN
ajcp-4886	119	58	of	of	ADP
ajcp-4886	119	59	nerve	nerve	NOUN
ajcp-4886	119	60	cells	cell	NOUN
ajcp-4886	119	61	(	(	PUNCT
ajcp-4886	119	62	cline	cline	PROPN
ajcp-4886	119	63	et	et	PROPN
ajcp-4886	119	64	al	al	PROPN
ajcp-4886	119	65	.	.	PROPN
ajcp-4886	119	66	,	,	PUNCT
ajcp-4886	119	67	2018	2018	NUM
ajcp-4886	119	68	)	)	PUNCT
ajcp-4886	119	69	.	.	PUNCT
ajcp-4886	120	1	chemical	chemical	NOUN
ajcp-4886	120	2	regulation	regulation	NOUN
ajcp-4886	120	3	of	of	ADP
ajcp-4886	120	4	amyloid	amyloid	NOUN
ajcp-4886	120	5	-	-	PUNCT
ajcp-4886	120	6	β	β	NOUN
ajcp-4886	120	7	oligomerization	oligomerization	NOUN
ajcp-4886	120	8	alzheimer	alzheimer	PROPN
ajcp-4886	120	9	’s	’s	PART
ajcp-4886	120	10	disease	disease	NOUN
ajcp-4886	120	11	and	and	CCONJ
ajcp-4886	120	12	related	related	ADJ
ajcp-4886	120	13	illnesses	illness	NOUN
ajcp-4886	120	14	are	be	AUX
ajcp-4886	120	15	characterized	characterize	VERB
ajcp-4886	120	16	by	by	ADP
ajcp-4886	120	17	a	a	DET
ajcp-4886	120	18	pathogenic	pathogenic	ADJ
ajcp-4886	120	19	process	process	NOUN
ajcp-4886	120	20	called	call	VERB
ajcp-4886	120	21	amyloid	amyloid	NOUN
ajcp-4886	120	22	-	-	PUNCT
ajcp-4886	120	23	beta	beta	NOUN
ajcp-4886	120	24	aggregation	aggregation	NOUN
ajcp-4886	120	25	.	.	PUNCT
ajcp-4886	121	1	in	in	ADP
ajcp-4886	121	2	order	order	NOUN
ajcp-4886	121	3	to	to	PART
ajcp-4886	121	4	develop	develop	VERB
ajcp-4886	121	5	effective	effective	ADJ
ajcp-4886	121	6	treatments	treatment	NOUN
ajcp-4886	121	7	(	(	PUNCT
ajcp-4886	121	8	cline	cline	PROPN
ajcp-4886	121	9	et	et	PROPN
ajcp-4886	121	10	al	al	PROPN
ajcp-4886	121	11	.	.	PROPN
ajcp-4886	121	12	,	,	PUNCT
ajcp-4886	121	13	2018	2018	NUM
ajcp-4886	121	14	)	)	PUNCT
ajcp-4886	121	15	.	.	PUNCT
ajcp-4886	122	1	understanding	understand	VERB
ajcp-4886	122	2	how	how	SCONJ
ajcp-4886	122	3	this	this	DET
ajcp-4886	122	4	aggregation	aggregation	NOUN
ajcp-4886	122	5	is	be	AUX
ajcp-4886	122	6	made	make	VERB
ajcp-4886	122	7	is	be	AUX
ajcp-4886	122	8	crucial	crucial	ADJ
ajcp-4886	122	9	.	.	PUNCT
ajcp-4886	123	1	treatment	treatment	NOUN
ajcp-4886	123	2	options	option	NOUN
ajcp-4886	123	3	include	include	VERB
ajcp-4886	123	4	gal-201	gal-201	VERB
ajcp-4886	123	5	,	,	PUNCT
ajcp-4886	123	6	which	which	PRON
ajcp-4886	123	7	is	be	AUX
ajcp-4886	123	8	thought	think	VERB
ajcp-4886	123	9	figure	figure	NOUN
ajcp-4886	123	10	3	3	NUM
ajcp-4886	123	11	:	:	PUNCT
ajcp-4886	123	12	(	(	PUNCT
ajcp-4886	123	13	a	a	X
ajcp-4886	123	14	)	)	PUNCT
ajcp-4886	123	15	structure	structure	NOUN
ajcp-4886	123	16	of	of	ADP
ajcp-4886	123	17	toxic	toxic	ADJ
ajcp-4886	123	18	and	and	CCONJ
ajcp-4886	123	19	less	less	ADV
ajcp-4886	123	20	toxic	toxic	ADJ
ajcp-4886	123	21	conformers	conformer	NOUN
ajcp-4886	123	22	with	with	ADP
ajcp-4886	123	23	a	a	DET
ajcp-4886	123	24	turn	turn	NOUN
ajcp-4886	123	25	at	at	ADP
ajcp-4886	123	26	positions	position	NOUN
ajcp-4886	123	27	22/23	22/23	NUM
ajcp-4886	123	28	and	and	CCONJ
ajcp-4886	123	29	25/26	25/26	NUM
ajcp-4886	123	30	,	,	PUNCT
ajcp-4886	123	31	respectively.20	respectively.20	NOUN
ajcp-4886	123	32	(	(	PUNCT
ajcp-4886	123	33	b	b	NOUN
ajcp-4886	123	34	)	)	PUNCT
ajcp-4886	123	35	structure	structure	NOUN
ajcp-4886	123	36	of	of	ADP
ajcp-4886	123	37	cross	cross	ADJ
ajcp-4886	123	38	-	-	ADJ
ajcp-4886	123	39	linked	link	VERB
ajcp-4886	123	40	aβ42	aβ42	PROPN
ajcp-4886	123	41	analogues	analogue	NOUN
ajcp-4886	123	42	(	(	PUNCT
ajcp-4886	123	43	1–6	1–6	NUM
ajcp-4886	123	44	)	)	PUNCT
ajcp-4886	123	45	.	.	PUNCT
ajcp-4886	124	1	adopted	adopt	VERB
ajcp-4886	124	2	from	from	ADP
ajcp-4886	124	3	ref	ref	NOUN
ajcp-4886	124	4	(	(	PUNCT
ajcp-4886	124	5	matsushima	matsushima	PROPN
ajcp-4886	124	6	et	et	PROPN
ajcp-4886	124	7	al	al	PROPN
ajcp-4886	124	8	.	.	PROPN
ajcp-4886	124	9	,	,	PUNCT
ajcp-4886	124	10	2022	2022	NUM
ajcp-4886	124	11	)	)	PUNCT
ajcp-4886	124	12	role	role	NOUN
ajcp-4886	124	13	in	in	ADP
ajcp-4886	124	14	alzheimer	alzheimer	PROPN
ajcp-4886	124	15	’s	’s	PART
ajcp-4886	124	16	pathology	pathology	NOUN
ajcp-4886	124	17	it	it	PRON
ajcp-4886	124	18	is	be	AUX
ajcp-4886	124	19	widely	widely	ADV
ajcp-4886	124	20	acknowledged	acknowledge	VERB
ajcp-4886	124	21	that	that	SCONJ
ajcp-4886	124	22	aβos	aβos	PROPN
ajcp-4886	124	23	are	be	AUX
ajcp-4886	124	24	important	important	ADJ
ajcp-4886	124	25	players	player	NOUN
ajcp-4886	124	26	in	in	ADP
ajcp-4886	124	27	the	the	DET
ajcp-4886	124	28	pathogenetic	pathogenetic	ADJ
ajcp-4886	124	29	mechanisms	mechanism	NOUN
ajcp-4886	124	30	of	of	ADP
ajcp-4886	124	31	ad	ad	NOUN
ajcp-4886	124	32	because	because	SCONJ
ajcp-4886	124	33	of	of	ADP
ajcp-4886	124	34	their	their	PRON
ajcp-4886	124	35	capacity	capacity	NOUN
ajcp-4886	124	36	to	to	PART
ajcp-4886	124	37	cause	cause	VERB
ajcp-4886	124	38	neurotoxicity	neurotoxicity	NOUN
ajcp-4886	124	39	,	,	PUNCT
ajcp-4886	124	40	synaptotoxicity	synaptotoxicity	NOUN
ajcp-4886	124	41	,	,	PUNCT
ajcp-4886	124	42	and	and	CCONJ
ajcp-4886	124	43	neuroinflammation	neuroinflammation	NOUN
ajcp-4886	124	44	,	,	PUNCT
ajcp-4886	124	45	and	and	CCONJ
ajcp-4886	124	46	because	because	SCONJ
ajcp-4886	124	47	these	these	DET
ajcp-4886	124	48	effects	effect	NOUN
ajcp-4886	124	49	can	can	AUX
ajcp-4886	124	50	explain	explain	VERB
ajcp-4886	124	51	the	the	DET
ajcp-4886	124	52	neuropathological	neuropathological	ADJ
ajcp-4886	124	53	characteristics	characteristic	NOUN
ajcp-4886	124	54	of	of	ADP
ajcp-4886	124	55	ad	ad	NOUN
ajcp-4886	124	56	.	.	PUNCT
ajcp-4886	125	1	pa	pa	PROPN
ajcp-4886	125	2	ge	ge	PROPN
ajcp-4886	125	3	20	20	NUM
ajcp-4886	125	4	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-4886	125	5	am	be	AUX
ajcp-4886	125	6	.	.	PUNCT
ajcp-4886	126	1	j.	j.	PROPN
ajcp-4886	126	2	chem	chem	PROPN
ajcp-4886	126	3	.	.	PUNCT
ajcp-4886	127	1	pharm	pharm	PROPN
ajcp-4886	127	2	.	.	PUNCT
ajcp-4886	128	1	4(1	4(1	NOUN
ajcp-4886	128	2	)	)	PUNCT
ajcp-4886	129	1	16	16	NUM
ajcp-4886	129	2	-	-	SYM
ajcp-4886	129	3	28	28	NUM
ajcp-4886	129	4	,	,	PUNCT
ajcp-4886	129	5	2025	2025	NUM
ajcp-4886	129	6	to	to	PART
ajcp-4886	129	7	bind	bind	VERB
ajcp-4886	129	8	preferentially	preferentially	ADV
ajcp-4886	129	9	to	to	ADP
ajcp-4886	129	10	mis	mi	NOUN
ajcp-4886	129	11	-	-	PUNCT
ajcp-4886	129	12	folded	fold	VERB
ajcp-4886	129	13	aβ1	aβ1	NOUN
ajcp-4886	129	14	-	-	PUNCT
ajcp-4886	129	15	42	42	NUM
ajcp-4886	129	16	monomers	monomer	NOUN
ajcp-4886	129	17	.	.	PUNCT
ajcp-4886	130	1	this	this	DET
ajcp-4886	130	2	high	high	ADJ
ajcp-4886	130	3	-	-	PUNCT
ajcp-4886	130	4	affinity	affinity	NOUN
ajcp-4886	130	5	binding	bind	VERB
ajcp-4886	130	6	prevents	prevent	VERB
ajcp-4886	130	7	larger	large	ADJ
ajcp-4886	130	8	aggregates	aggregate	NOUN
ajcp-4886	130	9	and	and	CCONJ
ajcp-4886	130	10	harmful	harmful	ADJ
ajcp-4886	130	11	oligomers	oligomer	NOUN
ajcp-4886	130	12	from	from	ADP
ajcp-4886	130	13	forming	form	VERB
ajcp-4886	130	14	by	by	ADP
ajcp-4886	130	15	interfering	interfere	VERB
ajcp-4886	130	16	with	with	ADP
ajcp-4886	130	17	the	the	DET
ajcp-4886	130	18	aggregation	aggregation	NOUN
ajcp-4886	130	19	process	process	NOUN
ajcp-4886	130	20	.	.	PUNCT
ajcp-4886	131	1	through	through	ADP
ajcp-4886	131	2	its	its	PRON
ajcp-4886	131	3	ability	ability	NOUN
ajcp-4886	131	4	to	to	PART
ajcp-4886	131	5	inhibit	inhibit	VERB
ajcp-4886	131	6	aβ	aβ	DET
ajcp-4886	131	7	aggregation	aggregation	NOUN
ajcp-4886	131	8	,	,	PUNCT
ajcp-4886	131	9	gal-201	gal-201	VERB
ajcp-4886	131	10	may	may	AUX
ajcp-4886	131	11	be	be	AUX
ajcp-4886	131	12	able	able	ADJ
ajcp-4886	131	13	to	to	PART
ajcp-4886	131	14	prevent	prevent	VERB
ajcp-4886	131	15	or	or	CCONJ
ajcp-4886	131	16	slow	slow	VERB
ajcp-4886	131	17	the	the	DET
ajcp-4886	131	18	onset	onset	NOUN
ajcp-4886	131	19	of	of	ADP
ajcp-4886	131	20	amyloid	amyloid	NOUN
ajcp-4886	131	21	-	-	PUNCT
ajcp-4886	131	22	beta	beta	NOUN
ajcp-4886	131	23	-	-	PUNCT
ajcp-4886	131	24	related	relate	VERB
ajcp-4886	131	25	neurodegenerative	neurodegenerative	ADJ
ajcp-4886	131	26	diseases	disease	NOUN
ajcp-4886	131	27	,	,	PUNCT
ajcp-4886	131	28	such	such	ADJ
ajcp-4886	131	29	as	as	ADP
ajcp-4886	131	30	alzheimer	alzheimer	PROPN
ajcp-4886	131	31	’s	’s	PART
ajcp-4886	131	32	(	(	PUNCT
ajcp-4886	131	33	russ	russ	PROPN
ajcp-4886	131	34	et	et	PROPN
ajcp-4886	131	35	al	al	PROPN
ajcp-4886	131	36	.	.	PROPN
ajcp-4886	131	37	,	,	PUNCT
ajcp-4886	131	38	2022	2022	NUM
ajcp-4886	131	39	)	)	PUNCT
ajcp-4886	131	40	.	.	PUNCT
ajcp-4886	132	1	there	there	PRON
ajcp-4886	132	2	are	be	VERB
ajcp-4886	132	3	now	now	ADV
ajcp-4886	132	4	multiple	multiple	ADJ
ajcp-4886	132	5	strategies	strategy	NOUN
ajcp-4886	132	6	to	to	PART
ajcp-4886	132	7	combat	combat	VERB
ajcp-4886	132	8	the	the	DET
ajcp-4886	132	9	alzheimer’s	alzheimer’s	ADV
ajcp-4886	132	10	-	-	PUNCT
ajcp-4886	132	11	related	relate	VERB
ajcp-4886	132	12	aβ	aβ	NOUN
ajcp-4886	132	13	assemblies	assembly	NOUN
ajcp-4886	132	14	(	(	PUNCT
ajcp-4886	132	15	fish	fish	NOUN
ajcp-4886	132	16	et	et	PROPN
ajcp-4886	132	17	al	al	PROPN
ajcp-4886	132	18	.	.	PROPN
ajcp-4886	132	19	,	,	PUNCT
ajcp-4886	132	20	2019	2019	NUM
ajcp-4886	132	21	)	)	PUNCT
ajcp-4886	132	22	.	.	PUNCT
ajcp-4886	133	1	immunotherapeutic	immunotherapeutic	ADJ
ajcp-4886	133	2	vaccinations	vaccination	NOUN
ajcp-4886	133	3	,	,	PUNCT
ajcp-4886	133	4	antibodies	antibodie	VERB
ajcp-4886	133	5	,	,	PUNCT
ajcp-4886	133	6	peptides	peptide	NOUN
ajcp-4886	133	7	,	,	PUNCT
ajcp-4886	133	8	and	and	CCONJ
ajcp-4886	133	9	nanoparticles	nanoparticle	NOUN
ajcp-4886	133	10	are	be	AUX
ajcp-4886	133	11	a	a	DET
ajcp-4886	133	12	few	few	ADJ
ajcp-4886	133	13	of	of	ADP
ajcp-4886	133	14	the	the	DET
ajcp-4886	133	15	tactics	tactic	NOUN
ajcp-4886	133	16	.	.	PUNCT
ajcp-4886	134	1	many	many	ADJ
ajcp-4886	134	2	compounds	compound	NOUN
ajcp-4886	134	3	,	,	PUNCT
ajcp-4886	134	4	such	such	ADJ
ajcp-4886	134	5	as	as	ADP
ajcp-4886	134	6	congo	congo	PROPN
ajcp-4886	134	7	red	red	PROPN
ajcp-4886	134	8	,	,	PUNCT
ajcp-4886	134	9	lpffd	lpffd	PROPN
ajcp-4886	134	10	,	,	PUNCT
ajcp-4886	134	11	myricetin	myricetin	PROPN
ajcp-4886	134	12	,	,	PUNCT
ajcp-4886	134	13	melatonin	melatonin	NOUN
ajcp-4886	134	14	,	,	PUNCT
ajcp-4886	134	15	9,10	9,10	NUM
ajcp-4886	134	16	-	-	PUNCT
ajcp-4886	134	17	anthraquinone	anthraquinone	NOUN
ajcp-4886	134	18	,	,	PUNCT
ajcp-4886	134	19	trehalose	trehalose	INTJ
ajcp-4886	134	20	,	,	PUNCT
ajcp-4886	134	21	thioflavin	thioflavin	PROPN
ajcp-4886	134	22	t	t	PROPN
ajcp-4886	134	23	,	,	PUNCT
ajcp-4886	134	24	n	n	CCONJ
ajcp-4886	134	25	-	-	PUNCT
ajcp-4886	134	26	methylated	methylate	VERB
ajcp-4886	134	27	peptides	peptide	NOUN
ajcp-4886	134	28	,	,	PUNCT
ajcp-4886	134	29	polyphenol	polyphenol	NOUN
ajcp-4886	134	30	egcg	egcg	NOUN
ajcp-4886	134	31	,	,	PUNCT
ajcp-4886	134	32	ibuprofen	ibuprofen	NOUN
ajcp-4886	134	33	,	,	PUNCT
ajcp-4886	134	34	naproxen	naproxen	NOUN
ajcp-4886	134	35	,	,	PUNCT
ajcp-4886	134	36	morin	morin	NOUN
ajcp-4886	134	37	,	,	PUNCT
ajcp-4886	134	38	and	and	CCONJ
ajcp-4886	134	39	particular	particular	ADJ
ajcp-4886	134	40	polyphenolic	polyphenolic	ADJ
ajcp-4886	134	41	compounds	compound	NOUN
ajcp-4886	134	42	,	,	PUNCT
ajcp-4886	134	43	have	have	AUX
ajcp-4886	134	44	shown	show	VERB
ajcp-4886	134	45	promise	promise	NOUN
ajcp-4886	134	46	in	in	ADP
ajcp-4886	134	47	blocking	block	VERB
ajcp-4886	134	48	aβ	aβ	DET
ajcp-4886	134	49	aggregation	aggregation	NOUN
ajcp-4886	134	50	and	and	CCONJ
ajcp-4886	134	51	upsetting	upsetting	ADJ
ajcp-4886	134	52	beta	beta	ADJ
ajcp-4886	134	53	sheet	sheet	NOUN
ajcp-4886	134	54	structures	structure	NOUN
ajcp-4886	134	55	(	(	PUNCT
ajcp-4886	134	56	grasso	grasso	PROPN
ajcp-4886	134	57	&	&	CCONJ
ajcp-4886	134	58	danani	danani	PROPN
ajcp-4886	134	59	,	,	PUNCT
ajcp-4886	134	60	2020	2020	NUM
ajcp-4886	134	61	)	)	PUNCT
ajcp-4886	134	62	.	.	PUNCT
ajcp-4886	135	1	plants	plant	NOUN
ajcp-4886	135	2	like	like	ADP
ajcp-4886	135	3	berries	berry	NOUN
ajcp-4886	135	4	and	and	CCONJ
ajcp-4886	135	5	grapes	grape	NOUN
ajcp-4886	135	6	contain	contain	VERB
ajcp-4886	135	7	a	a	DET
ajcp-4886	135	8	polyphenolic	polyphenolic	ADJ
ajcp-4886	135	9	flavonoid	flavonoid	NOUN
ajcp-4886	135	10	called	call	VERB
ajcp-4886	135	11	myricetin	myricetin	PROPN
ajcp-4886	135	12	,	,	PUNCT
ajcp-4886	135	13	which	which	PRON
ajcp-4886	135	14	has	have	VERB
ajcp-4886	135	15	a	a	DET
ajcp-4886	135	16	variety	variety	NOUN
ajcp-4886	135	17	of	of	ADP
ajcp-4886	135	18	biological	biological	ADJ
ajcp-4886	135	19	activities	activity	NOUN
ajcp-4886	135	20	such	such	ADJ
ajcp-4886	135	21	as	as	ADP
ajcp-4886	135	22	antibacterial	antibacterial	ADJ
ajcp-4886	135	23	,	,	PUNCT
ajcp-4886	135	24	anti	anti	ADJ
ajcp-4886	135	25	-	-	ADJ
ajcp-4886	135	26	inflammatory	inflammatory	ADJ
ajcp-4886	135	27	,	,	PUNCT
ajcp-4886	135	28	and	and	CCONJ
ajcp-4886	135	29	antioxidant	antioxidant	ADJ
ajcp-4886	135	30	properties	property	NOUN
ajcp-4886	135	31	.	.	PUNCT
ajcp-4886	136	1	inhibition	inhibition	NOUN
ajcp-4886	136	2	of	of	ADP
ajcp-4886	136	3	aβ	aβ	PRON
ajcp-4886	136	4	oligomerization	oligomerization	NOUN
ajcp-4886	136	5	by	by	ADP
ajcp-4886	136	6	myricetin	myricetin	NOUN
ajcp-4886	136	7	has	have	AUX
ajcp-4886	136	8	also	also	ADV
ajcp-4886	136	9	been	be	AUX
ajcp-4886	136	10	demonstrated	demonstrate	VERB
ajcp-4886	136	11	(	(	PUNCT
ajcp-4886	136	12	araki	araki	PROPN
ajcp-4886	136	13	&	&	CCONJ
ajcp-4886	136	14	kametani	kametani	PROPN
ajcp-4886	136	15	,	,	PUNCT
ajcp-4886	136	16	2022	2022	NUM
ajcp-4886	136	17	)	)	PUNCT
ajcp-4886	136	18	.	.	PUNCT
ajcp-4886	137	1	anti	anti	ADJ
ajcp-4886	137	2	-	-	ADJ
ajcp-4886	137	3	aβ	aβ	ADJ
ajcp-4886	137	4	monoclonal	monoclonal	NOUN
ajcp-4886	137	5	antibodies	antibody	NOUN
ajcp-4886	137	6	have	have	VERB
ajcp-4886	137	7	the	the	DET
ajcp-4886	137	8	ability	ability	NOUN
ajcp-4886	137	9	to	to	PART
ajcp-4886	137	10	stop	stop	VERB
ajcp-4886	137	11	aβ	aβ	PRON
ajcp-4886	137	12	monomers	monomer	NOUN
ajcp-4886	137	13	from	from	ADP
ajcp-4886	137	14	forming	form	VERB
ajcp-4886	137	15	fibrillar	fibrillar	ADJ
ajcp-4886	137	16	aggregates	aggregate	NOUN
ajcp-4886	137	17	in	in	ADP
ajcp-4886	137	18	vitro	vitro	NOUN
ajcp-4886	137	19	and	and	CCONJ
ajcp-4886	137	20	to	to	PART
ajcp-4886	137	21	change	change	VERB
ajcp-4886	137	22	fibrillar	fibrillar	ADJ
ajcp-4886	137	23	aggregates	aggregate	NOUN
ajcp-4886	137	24	into	into	ADP
ajcp-4886	137	25	an	an	DET
ajcp-4886	137	26	amorphous	amorphous	ADJ
ajcp-4886	137	27	form	form	NOUN
ajcp-4886	137	28	.	.	PUNCT
ajcp-4886	138	1	it	it	PRON
ajcp-4886	138	2	’s	’	VERB
ajcp-4886	138	3	interesting	interesting	ADJ
ajcp-4886	138	4	to	to	PART
ajcp-4886	138	5	note	note	VERB
ajcp-4886	138	6	that	that	SCONJ
ajcp-4886	138	7	these	these	DET
ajcp-4886	138	8	mechanisms	mechanism	NOUN
ajcp-4886	138	9	’	'	PUNCT
ajcp-4886	138	10	effectiveness	effectiveness	NOUN
ajcp-4886	138	11	is	be	AUX
ajcp-4886	138	12	influenced	influence	VERB
ajcp-4886	138	13	by	by	ADP
ajcp-4886	138	14	antibody	antibody	NOUN
ajcp-4886	138	15	concentration	concentration	NOUN
ajcp-4886	138	16	(	(	PUNCT
ajcp-4886	138	17	mantile	mantile	PROPN
ajcp-4886	138	18	&	&	CCONJ
ajcp-4886	138	19	prisco	prisco	PROPN
ajcp-4886	138	20	,	,	PUNCT
ajcp-4886	138	21	2020	2020	NUM
ajcp-4886	138	22	)	)	PUNCT
ajcp-4886	138	23	.	.	PUNCT
ajcp-4886	139	1	there	there	PRON
ajcp-4886	139	2	have	have	AUX
ajcp-4886	139	3	been	be	AUX
ajcp-4886	139	4	reports	report	NOUN
ajcp-4886	139	5	of	of	ADP
ajcp-4886	139	6	certain	certain	ADJ
ajcp-4886	139	7	anti	anti	ADJ
ajcp-4886	139	8	-	-	ADJ
ajcp-4886	139	9	aβ	aβ	ADJ
ajcp-4886	139	10	antibodies	antibody	NOUN
ajcp-4886	139	11	binding	bind	VERB
ajcp-4886	139	12	directly	directly	ADV
ajcp-4886	139	13	to	to	ADP
ajcp-4886	139	14	aβ	aβ	PROPN
ajcp-4886	139	15	,	,	PUNCT
ajcp-4886	139	16	which	which	PRON
ajcp-4886	139	17	either	either	CCONJ
ajcp-4886	139	18	dissolve	dissolve	VERB
ajcp-4886	139	19	aβ	aβ	DET
ajcp-4886	139	20	aggregates	aggregate	NOUN
ajcp-4886	139	21	in	in	ADP
ajcp-4886	139	22	vitro	vitro	X
ajcp-4886	139	23	or	or	CCONJ
ajcp-4886	139	24	prevents	prevent	VERB
ajcp-4886	139	25	aβ	aβ	NOUN
ajcp-4886	139	26	from	from	ADP
ajcp-4886	139	27	oligomerizing	oligomerize	VERB
ajcp-4886	139	28	and	and	CCONJ
ajcp-4886	139	29	forming	form	VERB
ajcp-4886	139	30	fibrils	fibril	NOUN
ajcp-4886	139	31	.	.	PUNCT
ajcp-4886	140	1	particular	particular	ADJ
ajcp-4886	141	1	aβ	aβ	VERB
ajcp-4886	141	2	antibodies	antibody	NOUN
ajcp-4886	141	3	with	with	ADP
ajcp-4886	141	4	specific	specific	ADJ
ajcp-4886	141	5	conformations	conformation	NOUN
ajcp-4886	141	6	target	target	NOUN
ajcp-4886	141	7	pre	pre	ADJ
ajcp-4886	141	8	-	-	ADJ
ajcp-4886	141	9	existing	exist	VERB
ajcp-4886	141	10	brain	brain	NOUN
ajcp-4886	141	11	plaques	plaque	NOUN
ajcp-4886	141	12	and	and	CCONJ
ajcp-4886	141	13	cause	cause	VERB
ajcp-4886	141	14	direct	direct	ADJ
ajcp-4886	141	15	in	in	ADP
ajcp-4886	141	16	vivo	vivo	ADJ
ajcp-4886	141	17	disintegration	disintegration	NOUN
ajcp-4886	141	18	.	.	PUNCT
ajcp-4886	142	1	according	accord	VERB
ajcp-4886	142	2	to	to	ADP
ajcp-4886	142	3	these	these	DET
ajcp-4886	142	4	results	result	NOUN
ajcp-4886	142	5	,	,	PUNCT
ajcp-4886	142	6	aβ	aβ	DET
ajcp-4886	142	7	aggregation	aggregation	NOUN
ajcp-4886	142	8	may	may	AUX
ajcp-4886	142	9	be	be	AUX
ajcp-4886	142	10	impacted	impact	VERB
ajcp-4886	142	11	by	by	ADP
ajcp-4886	142	12	the	the	DET
ajcp-4886	142	13	direct	direct	ADJ
ajcp-4886	142	14	interaction	interaction	NOUN
ajcp-4886	142	15	of	of	ADP
ajcp-4886	142	16	anti	anti	ADJ
ajcp-4886	142	17	-	-	ADJ
ajcp-4886	142	18	aβ	aβ	ADJ
ajcp-4886	142	19	antibodies	antibodie	VERB
ajcp-4886	142	20	with	with	ADP
ajcp-4886	142	21	aβ	aβ	PRON
ajcp-4886	142	22	in	in	ADP
ajcp-4886	142	23	both	both	PRON
ajcp-4886	142	24	vitro	vitro	X
ajcp-4886	142	25	and	and	CCONJ
ajcp-4886	142	26	in	in	ADP
ajcp-4886	142	27	vivo	vivo	ADJ
ajcp-4886	142	28	settings	setting	NOUN
ajcp-4886	142	29	(	(	PUNCT
ajcp-4886	142	30	liu	liu	PROPN
ajcp-4886	142	31	et	et	PROPN
ajcp-4886	142	32	al	al	PROPN
ajcp-4886	142	33	.	.	PROPN
ajcp-4886	142	34	,	,	PUNCT
ajcp-4886	142	35	2025	2025	NUM
ajcp-4886	142	36	)	)	PUNCT
ajcp-4886	142	37	.	.	PUNCT
ajcp-4886	143	1	a	a	DET
ajcp-4886	143	2	phase	phase	NOUN
ajcp-4886	143	3	iii	iii	NUM
ajcp-4886	143	4	clinical	clinical	ADJ
ajcp-4886	143	5	trial	trial	NOUN
ajcp-4886	143	6	for	for	ADP
ajcp-4886	143	7	four	four	NUM
ajcp-4886	143	8	monoclonal	monoclonal	NOUN
ajcp-4886	143	9	anti	anti	ADJ
ajcp-4886	143	10	-	-	ADJ
ajcp-4886	143	11	aβ	aβ	ADJ
ajcp-4886	143	12	antibodies	antibody	NOUN
ajcp-4886	143	13	—	—	PUNCT
ajcp-4886	143	14	adecaluzumab	adecaluzumab	NOUN
ajcp-4886	143	15	,	,	PUNCT
ajcp-4886	143	16	ban2401	ban2401	NOUN
ajcp-4886	143	17	,	,	PUNCT
ajcp-4886	143	18	gantenerumab	gantenerumab	NOUN
ajcp-4886	143	19	,	,	PUNCT
ajcp-4886	143	20	and	and	CCONJ
ajcp-4886	143	21	solanezumab	solanezumab	NOUN
ajcp-4886	143	22	—	—	PUNCT
ajcp-4886	143	23	has	have	AUX
ajcp-4886	143	24	begun	begin	VERB
ajcp-4886	143	25	,	,	PUNCT
ajcp-4886	143	26	according	accord	VERB
ajcp-4886	143	27	to	to	ADP
ajcp-4886	143	28	a	a	DET
ajcp-4886	143	29	recent	recent	ADJ
ajcp-4886	143	30	study	study	NOUN
ajcp-4886	143	31	.	.	PUNCT
ajcp-4886	144	1	aducanumab	aducanumab	NOUN
ajcp-4886	144	2	is	be	AUX
ajcp-4886	144	3	a	a	DET
ajcp-4886	144	4	human	human	ADJ
ajcp-4886	144	5	igg1	igg1	NOUN
ajcp-4886	144	6	antibody	antibody	NOUN
ajcp-4886	144	7	that	that	PRON
ajcp-4886	144	8	targets	target	VERB
ajcp-4886	144	9	only	only	ADV
ajcp-4886	144	10	soluble	soluble	ADJ
ajcp-4886	144	11	oligomers	oligomer	NOUN
ajcp-4886	144	12	and	and	CCONJ
ajcp-4886	144	13	insoluble	insoluble	ADJ
ajcp-4886	144	14	fibrils	fibril	NOUN
ajcp-4886	144	15	of	of	ADP
ajcp-4886	144	16	aβ	aβ	NOUN
ajcp-4886	144	17	.	.	PUNCT
ajcp-4886	145	1	it	it	PRON
ajcp-4886	145	2	was	be	AUX
ajcp-4886	145	3	chosen	choose	VERB
ajcp-4886	145	4	through	through	ADP
ajcp-4886	145	5	memory	memory	NOUN
ajcp-4886	145	6	b	b	PROPN
ajcp-4886	145	7	cell	cell	NOUN
ajcp-4886	145	8	screening	screen	VERB
ajcp-4886	145	9	in	in	ADP
ajcp-4886	145	10	healthy	healthy	ADJ
ajcp-4886	145	11	elderly	elderly	ADJ
ajcp-4886	145	12	individuals	individual	NOUN
ajcp-4886	145	13	(	(	PUNCT
ajcp-4886	145	14	panza	panza	NOUN
ajcp-4886	145	15	et	et	PROPN
ajcp-4886	145	16	al	al	PROPN
ajcp-4886	145	17	.	.	PROPN
ajcp-4886	145	18	,	,	PUNCT
ajcp-4886	145	19	2025	2025	NUM
ajcp-4886	145	20	)	)	PUNCT
ajcp-4886	145	21	.	.	PUNCT
ajcp-4886	146	1	the	the	DET
ajcp-4886	146	2	fda	fda	PROPN
ajcp-4886	146	3	has	have	AUX
ajcp-4886	146	4	recently	recently	ADV
ajcp-4886	146	5	approved	approve	VERB
ajcp-4886	146	6	it	it	PRON
ajcp-4886	146	7	as	as	ADP
ajcp-4886	146	8	an	an	DET
ajcp-4886	146	9	immunotherapy	immunotherapy	NOUN
ajcp-4886	146	10	for	for	ADP
ajcp-4886	146	11	ad	ad	NOUN
ajcp-4886	146	12	.	.	PUNCT
ajcp-4886	146	13	aducanumab	aducanumab	NOUN
ajcp-4886	146	14	(	(	PUNCT
ajcp-4886	146	15	biib037	biib037	PROPN
ajcp-4886	146	16	)	)	PUNCT
ajcp-4886	146	17	is	be	AUX
ajcp-4886	146	18	a	a	DET
ajcp-4886	146	19	monoclonal	monoclonal	NOUN
ajcp-4886	146	20	antibody	antibody	NOUN
ajcp-4886	146	21	of	of	ADP
ajcp-4886	146	22	human	human	ADJ
ajcp-4886	146	23	igg1	igg1	NOUN
ajcp-4886	146	24	that	that	PRON
ajcp-4886	146	25	forms	form	VERB
ajcp-4886	146	26	an	an	DET
ajcp-4886	146	27	extended	extended	ADJ
ajcp-4886	146	28	conformation	conformation	NOUN
ajcp-4886	146	29	with	with	ADP
ajcp-4886	146	30	the	the	DET
ajcp-4886	146	31	n	n	DET
ajcp-4886	146	32	terminus	terminus	NOUN
ajcp-4886	146	33	of	of	ADP
ajcp-4886	146	34	aβ	aβ	NOUN
ajcp-4886	146	35	.	.	PUNCT
ajcp-4886	147	1	it	it	PRON
ajcp-4886	147	2	targets	target	VERB
ajcp-4886	147	3	aggregates	aggregate	NOUN
ajcp-4886	147	4	of	of	ADP
ajcp-4886	147	5	aβ	aβ	NOUN
ajcp-4886	147	6	,	,	PUNCT
ajcp-4886	147	7	including	include	VERB
ajcp-4886	147	8	insoluble	insoluble	ADJ
ajcp-4886	147	9	fibrils	fibril	NOUN
ajcp-4886	147	10	and	and	CCONJ
ajcp-4886	147	11	soluble	soluble	ADJ
ajcp-4886	147	12	oligomers	oligomer	NOUN
ajcp-4886	147	13	(	(	PUNCT
ajcp-4886	147	14	song	song	NOUN
ajcp-4886	147	15	et	et	PROPN
ajcp-4886	147	16	al	al	PROPN
ajcp-4886	147	17	.	.	PROPN
ajcp-4886	147	18	,	,	PUNCT
ajcp-4886	147	19	2022	2022	NUM
ajcp-4886	147	20	)	)	PUNCT
ajcp-4886	147	21	.	.	PUNCT
ajcp-4886	148	1	using	use	VERB
ajcp-4886	148	2	molecular	molecular	ADJ
ajcp-4886	148	3	docking	docking	NOUN
ajcp-4886	148	4	,	,	PUNCT
ajcp-4886	148	5	the	the	DET
ajcp-4886	148	6	virtual	virtual	ADJ
ajcp-4886	148	7	peptide	peptide	NOUN
ajcp-4886	148	8	p21	p21	NOUN
ajcp-4886	148	9	is	be	AUX
ajcp-4886	148	10	able	able	ADJ
ajcp-4886	148	11	to	to	PART
ajcp-4886	148	12	effectively	effectively	ADV
ajcp-4886	148	13	inhibit	inhibit	VERB
ajcp-4886	148	14	the	the	DET
ajcp-4886	148	15	aggregation	aggregation	NOUN
ajcp-4886	148	16	of	of	ADP
ajcp-4886	148	17	aβ1	aβ1	NOUN
ajcp-4886	148	18	-	-	PUNCT
ajcp-4886	148	19	42	42	NUM
ajcp-4886	148	20	proteins	protein	NOUN
ajcp-4886	148	21	,	,	PUNCT
ajcp-4886	148	22	thereby	thereby	ADV
ajcp-4886	148	23	decreasing	decrease	VERB
ajcp-4886	148	24	neurotoxicity	neurotoxicity	NOUN
ajcp-4886	148	25	(	(	PUNCT
ajcp-4886	148	26	wu	wu	PROPN
ajcp-4886	148	27	et	et	PROPN
ajcp-4886	148	28	al	al	PROPN
ajcp-4886	148	29	.	.	PROPN
ajcp-4886	148	30	,	,	PUNCT
ajcp-4886	148	31	2023	2023	NUM
ajcp-4886	148	32	)	)	PUNCT
ajcp-4886	148	33	.	.	PUNCT
ajcp-4886	149	1	two	two	NUM
ajcp-4886	149	2	classes	class	NOUN
ajcp-4886	149	3	of	of	ADP
ajcp-4886	149	4	poly	poly	ADJ
ajcp-4886	149	5	-	-	PUNCT
ajcp-4886	149	6	phenols	phenol	NOUN
ajcp-4886	149	7	inhibit	inhibit	VERB
ajcp-4886	149	8	the	the	DET
ajcp-4886	149	9	aggregation	aggregation	NOUN
ajcp-4886	149	10	of	of	ADP
ajcp-4886	149	11	aβ	aβ	PRON
ajcp-4886	149	12	in	in	ADP
ajcp-4886	149	13	distinct	distinct	ADJ
ajcp-4886	149	14	ways	way	NOUN
ajcp-4886	149	15	.	.	PUNCT
ajcp-4886	150	1	on	on	ADP
ajcp-4886	150	2	the	the	DET
ajcp-4886	150	3	one	one	NUM
ajcp-4886	150	4	hand	hand	NOUN
ajcp-4886	150	5	,	,	PUNCT
ajcp-4886	150	6	flavonoids	flavonoid	NOUN
ajcp-4886	150	7	led	lead	VERB
ajcp-4886	150	8	to	to	ADP
ajcp-4886	150	9	the	the	DET
ajcp-4886	150	10	formation	formation	NOUN
ajcp-4886	150	11	of	of	ADP
ajcp-4886	150	12	spherical	spherical	ADJ
ajcp-4886	150	13	,	,	PUNCT
ajcp-4886	150	14	unstructured	unstructured	ADJ
ajcp-4886	150	15	aggregates	aggregate	NOUN
ajcp-4886	150	16	and	and	CCONJ
ajcp-4886	150	17	completely	completely	ADV
ajcp-4886	150	18	inhibited	inhibit	VERB
ajcp-4886	150	19	the	the	DET
ajcp-4886	150	20	fibrillation	fibrillation	NOUN
ajcp-4886	150	21	of	of	ADP
ajcp-4886	150	22	aβ	aβ	DET
ajcp-4886	150	23	monomers	monomer	NOUN
ajcp-4886	150	24	.	.	PUNCT
ajcp-4886	151	1	conversely	conversely	ADV
ajcp-4886	151	2	,	,	PUNCT
ajcp-4886	151	3	stilbenes	stilbene	NOUN
ajcp-4886	151	4	suppressed	suppress	VERB
ajcp-4886	151	5	aβ	aβ	DET
ajcp-4886	151	6	aggregation	aggregation	NOUN
ajcp-4886	151	7	,	,	PUNCT
ajcp-4886	151	8	although	although	SCONJ
ajcp-4886	151	9	to	to	ADP
ajcp-4886	151	10	a	a	DET
ajcp-4886	151	11	much	much	ADV
ajcp-4886	151	12	smaller	small	ADJ
ajcp-4886	151	13	degree	degree	NOUN
ajcp-4886	151	14	.	.	PUNCT
ajcp-4886	152	1	remarkably	remarkably	ADV
ajcp-4886	152	2	,	,	PUNCT
ajcp-4886	152	3	the	the	DET
ajcp-4886	152	4	common	common	ADJ
ajcp-4886	152	5	stilbene	stilbene	NOUN
ajcp-4886	152	6	resveratrol	resveratrol	NOUN
ajcp-4886	152	7	speed	speed	NOUN
ajcp-4886	152	8	up	up	ADP
ajcp-4886	152	9	the	the	DET
ajcp-4886	152	10	production	production	NOUN
ajcp-4886	152	11	of	of	ADP
ajcp-4886	152	12	aβ	aβ	NOUN
ajcp-4886	152	13	fibrils	fibril	NOUN
ajcp-4886	152	14	(	(	PUNCT
ajcp-4886	152	15	phan	phan	PROPN
ajcp-4886	152	16	et	et	PROPN
ajcp-4886	152	17	al	al	PROPN
ajcp-4886	152	18	.	.	PROPN
ajcp-4886	152	19	,	,	PUNCT
ajcp-4886	152	20	2019	2019	NUM
ajcp-4886	152	21	)	)	PUNCT
ajcp-4886	152	22	.	.	PUNCT
ajcp-4886	153	1	metal	metal	NOUN
ajcp-4886	153	2	ions	ion	NOUN
ajcp-4886	153	3	have	have	AUX
ajcp-4886	153	4	been	be	AUX
ajcp-4886	153	5	shown	show	VERB
ajcp-4886	153	6	to	to	PART
ajcp-4886	153	7	either	either	CCONJ
ajcp-4886	153	8	accelerate	accelerate	VERB
ajcp-4886	153	9	or	or	CCONJ
ajcp-4886	153	10	slow	slow	VERB
ajcp-4886	153	11	down	down	ADP
ajcp-4886	153	12	aβ	aβ	DET
ajcp-4886	153	13	aggregation	aggregation	NOUN
ajcp-4886	153	14	based	base	VERB
ajcp-4886	153	15	on	on	ADP
ajcp-4886	153	16	the	the	DET
ajcp-4886	153	17	total	total	ADJ
ajcp-4886	153	18	metal	metal	NOUN
ajcp-4886	153	19	ion	ion	NOUN
ajcp-4886	153	20	concentration	concentration	NOUN
ajcp-4886	153	21	and	and	CCONJ
ajcp-4886	153	22	metal	metal	NOUN
ajcp-4886	153	23	:	:	PUNCT
ajcp-4886	153	24	aβ	aβ	NUM
ajcp-4886	153	25	ratio	ratio	NOUN
ajcp-4886	153	26	,	,	PUNCT
ajcp-4886	153	27	as	as	SCONJ
ajcp-4886	153	28	has	have	AUX
ajcp-4886	153	29	been	be	AUX
ajcp-4886	153	30	covered	cover	VERB
ajcp-4886	153	31	in	in	ADP
ajcp-4886	153	32	multiple	multiple	ADJ
ajcp-4886	153	33	review	review	NOUN
ajcp-4886	153	34	articles	article	NOUN
ajcp-4886	153	35	.	.	PUNCT
ajcp-4886	154	1	while	while	SCONJ
ajcp-4886	154	2	it	it	PRON
ajcp-4886	154	3	has	have	AUX
ajcp-4886	154	4	been	be	AUX
ajcp-4886	154	5	demonstrated	demonstrate	VERB
ajcp-4886	154	6	that	that	SCONJ
ajcp-4886	154	7	cu	cu	PROPN
ajcp-4886	154	8	(	(	PUNCT
ajcp-4886	154	9	ii	ii	PROPN
ajcp-4886	154	10	)	)	PUNCT
ajcp-4886	154	11	,	,	PUNCT
ajcp-4886	154	12	zn(ii	zn(ii	NUM
ajcp-4886	154	13	)	)	PUNCT
ajcp-4886	154	14	,	,	PUNCT
ajcp-4886	154	15	and	and	CCONJ
ajcp-4886	154	16	ag(i	ag(i	VERB
ajcp-4886	154	17	)	)	PUNCT
ajcp-4886	154	18	slow	slow	VERB
ajcp-4886	154	19	down	down	ADP
ajcp-4886	154	20	aβ	aβ	DET
ajcp-4886	154	21	fibrillization	fibrillization	NOUN
ajcp-4886	154	22	at	at	ADP
ajcp-4886	154	23	low	low	ADJ
ajcp-4886	154	24	metal	metal	NOUN
ajcp-4886	154	25	ion	ion	NOUN
ajcp-4886	154	26	concentrations	concentration	NOUN
ajcp-4886	154	27	,	,	PUNCT
ajcp-4886	154	28	aβ	aβ	DET
ajcp-4886	154	29	aggregation	aggregation	NOUN
ajcp-4886	154	30	can	can	AUX
ajcp-4886	154	31	be	be	AUX
ajcp-4886	154	32	stimulated	stimulate	VERB
ajcp-4886	154	33	at	at	ADP
ajcp-4886	154	34	high	high	ADJ
ajcp-4886	154	35	concentrations	concentration	NOUN
ajcp-4886	154	36	,	,	PUNCT
ajcp-4886	154	37	leading	lead	VERB
ajcp-4886	154	38	to	to	ADP
ajcp-4886	154	39	the	the	DET
ajcp-4886	154	40	formation	formation	NOUN
ajcp-4886	154	41	of	of	ADP
ajcp-4886	154	42	amorphous	amorphous	ADJ
ajcp-4886	154	43	aggregates	aggregate	NOUN
ajcp-4886	154	44	.	.	PUNCT
ajcp-4886	155	1	figure	figure	VERB
ajcp-4886	155	2	4	4	NUM
ajcp-4886	155	3	:	:	PUNCT
ajcp-4886	155	4	model	model	NOUN
ajcp-4886	155	5	for	for	ADP
ajcp-4886	155	6	mechanism	mechanism	NOUN
ajcp-4886	155	7	of	of	ADP
ajcp-4886	155	8	action	action	NOUN
ajcp-4886	155	9	of	of	ADP
ajcp-4886	155	10	metal	metal	NOUN
ajcp-4886	155	11	ion	ion	NOUN
ajcp-4886	155	12	-	-	PUNCT
ajcp-4886	155	13	modulated	modulate	VERB
ajcp-4886	155	14	aβ	aβ	NOUN
ajcp-4886	155	15	self	self	NOUN
ajcp-4886	155	16	-	-	PUNCT
ajcp-4886	155	17	assembly	assembly	NOUN
ajcp-4886	155	18	transition	transition	NOUN
ajcp-4886	155	19	-	-	PUNCT
ajcp-4886	155	20	metal	metal	NOUN
ajcp-4886	155	21	ions	ion	NOUN
ajcp-4886	155	22	,	,	PUNCT
ajcp-4886	155	23	in	in	ADP
ajcp-4886	155	24	particular	particular	ADJ
ajcp-4886	155	25	referring	refer	VERB
ajcp-4886	155	26	to	to	ADP
ajcp-4886	155	27	cu	cu	PROPN
ajcp-4886	155	28	(	(	PUNCT
ajcp-4886	155	29	ii	ii	PROPN
ajcp-4886	155	30	)	)	PUNCT
ajcp-4886	155	31	,	,	PUNCT
ajcp-4886	155	32	zn(ii	zn(ii	NUM
ajcp-4886	155	33	)	)	PUNCT
ajcp-4886	155	34	,	,	PUNCT
ajcp-4886	155	35	and	and	CCONJ
ajcp-4886	155	36	ag(i	ag(i	VERB
ajcp-4886	155	37	)	)	PUNCT
ajcp-4886	155	38	ions	ion	NOUN
ajcp-4886	155	39	,	,	PUNCT
ajcp-4886	155	40	specifically	specifically	ADV
ajcp-4886	155	41	prevent	prevent	VERB
ajcp-4886	155	42	fibril	fibril	ADJ
ajcp-4886	155	43	-	-	PUNCT
ajcp-4886	155	44	end	end	NOUN
ajcp-4886	155	45	elongation	elongation	NOUN
ajcp-4886	155	46	events	event	NOUN
ajcp-4886	155	47	by	by	ADP
ajcp-4886	155	48	forming	form	VERB
ajcp-4886	155	49	a	a	DET
ajcp-4886	155	50	seemingly	seemingly	ADV
ajcp-4886	155	51	aggregationinert	aggregationinert	ADJ
ajcp-4886	155	52	metal	metal	NOUN
ajcp-4886	155	53	-	-	PUNCT
ajcp-4886	155	54	bound	bind	VERB
ajcp-4886	155	55	aβ	aβ	NOUN
ajcp-4886	155	56	complex	complex	ADJ
ajcp-4886	155	57	.	.	PUNCT
ajcp-4886	156	1	inhibition	inhibition	NOUN
ajcp-4886	156	2	of	of	ADP
ajcp-4886	156	3	fibril	fibril	ADJ
ajcp-4886	156	4	elongation	elongation	NOUN
ajcp-4886	156	5	predicts	predict	VERB
ajcp-4886	156	6	an	an	DET
ajcp-4886	156	7	enhanced	enhanced	ADJ
ajcp-4886	156	8	rate	rate	NOUN
ajcp-4886	156	9	of	of	ADP
ajcp-4886	156	10	oligomer	oligomer	ADJ
ajcp-4886	156	11	generation	generation	NOUN
ajcp-4886	156	12	.	.	PUNCT
ajcp-4886	157	1	at	at	ADP
ajcp-4886	157	2	high	high	ADJ
ajcp-4886	157	3	metal	metal	NOUN
ajcp-4886	157	4	ion	ion	NOUN
ajcp-4886	157	5	concentration	concentration	NOUN
ajcp-4886	157	6	,	,	PUNCT
ajcp-4886	157	7	other	other	ADJ
ajcp-4886	157	8	aggregation	aggregation	NOUN
ajcp-4886	157	9	processes	process	NOUN
ajcp-4886	157	10	dominate	dominate	VERB
ajcp-4886	157	11	,	,	PUNCT
ajcp-4886	157	12	and	and	CCONJ
ajcp-4886	157	13	amorphous	amorphous	ADJ
ajcp-4886	157	14	aggregates	aggregate	NOUN
ajcp-4886	157	15	are	be	AUX
ajcp-4886	157	16	formed	form	VERB
ajcp-4886	157	17	.	.	PUNCT
ajcp-4886	158	1	(	(	PUNCT
ajcp-4886	158	2	b	b	X
ajcp-4886	158	3	)	)	PUNCT
ajcp-4886	158	4	an	an	DET
ajcp-4886	158	5	energy	energy	NOUN
ajcp-4886	158	6	diagram	diagram	NOUN
ajcp-4886	158	7	shows	show	VERB
ajcp-4886	158	8	the	the	DET
ajcp-4886	158	9	concentration	concentration	NOUN
ajcp-4886	158	10	-	-	PUNCT
ajcp-4886	158	11	dependent	dependent	ADJ
ajcp-4886	158	12	formation	formation	NOUN
ajcp-4886	158	13	of	of	ADP
ajcp-4886	158	14	aβ	aβ	NOUN
ajcp-4886	158	15	fibrils	fibril	NOUN
ajcp-4886	158	16	and	and	CCONJ
ajcp-4886	158	17	amorphous	amorphous	ADJ
ajcp-4886	158	18	aβ	aβ	NOUN
ajcp-4886	158	19	aggregates	aggregate	NOUN
ajcp-4886	158	20	,	,	PUNCT
ajcp-4886	158	21	where	where	SCONJ
ajcp-4886	158	22	an	an	DET
ajcp-4886	158	23	increased	increased	ADJ
ajcp-4886	158	24	concentration	concentration	NOUN
ajcp-4886	158	25	of	of	ADP
ajcp-4886	158	26	aβ	aβ	PRON
ajcp-4886	158	27	generally	generally	ADV
ajcp-4886	158	28	enhances	enhance	VERB
ajcp-4886	158	29	aggregation	aggregation	NOUN
ajcp-4886	158	30	and	and	CCONJ
ajcp-4886	158	31	the	the	DET
ajcp-4886	158	32	energy	energy	NOUN
ajcp-4886	158	33	barrier	barrier	NOUN
ajcp-4886	158	34	toward	toward	ADP
ajcp-4886	158	35	amorphous	amorphous	ADJ
ajcp-4886	158	36	aggregate	aggregate	ADJ
ajcp-4886	158	37	formation	formation	NOUN
ajcp-4886	158	38	is	be	AUX
ajcp-4886	158	39	determined	determine	VERB
ajcp-4886	158	40	by	by	ADP
ajcp-4886	158	41	the	the	DET
ajcp-4886	158	42	metal	metal	NOUN
ajcp-4886	158	43	ion	ion	NOUN
ajcp-4886	158	44	concentration	concentration	NOUN
ajcp-4886	158	45	.	.	PUNCT
ajcp-4886	159	1	copy	copy	VERB
ajcp-4886	159	2	from	from	ADP
ajcp-4886	159	3	ref	ref	PROPN
ajcp-4886	159	4	(	(	PUNCT
ajcp-4886	159	5	abelein	abelein	ADJ
ajcp-4886	159	6	,	,	PUNCT
ajcp-4886	159	7	2023	2023	NUM
ajcp-4886	159	8	)	)	PUNCT
ajcp-4886	159	9	.	.	PUNCT
ajcp-4886	160	1	metal	metal	NOUN
ajcp-4886	160	2	ions	ion	NOUN
ajcp-4886	160	3	,	,	PUNCT
ajcp-4886	160	4	particularly	particularly	ADV
ajcp-4886	160	5	zn2	zn2	PROPN
ajcp-4886	160	6	+	+	PROPN
ajcp-4886	160	7	and	and	CCONJ
ajcp-4886	160	8	cu2	cu2	NOUN
ajcp-4886	160	9	+	+	PROPN
ajcp-4886	160	10	,	,	PUNCT
ajcp-4886	160	11	have	have	VERB
ajcp-4886	160	12	a	a	DET
ajcp-4886	160	13	strong	strong	ADJ
ajcp-4886	160	14	affinity	affinity	NOUN
ajcp-4886	160	15	for	for	ADP
ajcp-4886	160	16	binding	bind	VERB
ajcp-4886	160	17	to	to	ADP
ajcp-4886	160	18	aβ	aβ	NUM
ajcp-4886	160	19	,	,	PUNCT
ajcp-4886	160	20	which	which	PRON
ajcp-4886	160	21	can	can	AUX
ajcp-4886	160	22	facilitate	facilitate	VERB
ajcp-4886	160	23	aβ	aβ	PRON
ajcp-4886	160	24	nucleation	nucleation	NOUN
ajcp-4886	160	25	and	and	CCONJ
ajcp-4886	160	26	aggregation	aggregation	NOUN
ajcp-4886	160	27	(	(	PUNCT
ajcp-4886	160	28	rana	rana	PROPN
ajcp-4886	160	29	&	&	CCONJ
ajcp-4886	160	30	sharma	sharma	PROPN
ajcp-4886	160	31	,	,	PUNCT
ajcp-4886	160	32	2019	2019	NUM
ajcp-4886	160	33	)	)	PUNCT
ajcp-4886	160	34	.	.	PUNCT
ajcp-4886	161	1	according	accord	VERB
ajcp-4886	161	2	to	to	ADP
ajcp-4886	161	3	a	a	DET
ajcp-4886	161	4	recent	recent	ADJ
ajcp-4886	161	5	study	study	NOUN
ajcp-4886	161	6	,	,	PUNCT
ajcp-4886	161	7	quinoline	quinoline	NOUN
ajcp-4886	161	8	-	-	PUNCT
ajcp-4886	161	9	derived	derive	VERB
ajcp-4886	161	10	halfcurcumin	halfcurcumin	NOUN
ajcp-4886	161	11	dioxaborine	dioxaborine	NOUN
ajcp-4886	161	12	(	(	PUNCT
ajcp-4886	161	13	q	q	NOUN
ajcp-4886	161	14	-	-	PUNCT
ajcp-4886	161	15	ob	ob	NOUN
ajcp-4886	161	16	)	)	PUNCT
ajcp-4886	161	17	was	be	AUX
ajcp-4886	161	18	made	make	VERB
ajcp-4886	161	19	in	in	ADP
ajcp-4886	161	20	order	order	NOUN
ajcp-4886	161	21	to	to	PART
ajcp-4886	161	22	identify	identify	VERB
ajcp-4886	161	23	the	the	DET
ajcp-4886	161	24	early	early	ADJ
ajcp-4886	161	25	stage	stage	NOUN
ajcp-4886	161	26	of	of	ADP
ajcp-4886	161	27	ad	ad	NOUN
ajcp-4886	161	28	by	by	ADP
ajcp-4886	161	29	detecting	detect	VERB
ajcp-4886	161	30	the	the	DET
ajcp-4886	161	31	oligomeric	oligomeric	ADJ
ajcp-4886	161	32	aβ1	aβ1	NOUN
ajcp-4886	161	33	-	-	PUNCT
ajcp-4886	161	34	42	42	NUM
ajcp-4886	161	35	over	over	ADP
ajcp-4886	161	36	monomer	monomer	NOUN
ajcp-4886	161	37	and	and	CCONJ
ajcp-4886	161	38	filaments	filament	NOUN
ajcp-4886	161	39	in	in	ADP
ajcp-4886	161	40	the	the	DET
ajcp-4886	161	41	complex	complex	ADJ
ajcp-4886	161	42	aβ	aβ	DET
ajcp-4886	161	43	self	self	NOUN
ajcp-4886	161	44	-	-	PUNCT
ajcp-4886	161	45	assembly	assembly	NOUN
ajcp-4886	161	46	cascade	cascade	NOUN
ajcp-4886	161	47	.	.	PUNCT
ajcp-4886	162	1	in	in	ADP
ajcp-4886	162	2	ad	ad	NOUN
ajcp-4886	162	3	transgenic	transgenic	NOUN
ajcp-4886	162	4	mice	mouse	NOUN
ajcp-4886	162	5	,	,	PUNCT
ajcp-4886	162	6	q	q	NOUN
ajcp-4886	162	7	-	-	PUNCT
ajcp-4886	162	8	ob	ob	ADJ
ajcp-4886	162	9	pa	pa	PROPN
ajcp-4886	162	10	ge	ge	PROPN
ajcp-4886	162	11	21	21	NUM
ajcp-4886	162	12	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-4886	162	13	am	be	AUX
ajcp-4886	162	14	.	.	PUNCT
ajcp-4886	163	1	j.	j.	PROPN
ajcp-4886	163	2	chem	chem	PROPN
ajcp-4886	163	3	.	.	PUNCT
ajcp-4886	164	1	pharm	pharm	PROPN
ajcp-4886	164	2	.	.	PUNCT
ajcp-4886	165	1	4(1	4(1	NOUN
ajcp-4886	165	2	)	)	PUNCT
ajcp-4886	166	1	16	16	NUM
ajcp-4886	166	2	-	-	SYM
ajcp-4886	166	3	28	28	NUM
ajcp-4886	166	4	,	,	PUNCT
ajcp-4886	166	5	2025	2025	NUM
ajcp-4886	166	6	demonstrated	demonstrate	VERB
ajcp-4886	166	7	exceptional	exceptional	ADJ
ajcp-4886	166	8	blood	blood	NOUN
ajcp-4886	166	9	-	-	PUNCT
ajcp-4886	166	10	brain	brain	NOUN
ajcp-4886	166	11	barrier	barrier	NOUN
ajcp-4886	166	12	(	(	PUNCT
ajcp-4886	166	13	bbb	bbb	NOUN
ajcp-4886	166	14	)	)	PUNCT
ajcp-4886	166	15	penetrability	penetrability	NOUN
ajcp-4886	166	16	and	and	CCONJ
ajcp-4886	166	17	in	in	ADP
ajcp-4886	166	18	vivo	vivo	ADJ
ajcp-4886	166	19	imaging	imaging	NOUN
ajcp-4886	166	20	of	of	ADP
ajcp-4886	166	21	aβ	aβ	PRON
ajcp-4886	166	22	(	(	PUNCT
ajcp-4886	166	23	an	an	DET
ajcp-4886	166	24	et	et	PROPN
ajcp-4886	166	25	al	al	PROPN
ajcp-4886	166	26	.	.	PROPN
ajcp-4886	166	27	,	,	PUNCT
ajcp-4886	166	28	2024	2024	NUM
ajcp-4886	166	29	)	)	PUNCT
ajcp-4886	166	30	.	.	PUNCT
ajcp-4886	167	1	the	the	DET
ajcp-4886	167	2	studies	study	NOUN
ajcp-4886	167	3	of	of	ADP
ajcp-4886	167	4	anti	anti	NOUN
ajcp-4886	167	5	-	-	ADJ
ajcp-4886	167	6	aβ	aβ	ADJ
ajcp-4886	167	7	3d6	3d6	NUM
ajcp-4886	167	8	antibody	antibody	NOUN
ajcp-4886	167	9	is	be	AUX
ajcp-4886	167	10	said	say	VERB
ajcp-4886	167	11	to	to	PART
ajcp-4886	167	12	stop	stop	VERB
ajcp-4886	167	13	the	the	DET
ajcp-4886	167	14	development	development	NOUN
ajcp-4886	167	15	of	of	ADP
ajcp-4886	167	16	new	new	ADJ
ajcp-4886	167	17	aβ	aβ	NOUN
ajcp-4886	167	18	plaques	plaque	NOUN
ajcp-4886	167	19	in	in	ADP
ajcp-4886	167	20	the	the	DET
ajcp-4886	167	21	brain	brain	NOUN
ajcp-4886	167	22	,	,	PUNCT
ajcp-4886	167	23	but	but	CCONJ
ajcp-4886	167	24	it	it	PRON
ajcp-4886	167	25	does	do	AUX
ajcp-4886	167	26	n’t	not	PART
ajcp-4886	167	27	eliminate	eliminate	VERB
ajcp-4886	167	28	those	those	PRON
ajcp-4886	167	29	that	that	PRON
ajcp-4886	167	30	already	already	ADV
ajcp-4886	167	31	exist	exist	VERB
ajcp-4886	167	32	.	.	PUNCT
ajcp-4886	168	1	additionally	additionally	ADV
ajcp-4886	168	2	,	,	PUNCT
ajcp-4886	168	3	3d6	3d6	NUM
ajcp-4886	168	4	inhibited	inhibit	VERB
ajcp-4886	168	5	the	the	DET
ajcp-4886	168	6	aggregation	aggregation	NOUN
ajcp-4886	168	7	of	of	ADP
ajcp-4886	168	8	aβ	aβ	PROPN
ajcp-4886	168	9	(	(	PUNCT
ajcp-4886	168	10	amano	amano	PROPN
ajcp-4886	168	11	et	et	PROPN
ajcp-4886	168	12	al	al	PROPN
ajcp-4886	168	13	.	.	PROPN
ajcp-4886	168	14	,	,	PUNCT
ajcp-4886	168	15	2023	2023	NUM
ajcp-4886	168	16	)	)	PUNCT
ajcp-4886	168	17	.	.	PUNCT
ajcp-4886	169	1	the	the	DET
ajcp-4886	169	2	relationships	relationship	NOUN
ajcp-4886	169	3	between	between	ADP
ajcp-4886	169	4	the	the	DET
ajcp-4886	169	5	aβ	aβ	NOUN
ajcp-4886	169	6	peptide	peptide	NOUN
ajcp-4886	169	7	and	and	CCONJ
ajcp-4886	169	8	the	the	DET
ajcp-4886	169	9	main	main	ADJ
ajcp-4886	169	10	aβ	aβ	NOUN
ajcp-4886	169	11	aggregation	aggregation	NOUN
ajcp-4886	169	12	inhibitors	inhibitor	NOUN
ajcp-4886	169	13	,	,	PUNCT
ajcp-4886	169	14	geraniin	geraniin	NOUN
ajcp-4886	169	15	(	(	PUNCT
ajcp-4886	169	16	1	1	NUM
ajcp-4886	169	17	)	)	PUNCT
ajcp-4886	169	18	,	,	PUNCT
ajcp-4886	169	19	gallic	gallic	NOUN
ajcp-4886	169	20	acid	acid	NOUN
ajcp-4886	169	21	(	(	PUNCT
ajcp-4886	169	22	2	2	NUM
ajcp-4886	169	23	)	)	PUNCT
ajcp-4886	169	24	,	,	PUNCT
ajcp-4886	169	25	and	and	CCONJ
ajcp-4886	169	26	corilagin	corilagin	NOUN
ajcp-4886	169	27	(	(	PUNCT
ajcp-4886	169	28	5	5	NUM
ajcp-4886	169	29	)	)	PUNCT
ajcp-4886	169	30	,	,	PUNCT
ajcp-4886	169	31	were	be	AUX
ajcp-4886	169	32	investigated	investigate	VERB
ajcp-4886	169	33	using	use	VERB
ajcp-4886	169	34	std	std	NOUN
ajcp-4886	169	35	nmr	nmr	NOUN
ajcp-4886	169	36	spectra	spectra	NOUN
ajcp-4886	169	37	.	.	PUNCT
ajcp-4886	170	1	this	this	DET
ajcp-4886	170	2	study	study	NOUN
ajcp-4886	170	3	implies	imply	VERB
ajcp-4886	170	4	that	that	SCONJ
ajcp-4886	170	5	smaller	small	ADJ
ajcp-4886	170	6	soluble	soluble	ADJ
ajcp-4886	170	7	aβ	aβ	NOUN
ajcp-4886	170	8	aggregates	aggregate	NOUN
ajcp-4886	170	9	are	be	AUX
ajcp-4886	170	10	inhibited	inhibit	VERB
ajcp-4886	170	11	by	by	ADP
ajcp-4886	170	12	corilagin	corilagin	NOUN
ajcp-4886	170	13	(	(	PUNCT
ajcp-4886	170	14	5	5	NUM
ajcp-4886	170	15	)	)	PUNCT
ajcp-4886	170	16	,	,	PUNCT
ajcp-4886	170	17	whereas	whereas	SCONJ
ajcp-4886	170	18	larger	large	ADJ
ajcp-4886	170	19	insoluble	insoluble	ADJ
ajcp-4886	170	20	aβ	aβ	NOUN
ajcp-4886	170	21	aggregates	aggregate	NOUN
ajcp-4886	170	22	are	be	AUX
ajcp-4886	170	23	inhibited	inhibit	VERB
ajcp-4886	170	24	by	by	ADP
ajcp-4886	170	25	gallic	gallic	ADJ
ajcp-4886	170	26	acid	acid	NOUN
ajcp-4886	170	27	(	(	PUNCT
ajcp-4886	170	28	2	2	NUM
ajcp-4886	170	29	)	)	PUNCT
ajcp-4886	170	30	.	.	PUNCT
ajcp-4886	171	1	corilagin	corilagin	NOUN
ajcp-4886	171	2	(	(	PUNCT
ajcp-4886	171	3	5	5	NUM
ajcp-4886	171	4	)	)	PUNCT
ajcp-4886	171	5	only	only	ADV
ajcp-4886	171	6	interacts	interact	VERB
ajcp-4886	171	7	with	with	ADP
ajcp-4886	171	8	soluble	soluble	ADJ
ajcp-4886	171	9	aβ	aβ	NOUN
ajcp-4886	171	10	,	,	PUNCT
ajcp-4886	171	11	as	as	SCONJ
ajcp-4886	171	12	demonstrated	demonstrate	VERB
ajcp-4886	171	13	by	by	ADP
ajcp-4886	171	14	this	this	PRON
ajcp-4886	171	15	as	as	ADV
ajcp-4886	171	16	well	well	ADV
ajcp-4886	171	17	(	(	PUNCT
ajcp-4886	171	18	kubo	kubo	PROPN
ajcp-4886	171	19	et	et	PROPN
ajcp-4886	171	20	al	al	PROPN
ajcp-4886	171	21	.	.	PROPN
ajcp-4886	171	22	,	,	PUNCT
ajcp-4886	171	23	2022	2022	NUM
ajcp-4886	171	24	)	)	PUNCT
ajcp-4886	171	25	.	.	PUNCT
ajcp-4886	172	1	certain	certain	ADJ
ajcp-4886	172	2	classes	class	NOUN
ajcp-4886	172	3	,	,	PUNCT
ajcp-4886	172	4	like	like	ADP
ajcp-4886	172	5	polyphenols	polyphenol	NOUN
ajcp-4886	172	6	and	and	CCONJ
ajcp-4886	172	7	tetracyclines	tetracycline	NOUN
ajcp-4886	172	8	,	,	PUNCT
ajcp-4886	172	9	can	can	AUX
ajcp-4886	172	10	prevent	prevent	VERB
ajcp-4886	172	11	the	the	DET
ajcp-4886	172	12	aggregation	aggregation	NOUN
ajcp-4886	172	13	of	of	ADP
ajcp-4886	172	14	various	various	ADJ
ajcp-4886	172	15	unrelated	unrelated	ADJ
ajcp-4886	172	16	amyloidogenic	amyloidogenic	ADJ
ajcp-4886	172	17	proteins	protein	NOUN
ajcp-4886	172	18	,	,	PUNCT
ajcp-4886	172	19	like	like	ADP
ajcp-4886	172	20	islet	islet	NOUN
ajcp-4886	172	21	amyloid	amyloid	NOUN
ajcp-4886	172	22	polypeptide	polypeptide	ADJ
ajcp-4886	172	23	(	(	PUNCT
ajcp-4886	172	24	iapp	iapp	PROPN
ajcp-4886	172	25	)	)	PUNCT
ajcp-4886	172	26	,	,	PUNCT
ajcp-4886	172	27	which	which	PRON
ajcp-4886	172	28	is	be	AUX
ajcp-4886	172	29	linked	link	VERB
ajcp-4886	172	30	to	to	ADP
ajcp-4886	172	31	type-2	type-2	NUM
ajcp-4886	172	32	diabetes	diabetes	NOUN
ajcp-4886	172	33	,	,	PUNCT
ajcp-4886	172	34	and	and	CCONJ
ajcp-4886	172	35	α	α	X
ajcp-4886	172	36	-	-	PUNCT
ajcp-4886	172	37	synuclein	synuclein	NOUN
ajcp-4886	172	38	,	,	PUNCT
ajcp-4886	172	39	which	which	PRON
ajcp-4886	172	40	is	be	AUX
ajcp-4886	172	41	linked	link	VERB
ajcp-4886	172	42	to	to	ADP
ajcp-4886	172	43	parkinson	parkinson	NOUN
ajcp-4886	172	44	’s	’s	PART
ajcp-4886	172	45	disease	disease	NOUN
ajcp-4886	172	46	.	.	PUNCT
ajcp-4886	173	1	it	it	PRON
ajcp-4886	173	2	’s	’	VERB
ajcp-4886	173	3	likely	likely	ADJ
ajcp-4886	173	4	that	that	SCONJ
ajcp-4886	173	5	their	their	PRON
ajcp-4886	173	6	mechanisms	mechanism	NOUN
ajcp-4886	173	7	of	of	ADP
ajcp-4886	173	8	action	action	NOUN
ajcp-4886	173	9	are	be	AUX
ajcp-4886	173	10	partially	partially	ADV
ajcp-4886	173	11	overlapped	overlap	VERB
ajcp-4886	173	12	(	(	PUNCT
ajcp-4886	173	13	martinez	martinez	PROPN
ajcp-4886	173	14	pomier	pomier	PROPN
ajcp-4886	173	15	et	et	PROPN
ajcp-4886	173	16	al	al	PROPN
ajcp-4886	173	17	.	.	PROPN
ajcp-4886	173	18	,	,	PUNCT
ajcp-4886	173	19	2020	2020	NUM
ajcp-4886	173	20	)	)	PUNCT
ajcp-4886	173	21	.	.	PUNCT
ajcp-4886	174	1	many	many	ADJ
ajcp-4886	174	2	in	in	ADP
ajcp-4886	174	3	vitro	vitro	X
ajcp-4886	174	4	and	and	CCONJ
ajcp-4886	174	5	in	in	ADP
ajcp-4886	174	6	vivo	vivo	ADJ
ajcp-4886	174	7	investigations	investigation	NOUN
ajcp-4886	174	8	have	have	AUX
ajcp-4886	174	9	demonstrated	demonstrate	VERB
ajcp-4886	174	10	the	the	DET
ajcp-4886	174	11	potential	potential	NOUN
ajcp-4886	174	12	of	of	ADP
ajcp-4886	174	13	a	a	DET
ajcp-4886	174	14	variety	variety	NOUN
ajcp-4886	174	15	of	of	ADP
ajcp-4886	174	16	natural	natural	ADJ
ajcp-4886	174	17	compounds	compound	NOUN
ajcp-4886	174	18	as	as	ADP
ajcp-4886	174	19	therapeutic	therapeutic	ADJ
ajcp-4886	174	20	agents	agent	NOUN
ajcp-4886	174	21	against	against	ADP
ajcp-4886	174	22	the	the	DET
ajcp-4886	174	23	progression	progression	NOUN
ajcp-4886	174	24	of	of	ADP
ajcp-4886	174	25	ad	ad	NOUN
ajcp-4886	174	26	however	however	ADV
ajcp-4886	174	27	,	,	PUNCT
ajcp-4886	174	28	pre	pre	ADJ
ajcp-4886	174	29	-	-	ADJ
ajcp-4886	174	30	clinical	clinical	ADJ
ajcp-4886	174	31	and	and	CCONJ
ajcp-4886	174	32	clinical	clinical	ADJ
ajcp-4886	174	33	studies	study	NOUN
ajcp-4886	174	34	have	have	AUX
ajcp-4886	174	35	only	only	ADV
ajcp-4886	174	36	demonstrated	demonstrate	VERB
ajcp-4886	174	37	the	the	DET
ajcp-4886	174	38	efficacy	efficacy	NOUN
ajcp-4886	174	39	of	of	ADP
ajcp-4886	174	40	a	a	DET
ajcp-4886	174	41	small	small	ADJ
ajcp-4886	174	42	subset	subset	NOUN
ajcp-4886	174	43	of	of	ADP
ajcp-4886	174	44	these	these	DET
ajcp-4886	174	45	compounds	compound	NOUN
ajcp-4886	174	46	(	(	PUNCT
ajcp-4886	174	47	andrade	andrade	PROPN
ajcp-4886	174	48	et	et	PROPN
ajcp-4886	174	49	al	al	PROPN
ajcp-4886	174	50	.	.	PROPN
ajcp-4886	174	51	,	,	PUNCT
ajcp-4886	174	52	2019	2019	NUM
ajcp-4886	174	53	)	)	PUNCT
ajcp-4886	174	54	.	.	PUNCT
ajcp-4886	175	1	after	after	ADP
ajcp-4886	175	2	being	be	AUX
ajcp-4886	175	3	extracted	extract	VERB
ajcp-4886	175	4	from	from	ADP
ajcp-4886	175	5	red	red	ADJ
ajcp-4886	175	6	maples	maple	NOUN
ajcp-4886	175	7	,	,	PUNCT
ajcp-4886	175	8	ginsenalin	ginsenalin	PROPN
ajcp-4886	175	9	a	a	DET
ajcp-4886	175	10	(	(	PUNCT
ajcp-4886	175	11	ga	ga	NOUN
ajcp-4886	175	12	)	)	PUNCT
ajcp-4886	175	13	can	can	AUX
ajcp-4886	175	14	target	target	VERB
ajcp-4886	175	15	aβ42	aβ42	PROPN
ajcp-4886	175	16	fibrillogenesis	fibrillogenesis	NOUN
ajcp-4886	175	17	through	through	ADP
ajcp-4886	175	18	a	a	DET
ajcp-4886	175	19	variety	variety	NOUN
ajcp-4886	175	20	of	of	ADP
ajcp-4886	175	21	mechanisms	mechanism	NOUN
ajcp-4886	175	22	.	.	PUNCT
ajcp-4886	176	1	specifically	specifically	ADV
ajcp-4886	176	2	,	,	PUNCT
ajcp-4886	176	3	ga	ga	PROPN
ajcp-4886	176	4	can	can	AUX
ajcp-4886	176	5	bind	bind	VERB
ajcp-4886	176	6	to	to	ADP
ajcp-4886	176	7	monomers	monomer	NOUN
ajcp-4886	176	8	at	at	ADP
ajcp-4886	176	9	the	the	DET
ajcp-4886	176	10	early	early	ADJ
ajcp-4886	176	11	nucleation	nucleation	NOUN
ajcp-4886	176	12	phase	phase	NOUN
ajcp-4886	176	13	,	,	PUNCT
ajcp-4886	176	14	preventing	prevent	VERB
ajcp-4886	176	15	aβ	aβ	NOUN
ajcp-4886	176	16	–	–	PUNCT
ajcp-4886	176	17	aβ	aβ	NOUN
ajcp-4886	176	18	associations	association	NOUN
ajcp-4886	176	19	,	,	PUNCT
ajcp-4886	176	20	and	and	CCONJ
ajcp-4886	176	21	at	at	ADP
ajcp-4886	176	22	the	the	DET
ajcp-4886	176	23	later	later	ADJ
ajcp-4886	176	24	growth	growth	NOUN
ajcp-4886	176	25	phase	phase	NOUN
ajcp-4886	176	26	.	.	PUNCT
ajcp-4886	177	1	according	accord	VERB
ajcp-4886	177	2	to	to	ADP
ajcp-4886	177	3	toxicity	toxicity	NOUN
ajcp-4886	177	4	tests	test	NOUN
ajcp-4886	177	5	on	on	ADP
ajcp-4886	177	6	sh	sh	PROPN
ajcp-4886	177	7	-	-	PUNCT
ajcp-4886	177	8	sy5y	sy5y	PROPN
ajcp-4886	177	9	cells	cell	NOUN
ajcp-4886	177	10	,	,	PUNCT
ajcp-4886	177	11	pre	pre	ADJ
ajcp-4886	177	12	-	-	NOUN
ajcp-4886	177	13	incubation	incubation	NOUN
ajcp-4886	177	14	of	of	ADP
ajcp-4886	177	15	aβ42	aβ42	PROPN
ajcp-4886	177	16	solution	solution	NOUN
ajcp-4886	177	17	with	with	ADP
ajcp-4886	177	18	ga	ga	PROPN
ajcp-4886	177	19	results	result	NOUN
ajcp-4886	177	20	in	in	ADP
ajcp-4886	177	21	oligomers	oligomer	NOUN
ajcp-4886	177	22	that	that	PRON
ajcp-4886	177	23	do	do	AUX
ajcp-4886	177	24	not	not	PART
ajcp-4886	177	25	interact	interact	VERB
ajcp-4886	177	26	or	or	CCONJ
ajcp-4886	177	27	disturb	disturb	VERB
ajcp-4886	177	28	the	the	DET
ajcp-4886	177	29	integrity	integrity	NOUN
ajcp-4886	177	30	of	of	ADP
ajcp-4886	177	31	cellular	cellular	ADJ
ajcp-4886	177	32	membranes	membrane	NOUN
ajcp-4886	177	33	(	(	PUNCT
ajcp-4886	177	34	pagano	pagano	NOUN
ajcp-4886	177	35	et	et	NOUN
ajcp-4886	177	36	al	al	PROPN
ajcp-4886	177	37	.	.	PROPN
ajcp-4886	177	38	,	,	PUNCT
ajcp-4886	177	39	2020	2020	NUM
ajcp-4886	177	40	)	)	PUNCT
ajcp-4886	177	41	.	.	PUNCT
ajcp-4886	178	1	further	further	ADJ
ajcp-4886	178	2	evidence	evidence	NOUN
ajcp-4886	178	3	suggests	suggest	VERB
ajcp-4886	178	4	that	that	SCONJ
ajcp-4886	178	5	the	the	DET
ajcp-4886	178	6	antioxidant	antioxidant	ADJ
ajcp-4886	178	7	ferrulic	ferrulic	ADJ
ajcp-4886	178	8	acid	acid	NOUN
ajcp-4886	178	9	(	(	PUNCT
ajcp-4886	178	10	fa	fa	NOUN
ajcp-4886	178	11	)	)	PUNCT
ajcp-4886	178	12	,	,	PUNCT
ajcp-4886	178	13	which	which	PRON
ajcp-4886	178	14	is	be	AUX
ajcp-4886	178	15	found	find	VERB
ajcp-4886	178	16	in	in	ADP
ajcp-4886	178	17	plant	plant	NOUN
ajcp-4886	178	18	cell	cell	NOUN
ajcp-4886	178	19	walls	wall	NOUN
ajcp-4886	178	20	,	,	PUNCT
ajcp-4886	178	21	may	may	AUX
ajcp-4886	178	22	inhibit	inhibit	VERB
ajcp-4886	178	23	the	the	DET
ajcp-4886	178	24	aggregation	aggregation	NOUN
ajcp-4886	178	25	of	of	ADP
ajcp-4886	178	26	aβ	aβ	PROPN
ajcp-4886	178	27	(	(	PUNCT
ajcp-4886	178	28	thapliyal	thapliyal	NOUN
ajcp-4886	178	29	et	et	PROPN
ajcp-4886	178	30	al	al	PROPN
ajcp-4886	178	31	.	.	PROPN
ajcp-4886	178	32	,	,	PUNCT
ajcp-4886	178	33	2021	2021	NUM
ajcp-4886	178	34	)	)	PUNCT
ajcp-4886	178	35	.	.	PUNCT
ajcp-4886	179	1	the	the	DET
ajcp-4886	179	2	biomolecular	biomolecular	ADJ
ajcp-4886	179	3	targets	target	NOUN
ajcp-4886	179	4	linked	link	VERB
ajcp-4886	179	5	to	to	ADP
ajcp-4886	179	6	alzheimer	alzheimer	PROPN
ajcp-4886	179	7	’s	’s	PART
ajcp-4886	179	8	disease	disease	NOUN
ajcp-4886	179	9	(	(	PUNCT
ajcp-4886	179	10	ad	ad	NOUN
ajcp-4886	179	11	)	)	PUNCT
ajcp-4886	179	12	include	include	VERB
ajcp-4886	179	13	the	the	DET
ajcp-4886	179	14	nmda	nmda	ADJ
ajcp-4886	179	15	receptor	receptor	NOUN
ajcp-4886	179	16	,	,	PUNCT
ajcp-4886	179	17	aβ	aβ	DET
ajcp-4886	179	18	aggregation	aggregation	NOUN
ajcp-4886	179	19	,	,	PUNCT
ajcp-4886	179	20	ache	ache	ADV
ajcp-4886	179	21	,	,	PUNCT
ajcp-4886	179	22	and	and	CCONJ
ajcp-4886	179	23	monoamine	monoamine	ADJ
ajcp-4886	179	24	oxidase	oxidase	NOUN
ajcp-4886	179	25	(	(	PUNCT
ajcp-4886	179	26	mao	mao	PROPN
ajcp-4886	179	27	)	)	PUNCT
ajcp-4886	179	28	(	(	PUNCT
ajcp-4886	179	29	uddin	uddin	NOUN
ajcp-4886	179	30	et	et	PROPN
ajcp-4886	179	31	al	al	PROPN
ajcp-4886	179	32	.	.	PROPN
ajcp-4886	179	33	,	,	PUNCT
ajcp-4886	179	34	2020	2020	NUM
ajcp-4886	179	35	)	)	PUNCT
ajcp-4886	179	36	.	.	PUNCT
ajcp-4886	180	1	(	(	PUNCT
ajcp-4886	180	2	figure	figure	NOUN
ajcp-4886	180	3	5	5	NUM
ajcp-4886	180	4	)	)	PUNCT
ajcp-4886	180	5	shows	show	VERB
ajcp-4886	180	6	how	how	SCONJ
ajcp-4886	180	7	harmine	harmine	NOUN
ajcp-4886	180	8	and	and	CCONJ
ajcp-4886	180	9	its	its	PRON
ajcp-4886	180	10	derivatives	derivative	NOUN
ajcp-4886	180	11	bind	bind	VERB
ajcp-4886	180	12	to	to	ADP
ajcp-4886	180	13	numerous	numerous	ADJ
ajcp-4886	180	14	targets	target	NOUN
ajcp-4886	180	15	.	.	PUNCT
ajcp-4886	181	1	harmine	harmine	NOUN
ajcp-4886	181	2	treatments	treatment	NOUN
ajcp-4886	181	3	decrease	decrease	VERB
ajcp-4886	181	4	scopolamineinduced	scopolamineinduce	VERB
ajcp-4886	181	5	cognitive	cognitive	ADJ
ajcp-4886	181	6	impairment	impairment	NOUN
ajcp-4886	181	7	in	in	ADP
ajcp-4886	181	8	mice	mouse	NOUN
ajcp-4886	181	9	and	and	CCONJ
ajcp-4886	181	10	enhance	enhance	VERB
ajcp-4886	181	11	spatial	spatial	ADJ
ajcp-4886	181	12	learning	learning	NOUN
ajcp-4886	181	13	,	,	PUNCT
ajcp-4886	181	14	memory	memory	NOUN
ajcp-4886	181	15	in	in	ADP
ajcp-4886	181	16	transgenic	transgenic	NOUN
ajcp-4886	181	17	mice	mouse	NOUN
ajcp-4886	181	18	,	,	PUNCT
ajcp-4886	181	19	short	short	ADJ
ajcp-4886	181	20	-	-	PUNCT
ajcp-4886	181	21	term	term	NOUN
ajcp-4886	181	22	memory	memory	NOUN
ajcp-4886	181	23	in	in	ADP
ajcp-4886	181	24	aged	aged	ADJ
ajcp-4886	181	25	rats	rat	NOUN
ajcp-4886	181	26	,	,	PUNCT
ajcp-4886	181	27	and	and	CCONJ
ajcp-4886	181	28	all	all	PRON
ajcp-4886	181	29	of	of	ADP
ajcp-4886	181	30	these	these	DET
ajcp-4886	181	31	outcomes	outcome	NOUN
ajcp-4886	181	32	.	.	PUNCT
ajcp-4886	182	1	this	this	PRON
ajcp-4886	182	2	illustrates	illustrate	VERB
ajcp-4886	182	3	how	how	SCONJ
ajcp-4886	182	4	harmine	harmine	NOUN
ajcp-4886	182	5	targets	target	VERB
ajcp-4886	182	6	different	different	ADJ
ajcp-4886	182	7	aspects	aspect	NOUN
ajcp-4886	182	8	of	of	ADP
ajcp-4886	182	9	the	the	DET
ajcp-4886	182	10	disease	disease	NOUN
ajcp-4886	182	11	and	and	CCONJ
ajcp-4886	182	12	has	have	VERB
ajcp-4886	182	13	the	the	DET
ajcp-4886	182	14	potential	potential	NOUN
ajcp-4886	182	15	to	to	PART
ajcp-4886	182	16	be	be	AUX
ajcp-4886	182	17	a	a	DET
ajcp-4886	182	18	multimodal	multimodal	ADJ
ajcp-4886	182	19	treatment	treatment	NOUN
ajcp-4886	182	20	for	for	ADP
ajcp-4886	182	21	alzheimer	alzheimer	PROPN
ajcp-4886	182	22	’s	’s	PART
ajcp-4886	182	23	(	(	PUNCT
ajcp-4886	182	24	du	du	PROPN
ajcp-4886	182	25	et	et	PROPN
ajcp-4886	182	26	al	al	PROPN
ajcp-4886	182	27	.	.	PROPN
ajcp-4886	182	28	,	,	PUNCT
ajcp-4886	182	29	2023	2023	NUM
ajcp-4886	182	30	)	)	PUNCT
ajcp-4886	182	31	.	.	PUNCT
ajcp-4886	183	1	study	study	NOUN
ajcp-4886	183	2	investigated	investigate	VERB
ajcp-4886	183	3	the	the	DET
ajcp-4886	183	4	potential	potential	ADJ
ajcp-4886	183	5	therapeutic	therapeutic	ADJ
ajcp-4886	183	6	effects	effect	NOUN
ajcp-4886	183	7	of	of	ADP
ajcp-4886	183	8	gnrb1	gnrb1	NOUN
ajcp-4886	183	9	,	,	PUNCT
ajcp-4886	183	10	sa	sa	PROPN
ajcp-4886	183	11	,	,	PUNCT
ajcp-4886	183	12	and	and	CCONJ
ajcp-4886	183	13	dmyr	dmyr	VERB
ajcp-4886	183	14	on	on	ADP
ajcp-4886	183	15	aβ	aβ	PRON
ajcp-4886	183	16	aggregation	aggregation	NOUN
ajcp-4886	183	17	in	in	ADP
ajcp-4886	183	18	ad	ad	NOUN
ajcp-4886	183	19	.	.	PUNCT
ajcp-4886	184	1	our	our	PRON
ajcp-4886	184	2	study	study	NOUN
ajcp-4886	184	3	suggests	suggest	VERB
ajcp-4886	184	4	that	that	SCONJ
ajcp-4886	184	5	since	since	SCONJ
ajcp-4886	184	6	sa	sa	PROPN
ajcp-4886	184	7	,	,	PUNCT
ajcp-4886	184	8	gnrb1	gnrb1	NOUN
ajcp-4886	184	9	,	,	PUNCT
ajcp-4886	184	10	and	and	CCONJ
ajcp-4886	184	11	dmyr	dmyr	PROPN
ajcp-4886	184	12	target	target	VERB
ajcp-4886	184	13	aβ	aβ	DET
ajcp-4886	184	14	aggregation	aggregation	NOUN
ajcp-4886	184	15	,	,	PUNCT
ajcp-4886	184	16	they	they	PRON
ajcp-4886	184	17	might	might	AUX
ajcp-4886	184	18	be	be	AUX
ajcp-4886	184	19	appealing	appeal	VERB
ajcp-4886	184	20	treatment	treatment	NOUN
ajcp-4886	184	21	options	option	NOUN
ajcp-4886	184	22	for	for	ADP
ajcp-4886	184	23	ad	ad	NOUN
ajcp-4886	184	24	based	base	VERB
ajcp-4886	184	25	on	on	ADP
ajcp-4886	184	26	the	the	DET
ajcp-4886	184	27	amyloid	amyloid	NOUN
ajcp-4886	184	28	hypothesis	hypothesis	NOUN
ajcp-4886	184	29	(	(	PUNCT
ajcp-4886	184	30	sharari	sharari	PROPN
ajcp-4886	184	31	et	et	PROPN
ajcp-4886	184	32	al	al	PROPN
ajcp-4886	184	33	.	.	PROPN
ajcp-4886	184	34	,	,	PUNCT
ajcp-4886	184	35	2023	2023	NUM
ajcp-4886	184	36	)	)	PUNCT
ajcp-4886	184	37	.	.	PUNCT
ajcp-4886	185	1	by	by	ADP
ajcp-4886	185	2	significantly	significantly	ADV
ajcp-4886	185	3	binding	bind	VERB
ajcp-4886	185	4	to	to	ADP
ajcp-4886	185	5	aβ	aβ	NOUN
ajcp-4886	185	6	oligomers	oligomer	NOUN
ajcp-4886	185	7	and	and	CCONJ
ajcp-4886	185	8	monomers	monomer	NOUN
ajcp-4886	185	9	,	,	PUNCT
ajcp-4886	185	10	the	the	DET
ajcp-4886	185	11	nanoparticles	nanoparticle	NOUN
ajcp-4886	185	12	(	(	PUNCT
ajcp-4886	185	13	np@	np@	NOUN
ajcp-4886	185	14	sio2@f	sio2@f	PROPN
ajcp-4886	185	15	-	-	PUNCT
ajcp-4886	185	16	sloh	sloh	NOUN
ajcp-4886	185	17	)	)	PUNCT
ajcp-4886	185	18	reduce	reduce	VERB
ajcp-4886	185	19	aβ	aβ	DET
ajcp-4886	185	20	aggregation	aggregation	NOUN
ajcp-4886	185	21	,	,	PUNCT
ajcp-4886	185	22	as	as	SCONJ
ajcp-4886	185	23	confirmed	confirm	VERB
ajcp-4886	185	24	by	by	ADP
ajcp-4886	185	25	the	the	DET
ajcp-4886	185	26	tht	tht	PROPN
ajcp-4886	185	27	fluorescence	fluorescence	NOUN
ajcp-4886	185	28	experiment	experiment	NOUN
ajcp-4886	185	29	.	.	PUNCT
ajcp-4886	186	1	this	this	PRON
ajcp-4886	186	2	suggests	suggest	VERB
ajcp-4886	186	3	the	the	DET
ajcp-4886	186	4	potential	potential	NOUN
ajcp-4886	186	5	for	for	ADP
ajcp-4886	186	6	alzheimer	alzheimer	PROPN
ajcp-4886	186	7	’s	’s	PART
ajcp-4886	186	8	disease	disease	NOUN
ajcp-4886	186	9	(	(	PUNCT
ajcp-4886	186	10	ad	ad	NOUN
ajcp-4886	186	11	)	)	PUNCT
ajcp-4886	186	12	treatment	treatment	NOUN
ajcp-4886	186	13	.	.	PUNCT
ajcp-4886	187	1	aβ	aβ	DET
ajcp-4886	187	2	species	specie	NOUN
ajcp-4886	187	3	ranging	range	VERB
ajcp-4886	187	4	from	from	ADP
ajcp-4886	187	5	aβ42	aβ42	PROPN
ajcp-4886	187	6	monomers	monomer	NOUN
ajcp-4886	187	7	and	and	CCONJ
ajcp-4886	187	8	oligomers	oligomer	NOUN
ajcp-4886	187	9	to	to	PART
ajcp-4886	187	10	gd3	gd3	VERB
ajcp-4886	187	11	+	+	PROPN
ajcp-4886	187	12	-based	-based	ADJ
ajcp-4886	187	13	nps	nps	PROPN
ajcp-4886	187	14	with	with	ADP
ajcp-4886	187	15	f	f	NOUN
ajcp-4886	187	16	-	-	PUNCT
ajcp-4886	187	17	sloh	sloh	ADJ
ajcp-4886	187	18	surface	surface	NOUN
ajcp-4886	187	19	functionalization	functionalization	NOUN
ajcp-4886	187	20	lessen	lessen	VERB
ajcp-4886	187	21	neurotoxicity	neurotoxicity	NOUN
ajcp-4886	187	22	as	as	ADV
ajcp-4886	187	23	well	well	ADV
ajcp-4886	187	24	.	.	PUNCT
ajcp-4886	188	1	additionally	additionally	ADV
ajcp-4886	188	2	,	,	PUNCT
ajcp-4886	188	3	the	the	DET
ajcp-4886	188	4	nps	nps	PROPN
ajcp-4886	188	5	effectively	effectively	ADV
ajcp-4886	188	6	stop	stop	VERB
ajcp-4886	188	7	aβ	aβ	DET
ajcp-4886	188	8	species	specie	NOUN
ajcp-4886	188	9	from	from	ADP
ajcp-4886	188	10	generating	generate	VERB
ajcp-4886	188	11	reactive	reactive	ADJ
ajcp-4886	188	12	oxygen	oxygen	NOUN
ajcp-4886	188	13	species	specie	NOUN
ajcp-4886	188	14	(	(	PUNCT
ajcp-4886	188	15	ros	ros	PROPN
ajcp-4886	188	16	)	)	PUNCT
ajcp-4886	188	17	,	,	PUNCT
ajcp-4886	188	18	indicating	indicate	VERB
ajcp-4886	188	19	that	that	SCONJ
ajcp-4886	188	20	ad	ad	NOUN
ajcp-4886	188	21	treatments	treatment	NOUN
ajcp-4886	188	22	may	may	AUX
ajcp-4886	188	23	be	be	AUX
ajcp-4886	188	24	possible	possible	ADJ
ajcp-4886	188	25	with	with	ADP
ajcp-4886	188	26	them	they	PRON
ajcp-4886	188	27	(	(	PUNCT
ajcp-4886	188	28	wang	wang	PROPN
ajcp-4886	188	29	et	et	PROPN
ajcp-4886	188	30	al	al	PROPN
ajcp-4886	188	31	.	.	PROPN
ajcp-4886	188	32	,	,	PUNCT
ajcp-4886	188	33	2020	2020	NUM
ajcp-4886	188	34	)	)	PUNCT
ajcp-4886	188	35	.	.	PUNCT
ajcp-4886	189	1	figure	figure	VERB
ajcp-4886	189	2	5	5	NUM
ajcp-4886	189	3	:	:	PUNCT
ajcp-4886	189	4	chemical	chemical	NOUN
ajcp-4886	189	5	structures	structure	NOUN
ajcp-4886	189	6	of	of	ADP
ajcp-4886	189	7	harmine	harmine	NOUN
ajcp-4886	189	8	and	and	CCONJ
ajcp-4886	189	9	its	its	PRON
ajcp-4886	189	10	derivatives	derivative	NOUN
ajcp-4886	189	11	.	.	PUNCT
ajcp-4886	190	1	copy	copy	VERB
ajcp-4886	190	2	from	from	ADP
ajcp-4886	190	3	ref	ref	NOUN
ajcp-4886	190	4	(	(	PUNCT
ajcp-4886	190	5	du	du	PROPN
ajcp-4886	190	6	et	et	PROPN
ajcp-4886	190	7	al	al	PROPN
ajcp-4886	190	8	.	.	PROPN
ajcp-4886	190	9	,	,	PUNCT
ajcp-4886	190	10	2023	2023	NUM
ajcp-4886	190	11	)	)	PUNCT
ajcp-4886	190	12	stabilization	stabilization	NOUN
ajcp-4886	190	13	of	of	ADP
ajcp-4886	190	14	amyloid	amyloid	NOUN
ajcp-4886	190	15	-	-	PUNCT
ajcp-4886	190	16	β	β	NOUN
ajcp-4886	190	17	oligomers	oligomer	NOUN
ajcp-4886	190	18	a	a	DET
ajcp-4886	190	19	number	number	NOUN
ajcp-4886	190	20	of	of	ADP
ajcp-4886	190	21	tiny	tiny	ADJ
ajcp-4886	190	22	compounds	compound	NOUN
ajcp-4886	190	23	have	have	AUX
ajcp-4886	190	24	been	be	AUX
ajcp-4886	190	25	demonstrated	demonstrate	VERB
ajcp-4886	190	26	to	to	PART
ajcp-4886	190	27	be	be	AUX
ajcp-4886	190	28	useful	useful	ADJ
ajcp-4886	190	29	anti	anti	ADJ
ajcp-4886	190	30	-	-	ADJ
ajcp-4886	190	31	aggregating	aggregating	ADJ
ajcp-4886	190	32	agents	agent	NOUN
ajcp-4886	190	33	in	in	ADP
ajcp-4886	190	34	the	the	DET
ajcp-4886	190	35	treatment	treatment	NOUN
ajcp-4886	190	36	of	of	ADP
ajcp-4886	190	37	alzheimer	alzheimer	PROPN
ajcp-4886	190	38	’s	’s	PART
ajcp-4886	190	39	disease	disease	NOUN
ajcp-4886	190	40	,	,	PUNCT
ajcp-4886	190	41	including	include	VERB
ajcp-4886	190	42	curcumin	curcumin	NOUN
ajcp-4886	190	43	,	,	PUNCT
ajcp-4886	190	44	resveratrol	resveratrol	NOUN
ajcp-4886	190	45	,	,	PUNCT
ajcp-4886	190	46	ellagic	ellagic	ADJ
ajcp-4886	190	47	acid	acid	NOUN
ajcp-4886	190	48	,	,	PUNCT
ajcp-4886	190	49	meric	meric	PROPN
ajcp-4886	190	50	decapeptide	decapeptide	PROPN
ajcp-4886	190	51	rk10	rk10	PROPN
ajcp-4886	190	52	,	,	PUNCT
ajcp-4886	190	53	and	and	CCONJ
ajcp-4886	190	54	epigallocatechin3	epigallocatechin3	NOUN
ajcp-4886	190	55	-	-	PUNCT
ajcp-4886	190	56	gallate	gallate	NOUN
ajcp-4886	190	57	(	(	PUNCT
ajcp-4886	190	58	egcg	egcg	NOUN
ajcp-4886	190	59	)	)	PUNCT
ajcp-4886	190	60	(	(	PUNCT
ajcp-4886	190	61	mohammed	mohammed	PROPN
ajcp-4886	190	62	et	et	PROPN
ajcp-4886	190	63	al	al	PROPN
ajcp-4886	190	64	.	.	PROPN
ajcp-4886	190	65	,	,	PUNCT
ajcp-4886	190	66	2023	2023	NUM
ajcp-4886	190	67	)	)	PUNCT
ajcp-4886	190	68	.	.	PUNCT
ajcp-4886	191	1	the	the	DET
ajcp-4886	191	2	active	active	ADJ
ajcp-4886	191	3	polyphenol	polyphenol	NOUN
ajcp-4886	191	4	found	find	VERB
ajcp-4886	191	5	in	in	ADP
ajcp-4886	191	6	green	green	ADJ
ajcp-4886	191	7	tea	tea	NOUN
ajcp-4886	191	8	,	,	PUNCT
ajcp-4886	191	9	called	call	VERB
ajcp-4886	191	10	epigallocatechin-3gallate	epigallocatechin-3gallate	PROPN
ajcp-4886	191	11	(	(	PUNCT
ajcp-4886	191	12	egcg	egcg	NOUN
ajcp-4886	191	13	)	)	PUNCT
ajcp-4886	191	14	,	,	PUNCT
ajcp-4886	191	15	has	have	AUX
ajcp-4886	191	16	drawn	draw	VERB
ajcp-4886	191	17	a	a	DET
ajcp-4886	191	18	lot	lot	NOUN
ajcp-4886	191	19	of	of	ADP
ajcp-4886	191	20	interest	interest	NOUN
ajcp-4886	191	21	because	because	SCONJ
ajcp-4886	191	22	of	of	ADP
ajcp-4886	191	23	its	its	PRON
ajcp-4886	191	24	potential	potential	NOUN
ajcp-4886	191	25	for	for	ADP
ajcp-4886	191	26	health	health	NOUN
ajcp-4886	191	27	benefits	benefit	NOUN
ajcp-4886	191	28	,	,	PUNCT
ajcp-4886	191	29	which	which	PRON
ajcp-4886	191	30	include	include	VERB
ajcp-4886	191	31	anti	anti	ADJ
ajcp-4886	191	32	-	-	ADJ
ajcp-4886	191	33	oxidation	oxidation	ADJ
ajcp-4886	191	34	,	,	PUNCT
ajcp-4886	191	35	radical	radical	ADJ
ajcp-4886	191	36	scavenging	scavenging	NOUN
ajcp-4886	191	37	,	,	PUNCT
ajcp-4886	191	38	metal	metal	NOUN
ajcp-4886	191	39	chelating	chelating	NOUN
ajcp-4886	191	40	,	,	PUNCT
ajcp-4886	191	41	anti	anti	ADJ
ajcp-4886	191	42	-	-	ADJ
ajcp-4886	191	43	carcinogen	carcinogen	ADJ
ajcp-4886	191	44	,	,	PUNCT
ajcp-4886	191	45	antiapoptosis	antiapoptosis	NOUN
ajcp-4886	191	46	,	,	PUNCT
ajcp-4886	191	47	and	and	CCONJ
ajcp-4886	191	48	anti	anti	ADJ
ajcp-4886	191	49	-	-	ADJ
ajcp-4886	191	50	inflammatory	inflammatory	ADJ
ajcp-4886	191	51	qualities	quality	NOUN
ajcp-4886	191	52	(	(	PUNCT
ajcp-4886	191	53	mokra	mokra	NOUN
ajcp-4886	191	54	et	et	PROPN
ajcp-4886	191	55	al	al	PROPN
ajcp-4886	191	56	.	.	PROPN
ajcp-4886	191	57	,	,	PUNCT
ajcp-4886	191	58	2022	2022	NUM
ajcp-4886	191	59	)	)	PUNCT
ajcp-4886	191	60	.	.	PUNCT
ajcp-4886	192	1	egcg	egcg	PROPN
ajcp-4886	192	2	activates	activate	VERB
ajcp-4886	192	3	the	the	DET
ajcp-4886	192	4	proteolytic	proteolytic	ADJ
ajcp-4886	192	5	pathway	pathway	NOUN
ajcp-4886	192	6	of	of	ADP
ajcp-4886	192	7	nonamyloidogenic	nonamyloidogenic	ADJ
ajcp-4886	192	8	α	α	PROPN
ajcp-4886	192	9	-	-	PUNCT
ajcp-4886	192	10	secretase	secretase	NOUN
ajcp-4886	192	11	,	,	PUNCT
ajcp-4886	192	12	which	which	PRON
ajcp-4886	192	13	inhibits	inhibit	VERB
ajcp-4886	192	14	the	the	DET
ajcp-4886	192	15	aging	age	VERB
ajcp-4886	192	16	process	process	NOUN
ajcp-4886	192	17	of	of	ADP
ajcp-4886	192	18	the	the	DET
ajcp-4886	192	19	brain	brain	NOUN
ajcp-4886	192	20	and	and	CCONJ
ajcp-4886	192	21	lowers	lower	VERB
ajcp-4886	192	22	aβ	aβ	DET
ajcp-4886	192	23	levels	level	NOUN
ajcp-4886	192	24	,	,	PUNCT
ajcp-4886	192	25	according	accord	VERB
ajcp-4886	192	26	to	to	ADP
ajcp-4886	192	27	several	several	ADJ
ajcp-4886	192	28	studies	study	NOUN
ajcp-4886	192	29	(	(	PUNCT
ajcp-4886	192	30	bao	bao	PROPN
ajcp-4886	192	31	et	et	PROPN
ajcp-4886	192	32	al	al	PROPN
ajcp-4886	192	33	.	.	PROPN
ajcp-4886	192	34	,	,	PUNCT
ajcp-4886	192	35	2020	2020	NUM
ajcp-4886	192	36	)	)	PUNCT
ajcp-4886	192	37	.	.	PUNCT
ajcp-4886	193	1	apart	apart	ADV
ajcp-4886	193	2	from	from	ADP
ajcp-4886	193	3	its	its	PRON
ajcp-4886	193	4	potential	potential	NOUN
ajcp-4886	193	5	to	to	PART
ajcp-4886	193	6	prevent	prevent	VERB
ajcp-4886	193	7	the	the	DET
ajcp-4886	193	8	creation	creation	NOUN
ajcp-4886	193	9	of	of	ADP
ajcp-4886	193	10	harmful	harmful	ADJ
ajcp-4886	193	11	prefibrillar	prefibrillar	ADJ
ajcp-4886	193	12	oligomers	oligomer	NOUN
ajcp-4886	193	13	,	,	PUNCT
ajcp-4886	193	14	pa	pa	PROPN
ajcp-4886	193	15	ge	ge	PROPN
ajcp-4886	193	16	22	22	NUM
ajcp-4886	193	17	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-4886	193	18	am	be	AUX
ajcp-4886	193	19	.	.	PUNCT
ajcp-4886	194	1	j.	j.	PROPN
ajcp-4886	194	2	chem	chem	PROPN
ajcp-4886	194	3	.	.	PUNCT
ajcp-4886	195	1	pharm	pharm	PROPN
ajcp-4886	195	2	.	.	PUNCT
ajcp-4886	196	1	4(1	4(1	NOUN
ajcp-4886	196	2	)	)	PUNCT
ajcp-4886	197	1	16	16	NUM
ajcp-4886	197	2	-	-	SYM
ajcp-4886	197	3	28	28	NUM
ajcp-4886	197	4	,	,	PUNCT
ajcp-4886	197	5	2025	2025	NUM
ajcp-4886	197	6	egcg	egcg	NOUN
ajcp-4886	197	7	has	have	AUX
ajcp-4886	197	8	also	also	ADV
ajcp-4886	197	9	been	be	AUX
ajcp-4886	197	10	proposed	propose	VERB
ajcp-4886	197	11	as	as	ADP
ajcp-4886	197	12	a	a	DET
ajcp-4886	197	13	possible	possible	ADJ
ajcp-4886	197	14	remodeler	remodeler	NOUN
ajcp-4886	197	15	of	of	ADP
ajcp-4886	197	16	preexisting	preexist	VERB
ajcp-4886	197	17	amyloid	amyloid	NOUN
ajcp-4886	197	18	fibrils	fibril	NOUN
ajcp-4886	197	19	.	.	PUNCT
ajcp-4886	198	1	since	since	SCONJ
ajcp-4886	198	2	egcg	egcg	NOUN
ajcp-4886	198	3	is	be	AUX
ajcp-4886	198	4	unstable	unstable	ADJ
ajcp-4886	198	5	and	and	CCONJ
ajcp-4886	198	6	oxidizes	oxidize	VERB
ajcp-4886	198	7	quickly	quickly	ADV
ajcp-4886	198	8	to	to	PART
ajcp-4886	198	9	produce	produce	VERB
ajcp-4886	198	10	a	a	DET
ajcp-4886	198	11	range	range	NOUN
ajcp-4886	198	12	of	of	ADP
ajcp-4886	198	13	products	product	NOUN
ajcp-4886	198	14	,	,	PUNCT
ajcp-4886	198	15	most	most	ADJ
ajcp-4886	198	16	research	research	NOUN
ajcp-4886	198	17	is	be	AUX
ajcp-4886	198	18	done	do	VERB
ajcp-4886	198	19	at	at	ADP
ajcp-4886	198	20	physiological	physiological	ADJ
ajcp-4886	198	21	ph	ph	NOUN
ajcp-4886	198	22	(	(	PUNCT
ajcp-4886	198	23	sternke	sternke	NOUN
ajcp-4886	198	24	-	-	PUNCT
ajcp-4886	198	25	hoffmann	hoffmann	PROPN
ajcp-4886	198	26	et	et	PROPN
ajcp-4886	198	27	al	al	PROPN
ajcp-4886	198	28	.	.	PROPN
ajcp-4886	198	29	,	,	PUNCT
ajcp-4886	198	30	2020	2020	NUM
ajcp-4886	198	31	)	)	PUNCT
ajcp-4886	198	32	.	.	PUNCT
ajcp-4886	199	1	research	research	NOUN
ajcp-4886	199	2	has	have	AUX
ajcp-4886	199	3	demonstrated	demonstrate	VERB
ajcp-4886	199	4	that	that	SCONJ
ajcp-4886	199	5	polyphenols	polyphenol	NOUN
ajcp-4886	199	6	can	can	AUX
ajcp-4886	199	7	either	either	CCONJ
ajcp-4886	199	8	stop	stop	VERB
ajcp-4886	199	9	aβ	aβ	PRON
ajcp-4886	199	10	oligomerization	oligomerization	NOUN
ajcp-4886	199	11	from	from	ADP
ajcp-4886	199	12	happening	happen	VERB
ajcp-4886	199	13	or	or	CCONJ
ajcp-4886	199	14	restructure	restructure	NOUN
ajcp-4886	199	15	and	and	CCONJ
ajcp-4886	199	16	stabilize	stabilize	VERB
ajcp-4886	199	17	aβ	aβ	NOUN
ajcp-4886	199	18	oligomers	oligomer	NOUN
ajcp-4886	199	19	into	into	ADP
ajcp-4886	199	20	forms	form	NOUN
ajcp-4886	199	21	that	that	PRON
ajcp-4886	199	22	are	be	AUX
ajcp-4886	199	23	safe	safe	ADJ
ajcp-4886	199	24	.	.	PUNCT
ajcp-4886	200	1	to	to	PART
ajcp-4886	200	2	produce	produce	VERB
ajcp-4886	200	3	unstructured	unstructured	ADJ
ajcp-4886	200	4	aβ	aβ	NOUN
ajcp-4886	200	5	oligomers	oligomer	NOUN
ajcp-4886	200	6	,	,	PUNCT
ajcp-4886	200	7	egcg	egcg	NOUN
ajcp-4886	200	8	inhibits	inhibit	VERB
ajcp-4886	200	9	aβ	aβ	ADP
ajcp-4886	200	10	fibrillogenesis	fibrillogenesis	PROPN
ajcp-4886	200	11	.	.	PUNCT
ajcp-4886	201	1	smaller	small	ADJ
ajcp-4886	201	2	,	,	PUNCT
ajcp-4886	201	3	more	more	ADV
ajcp-4886	201	4	amorphous	amorphous	ADJ
ajcp-4886	201	5	,	,	PUNCT
ajcp-4886	201	6	nontoxic	nontoxic	ADJ
ajcp-4886	201	7	protein	protein	NOUN
ajcp-4886	201	8	aggregates	aggregate	NOUN
ajcp-4886	201	9	are	be	AUX
ajcp-4886	201	10	assembled	assemble	VERB
ajcp-4886	201	11	from	from	ADP
ajcp-4886	201	12	freshly	freshly	ADV
ajcp-4886	201	13	formed	form	VERB
ajcp-4886	201	14	oligomers	oligomer	NOUN
ajcp-4886	201	15	with	with	ADP
ajcp-4886	201	16	its	its	PRON
ajcp-4886	201	17	assistance	assistance	NOUN
ajcp-4886	201	18	(	(	PUNCT
ajcp-4886	201	19	el	el	PROPN
ajcp-4886	201	20	gaamouch	gaamouch	PROPN
ajcp-4886	201	21	et	et	PROPN
ajcp-4886	201	22	al	al	PROPN
ajcp-4886	201	23	.	.	PROPN
ajcp-4886	201	24	,	,	PUNCT
ajcp-4886	201	25	2022	2022	NUM
ajcp-4886	201	26	)	)	PUNCT
ajcp-4886	201	27	.	.	PUNCT
ajcp-4886	202	1	catecholamine	catecholamine	NOUN
ajcp-4886	202	2	neurotransmitters	neurotransmitter	NOUN
ajcp-4886	202	3	have	have	VERB
ajcp-4886	202	4	the	the	DET
ajcp-4886	202	5	ability	ability	NOUN
ajcp-4886	202	6	to	to	PART
ajcp-4886	202	7	maintain	maintain	VERB
ajcp-4886	202	8	aβ	aβ	NOUN
ajcp-4886	202	9	in	in	ADP
ajcp-4886	202	10	its	its	PRON
ajcp-4886	202	11	oligomeric	oligomeric	ADJ
ajcp-4886	202	12	state	state	NOUN
ajcp-4886	202	13	,	,	PUNCT
ajcp-4886	202	14	according	accord	VERB
ajcp-4886	202	15	to	to	ADP
ajcp-4886	202	16	studies	study	NOUN
ajcp-4886	202	17	.	.	PUNCT
ajcp-4886	203	1	indeed	indeed	ADV
ajcp-4886	203	2	,	,	PUNCT
ajcp-4886	203	3	aβ	aβ	DET
ajcp-4886	203	4	oligomer	oligomer	ADJ
ajcp-4886	203	5	stabilization	stabilization	NOUN
ajcp-4886	203	6	may	may	AUX
ajcp-4886	203	7	involve	involve	VERB
ajcp-4886	203	8	the	the	DET
ajcp-4886	203	9	cooperation	cooperation	NOUN
ajcp-4886	203	10	of	of	ADP
ajcp-4886	203	11	ne	ne	PROPN
ajcp-4886	203	12	and	and	CCONJ
ajcp-4886	203	13	da	da	NOUN
ajcp-4886	203	14	.	.	PUNCT
ajcp-4886	204	1	an	an	DET
ajcp-4886	204	2	elevated	elevated	ADJ
ajcp-4886	204	3	oligomer	oligomer	ADJ
ajcp-4886	204	4	concentration	concentration	NOUN
ajcp-4886	204	5	is	be	AUX
ajcp-4886	204	6	indicated	indicate	VERB
ajcp-4886	204	7	by	by	ADP
ajcp-4886	204	8	the	the	DET
ajcp-4886	204	9	aggregated	aggregated	ADJ
ajcp-4886	204	10	aβ	aβ	NOUN
ajcp-4886	204	11	,	,	PUNCT
ajcp-4886	204	12	which	which	PRON
ajcp-4886	204	13	is	be	AUX
ajcp-4886	204	14	significantly	significantly	ADV
ajcp-4886	204	15	blurred	blur	VERB
ajcp-4886	204	16	when	when	SCONJ
ajcp-4886	204	17	ne	ne	PROPN
ajcp-4886	204	18	and	and	CCONJ
ajcp-4886	204	19	da	da	PROPN
ajcp-4886	204	20	are	be	AUX
ajcp-4886	204	21	present	present	ADJ
ajcp-4886	204	22	(	(	PUNCT
ajcp-4886	204	23	allnutt	allnutt	PROPN
ajcp-4886	204	24	&	&	CCONJ
ajcp-4886	204	25	matera	matera	PROPN
ajcp-4886	204	26	,	,	PUNCT
ajcp-4886	204	27	2023	2023	NUM
ajcp-4886	204	28	)	)	PUNCT
ajcp-4886	204	29	.	.	PUNCT
ajcp-4886	205	1	figure	figure	VERB
ajcp-4886	205	2	6	6	NUM
ajcp-4886	205	3	:	:	PUNCT
ajcp-4886	205	4	structures	structure	NOUN
ajcp-4886	205	5	of	of	ADP
ajcp-4886	205	6	neurotransmitters	neurotransmitter	NOUN
ajcp-4886	205	7	examined	examine	VERB
ajcp-4886	205	8	for	for	ADP
ajcp-4886	205	9	stabilization	stabilization	NOUN
ajcp-4886	205	10	of	of	ADP
ajcp-4886	205	11	aβ	aβ	DET
ajcp-4886	205	12	oligomers	oligomer	NOUN
ajcp-4886	205	13	.	.	PUNCT
ajcp-4886	206	1	source	source	NOUN
ajcp-4886	206	2	:	:	PUNCT
ajcp-4886	206	3	adopted	adopt	VERB
ajcp-4886	206	4	from	from	ADP
ajcp-4886	206	5	(	(	PUNCT
ajcp-4886	206	6	allnutt	allnutt	PROPN
ajcp-4886	206	7	&	&	CCONJ
ajcp-4886	206	8	matera	matera	PROPN
ajcp-4886	206	9	,	,	PUNCT
ajcp-4886	206	10	2023	2023	NUM
ajcp-4886	206	11	)	)	PUNCT
ajcp-4886	206	12	an	an	DET
ajcp-4886	206	13	antioxidant	antioxidant	ADJ
ajcp-4886	206	14	,	,	PUNCT
ajcp-4886	206	15	anti	anti	ADJ
ajcp-4886	206	16	-	-	ADJ
ajcp-4886	206	17	inflammatory	inflammatory	ADJ
ajcp-4886	206	18	,	,	PUNCT
ajcp-4886	206	19	and	and	CCONJ
ajcp-4886	206	20	anticancer	anticancer	NOUN
ajcp-4886	206	21	polyphenolic	polyphenolic	NOUN
ajcp-4886	206	22	compound	compound	NOUN
ajcp-4886	206	23	is	be	AUX
ajcp-4886	206	24	curcumin	curcumin	NOUN
ajcp-4886	206	25	.	.	PUNCT
ajcp-4886	207	1	its	its	PRON
ajcp-4886	207	2	low	low	ADJ
ajcp-4886	207	3	bioavailability	bioavailability	NOUN
ajcp-4886	207	4	restricts	restrict	VERB
ajcp-4886	207	5	efficacy	efficacy	NOUN
ajcp-4886	207	6	despite	despite	SCONJ
ajcp-4886	207	7	its	its	PRON
ajcp-4886	207	8	possible	possible	ADJ
ajcp-4886	207	9	advantages	advantage	NOUN
ajcp-4886	207	10	in	in	ADP
ajcp-4886	207	11	alzheimer	alzheimer	PROPN
ajcp-4886	207	12	’s	’s	PART
ajcp-4886	207	13	disease	disease	NOUN
ajcp-4886	207	14	(	(	PUNCT
ajcp-4886	207	15	ad	ad	NOUN
ajcp-4886	207	16	)	)	PUNCT
ajcp-4886	207	17	models	model	NOUN
ajcp-4886	207	18	(	(	PUNCT
ajcp-4886	207	19	momma	momma	NOUN
ajcp-4886	207	20	et	et	PROPN
ajcp-4886	207	21	al	al	PROPN
ajcp-4886	207	22	.	.	PROPN
ajcp-4886	207	23	,	,	PUNCT
ajcp-4886	207	24	2023	2023	NUM
ajcp-4886	207	25	)	)	PUNCT
ajcp-4886	207	26	.	.	PUNCT
ajcp-4886	208	1	enhancing	enhance	VERB
ajcp-4886	208	2	bioavailability	bioavailability	NOUN
ajcp-4886	208	3	and	and	CCONJ
ajcp-4886	208	4	brain	brain	NOUN
ajcp-4886	208	5	translocation	translocation	NOUN
ajcp-4886	208	6	,	,	PUNCT
ajcp-4886	208	7	gt863	gt863	NOUN
ajcp-4886	208	8	,	,	PUNCT
ajcp-4886	208	9	a	a	DET
ajcp-4886	208	10	derivative	derivative	NOUN
ajcp-4886	208	11	of	of	ADP
ajcp-4886	208	12	curcumin	curcumin	NOUN
ajcp-4886	208	13	,	,	PUNCT
ajcp-4886	208	14	was	be	AUX
ajcp-4886	208	15	synthesized	synthesize	VERB
ajcp-4886	208	16	.	.	PUNCT
ajcp-4886	209	1	together	together	ADV
ajcp-4886	209	2	with	with	ADP
ajcp-4886	209	3	dual	dual	ADJ
ajcp-4886	209	4	stabilization	stabilization	NOUN
ajcp-4886	209	5	of	of	ADP
ajcp-4886	209	6	aβ	aβ	PRON
ajcp-4886	209	7	and	and	CCONJ
ajcp-4886	209	8	tau	tau	PROPN
ajcp-4886	209	9	aggregation	aggregation	NOUN
ajcp-4886	209	10	,	,	PUNCT
ajcp-4886	209	11	in	in	ADP
ajcp-4886	209	12	vivo	vivo	ADJ
ajcp-4886	209	13	studies	study	NOUN
ajcp-4886	209	14	showed	show	VERB
ajcp-4886	209	15	that	that	SCONJ
ajcp-4886	209	16	gt863	gt863	NOUN
ajcp-4886	209	17	could	could	AUX
ajcp-4886	209	18	ameliorate	ameliorate	VERB
ajcp-4886	209	19	cognitive	cognitive	ADJ
ajcp-4886	209	20	impairment	impairment	NOUN
ajcp-4886	209	21	in	in	ADP
ajcp-4886	209	22	an	an	DET
ajcp-4886	209	23	ad	ad	NOUN
ajcp-4886	209	24	mouse	mouse	NOUN
ajcp-4886	209	25	model	model	NOUN
ajcp-4886	209	26	.	.	PUNCT
ajcp-4886	210	1	it	it	PRON
ajcp-4886	210	2	would	would	AUX
ajcp-4886	210	3	seem	seem	VERB
ajcp-4886	210	4	from	from	ADP
ajcp-4886	210	5	this	this	PRON
ajcp-4886	210	6	that	that	SCONJ
ajcp-4886	210	7	gt863	gt863	NOUN
ajcp-4886	210	8	is	be	AUX
ajcp-4886	210	9	a	a	DET
ajcp-4886	210	10	good	good	ADJ
ajcp-4886	210	11	candidate	candidate	NOUN
ajcp-4886	210	12	for	for	ADP
ajcp-4886	210	13	more	more	ADJ
ajcp-4886	210	14	study	study	NOUN
ajcp-4886	210	15	in	in	ADP
ajcp-4886	210	16	the	the	DET
ajcp-4886	210	17	treatment	treatment	NOUN
ajcp-4886	210	18	of	of	ADP
ajcp-4886	210	19	ad	ad	NOUN
ajcp-4886	210	20	.	.	PUNCT
ajcp-4886	211	1	figure	figure	VERB
ajcp-4886	211	2	7	7	NUM
ajcp-4886	211	3	:	:	PUNCT
ajcp-4886	211	4	structures	structure	NOUN
ajcp-4886	211	5	of	of	ADP
ajcp-4886	211	6	gt863	gt863	NOUN
ajcp-4886	211	7	and	and	CCONJ
ajcp-4886	211	8	curcumin	curcumin	PROPN
ajcp-4886	211	9	.	.	PUNCT
ajcp-4886	212	1	source	source	NOUN
ajcp-4886	212	2	:	:	PUNCT
ajcp-4886	212	3	adopted	adopt	VERB
ajcp-4886	212	4	from	from	ADP
ajcp-4886	212	5	ref	ref	NOUN
ajcp-4886	212	6	(	(	PUNCT
ajcp-4886	212	7	zhou	zhou	X
ajcp-4886	212	8	et	et	PROPN
ajcp-4886	212	9	al	al	PROPN
ajcp-4886	212	10	.	.	PROPN
ajcp-4886	212	11	,	,	PUNCT
ajcp-4886	212	12	2022	2022	NUM
ajcp-4886	212	13	)	)	PUNCT
ajcp-4886	212	14	few	few	ADJ
ajcp-4886	212	15	compounds	compound	NOUN
ajcp-4886	212	16	that	that	PRON
ajcp-4886	212	17	can	can	AUX
ajcp-4886	212	18	disassemble	disassemble	VERB
ajcp-4886	212	19	pre	pre	ADJ
ajcp-4886	212	20	-	-	ADJ
ajcp-4886	212	21	formed	formed	ADJ
ajcp-4886	212	22	oligomers	oligomer	NOUN
ajcp-4886	212	23	have	have	AUX
ajcp-4886	212	24	progressed	progress	VERB
ajcp-4886	212	25	to	to	ADP
ajcp-4886	212	26	the	the	DET
ajcp-4886	212	27	point	point	NOUN
ajcp-4886	212	28	of	of	ADP
ajcp-4886	212	29	clinical	clinical	ADJ
ajcp-4886	212	30	trials	trial	NOUN
ajcp-4886	212	31	,	,	PUNCT
ajcp-4886	212	32	despite	despite	SCONJ
ajcp-4886	212	33	the	the	DET
ajcp-4886	212	34	fact	fact	NOUN
ajcp-4886	212	35	that	that	SCONJ
ajcp-4886	212	36	a	a	DET
ajcp-4886	212	37	large	large	ADJ
ajcp-4886	212	38	number	number	NOUN
ajcp-4886	212	39	of	of	ADP
ajcp-4886	212	40	aβ	aβ	PRON
ajcp-4886	212	41	aggregation	aggregation	NOUN
ajcp-4886	212	42	inhibitors	inhibitor	NOUN
ajcp-4886	212	43	have	have	AUX
ajcp-4886	212	44	been	be	AUX
ajcp-4886	212	45	discovered	discover	VERB
ajcp-4886	212	46	in	in	ADP
ajcp-4886	212	47	vitro	vitro	X
ajcp-4886	212	48	.	.	PUNCT
ajcp-4886	213	1	trimiprosate	trimiprosate	NOUN
ajcp-4886	213	2	,	,	PUNCT
ajcp-4886	213	3	also	also	ADV
ajcp-4886	213	4	known	know	VERB
ajcp-4886	213	5	as	as	ADP
ajcp-4886	213	6	3	3	NUM
ajcp-4886	213	7	-	-	PUNCT
ajcp-4886	213	8	amino-1	amino-1	NUM
ajcp-4886	213	9	-	-	PUNCT
ajcp-4886	213	10	propanesulfonic	propanesulfonic	ADJ
ajcp-4886	213	11	acid	acid	NOUN
ajcp-4886	213	12	;	;	PUNCT
ajcp-4886	213	13	alzhemedtm	alzhemedtm	VERB
ajcp-4886	213	14	)	)	PUNCT
ajcp-4886	213	15	,	,	PUNCT
ajcp-4886	213	16	has	have	AUX
ajcp-4886	213	17	been	be	AUX
ajcp-4886	213	18	shown	show	VERB
ajcp-4886	213	19	to	to	PART
ajcp-4886	213	20	bind	bind	VERB
ajcp-4886	213	21	preferentially	preferentially	ADV
ajcp-4886	213	22	to	to	AUX
ajcp-4886	213	23	pre	pre	ADJ
ajcp-4886	213	24	-	-	ADJ
ajcp-4886	213	25	fibrillar	fibrillar	ADJ
ajcp-4886	213	26	(	(	PUNCT
ajcp-4886	213	27	monomeric	monomeric	ADJ
ajcp-4886	213	28	and	and	CCONJ
ajcp-4886	213	29	oligomeric	oligomeric	ADJ
ajcp-4886	213	30	)	)	PUNCT
ajcp-4886	213	31	forms	form	NOUN
ajcp-4886	213	32	of	of	ADP
ajcp-4886	213	33	antibody	antibody	NOUN
ajcp-4886	213	34	,	,	PUNCT
ajcp-4886	213	35	thereby	thereby	ADV
ajcp-4886	213	36	preventing	prevent	VERB
ajcp-4886	213	37	their	their	PRON
ajcp-4886	213	38	conversion	conversion	NOUN
ajcp-4886	213	39	into	into	ADP
ajcp-4886	213	40	higher	high	ADJ
ajcp-4886	213	41	-	-	PUNCT
ajcp-4886	213	42	order	order	NOUN
ajcp-4886	213	43	oligomers	oligomer	NOUN
ajcp-4886	213	44	and	and	CCONJ
ajcp-4886	213	45	fibrils	fibril	NOUN
ajcp-4886	213	46	(	(	PUNCT
ajcp-4886	213	47	ono	ono	PROPN
ajcp-4886	213	48	&	&	CCONJ
ajcp-4886	213	49	tsuji	tsuji	PROPN
ajcp-4886	213	50	,	,	PUNCT
ajcp-4886	213	51	2020	2020	NUM
ajcp-4886	213	52	)	)	PUNCT
ajcp-4886	213	53	.	.	PUNCT
ajcp-4886	214	1	moreover	moreover	ADV
ajcp-4886	214	2	,	,	PUNCT
ajcp-4886	214	3	metal	metal	NOUN
ajcp-4886	214	4	ions	ion	NOUN
ajcp-4886	214	5	control	control	VERB
ajcp-4886	214	6	aβ	aβ	NOUN
ajcp-4886	214	7	polymorphism	polymorphism	NOUN
ajcp-4886	214	8	,	,	PUNCT
ajcp-4886	214	9	stability	stability	NOUN
ajcp-4886	214	10	,	,	PUNCT
ajcp-4886	214	11	and	and	CCONJ
ajcp-4886	214	12	aggregation	aggregation	NOUN
ajcp-4886	214	13	.	.	PUNCT
ajcp-4886	215	1	based	base	VERB
ajcp-4886	215	2	on	on	ADP
ajcp-4886	215	3	our	our	PRON
ajcp-4886	215	4	simulations	simulation	NOUN
ajcp-4886	215	5	,	,	PUNCT
ajcp-4886	215	6	the	the	DET
ajcp-4886	215	7	stabilizing	stabilize	VERB
ajcp-4886	215	8	effect	effect	NOUN
ajcp-4886	215	9	is	be	AUX
ajcp-4886	215	10	dependent	dependent	ADJ
ajcp-4886	215	11	on	on	ADP
ajcp-4886	215	12	the	the	DET
ajcp-4886	215	13	size	size	NOUN
ajcp-4886	215	14	of	of	ADP
ajcp-4886	215	15	the	the	DET
ajcp-4886	215	16	fibrillar	fibrillar	ADJ
ajcp-4886	215	17	oligomer	oligomer	NOUN
ajcp-4886	215	18	and	and	CCONJ
ajcp-4886	215	19	the	the	DET
ajcp-4886	215	20	type	type	NOUN
ajcp-4886	215	21	of	of	ADP
ajcp-4886	215	22	alkali	alkali	ADJ
ajcp-4886	215	23	ion	ion	NOUN
ajcp-4886	215	24	.	.	PUNCT
ajcp-4886	216	1	studies	study	NOUN
ajcp-4886	216	2	looked	look	VERB
ajcp-4886	216	3	at	at	ADP
ajcp-4886	216	4	how	how	SCONJ
ajcp-4886	216	5	fibrillar	fibrillar	ADJ
ajcp-4886	216	6	aβ	aβ	VERB
ajcp-4886	216	7	oligomers	oligomer	NOUN
ajcp-4886	216	8	of	of	ADP
ajcp-4886	216	9	different	different	ADJ
ajcp-4886	216	10	sizes	size	NOUN
ajcp-4886	216	11	were	be	AUX
ajcp-4886	216	12	affected	affect	VERB
ajcp-4886	216	13	by	by	ADP
ajcp-4886	216	14	the	the	DET
ajcp-4886	216	15	three	three	NUM
ajcp-4886	216	16	alkali	alkali	ADJ
ajcp-4886	216	17	metal	metal	NOUN
ajcp-4886	216	18	ions	ion	NOUN
ajcp-4886	216	19	li+	li+	NOUN
ajcp-4886	216	20	,	,	PUNCT
ajcp-4886	216	21	na+	na+	NOUN
ajcp-4886	216	22	,	,	PUNCT
ajcp-4886	216	23	and	and	CCONJ
ajcp-4886	216	24	k+	k+	X
ajcp-4886	216	25	(	(	PUNCT
ajcp-4886	216	26	huraskin	huraskin	X
ajcp-4886	216	27	&	&	CCONJ
ajcp-4886	216	28	horn	horn	NOUN
ajcp-4886	216	29	,	,	PUNCT
ajcp-4886	216	30	2019	2019	NUM
ajcp-4886	216	31	)	)	PUNCT
ajcp-4886	216	32	.	.	PUNCT
ajcp-4886	217	1	according	accord	VERB
ajcp-4886	217	2	to	to	ADP
ajcp-4886	217	3	recent	recent	ADJ
ajcp-4886	217	4	research	research	NOUN
ajcp-4886	217	5	,	,	PUNCT
ajcp-4886	217	6	small	small	ADJ
ajcp-4886	217	7	molecules	molecule	NOUN
ajcp-4886	217	8	with	with	ADP
ajcp-4886	217	9	anti	anti	ADJ
ajcp-4886	217	10	-	-	ADJ
ajcp-4886	217	11	oxidative	oxidative	ADJ
ajcp-4886	217	12	properties	property	NOUN
ajcp-4886	217	13	,	,	PUNCT
ajcp-4886	217	14	the	the	DET
ajcp-4886	217	15	majority	majority	NOUN
ajcp-4886	217	16	of	of	ADP
ajcp-4886	217	17	which	which	PRON
ajcp-4886	217	18	come	come	VERB
ajcp-4886	217	19	from	from	ADP
ajcp-4886	217	20	natural	natural	ADJ
ajcp-4886	217	21	sources	source	NOUN
ajcp-4886	217	22	,	,	PUNCT
ajcp-4886	217	23	can	can	AUX
ajcp-4886	217	24	lessen	lessen	VERB
ajcp-4886	217	25	the	the	DET
ajcp-4886	217	26	neurotoxicity	neurotoxicity	NOUN
ajcp-4886	217	27	of	of	ADP
ajcp-4886	217	28	aβos	aβos	PROPN
ajcp-4886	217	29	(	(	PUNCT
ajcp-4886	217	30	araki	araki	PROPN
ajcp-4886	217	31	&	&	CCONJ
ajcp-4886	217	32	kametani	kametani	PROPN
ajcp-4886	217	33	,	,	PUNCT
ajcp-4886	217	34	2022	2022	NUM
ajcp-4886	217	35	)	)	PUNCT
ajcp-4886	217	36	.	.	PUNCT
ajcp-4886	218	1	aβ42	aβ42	NOUN
ajcp-4886	218	2	aggregates	aggregate	NOUN
ajcp-4886	218	3	are	be	AUX
ajcp-4886	218	4	more	more	ADV
ajcp-4886	218	5	toxic	toxic	ADJ
ajcp-4886	218	6	than	than	ADP
ajcp-4886	218	7	the	the	DET
ajcp-4886	218	8	more	more	ADV
ajcp-4886	218	9	prevalent	prevalent	ADJ
ajcp-4886	218	10	aβ40	aβ40	PROPN
ajcp-4886	218	11	because	because	SCONJ
ajcp-4886	218	12	aβ42	aβ42	NOUN
ajcp-4886	218	13	peptides	peptide	NOUN
ajcp-4886	218	14	can	can	AUX
ajcp-4886	218	15	form	form	VERB
ajcp-4886	218	16	three	three	NUM
ajcp-4886	218	17	-	-	PUNCT
ajcp-4886	218	18	stranded	strand	VERB
ajcp-4886	218	19	motifs	motif	NOUN
ajcp-4886	218	20	,	,	PUNCT
ajcp-4886	218	21	which	which	PRON
ajcp-4886	218	22	enable	enable	VERB
ajcp-4886	218	23	them	they	PRON
ajcp-4886	218	24	to	to	PART
ajcp-4886	218	25	assemble	assemble	VERB
ajcp-4886	218	26	into	into	ADP
ajcp-4886	218	27	poreforming	poreforming	NOUN
ajcp-4886	218	28	aggregates	aggregate	NOUN
ajcp-4886	218	29	(	(	PUNCT
ajcp-4886	218	30	ringor	ringor	ADJ
ajcp-4886	218	31	barrel	barrel	NOUN
ajcp-4886	218	32	-	-	PUNCT
ajcp-4886	218	33	shaped	shape	VERB
ajcp-4886	218	34	)	)	PUNCT
ajcp-4886	218	35	,	,	PUNCT
ajcp-4886	218	36	and	and	CCONJ
ajcp-4886	218	37	the	the	DET
ajcp-4886	218	38	brain	brain	NOUN
ajcp-4886	218	39	environment	environment	NOUN
ajcp-4886	218	40	—	—	PUNCT
ajcp-4886	218	41	specifically	specifically	ADV
ajcp-4886	218	42	,	,	PUNCT
ajcp-4886	218	43	the	the	DET
ajcp-4886	218	44	presence	presence	NOUN
ajcp-4886	218	45	of	of	ADP
ajcp-4886	218	46	fatty	fatty	NOUN
ajcp-4886	218	47	acids	acid	NOUN
ajcp-4886	218	48	—	—	PUNCT
ajcp-4886	218	49	enhances	enhance	VERB
ajcp-4886	218	50	the	the	DET
ajcp-4886	218	51	formation	formation	NOUN
ajcp-4886	218	52	of	of	ADP
ajcp-4886	218	53	these	these	DET
ajcp-4886	218	54	aggregates	aggregate	NOUN
ajcp-4886	218	55	.	.	PUNCT
ajcp-4886	219	1	we	we	PRON
ajcp-4886	219	2	discover	discover	VERB
ajcp-4886	219	3	that	that	SCONJ
ajcp-4886	219	4	lauric	lauric	ADJ
ajcp-4886	219	5	acid	acid	NOUN
ajcp-4886	219	6	stabilizes	stabilize	VERB
ajcp-4886	219	7	these	these	DET
ajcp-4886	219	8	aggregates	aggregate	NOUN
ajcp-4886	219	9	(	(	PUNCT
ajcp-4886	219	10	khatua	khatua	NOUN
ajcp-4886	219	11	et	et	PROPN
ajcp-4886	219	12	al	al	PROPN
ajcp-4886	219	13	.	.	PROPN
ajcp-4886	219	14	,	,	PUNCT
ajcp-4886	219	15	2021	2021	NUM
ajcp-4886	219	16	)	)	PUNCT
ajcp-4886	219	17	.	.	PUNCT
ajcp-4886	220	1	degradation	degradation	NOUN
ajcp-4886	220	2	of	of	ADP
ajcp-4886	220	3	amyloid	amyloid	NOUN
ajcp-4886	220	4	-	-	PUNCT
ajcp-4886	220	5	β	β	NOUN
ajcp-4886	220	6	oligomers	oligomer	NOUN
ajcp-4886	220	7	the	the	DET
ajcp-4886	220	8	degradation	degradation	NOUN
ajcp-4886	220	9	of	of	ADP
ajcp-4886	220	10	aβ	aβ	PRON
ajcp-4886	220	11	in	in	ADP
ajcp-4886	220	12	the	the	DET
ajcp-4886	220	13	brains	brain	NOUN
ajcp-4886	220	14	of	of	ADP
ajcp-4886	220	15	ad	ad	NOUN
ajcp-4886	220	16	patients	patient	NOUN
ajcp-4886	220	17	is	be	AUX
ajcp-4886	220	18	a	a	DET
ajcp-4886	220	19	crucial	crucial	ADJ
ajcp-4886	220	20	area	area	NOUN
ajcp-4886	220	21	of	of	ADP
ajcp-4886	220	22	study	study	NOUN
ajcp-4886	220	23	to	to	PART
ajcp-4886	220	24	help	help	VERB
ajcp-4886	220	25	understand	understand	VERB
ajcp-4886	220	26	the	the	DET
ajcp-4886	220	27	underlying	underlying	ADJ
ajcp-4886	220	28	mechanism	mechanism	NOUN
ajcp-4886	220	29	of	of	ADP
ajcp-4886	220	30	aβ	aβ	DET
ajcp-4886	220	31	degradation	degradation	NOUN
ajcp-4886	220	32	and	and	CCONJ
ajcp-4886	220	33	to	to	PART
ajcp-4886	220	34	shed	shed	VERB
ajcp-4886	220	35	light	light	NOUN
ajcp-4886	220	36	on	on	ADP
ajcp-4886	220	37	the	the	DET
ajcp-4886	220	38	disease	disease	NOUN
ajcp-4886	220	39	’s	’s	PART
ajcp-4886	220	40	pathogenesis	pathogenesis	NOUN
ajcp-4886	220	41	(	(	PUNCT
ajcp-4886	220	42	zhang	zhang	PROPN
ajcp-4886	220	43	et	et	PROPN
ajcp-4886	220	44	al	al	PROPN
ajcp-4886	220	45	.	.	PROPN
ajcp-4886	220	46	,	,	PUNCT
ajcp-4886	220	47	2020	2020	NUM
ajcp-4886	220	48	)	)	PUNCT
ajcp-4886	220	49	.	.	PUNCT
ajcp-4886	221	1	degrading	degrade	VERB
ajcp-4886	221	2	the	the	DET
ajcp-4886	221	3	levels	level	NOUN
ajcp-4886	221	4	of	of	ADP
ajcp-4886	221	5	accumulated	accumulate	VERB
ajcp-4886	221	6	aβ	aβ	NOUN
ajcp-4886	221	7	aggregates	aggregate	NOUN
ajcp-4886	221	8	and	and	CCONJ
ajcp-4886	221	9	inhibiting	inhibit	VERB
ajcp-4886	221	10	aβ	aβ	NOUN
ajcp-4886	221	11	aggregation	aggregation	NOUN
ajcp-4886	221	12	are	be	AUX
ajcp-4886	221	13	therefore	therefore	ADV
ajcp-4886	221	14	important	important	ADJ
ajcp-4886	221	15	,	,	PUNCT
ajcp-4886	221	16	and	and	CCONJ
ajcp-4886	221	17	doing	do	VERB
ajcp-4886	221	18	so	so	ADV
ajcp-4886	221	19	has	have	AUX
ajcp-4886	221	20	become	become	VERB
ajcp-4886	221	21	essential	essential	ADJ
ajcp-4886	221	22	for	for	ADP
ajcp-4886	221	23	the	the	DET
ajcp-4886	221	24	potential	potential	ADJ
ajcp-4886	221	25	application	application	NOUN
ajcp-4886	221	26	as	as	ADP
ajcp-4886	221	27	an	an	DET
ajcp-4886	221	28	appealing	appealing	ADJ
ajcp-4886	221	29	therapeutic	therapeutic	ADJ
ajcp-4886	221	30	and	and	CCONJ
ajcp-4886	221	31	preventive	preventive	ADJ
ajcp-4886	221	32	strategy	strategy	NOUN
ajcp-4886	221	33	for	for	ADP
ajcp-4886	221	34	the	the	DET
ajcp-4886	221	35	treatment	treatment	NOUN
ajcp-4886	221	36	of	of	ADP
ajcp-4886	221	37	ad	ad	NOUN
ajcp-4886	221	38	(	(	PUNCT
ajcp-4886	221	39	cheng	cheng	PROPN
ajcp-4886	221	40	et	et	PROPN
ajcp-4886	221	41	al	al	PROPN
ajcp-4886	221	42	.	.	PROPN
ajcp-4886	221	43	,	,	PUNCT
ajcp-4886	221	44	2020	2020	NUM
ajcp-4886	221	45	)	)	PUNCT
ajcp-4886	221	46	.	.	PUNCT
ajcp-4886	222	1	furthermore	furthermore	ADV
ajcp-4886	222	2	,	,	PUNCT
ajcp-4886	222	3	there	there	PRON
ajcp-4886	222	4	are	be	VERB
ajcp-4886	222	5	still	still	ADV
ajcp-4886	222	6	few	few	ADJ
ajcp-4886	222	7	ways	way	NOUN
ajcp-4886	222	8	to	to	PART
ajcp-4886	222	9	assess	assess	VERB
ajcp-4886	222	10	the	the	DET
ajcp-4886	222	11	degree	degree	NOUN
ajcp-4886	222	12	of	of	ADP
ajcp-4886	222	13	aβ	aβ	DET
ajcp-4886	222	14	degradation	degradation	NOUN
ajcp-4886	222	15	.	.	PUNCT
ajcp-4886	223	1	pa	pa	PROPN
ajcp-4886	223	2	ge	ge	PROPN
ajcp-4886	223	3	23	23	NUM
ajcp-4886	224	1	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-4886	224	2	am	be	AUX
ajcp-4886	224	3	.	.	PUNCT
ajcp-4886	225	1	j.	j.	PROPN
ajcp-4886	225	2	chem	chem	PROPN
ajcp-4886	225	3	.	.	PUNCT
ajcp-4886	226	1	pharm	pharm	PROPN
ajcp-4886	226	2	.	.	PUNCT
ajcp-4886	227	1	4(1	4(1	NOUN
ajcp-4886	227	2	)	)	PUNCT
ajcp-4886	228	1	16	16	NUM
ajcp-4886	228	2	-	-	SYM
ajcp-4886	228	3	28	28	NUM
ajcp-4886	228	4	,	,	PUNCT
ajcp-4886	228	5	2025	2025	NUM
ajcp-4886	228	6	circular	circular	ADJ
ajcp-4886	228	7	dichroism	dichroism	NOUN
ajcp-4886	228	8	(	(	PUNCT
ajcp-4886	228	9	cd	cd	PROPN
ajcp-4886	228	10	)	)	PUNCT
ajcp-4886	228	11	and	and	CCONJ
ajcp-4886	228	12	the	the	DET
ajcp-4886	228	13	thioflavin	thioflavin	PROPN
ajcp-4886	228	14	-	-	PUNCT
ajcp-4886	228	15	t	t	PROPN
ajcp-4886	228	16	(	(	PUNCT
ajcp-4886	228	17	tht	tht	NOUN
ajcp-4886	228	18	)	)	PUNCT
ajcp-4886	228	19	fluorescence	fluorescence	NOUN
ajcp-4886	228	20	assay	assay	NOUN
ajcp-4886	228	21	are	be	AUX
ajcp-4886	228	22	frequently	frequently	ADV
ajcp-4886	228	23	used	use	VERB
ajcp-4886	228	24	to	to	PART
ajcp-4886	228	25	look	look	VERB
ajcp-4886	228	26	into	into	ADP
ajcp-4886	228	27	how	how	SCONJ
ajcp-4886	228	28	the	the	DET
ajcp-4886	228	29	β	β	NOUN
ajcp-4886	228	30	-	-	ADJ
ajcp-4886	228	31	sheet	sheet	NOUN
ajcp-4886	228	32	structure	structure	NOUN
ajcp-4886	228	33	in	in	ADP
ajcp-4886	228	34	aβ	aβ	PRON
ajcp-4886	228	35	aggregates	aggregate	NOUN
ajcp-4886	228	36	is	be	AUX
ajcp-4886	228	37	being	be	AUX
ajcp-4886	228	38	destroyed	destroy	VERB
ajcp-4886	228	39	(	(	PUNCT
ajcp-4886	228	40	gao	gao	PROPN
ajcp-4886	228	41	et	et	PROPN
ajcp-4886	228	42	al	al	PROPN
ajcp-4886	228	43	.	.	PROPN
ajcp-4886	228	44	,	,	PUNCT
ajcp-4886	228	45	2022	2022	NUM
ajcp-4886	228	46	)	)	PUNCT
ajcp-4886	228	47	.	.	PUNCT
ajcp-4886	229	1	by	by	ADP
ajcp-4886	229	2	tracking	track	VERB
ajcp-4886	229	3	the	the	DET
ajcp-4886	229	4	decrease	decrease	NOUN
ajcp-4886	229	5	in	in	ADP
ajcp-4886	229	6	aβ	aβ	DET
ajcp-4886	229	7	concentration	concentration	NOUN
ajcp-4886	229	8	over	over	ADP
ajcp-4886	229	9	time	time	NOUN
ajcp-4886	229	10	,	,	PUNCT
ajcp-4886	229	11	the	the	DET
ajcp-4886	229	12	aβ	aβ	NOUN
ajcp-4886	229	13	degradation	degradation	NOUN
ajcp-4886	229	14	has	have	AUX
ajcp-4886	229	15	also	also	ADV
ajcp-4886	229	16	been	be	AUX
ajcp-4886	229	17	identified	identify	VERB
ajcp-4886	229	18	using	use	VERB
ajcp-4886	229	19	sandwich	sandwich	NOUN
ajcp-4886	229	20	enzyme	enzyme	NOUN
ajcp-4886	229	21	-	-	PUNCT
ajcp-4886	229	22	linked	link	VERB
ajcp-4886	229	23	immunosorbent	immunosorbent	NOUN
ajcp-4886	229	24	assay	assay	PROPN
ajcp-4886	229	25	(	(	PUNCT
ajcp-4886	229	26	elisa	elisa	NOUN
ajcp-4886	229	27	)	)	PUNCT
ajcp-4886	229	28	and	and	CCONJ
ajcp-4886	229	29	western	western	ADJ
ajcp-4886	229	30	blot	blot	NOUN
ajcp-4886	229	31	techniques	technique	NOUN
ajcp-4886	229	32	(	(	PUNCT
ajcp-4886	229	33	rostami	rostami	NOUN
ajcp-4886	229	34	et	et	PROPN
ajcp-4886	229	35	al	al	PROPN
ajcp-4886	229	36	.	.	PROPN
ajcp-4886	229	37	,	,	PUNCT
ajcp-4886	229	38	2021	2021	NUM
ajcp-4886	229	39	)	)	PUNCT
ajcp-4886	229	40	.	.	PUNCT
ajcp-4886	230	1	these	these	DET
ajcp-4886	230	2	methods	method	NOUN
ajcp-4886	230	3	do	do	AUX
ajcp-4886	230	4	,	,	PUNCT
ajcp-4886	230	5	however	however	ADV
ajcp-4886	230	6	,	,	PUNCT
ajcp-4886	230	7	still	still	ADV
ajcp-4886	230	8	have	have	VERB
ajcp-4886	230	9	a	a	DET
ajcp-4886	230	10	number	number	NOUN
ajcp-4886	230	11	of	of	ADP
ajcp-4886	230	12	drawbacks	drawback	NOUN
ajcp-4886	230	13	,	,	PUNCT
ajcp-4886	230	14	including	include	VERB
ajcp-4886	230	15	a	a	DET
ajcp-4886	230	16	high	high	ADJ
ajcp-4886	230	17	potential	potential	NOUN
ajcp-4886	230	18	for	for	ADP
ajcp-4886	230	19	false	false	ADJ
ajcp-4886	230	20	positive/	positive/	NUM
ajcp-4886	230	21	negative	negative	ADJ
ajcp-4886	230	22	results	result	NOUN
ajcp-4886	230	23	or	or	CCONJ
ajcp-4886	230	24	results	result	NOUN
ajcp-4886	230	25	that	that	PRON
ajcp-4886	230	26	are	be	AUX
ajcp-4886	230	27	subject	subject	ADJ
ajcp-4886	230	28	to	to	ADP
ajcp-4886	230	29	subjectivity	subjectivity	NOUN
ajcp-4886	230	30	,	,	PUNCT
ajcp-4886	230	31	the	the	DET
ajcp-4886	230	32	need	need	NOUN
ajcp-4886	230	33	for	for	ADP
ajcp-4886	230	34	careful	careful	ADJ
ajcp-4886	230	35	handling	handling	NOUN
ajcp-4886	230	36	and	and	CCONJ
ajcp-4886	230	37	accuracy	accuracy	NOUN
ajcp-4886	230	38	at	at	ADP
ajcp-4886	230	39	every	every	DET
ajcp-4886	230	40	stage	stage	NOUN
ajcp-4886	230	41	,	,	PUNCT
ajcp-4886	230	42	and	and	CCONJ
ajcp-4886	230	43	high	high	ADJ
ajcp-4886	230	44	individual	individual	ADJ
ajcp-4886	230	45	costs	cost	NOUN
ajcp-4886	230	46	associated	associate	VERB
ajcp-4886	230	47	with	with	ADP
ajcp-4886	230	48	the	the	DET
ajcp-4886	230	49	preparation	preparation	NOUN
ajcp-4886	230	50	of	of	ADP
ajcp-4886	230	51	antibodies	antibody	NOUN
ajcp-4886	230	52	and	and	CCONJ
ajcp-4886	230	53	culture	culture	NOUN
ajcp-4886	230	54	media	medium	NOUN
ajcp-4886	230	55	.	.	PUNCT
ajcp-4886	231	1	to	to	PART
ajcp-4886	231	2	measure	measure	VERB
ajcp-4886	231	3	the	the	DET
ajcp-4886	231	4	enzymatic	enzymatic	ADJ
ajcp-4886	231	5	breakdown	breakdown	NOUN
ajcp-4886	231	6	of	of	ADP
ajcp-4886	231	7	aβ	aβ	NOUN
ajcp-4886	231	8	,	,	PUNCT
ajcp-4886	231	9	some	some	DET
ajcp-4886	231	10	peptide	peptide	ADJ
ajcp-4886	231	11	mapping	mapping	NOUN
ajcp-4886	231	12	investigations	investigation	NOUN
ajcp-4886	231	13	are	be	AUX
ajcp-4886	231	14	carried	carry	VERB
ajcp-4886	231	15	out	out	ADP
ajcp-4886	231	16	,	,	PUNCT
ajcp-4886	231	17	which	which	PRON
ajcp-4886	231	18	involve	involve	VERB
ajcp-4886	231	19	gathering	gather	VERB
ajcp-4886	231	20	fractions	fraction	NOUN
ajcp-4886	231	21	from	from	ADP
ajcp-4886	231	22	liquid	liquid	ADJ
ajcp-4886	231	23	chromatography	chromatography	NOUN
ajcp-4886	231	24	(	(	PUNCT
ajcp-4886	231	25	lc	lc	PROPN
ajcp-4886	231	26	)	)	PUNCT
ajcp-4886	231	27	and	and	CCONJ
ajcp-4886	231	28	then	then	ADV
ajcp-4886	231	29	using	use	VERB
ajcp-4886	231	30	off	off	ADP
ajcp-4886	231	31	-	-	PUNCT
ajcp-4886	231	32	line	line	NOUN
ajcp-4886	231	33	mass	mass	NOUN
ajcp-4886	231	34	spectrometry	spectrometry	NOUN
ajcp-4886	231	35	(	(	PUNCT
ajcp-4886	231	36	ms	ms	PROPN
ajcp-4886	231	37	)	)	PUNCT
ajcp-4886	231	38	(	(	PUNCT
ajcp-4886	231	39	moracci	moracci	PROPN
ajcp-4886	231	40	et	et	PROPN
ajcp-4886	231	41	al	al	PROPN
ajcp-4886	231	42	.	.	PROPN
ajcp-4886	231	43	,	,	PUNCT
ajcp-4886	231	44	2021	2021	NUM
ajcp-4886	231	45	)	)	PUNCT
ajcp-4886	231	46	.	.	PUNCT
ajcp-4886	232	1	studies	study	NOUN
ajcp-4886	232	2	conducted	conduct	VERB
ajcp-4886	232	3	recently	recently	ADV
ajcp-4886	232	4	indicate	indicate	VERB
ajcp-4886	232	5	that	that	DET
ajcp-4886	232	6	nattokinase	nattokinase	NOUN
ajcp-4886	232	7	(	(	PUNCT
ajcp-4886	232	8	nk	nk	PROPN
ajcp-4886	232	9	)	)	PUNCT
ajcp-4886	232	10	may	may	AUX
ajcp-4886	232	11	play	play	VERB
ajcp-4886	232	12	a	a	DET
ajcp-4886	232	13	part	part	NOUN
ajcp-4886	232	14	in	in	ADP
ajcp-4886	232	15	the	the	DET
ajcp-4886	232	16	treatment	treatment	NOUN
ajcp-4886	232	17	of	of	ADP
ajcp-4886	232	18	diseases	disease	NOUN
ajcp-4886	232	19	related	relate	VERB
ajcp-4886	232	20	to	to	ADP
ajcp-4886	232	21	aβ42	aβ42	PROPN
ajcp-4886	232	22	aggregates	aggregate	NOUN
ajcp-4886	232	23	,	,	PUNCT
ajcp-4886	232	24	like	like	ADP
ajcp-4886	232	25	ad	ad	NOUN
ajcp-4886	232	26	,	,	PUNCT
ajcp-4886	232	27	as	as	SCONJ
ajcp-4886	232	28	it	it	PRON
ajcp-4886	232	29	can	can	AUX
ajcp-4886	232	30	gradually	gradually	ADV
ajcp-4886	232	31	break	break	VERB
ajcp-4886	232	32	down	down	ADP
ajcp-4886	232	33	aβ42	aβ42	PROPN
ajcp-4886	232	34	aggregates	aggregate	NOUN
ajcp-4886	232	35	at	at	ADP
ajcp-4886	232	36	neutral	neutral	ADJ
ajcp-4886	232	37	ph	ph	ADJ
ajcp-4886	232	38	and	and	CCONJ
ajcp-4886	232	39	body	body	NOUN
ajcp-4886	232	40	temperature	temperature	NOUN
ajcp-4886	232	41	(	(	PUNCT
ajcp-4886	232	42	chen	chen	PROPN
ajcp-4886	232	43	et	et	PROPN
ajcp-4886	232	44	al	al	PROPN
ajcp-4886	232	45	.	.	PROPN
ajcp-4886	232	46	,	,	PUNCT
ajcp-4886	232	47	2018	2018	NUM
ajcp-4886	232	48	)	)	PUNCT
ajcp-4886	232	49	.	.	PUNCT
ajcp-4886	233	1	after	after	ADP
ajcp-4886	233	2	then	then	ADV
ajcp-4886	233	3	,	,	PUNCT
ajcp-4886	233	4	aβ	aβ	PRON
ajcp-4886	233	5	is	be	AUX
ajcp-4886	233	6	eliminated	eliminate	VERB
ajcp-4886	233	7	by	by	ADP
ajcp-4886	233	8	non	non	ADJ
ajcp-4886	233	9	-	-	ADJ
ajcp-4886	233	10	proteolytic	proteolytic	ADJ
ajcp-4886	233	11	or	or	CCONJ
ajcp-4886	233	12	enzyme	enzyme	NOUN
ajcp-4886	233	13	-	-	PUNCT
ajcp-4886	233	14	mediated	mediate	VERB
ajcp-4886	233	15	mechanisms	mechanism	NOUN
ajcp-4886	233	16	.	.	PUNCT
ajcp-4886	234	1	there	there	PRON
ajcp-4886	234	2	are	be	VERB
ajcp-4886	234	3	currently	currently	ADV
ajcp-4886	234	4	about	about	ADV
ajcp-4886	234	5	20	20	NUM
ajcp-4886	234	6	different	different	ADJ
ajcp-4886	234	7	proteases	protease	NOUN
ajcp-4886	234	8	known	know	VERB
ajcp-4886	234	9	as	as	ADP
ajcp-4886	234	10	aβ	aβ	DET
ajcp-4886	234	11	degrading	degrade	VERB
ajcp-4886	234	12	enzymes	enzyme	NOUN
ajcp-4886	234	13	(	(	PUNCT
ajcp-4886	234	14	ades	ade	NOUN
ajcp-4886	234	15	)	)	PUNCT
ajcp-4886	234	16	,	,	PUNCT
ajcp-4886	234	17	which	which	PRON
ajcp-4886	234	18	mediate	mediate	VERB
ajcp-4886	234	19	the	the	DET
ajcp-4886	234	20	proteolytic	proteolytic	ADJ
ajcp-4886	234	21	degradation	degradation	NOUN
ajcp-4886	234	22	of	of	ADP
ajcp-4886	234	23	aβ	aβ	PROPN
ajcp-4886	234	24	(	(	PUNCT
ajcp-4886	234	25	sikanyika	sikanyika	X
ajcp-4886	234	26	et	et	PROPN
ajcp-4886	234	27	al	al	PROPN
ajcp-4886	234	28	.	.	PROPN
ajcp-4886	234	29	,	,	PUNCT
ajcp-4886	234	30	2019	2019	NUM
ajcp-4886	234	31	)	)	PUNCT
ajcp-4886	234	32	.	.	PUNCT
ajcp-4886	235	1	aβ	aβ	DET
ajcp-4886	235	2	clearance	clearance	NOUN
ajcp-4886	235	3	can	can	AUX
ajcp-4886	235	4	be	be	AUX
ajcp-4886	235	5	categorized	categorize	VERB
ajcp-4886	235	6	into	into	ADP
ajcp-4886	235	7	two	two	NUM
ajcp-4886	235	8	main	main	ADJ
ajcp-4886	235	9	groups	group	NOUN
ajcp-4886	235	10	:	:	PUNCT
ajcp-4886	235	11	enzymatic	enzymatic	ADJ
ajcp-4886	235	12	and	and	CCONJ
ajcp-4886	235	13	non	non	ADJ
ajcp-4886	235	14	-	-	ADJ
ajcp-4886	235	15	enzymatic	enzymatic	ADJ
ajcp-4886	235	16	.	.	PUNCT
ajcp-4886	236	1	enzymatic	enzymatic	ADJ
ajcp-4886	236	2	clearance	clearance	NOUN
ajcp-4886	236	3	involves	involve	VERB
ajcp-4886	236	4	the	the	DET
ajcp-4886	236	5	action	action	NOUN
ajcp-4886	236	6	of	of	ADP
ajcp-4886	236	7	aβ	aβ	ADV
ajcp-4886	236	8	-	-	PUNCT
ajcp-4886	236	9	degrading	degrade	VERB
ajcp-4886	236	10	enzymes	enzyme	NOUN
ajcp-4886	236	11	(	(	PUNCT
ajcp-4886	236	12	ades	ade	NOUN
ajcp-4886	236	13	)	)	PUNCT
ajcp-4886	236	14	,	,	PUNCT
ajcp-4886	236	15	which	which	PRON
ajcp-4886	236	16	function	function	VERB
ajcp-4886	236	17	as	as	SCONJ
ajcp-4886	236	18	proteases	protease	NOUN
ajcp-4886	236	19	to	to	PART
ajcp-4886	236	20	break	break	VERB
ajcp-4886	236	21	down	down	ADP
ajcp-4886	236	22	aβ	aβ	NOUN
ajcp-4886	236	23	peptides	peptide	NOUN
ajcp-4886	236	24	into	into	ADP
ajcp-4886	236	25	smaller	small	ADJ
ajcp-4886	236	26	,	,	PUNCT
ajcp-4886	236	27	less	less	ADV
ajcp-4886	236	28	harmful	harmful	ADJ
ajcp-4886	236	29	forms	form	NOUN
ajcp-4886	236	30	.	.	PUNCT
ajcp-4886	237	1	while	while	SCONJ
ajcp-4886	237	2	most	most	ADJ
ajcp-4886	237	3	degradation	degradation	NOUN
ajcp-4886	237	4	is	be	AUX
ajcp-4886	237	5	believed	believe	VERB
ajcp-4886	237	6	to	to	PART
ajcp-4886	237	7	occur	occur	VERB
ajcp-4886	237	8	within	within	ADP
ajcp-4886	237	9	the	the	DET
ajcp-4886	237	10	brain	brain	NOUN
ajcp-4886	237	11	,	,	PUNCT
ajcp-4886	237	12	clearance	clearance	NOUN
ajcp-4886	237	13	may	may	AUX
ajcp-4886	237	14	also	also	ADV
ajcp-4886	237	15	happen	happen	VERB
ajcp-4886	237	16	in	in	ADP
ajcp-4886	237	17	other	other	ADJ
ajcp-4886	237	18	areas	area	NOUN
ajcp-4886	237	19	where	where	SCONJ
ajcp-4886	237	20	aβ	aβ	NOUN
ajcp-4886	237	21	is	be	AUX
ajcp-4886	237	22	found	find	VERB
ajcp-4886	237	23	after	after	ADP
ajcp-4886	237	24	being	be	AUX
ajcp-4886	237	25	cleared	clear	VERB
ajcp-4886	237	26	from	from	ADP
ajcp-4886	237	27	the	the	DET
ajcp-4886	237	28	brain	brain	NOUN
ajcp-4886	237	29	.	.	PUNCT
ajcp-4886	238	1	a	a	DET
ajcp-4886	238	2	variety	variety	NOUN
ajcp-4886	238	3	of	of	ADP
ajcp-4886	238	4	ades	ade	NOUN
ajcp-4886	238	5	have	have	AUX
ajcp-4886	238	6	been	be	AUX
ajcp-4886	238	7	found	find	VERB
ajcp-4886	238	8	from	from	ADP
ajcp-4886	238	9	different	different	ADJ
ajcp-4886	238	10	classes	class	NOUN
ajcp-4886	238	11	of	of	ADP
ajcp-4886	238	12	proteases	protease	NOUN
ajcp-4886	238	13	,	,	PUNCT
ajcp-4886	238	14	including	include	VERB
ajcp-4886	238	15	metallo	metallo	NOUN
ajcp-4886	238	16	-	-	PUNCT
ajcp-4886	238	17	serine	serine	NOUN
ajcp-4886	238	18	,	,	PUNCT
ajcp-4886	238	19	aspartyl	aspartyl	NOUN
ajcp-4886	238	20	,	,	PUNCT
ajcp-4886	238	21	cysteine	cysteine	NOUN
ajcp-4886	238	22	,	,	PUNCT
ajcp-4886	238	23	and	and	CCONJ
ajcp-4886	238	24	threonine	threonine	ADJ
ajcp-4886	238	25	proteases	protease	NOUN
ajcp-4886	238	26	(	(	PUNCT
ajcp-4886	238	27	see	see	VERB
ajcp-4886	238	28	table	table	NOUN
ajcp-4886	238	29	1	1	NUM
ajcp-4886	238	30	)	)	PUNCT
ajcp-4886	238	31	.	.	PUNCT
ajcp-4886	239	1	many	many	ADJ
ajcp-4886	239	2	of	of	ADP
ajcp-4886	239	3	these	these	DET
ajcp-4886	239	4	proteases	protease	NOUN
ajcp-4886	239	5	have	have	VERB
ajcp-4886	239	6	the	the	DET
ajcp-4886	239	7	ability	ability	NOUN
ajcp-4886	239	8	to	to	PART
ajcp-4886	239	9	break	break	VERB
ajcp-4886	239	10	down	down	ADP
ajcp-4886	239	11	multiple	multiple	ADJ
ajcp-4886	239	12	peptide	peptide	NOUN
ajcp-4886	239	13	substrates	substrate	NOUN
ajcp-4886	239	14	in	in	ADP
ajcp-4886	239	15	various	various	ADJ
ajcp-4886	239	16	tissue	tissue	NOUN
ajcp-4886	239	17	locations	location	NOUN
ajcp-4886	239	18	(	(	PUNCT
ajcp-4886	239	19	żukowska	żukowska	PROPN
ajcp-4886	239	20	et	et	PROPN
ajcp-4886	239	21	al	al	PROPN
ajcp-4886	239	22	.	.	PROPN
ajcp-4886	239	23	,	,	PUNCT
ajcp-4886	239	24	2023	2023	NUM
ajcp-4886	239	25	)	)	PUNCT
ajcp-4886	239	26	.	.	PUNCT
ajcp-4886	240	1	neprilysin	neprilysin	NOUN
ajcp-4886	240	2	(	(	PUNCT
ajcp-4886	240	3	nep	nep	NOUN
ajcp-4886	240	4	)	)	PUNCT
ajcp-4886	240	5	and	and	CCONJ
ajcp-4886	240	6	insulindegrading	insulindegrading	ADJ
ajcp-4886	240	7	enzyme	enzyme	NOUN
ajcp-4886	240	8	(	(	PUNCT
ajcp-4886	240	9	ide	ide	NOUN
ajcp-4886	240	10	)	)	PUNCT
ajcp-4886	240	11	are	be	AUX
ajcp-4886	240	12	the	the	DET
ajcp-4886	240	13	most	most	ADV
ajcp-4886	240	14	well	well	ADV
ajcp-4886	240	15	-	-	PUNCT
ajcp-4886	240	16	characterized	characterize	VERB
ajcp-4886	240	17	aβdps	aβdp	NOUN
ajcp-4886	240	18	.	.	PUNCT
ajcp-4886	241	1	they	they	PRON
ajcp-4886	241	2	are	be	AUX
ajcp-4886	241	3	both	both	PRON
ajcp-4886	241	4	zinc	zinc	NOUN
ajcp-4886	241	5	-	-	PUNCT
ajcp-4886	241	6	metalloendopeptidases	metalloendopeptidase	NOUN
ajcp-4886	241	7	that	that	PRON
ajcp-4886	241	8	are	be	AUX
ajcp-4886	241	9	primarily	primarily	ADV
ajcp-4886	241	10	involved	involve	VERB
ajcp-4886	241	11	in	in	ADP
ajcp-4886	241	12	the	the	DET
ajcp-4886	241	13	breakdown	breakdown	NOUN
ajcp-4886	241	14	of	of	ADP
ajcp-4886	241	15	monomeric	monomeric	ADJ
ajcp-4886	241	16	species	specie	NOUN
ajcp-4886	241	17	,	,	PUNCT
ajcp-4886	241	18	though	though	SCONJ
ajcp-4886	241	19	neprilysin	neprilysin	NOUN
ajcp-4886	241	20	has	have	AUX
ajcp-4886	241	21	also	also	ADV
ajcp-4886	241	22	been	be	AUX
ajcp-4886	241	23	reported	report	VERB
ajcp-4886	241	24	to	to	PART
ajcp-4886	241	25	hydrolyze	hydrolyze	VERB
ajcp-4886	241	26	aβ	aβ	DET
ajcp-4886	241	27	oligomers	oligomer	NOUN
ajcp-4886	241	28	(	(	PUNCT
ajcp-4886	241	29	de	de	X
ajcp-4886	241	30	dios	dios	X
ajcp-4886	241	31	et	et	PROPN
ajcp-4886	241	32	al	al	PROPN
ajcp-4886	241	33	.	.	PROPN
ajcp-4886	241	34	,	,	PUNCT
ajcp-4886	241	35	2019	2019	NUM
ajcp-4886	241	36	)	)	PUNCT
ajcp-4886	241	37	.	.	PUNCT
ajcp-4886	242	1	insulindegrading	insulindegrade	VERB
ajcp-4886	242	2	enzyme	enzyme	NOUN
ajcp-4886	242	3	(	(	PUNCT
ajcp-4886	242	4	ide	ide	NOUN
ajcp-4886	242	5	)	)	PUNCT
ajcp-4886	242	6	is	be	AUX
ajcp-4886	242	7	a	a	DET
ajcp-4886	242	8	widely	widely	ADV
ajcp-4886	242	9	distributed	distribute	VERB
ajcp-4886	242	10	zn2+metalloprotease	zn2+metalloprotease	NUM
ajcp-4886	242	11	present	present	ADJ
ajcp-4886	242	12	in	in	ADP
ajcp-4886	242	13	various	various	ADJ
ajcp-4886	242	14	human	human	ADJ
ajcp-4886	242	15	tissues	tissue	NOUN
ajcp-4886	242	16	and	and	CCONJ
ajcp-4886	242	17	organs	organ	NOUN
ajcp-4886	242	18	.	.	PUNCT
ajcp-4886	243	1	extensive	extensive	ADJ
ajcp-4886	243	2	research	research	NOUN
ajcp-4886	243	3	has	have	AUX
ajcp-4886	243	4	suggested	suggest	VERB
ajcp-4886	243	5	a	a	DET
ajcp-4886	243	6	strong	strong	ADJ
ajcp-4886	243	7	link	link	NOUN
ajcp-4886	243	8	between	between	ADP
ajcp-4886	243	9	ide	ide	PROPN
ajcp-4886	243	10	and	and	CCONJ
ajcp-4886	243	11	alzheimer	alzheimer	NOUN
ajcp-4886	243	12	’s	’s	PART
ajcp-4886	243	13	disease	disease	NOUN
ajcp-4886	243	14	(	(	PUNCT
ajcp-4886	243	15	ad	ad	NOUN
ajcp-4886	243	16	)	)	PUNCT
ajcp-4886	243	17	.	.	PUNCT
ajcp-4886	244	1	clinical	clinical	ADJ
ajcp-4886	244	2	and	and	CCONJ
ajcp-4886	244	3	in	in	ADP
ajcp-4886	244	4	vivo	vivo	ADJ
ajcp-4886	244	5	investigations	investigation	NOUN
ajcp-4886	244	6	have	have	AUX
ajcp-4886	244	7	consistently	consistently	ADV
ajcp-4886	244	8	shown	show	VERB
ajcp-4886	244	9	that	that	SCONJ
ajcp-4886	244	10	reduced	reduce	VERB
ajcp-4886	244	11	ide	ide	NOUN
ajcp-4886	244	12	levels	level	NOUN
ajcp-4886	244	13	in	in	ADP
ajcp-4886	244	14	the	the	DET
ajcp-4886	244	15	brain	brain	NOUN
ajcp-4886	244	16	of	of	ADP
ajcp-4886	244	17	ad	ad	NOUN
ajcp-4886	244	18	patients	patient	NOUN
ajcp-4886	244	19	contribute	contribute	VERB
ajcp-4886	244	20	to	to	ADP
ajcp-4886	244	21	the	the	DET
ajcp-4886	244	22	advancement	advancement	NOUN
ajcp-4886	244	23	of	of	ADP
ajcp-4886	244	24	the	the	DET
ajcp-4886	244	25	disease	disease	NOUN
ajcp-4886	244	26	(	(	PUNCT
ajcp-4886	244	27	abramov	abramov	NOUN
ajcp-4886	244	28	-	-	PUNCT
ajcp-4886	244	29	harpaz	harpaz	PROPN
ajcp-4886	244	30	&	&	CCONJ
ajcp-4886	244	31	miller	miller	PROPN
ajcp-4886	244	32	,	,	PUNCT
ajcp-4886	244	33	2022	2022	NUM
ajcp-4886	244	34	)	)	PUNCT
ajcp-4886	244	35	.	.	PUNCT
ajcp-4886	245	1	enzymes	enzyme	NOUN
ajcp-4886	245	2	such	such	ADJ
ajcp-4886	245	3	as	as	ADP
ajcp-4886	245	4	endothelinconverting	endothelinconverte	VERB
ajcp-4886	245	5	enzyme	enzyme	NOUN
ajcp-4886	245	6	,	,	PUNCT
ajcp-4886	245	7	neprilysin	neprilysin	NOUN
ajcp-4886	245	8	(	(	PUNCT
ajcp-4886	245	9	nep	nep	NOUN
ajcp-4886	245	10	)	)	PUNCT
ajcp-4886	245	11	,	,	PUNCT
ajcp-4886	245	12	insulindegrading	insulindegrade	VERB
ajcp-4886	245	13	enzyme	enzyme	NOUN
ajcp-4886	245	14	(	(	PUNCT
ajcp-4886	245	15	ide	ide	NOUN
ajcp-4886	245	16	)	)	PUNCT
ajcp-4886	245	17	,	,	PUNCT
ajcp-4886	245	18	and	and	CCONJ
ajcp-4886	245	19	matrix	matrix	NOUN
ajcp-4886	245	20	metalloproteinase9	metalloproteinase9	NOUN
ajcp-4886	245	21	show	show	VERB
ajcp-4886	245	22	a	a	DET
ajcp-4886	245	23	decrease	decrease	NOUN
ajcp-4886	245	24	in	in	ADP
ajcp-4886	245	25	the	the	DET
ajcp-4886	245	26	accumulation	accumulation	NOUN
ajcp-4886	245	27	of	of	ADP
ajcp-4886	245	28	aβ	aβ	NOUN
ajcp-4886	245	29	.	.	PUNCT
ajcp-4886	246	1	while	while	SCONJ
ajcp-4886	246	2	matrix	matrix	NOUN
ajcp-4886	246	3	metalloproteinase-9	metalloproteinase-9	NUM
ajcp-4886	246	4	enzyme	enzyme	NOUN
ajcp-4886	246	5	was	be	AUX
ajcp-4886	246	6	discovered	discover	VERB
ajcp-4886	246	7	to	to	PART
ajcp-4886	246	8	degrade	degrade	VERB
ajcp-4886	246	9	both	both	CCONJ
ajcp-4886	246	10	soluble	soluble	ADJ
ajcp-4886	246	11	aβ	aβ	NOUN
ajcp-4886	246	12	species	specie	NOUN
ajcp-4886	246	13	and	and	CCONJ
ajcp-4886	246	14	abfibers	abfiber	NOUN
ajcp-4886	246	15	,	,	PUNCT
ajcp-4886	246	16	ide	ide	NOUN
ajcp-4886	246	17	and	and	CCONJ
ajcp-4886	246	18	nep	nep	NOUN
ajcp-4886	246	19	are	be	AUX
ajcp-4886	246	20	reported	report	VERB
ajcp-4886	246	21	to	to	PART
ajcp-4886	246	22	be	be	AUX
ajcp-4886	246	23	able	able	ADJ
ajcp-4886	246	24	to	to	PART
ajcp-4886	246	25	remove	remove	VERB
ajcp-4886	246	26	soluble	soluble	ADJ
ajcp-4886	246	27	aβ	aβ	NOUN
ajcp-4886	246	28	(	(	PUNCT
ajcp-4886	246	29	sahoo	sahoo	PROPN
ajcp-4886	246	30	et	et	PROPN
ajcp-4886	246	31	al	al	PROPN
ajcp-4886	246	32	.	.	PROPN
ajcp-4886	246	33	,	,	PUNCT
ajcp-4886	246	34	2021	2021	NUM
ajcp-4886	246	35	)	)	PUNCT
ajcp-4886	246	36	.	.	PUNCT
ajcp-4886	247	1	zinc	zinc	NOUN
ajcp-4886	247	2	metalloproteases	metalloprotease	NOUN
ajcp-4886	247	3	known	know	VERB
ajcp-4886	247	4	as	as	ADP
ajcp-4886	247	5	endothelinconverting	endothelinconverte	VERB
ajcp-4886	247	6	enzymes	enzyme	NOUN
ajcp-4886	247	7	,	,	PUNCT
ajcp-4886	247	8	or	or	CCONJ
ajcp-4886	247	9	eces	ece	NOUN
ajcp-4886	247	10	,	,	PUNCT
ajcp-4886	247	11	are	be	AUX
ajcp-4886	247	12	made	make	VERB
ajcp-4886	247	13	by	by	ADP
ajcp-4886	247	14	astrocytes	astrocyte	NOUN
ajcp-4886	247	15	,	,	PUNCT
ajcp-4886	247	16	endothelial	endothelial	ADJ
ajcp-4886	247	17	cells	cell	NOUN
ajcp-4886	247	18	,	,	PUNCT
ajcp-4886	247	19	and	and	CCONJ
ajcp-4886	247	20	neurons	neuron	NOUN
ajcp-4886	247	21	.	.	PUNCT
ajcp-4886	248	1	ece-1	ece-1	NUM
ajcp-4886	248	2	and	and	CCONJ
ajcp-4886	248	3	ece-2	ece-2	ADV
ajcp-4886	248	4	exhibit	exhibit	VERB
ajcp-4886	248	5	59	59	NUM
ajcp-4886	248	6	%	%	NOUN
ajcp-4886	248	7	homology	homology	NOUN
ajcp-4886	248	8	and	and	CCONJ
ajcp-4886	248	9	comparable	comparable	ADJ
ajcp-4886	248	10	catalytic	catalytic	ADJ
ajcp-4886	248	11	activities	activity	NOUN
ajcp-4886	248	12	;	;	PUNCT
ajcp-4886	248	13	however	however	ADV
ajcp-4886	248	14	,	,	PUNCT
ajcp-4886	248	15	these	these	DET
ajcp-4886	248	16	activities	activity	NOUN
ajcp-4886	248	17	differ	differ	VERB
ajcp-4886	248	18	in	in	ADP
ajcp-4886	248	19	terms	term	NOUN
ajcp-4886	248	20	of	of	ADP
ajcp-4886	248	21	their	their	PRON
ajcp-4886	248	22	ideal	ideal	ADJ
ajcp-4886	248	23	ph	ph	NOUN
ajcp-4886	248	24	,	,	PUNCT
ajcp-4886	248	25	with	with	ADP
ajcp-4886	248	26	ece-1	ece-1	ADJ
ajcp-4886	248	27	activity	activity	NOUN
ajcp-4886	248	28	requiring	require	VERB
ajcp-4886	248	29	a	a	DET
ajcp-4886	248	30	physiological	physiological	ADJ
ajcp-4886	248	31	ph	ph	NOUN
ajcp-4886	248	32	and	and	CCONJ
ajcp-4886	248	33	ece-2	ece-2	PUNCT
ajcp-4886	248	34	activity	activity	NOUN
ajcp-4886	248	35	requiring	require	VERB
ajcp-4886	248	36	an	an	DET
ajcp-4886	248	37	acidic	acidic	ADJ
ajcp-4886	248	38	ph	ph	NOUN
ajcp-4886	248	39	(	(	PUNCT
ajcp-4886	248	40	5.5	5.5	NUM
ajcp-4886	248	41	)	)	PUNCT
ajcp-4886	248	42	.	.	PUNCT
ajcp-4886	249	1	they	they	PRON
ajcp-4886	249	2	were	be	AUX
ajcp-4886	249	3	proposed	propose	VERB
ajcp-4886	249	4	to	to	PART
ajcp-4886	249	5	be	be	AUX
ajcp-4886	249	6	involved	involve	VERB
ajcp-4886	249	7	in	in	ADP
ajcp-4886	249	8	the	the	DET
ajcp-4886	249	9	breakdown	breakdown	NOUN
ajcp-4886	249	10	of	of	ADP
ajcp-4886	249	11	monomeric	monomeric	ADJ
ajcp-4886	249	12	aβ	aβ	NOUN
ajcp-4886	249	13	before	before	ADP
ajcp-4886	249	14	its	its	PRON
ajcp-4886	249	15	secretion	secretion	NOUN
ajcp-4886	249	16	,	,	PUNCT
ajcp-4886	249	17	and	and	CCONJ
ajcp-4886	249	18	they	they	PRON
ajcp-4886	249	19	mainly	mainly	ADV
ajcp-4886	249	20	break	break	VERB
ajcp-4886	249	21	down	down	ADP
ajcp-4886	249	22	intracellular	intracellular	ADJ
ajcp-4886	249	23	aβ	aβ	NOUN
ajcp-4886	249	24	(	(	PUNCT
ajcp-4886	249	25	loeffler	loeffler	NOUN
ajcp-4886	249	26	,	,	PUNCT
ajcp-4886	249	27	2023	2023	NUM
ajcp-4886	249	28	)	)	PUNCT
ajcp-4886	249	29	.	.	PUNCT
ajcp-4886	250	1	one	one	NUM
ajcp-4886	250	2	important	important	ADJ
ajcp-4886	250	3	protease	protease	NOUN
ajcp-4886	250	4	that	that	PRON
ajcp-4886	250	5	breaks	break	VERB
ajcp-4886	250	6	down	down	ADP
ajcp-4886	250	7	fibrin	fibrin	NOUN
ajcp-4886	250	8	in	in	ADP
ajcp-4886	250	9	blood	blood	NOUN
ajcp-4886	250	10	clots	clot	NOUN
ajcp-4886	250	11	is	be	AUX
ajcp-4886	250	12	called	call	VERB
ajcp-4886	250	13	plismin	plismin	NOUN
ajcp-4886	250	14	(	(	PUNCT
ajcp-4886	250	15	plm	plm	PROPN
ajcp-4886	250	16	)	)	PUNCT
ajcp-4886	250	17	.	.	PUNCT
ajcp-4886	251	1	plm	plm	PROPN
ajcp-4886	251	2	,	,	PUNCT
ajcp-4886	251	3	along	along	ADP
ajcp-4886	251	4	with	with	ADP
ajcp-4886	251	5	tissue	tissue	NOUN
ajcp-4886	251	6	-	-	PUNCT
ajcp-4886	251	7	type	type	NOUN
ajcp-4886	251	8	plasminogen	plasminogen	NOUN
ajcp-4886	251	9	activator	activator	NOUN
ajcp-4886	251	10	(	(	PUNCT
ajcp-4886	251	11	tpa	tpa	NOUN
ajcp-4886	251	12	)	)	PUNCT
ajcp-4886	251	13	and	and	CCONJ
ajcp-4886	251	14	urokinase	urokinase	NOUN
ajcp-4886	251	15	-	-	PUNCT
ajcp-4886	251	16	type	type	NOUN
ajcp-4886	251	17	plasminogen	plasminogen	NOUN
ajcp-4886	251	18	activator	activator	NOUN
ajcp-4886	251	19	(	(	PUNCT
ajcp-4886	251	20	upa	upa	NOUN
ajcp-4886	251	21	)	)	PUNCT
ajcp-4886	251	22	,	,	PUNCT
ajcp-4886	251	23	is	be	AUX
ajcp-4886	251	24	one	one	NUM
ajcp-4886	251	25	of	of	ADP
ajcp-4886	251	26	the	the	DET
ajcp-4886	251	27	three	three	NUM
ajcp-4886	251	28	components	component	NOUN
ajcp-4886	251	29	of	of	ADP
ajcp-4886	251	30	plasmin	plasmin	NOUN
ajcp-4886	251	31	-	-	PUNCT
ajcp-4886	251	32	based	base	VERB
ajcp-4886	251	33	thrombolysis	thrombolysis	NOUN
ajcp-4886	251	34	(	(	PUNCT
ajcp-4886	251	35	yang	yang	PROPN
ajcp-4886	251	36	et	et	PROPN
ajcp-4886	251	37	al	al	PROPN
ajcp-4886	251	38	.	.	PROPN
ajcp-4886	251	39	,	,	PUNCT
ajcp-4886	251	40	2020	2020	NUM
ajcp-4886	251	41	)	)	PUNCT
ajcp-4886	251	42	.	.	PUNCT
ajcp-4886	252	1	plm	plm	PROPN
ajcp-4886	252	2	is	be	AUX
ajcp-4886	252	3	derived	derive	VERB
ajcp-4886	252	4	from	from	ADP
ajcp-4886	252	5	its	its	PRON
ajcp-4886	252	6	inactive	inactive	ADJ
ajcp-4886	252	7	form	form	NOUN
ajcp-4886	252	8	,	,	PUNCT
ajcp-4886	252	9	plasminogen	plasminogen	NOUN
ajcp-4886	252	10	(	(	PUNCT
ajcp-4886	252	11	plg	plg	NOUN
ajcp-4886	252	12	)	)	PUNCT
ajcp-4886	252	13	.	.	PUNCT
ajcp-4886	253	1	amyloid	amyloid	NOUN
ajcp-4886	253	2	-	-	PUNCT
ajcp-4886	253	3	beta	beta	NOUN
ajcp-4886	253	4	(	(	PUNCT
ajcp-4886	253	5	aβ	aβ	NOUN
ajcp-4886	253	6	)	)	PUNCT
ajcp-4886	253	7	has	have	AUX
ajcp-4886	253	8	been	be	AUX
ajcp-4886	253	9	shown	show	VERB
ajcp-4886	253	10	to	to	PART
ajcp-4886	253	11	be	be	AUX
ajcp-4886	253	12	directly	directly	ADV
ajcp-4886	253	13	degraded	degrade	VERB
ajcp-4886	253	14	by	by	ADP
ajcp-4886	253	15	plm	plm	PROPN
ajcp-4886	253	16	,	,	PUNCT
ajcp-4886	253	17	which	which	PRON
ajcp-4886	253	18	also	also	ADV
ajcp-4886	253	19	targets	target	VERB
ajcp-4886	253	20	its	its	PRON
ajcp-4886	253	21	monomeric	monomeric	ADJ
ajcp-4886	253	22	and	and	CCONJ
ajcp-4886	253	23	fibrillar	fibrillar	ADJ
ajcp-4886	253	24	forms	form	NOUN
ajcp-4886	253	25	while	while	SCONJ
ajcp-4886	253	26	lessening	lessen	VERB
ajcp-4886	253	27	their	their	PRON
ajcp-4886	253	28	toxicity	toxicity	NOUN
ajcp-4886	253	29	.	.	PUNCT
ajcp-4886	254	1	this	this	PRON
ajcp-4886	254	2	implies	imply	VERB
ajcp-4886	254	3	that	that	SCONJ
ajcp-4886	254	4	plm	plm	PROPN
ajcp-4886	254	5	may	may	AUX
ajcp-4886	254	6	have	have	VERB
ajcp-4886	254	7	a	a	DET
ajcp-4886	254	8	part	part	NOUN
ajcp-4886	254	9	in	in	ADP
ajcp-4886	254	10	resolving	resolve	VERB
ajcp-4886	254	11	aβ	aβ	NOUN
ajcp-4886	254	12	-	-	PUNCT
ajcp-4886	254	13	related	relate	VERB
ajcp-4886	254	14	problems	problem	NOUN
ajcp-4886	254	15	(	(	PUNCT
ajcp-4886	254	16	loeffler	loeffler	NOUN
ajcp-4886	254	17	,	,	PUNCT
ajcp-4886	254	18	2023	2023	NUM
ajcp-4886	254	19	)	)	PUNCT
ajcp-4886	254	20	.	.	PUNCT
ajcp-4886	255	1	table	table	NOUN
ajcp-4886	255	2	1	1	NUM
ajcp-4886	255	3	:	:	PUNCT
ajcp-4886	255	4	presents	present	VERB
ajcp-4886	255	5	a	a	DET
ajcp-4886	255	6	list	list	NOUN
ajcp-4886	255	7	of	of	ADP
ajcp-4886	255	8	enzymes	enzyme	NOUN
ajcp-4886	255	9	that	that	PRON
ajcp-4886	255	10	have	have	AUX
ajcp-4886	255	11	shown	show	VERB
ajcp-4886	255	12	the	the	DET
ajcp-4886	255	13	ability	ability	NOUN
ajcp-4886	255	14	to	to	PART
ajcp-4886	255	15	degrade	degrade	VERB
ajcp-4886	255	16	aβ	aβ	NOUN
ajcp-4886	255	17	in	in	ADP
ajcp-4886	255	18	laboratory	laboratory	NOUN
ajcp-4886	255	19	studies	study	NOUN
ajcp-4886	255	20	.	.	PUNCT
ajcp-4886	256	1	however	however	ADV
ajcp-4886	256	2	,	,	PUNCT
ajcp-4886	256	3	the	the	DET
ajcp-4886	256	4	complete	complete	ADJ
ajcp-4886	256	5	characterization	characterization	NOUN
ajcp-4886	256	6	of	of	ADP
ajcp-4886	256	7	each	each	DET
ajcp-4886	256	8	protein	protein	NOUN
ajcp-4886	256	9	’s	’s	PART
ajcp-4886	256	10	biological	biological	ADJ
ajcp-4886	256	11	significance	significance	NOUN
ajcp-4886	256	12	is	be	AUX
ajcp-4886	256	13	still	still	ADV
ajcp-4886	256	14	incomplete	incomplete	ADJ
ajcp-4886	256	15	.	.	PUNCT
ajcp-4886	257	1	neprilysin-2	neprilysin-2	X
ajcp-4886	257	2	(	(	PUNCT
ajcp-4886	257	3	nep-2	nep-2	NUM
ajcp-4886	257	4	)	)	PUNCT
ajcp-4886	257	5	is	be	AUX
ajcp-4886	257	6	referred	refer	VERB
ajcp-4886	257	7	to	to	ADP
ajcp-4886	257	8	by	by	ADP
ajcp-4886	257	9	various	various	ADJ
ajcp-4886	257	10	names	name	NOUN
ajcp-4886	257	11	in	in	ADP
ajcp-4886	257	12	the	the	DET
ajcp-4886	257	13	literature	literature	NOUN
ajcp-4886	257	14	,	,	PUNCT
ajcp-4886	257	15	including	include	VERB
ajcp-4886	257	16	sep	sep	PROPN
ajcp-4886	257	17	,	,	PUNCT
ajcp-4886	257	18	nl1	nl1	PROPN
ajcp-4886	257	19	,	,	PUNCT
ajcp-4886	257	20	mmel1	mmel1	PROPN
ajcp-4886	257	21	,	,	PUNCT
ajcp-4886	257	22	and	and	CCONJ
ajcp-4886	257	23	ne_plp	ne_plp	PROPN
ajcp-4886	257	24	.	.	PUNCT
ajcp-4886	258	1	aβ	aβ	PRON
ajcp-4886	258	2	degrading	degrade	VERB
ajcp-4886	258	3	enzymes	enzyme	NOUN
ajcp-4886	258	4	aβ	aβ	ADP
ajcp-4886	258	5	degrading	degrade	VERB
ajcp-4886	258	6	enzymes	enzyme	NOUN
ajcp-4886	258	7	neprilysin	neprilysin	NOUN
ajcp-4886	258	8	(	(	PUNCT
ajcp-4886	258	9	nep	nep	NOUN
ajcp-4886	258	10	)	)	PUNCT
ajcp-4886	258	11	matrix	matrix	NOUN
ajcp-4886	258	12	metalloprotease-14	metalloprotease-14	PROPN
ajcp-4886	258	13	(	(	PUNCT
ajcp-4886	258	14	mmp-14	mmp-14	NOUN
ajcp-4886	258	15	)	)	PUNCT
ajcp-4886	258	16	endothelin	endothelin	NOUN
ajcp-4886	258	17	-	-	PUNCT
ajcp-4886	258	18	converting	convert	VERB
ajcp-4886	258	19	enzyme-1	enzyme-1	NOUN
ajcp-4886	258	20	(	(	PUNCT
ajcp-4886	258	21	ece-1	ece-1	NOUN
ajcp-4886	258	22	)	)	PUNCT
ajcp-4886	258	23	myelin	myelin	ADJ
ajcp-4886	258	24	basic	basic	ADJ
ajcp-4886	258	25	protein	protein	NOUN
ajcp-4886	258	26	(	(	PUNCT
ajcp-4886	258	27	mbp	mbp	NOUN
ajcp-4886	258	28	)	)	PUNCT
ajcp-4886	258	29	endothelin	endothelin	NOUN
ajcp-4886	258	30	-	-	PUNCT
ajcp-4886	258	31	converting	convert	VERB
ajcp-4886	258	32	enzyme-2	enzyme-2	NUM
ajcp-4886	258	33	(	(	PUNCT
ajcp-4886	258	34	ece-2	ece-2	NOUN
ajcp-4886	258	35	)	)	PUNCT
ajcp-4886	258	36	plasmin	plasmin	ADJ
ajcp-4886	258	37	angiotensin-1	angiotensin-1	NUM
ajcp-4886	258	38	converting	convert	VERB
ajcp-4886	258	39	enzyme	enzyme	NOUN
ajcp-4886	258	40	(	(	PUNCT
ajcp-4886	258	41	ace	ace	NOUN
ajcp-4886	258	42	)	)	PUNCT
ajcp-4886	258	43	aminopeptidase	aminopeptidase	NOUN
ajcp-4886	258	44	a	a	DET
ajcp-4886	258	45	angiotensin	angiotensin	NOUN
ajcp-4886	258	46	converting	convert	VERB
ajcp-4886	258	47	enzyme-2	enzyme-2	NUM
ajcp-4886	258	48	(	(	PUNCT
ajcp-4886	258	49	ace-2	ace-2	NUM
ajcp-4886	258	50	)	)	PUNCT
ajcp-4886	258	51	mitochondrial	mitochondrial	ADJ
ajcp-4886	258	52	presequence	presequence	NOUN
ajcp-4886	258	53	protease	protease	NOUN
ajcp-4886	258	54	(	(	PUNCT
ajcp-4886	258	55	prep	prep	NOUN
ajcp-4886	258	56	)	)	PUNCT
ajcp-4886	258	57	insulin	insulin	NOUN
ajcp-4886	258	58	-	-	PUNCT
ajcp-4886	258	59	degrading	degrade	VERB
ajcp-4886	258	60	enzyme	enzyme	NOUN
ajcp-4886	258	61	(	(	PUNCT
ajcp-4886	258	62	ide	ide	NOUN
ajcp-4886	258	63	)	)	PUNCT
ajcp-4886	258	64	acyl	acyl	NOUN
ajcp-4886	258	65	peptide	peptide	NOUN
ajcp-4886	258	66	hydrolase	hydrolase	NOUN
ajcp-4886	258	67	(	(	PUNCT
ajcp-4886	258	68	apeh	apeh	NOUN
ajcp-4886	258	69	)	)	PUNCT
ajcp-4886	258	70	matrix	matrix	NOUN
ajcp-4886	258	71	metalloproteinase-2	metalloproteinase-2	NUM
ajcp-4886	258	72	(	(	PUNCT
ajcp-4886	258	73	mmp-2	mmp-2	NUM
ajcp-4886	258	74	)	)	PUNCT
ajcp-4886	258	75	cathepsin	cathepsin	NOUN
ajcp-4886	258	76	b	b	PROPN
ajcp-4886	258	77	matrix	matrix	NOUN
ajcp-4886	258	78	metalloproteinase-9	metalloproteinase-9	NUM
ajcp-4886	258	79	(	(	PUNCT
ajcp-4886	258	80	mmp-9	mmp-9	NUM
ajcp-4886	258	81	)	)	PUNCT
ajcp-4886	258	82	cathepsin	cathepsin	NOUN
ajcp-4886	258	83	d	d	X
ajcp-4886	258	84	beta	beta	NOUN
ajcp-4886	258	85	secretase	secretase	NOUN
ajcp-4886	258	86	1	1	NUM
ajcp-4886	258	87	(	(	PUNCT
ajcp-4886	258	88	bace	bace	NOUN
ajcp-4886	258	89	1	1	NUM
ajcp-4886	258	90	)	)	PUNCT
ajcp-4886	258	91	beta	beta	NOUN
ajcp-4886	258	92	secretase	secretase	NOUN
ajcp-4886	258	93	2	2	NUM
ajcp-4886	258	94	(	(	PUNCT
ajcp-4886	258	95	bace	bace	NOUN
ajcp-4886	258	96	2	2	NUM
ajcp-4886	258	97	)	)	PUNCT
ajcp-4886	258	98	26s	26s	PROPN
ajcp-4886	258	99	proteasome	proteasome	PROPN
ajcp-4886	258	100	.	.	PUNCT
ajcp-4886	259	1	source	source	NOUN
ajcp-4886	259	2	:	:	PUNCT
ajcp-4886	259	3	adopted	adopt	VERB
ajcp-4886	259	4	from	from	ADP
ajcp-4886	259	5	(	(	PUNCT
ajcp-4886	259	6	żukowska	żukowska	PROPN
ajcp-4886	259	7	et	et	PROPN
ajcp-4886	259	8	al	al	PROPN
ajcp-4886	259	9	.	.	PROPN
ajcp-4886	259	10	,	,	PUNCT
ajcp-4886	259	11	2023	2023	NUM
ajcp-4886	259	12	)	)	PUNCT
ajcp-4886	260	1	pa	pa	PROPN
ajcp-4886	260	2	ge	ge	PROPN
ajcp-4886	260	3	24	24	NUM
ajcp-4886	260	4	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-4886	260	5	am	be	AUX
ajcp-4886	260	6	.	.	PUNCT
ajcp-4886	261	1	j.	j.	PROPN
ajcp-4886	261	2	chem	chem	PROPN
ajcp-4886	261	3	.	.	PUNCT
ajcp-4886	262	1	pharm	pharm	PROPN
ajcp-4886	262	2	.	.	PUNCT
ajcp-4886	263	1	4(1	4(1	NOUN
ajcp-4886	263	2	)	)	PUNCT
ajcp-4886	264	1	16	16	NUM
ajcp-4886	264	2	-	-	SYM
ajcp-4886	264	3	28	28	NUM
ajcp-4886	264	4	,	,	PUNCT
ajcp-4886	264	5	2025	2025	NUM
ajcp-4886	264	6	conclusion	conclusion	NOUN
ajcp-4886	264	7	it	it	PRON
ajcp-4886	264	8	is	be	AUX
ajcp-4886	264	9	concluded	conclude	VERB
ajcp-4886	264	10	that	that	SCONJ
ajcp-4886	264	11	amyloid	amyloid	NOUN
ajcp-4886	264	12	-	-	PUNCT
ajcp-4886	264	13	beta	beta	NOUN
ajcp-4886	264	14	(	(	PUNCT
ajcp-4886	264	15	aβ	aβ	NOUN
ajcp-4886	264	16	)	)	PUNCT
ajcp-4886	264	17	oligomers	oligomer	NOUN
ajcp-4886	264	18	have	have	VERB
ajcp-4886	264	19	important	important	ADJ
ajcp-4886	264	20	role	role	NOUN
ajcp-4886	264	21	in	in	ADP
ajcp-4886	264	22	alzheimer	alzheimer	PROPN
ajcp-4886	264	23	’s	’s	PART
ajcp-4886	264	24	disease	disease	NOUN
ajcp-4886	264	25	(	(	PUNCT
ajcp-4886	264	26	ad	ad	NOUN
ajcp-4886	264	27	)	)	PUNCT
ajcp-4886	264	28	pathogenesis	pathogenesis	NOUN
ajcp-4886	264	29	,	,	PUNCT
ajcp-4886	264	30	neuroinflammation	neuroinflammation	NOUN
ajcp-4886	264	31	and	and	CCONJ
ajcp-4886	264	32	cognitive	cognitive	ADJ
ajcp-4886	264	33	decline	decline	NOUN
ajcp-4886	264	34	through	through	ADP
ajcp-4886	264	35	liquid	liquid	NOUN
ajcp-4886	264	36	-	-	PUNCT
ajcp-4886	264	37	liquid	liquid	NOUN
ajcp-4886	264	38	phase	phase	NOUN
ajcp-4886	264	39	separation	separation	NOUN
ajcp-4886	264	40	(	(	PUNCT
ajcp-4886	264	41	llps	llps	PROPN
ajcp-4886	264	42	)	)	PUNCT
ajcp-4886	264	43	and	and	CCONJ
ajcp-4886	264	44	dynamic	dynamic	ADJ
ajcp-4886	264	45	aggregation	aggregation	NOUN
ajcp-4886	264	46	.	.	PUNCT
ajcp-4886	265	1	this	this	DET
ajcp-4886	265	2	study	study	NOUN
ajcp-4886	265	3	highlighted	highlight	VERB
ajcp-4886	265	4	progress	progress	NOUN
ajcp-4886	265	5	in	in	ADP
ajcp-4886	265	6	targeting	target	VERB
ajcp-4886	265	7	aβ	aβ	ADP
ajcp-4886	265	8	oligomers	oligomer	NOUN
ajcp-4886	265	9	with	with	ADP
ajcp-4886	265	10	metal	metal	NOUN
ajcp-4886	265	11	complexes	complex	NOUN
ajcp-4886	265	12	,	,	PUNCT
ajcp-4886	265	13	small	small	ADJ
ajcp-4886	265	14	molecules	molecule	NOUN
ajcp-4886	265	15	and	and	CCONJ
ajcp-4886	265	16	immunotherapies	immunotherapy	NOUN
ajcp-4886	265	17	,	,	PUNCT
ajcp-4886	265	18	which	which	PRON
ajcp-4886	265	19	make	make	VERB
ajcp-4886	265	20	stable	stable	ADJ
ajcp-4886	265	21	nontoxic	nontoxic	ADJ
ajcp-4886	265	22	forms	form	NOUN
ajcp-4886	265	23	and	and	CCONJ
ajcp-4886	265	24	control	control	NOUN
ajcp-4886	265	25	aggregation	aggregation	NOUN
ajcp-4886	265	26	,	,	PUNCT
ajcp-4886	265	27	or	or	CCONJ
ajcp-4886	265	28	regulate	regulate	VERB
ajcp-4886	265	29	degradation	degradation	NOUN
ajcp-4886	265	30	.	.	PUNCT
ajcp-4886	266	1	main	main	ADJ
ajcp-4886	266	2	challenges	challenge	NOUN
ajcp-4886	266	3	include	include	VERB
ajcp-4886	266	4	the	the	DET
ajcp-4886	266	5	heterogeneity	heterogeneity	NOUN
ajcp-4886	266	6	in	in	ADP
ajcp-4886	266	7	structure	structure	NOUN
ajcp-4886	266	8	and	and	CCONJ
ajcp-4886	266	9	the	the	DET
ajcp-4886	266	10	desire	desire	NOUN
ajcp-4886	266	11	for	for	ADP
ajcp-4886	266	12	blood	blood	NOUN
ajcp-4886	266	13	-	-	PUNCT
ajcp-4886	266	14	brain	brain	NOUN
ajcp-4886	266	15	barrier	barrier	NOUN
ajcp-4886	266	16	-	-	PUNCT
ajcp-4886	266	17	permeable	permeable	ADJ
ajcp-4886	266	18	therapeutics	therapeutic	NOUN
ajcp-4886	266	19	.	.	PUNCT
ajcp-4886	267	1	innovative	innovative	ADJ
ajcp-4886	267	2	strategies	strategy	NOUN
ajcp-4886	267	3	,	,	PUNCT
ajcp-4886	267	4	such	such	ADJ
ajcp-4886	267	5	as	as	ADP
ajcp-4886	267	6	aβ	aβ	NOUN
ajcp-4886	267	7	-	-	PUNCT
ajcp-4886	267	8	degrading	degrade	VERB
ajcp-4886	267	9	enzymes	enzyme	NOUN
ajcp-4886	267	10	and	and	CCONJ
ajcp-4886	267	11	llps	llp	VERB
ajcp-4886	267	12	inhibitors	inhibitor	NOUN
ajcp-4886	267	13	,	,	PUNCT
ajcp-4886	267	14	offer	offer	VERB
ajcp-4886	267	15	breakthrough	breakthrough	NOUN
ajcp-4886	267	16	pathways	pathway	NOUN
ajcp-4886	267	17	for	for	ADP
ajcp-4886	267	18	early	early	ADJ
ajcp-4886	267	19	intervention	intervention	NOUN
ajcp-4886	267	20	.	.	PUNCT
ajcp-4886	268	1	future	future	ADJ
ajcp-4886	268	2	studies	study	NOUN
ajcp-4886	268	3	should	should	AUX
ajcp-4886	268	4	prefer	prefer	VERB
ajcp-4886	268	5	in	in	ADP
ajcp-4886	268	6	vivo	vivo	ADJ
ajcp-4886	268	7	validation	validation	NOUN
ajcp-4886	268	8	for	for	ADP
ajcp-4886	268	9	phase	phase	NOUN
ajcp-4886	268	10	-	-	PUNCT
ajcp-4886	268	11	separation	separation	NOUN
ajcp-4886	268	12	modulators	modulator	NOUN
ajcp-4886	268	13	,	,	PUNCT
ajcp-4886	268	14	microstructural	microstructural	ADJ
ajcp-4886	268	15	characterization	characterization	NOUN
ajcp-4886	268	16	of	of	ADP
ajcp-4886	268	17	oligomers	oligomer	NOUN
ajcp-4886	268	18	and	and	CCONJ
ajcp-4886	268	19	biomarkers	biomarker	NOUN
ajcp-4886	268	20	for	for	ADP
ajcp-4886	268	21	early	early	ADJ
ajcp-4886	268	22	detection	detection	NOUN
ajcp-4886	268	23	.	.	PUNCT
ajcp-4886	269	1	by	by	ADP
ajcp-4886	269	2	combining	combine	VERB
ajcp-4886	269	3	chemical	chemical	ADJ
ajcp-4886	269	4	biology	biology	NOUN
ajcp-4886	269	5	and	and	CCONJ
ajcp-4886	269	6	neurotherapeutics	neurotherapeutic	NOUN
ajcp-4886	269	7	,	,	PUNCT
ajcp-4886	269	8	this	this	DET
ajcp-4886	269	9	field	field	NOUN
ajcp-4886	269	10	proceeds	proceed	VERB
ajcp-4886	269	11	closer	close	ADV
ajcp-4886	269	12	to	to	ADP
ajcp-4886	269	13	disease	disease	NOUN
ajcp-4886	269	14	-	-	PUNCT
ajcp-4886	269	15	modifying	modify	VERB
ajcp-4886	269	16	treatments	treatment	NOUN
ajcp-4886	269	17	that	that	PRON
ajcp-4886	269	18	degrade	degrade	VERB
ajcp-4886	269	19	aβ	aβ	NOUN
ajcp-4886	269	20	toxicity	toxicity	NOUN
ajcp-4886	269	21	at	at	ADP
ajcp-4886	269	22	its	its	PRON
ajcp-4886	269	23	point	point	NOUN
ajcp-4886	269	24	source	source	NOUN
ajcp-4886	269	25	,	,	PUNCT
ajcp-4886	269	26	offering	offer	VERB
ajcp-4886	269	27	hope	hope	NOUN
ajcp-4886	269	28	for	for	ADP
ajcp-4886	269	29	overstaying	overstay	VERB
ajcp-4886	269	30	ad	ad	NOUN
ajcp-4886	269	31	progression	progression	NOUN
ajcp-4886	269	32	.	.	PUNCT
ajcp-4886	270	1	references	reference	NOUN
ajcp-4886	270	2	abelein	abelein	ADV
ajcp-4886	270	3	,	,	PUNCT
ajcp-4886	270	4	a.	a.	NOUN
ajcp-4886	270	5	(	(	PUNCT
ajcp-4886	270	6	2023	2023	NUM
ajcp-4886	270	7	)	)	PUNCT
ajcp-4886	270	8	.	.	PUNCT
ajcp-4886	271	1	metal	metal	NOUN
ajcp-4886	271	2	binding	binding	NOUN
ajcp-4886	271	3	of	of	ADP
ajcp-4886	271	4	alzheimer	alzheimer	PROPN
ajcp-4886	271	5	’s	’s	PART
ajcp-4886	271	6	amyloid	amyloid	NOUN
ajcp-4886	271	7	-	-	PUNCT
ajcp-4886	271	8	β	β	X
ajcp-4886	271	9	and	and	CCONJ
ajcp-4886	271	10	its	its	PRON
ajcp-4886	271	11	effect	effect	NOUN
ajcp-4886	271	12	on	on	ADP
ajcp-4886	271	13	peptide	peptide	ADJ
ajcp-4886	271	14	self	self	NOUN
ajcp-4886	271	15	-	-	PUNCT
ajcp-4886	271	16	assembly	assembly	NOUN
ajcp-4886	271	17	.	.	PUNCT
ajcp-4886	272	1	accounts	account	NOUN
ajcp-4886	272	2	of	of	ADP
ajcp-4886	272	3	chemical	chemical	NOUN
ajcp-4886	272	4	research	research	NOUN
ajcp-4886	272	5	,	,	PUNCT
ajcp-4886	272	6	56(19	56(19	NUM
ajcp-4886	272	7	)	)	PUNCT
ajcp-4886	272	8	,	,	PUNCT
ajcp-4886	272	9	2653	2653	NUM
ajcp-4886	272	10	-	-	SYM
ajcp-4886	272	11	2663	2663	NUM
ajcp-4886	272	12	.	.	PUNCT
ajcp-4886	273	1	https://doi.org/10.1021/acs.accounts.3c00370	https://doi.org/10.1021/acs.accounts.3c00370	PRON
ajcp-4886	273	2	abramov	abramov	NOUN
ajcp-4886	273	3	-	-	PUNCT
ajcp-4886	273	4	harpaz	harpaz	PROPN
ajcp-4886	273	5	,	,	PUNCT
ajcp-4886	273	6	k.	k.	PROPN
ajcp-4886	273	7	,	,	PUNCT
ajcp-4886	273	8	&	&	CCONJ
ajcp-4886	273	9	miller	miller	PROPN
ajcp-4886	273	10	,	,	PUNCT
ajcp-4886	273	11	y.	y.	PROPN
ajcp-4886	273	12	(	(	PUNCT
ajcp-4886	273	13	2022	2022	NUM
ajcp-4886	273	14	)	)	PUNCT
ajcp-4886	273	15	.	.	PUNCT
ajcp-4886	274	1	insights	insight	NOUN
ajcp-4886	274	2	into	into	ADP
ajcp-4886	274	3	non	non	ADJ
ajcp-4886	274	4	-	-	ADJ
ajcp-4886	274	5	proteolytic	proteolytic	ADJ
ajcp-4886	274	6	inhibitory	inhibitory	ADJ
ajcp-4886	274	7	mechanisms	mechanism	NOUN
ajcp-4886	274	8	of	of	ADP
ajcp-4886	274	9	polymorphic	polymorphic	ADJ
ajcp-4886	274	10	early	early	ADJ
ajcp-4886	274	11	-	-	PUNCT
ajcp-4886	274	12	stage	stage	NOUN
ajcp-4886	274	13	amyloid	amyloid	NOUN
ajcp-4886	274	14	β	β	X
ajcp-4886	274	15	oligomers	oligomer	NOUN
ajcp-4886	274	16	by	by	ADP
ajcp-4886	274	17	insulin	insulin	NOUN
ajcp-4886	274	18	degrading	degrade	VERB
ajcp-4886	274	19	enzyme	enzyme	NOUN
ajcp-4886	274	20	.	.	PUNCT
ajcp-4886	275	1	biomolecules	biomolecule	NOUN
ajcp-4886	275	2	,	,	PUNCT
ajcp-4886	275	3	12(12	12(12	NUM
ajcp-4886	275	4	)	)	PUNCT
ajcp-4886	275	5	.	.	PUNCT
ajcp-4886	276	1	https://doi.org/10.3390/biom12121886	https://doi.org/10.3390/biom12121886	PROPN
ajcp-4886	276	2	alberti	alberti	PROPN
ajcp-4886	276	3	,	,	PUNCT
ajcp-4886	276	4	s.	s.	PROPN
ajcp-4886	276	5	,	,	PUNCT
ajcp-4886	276	6	&	&	CCONJ
ajcp-4886	276	7	hyman	hyman	PROPN
ajcp-4886	276	8	,	,	PUNCT
ajcp-4886	276	9	a.	a.	NOUN
ajcp-4886	276	10	a.	a.	NOUN
ajcp-4886	276	11	(	(	PUNCT
ajcp-4886	276	12	2021	2021	NUM
ajcp-4886	276	13	)	)	PUNCT
ajcp-4886	276	14	.	.	PUNCT
ajcp-4886	277	1	biomolecular	biomolecular	ADJ
ajcp-4886	277	2	condensates	condensate	NOUN
ajcp-4886	277	3	at	at	ADP
ajcp-4886	277	4	the	the	DET
ajcp-4886	277	5	nexus	nexus	NOUN
ajcp-4886	277	6	of	of	ADP
ajcp-4886	277	7	cellular	cellular	ADJ
ajcp-4886	277	8	stress	stress	NOUN
ajcp-4886	277	9	,	,	PUNCT
ajcp-4886	277	10	protein	protein	NOUN
ajcp-4886	277	11	aggregation	aggregation	NOUN
ajcp-4886	277	12	disease	disease	NOUN
ajcp-4886	277	13	and	and	CCONJ
ajcp-4886	277	14	ageing	ageing	NOUN
ajcp-4886	277	15	.	.	PUNCT
ajcp-4886	278	1	nature	nature	NOUN
ajcp-4886	278	2	reviews	review	VERB
ajcp-4886	278	3	molecular	molecular	ADJ
ajcp-4886	278	4	cell	cell	NOUN
ajcp-4886	278	5	biology	biology	NOUN
ajcp-4886	278	6	,	,	PUNCT
ajcp-4886	278	7	22(3	22(3	NUM
ajcp-4886	278	8	)	)	PUNCT
ajcp-4886	278	9	,	,	PUNCT
ajcp-4886	278	10	196	196	NUM
ajcp-4886	278	11	-	-	SYM
ajcp-4886	278	12	213	213	NUM
ajcp-4886	278	13	.	.	PUNCT
ajcp-4886	279	1	https://doi	https://doi	NOUN
ajcp-4886	279	2	.	.	PUNCT
ajcp-4886	279	3	org/10.1038	org/10.1038	PROPN
ajcp-4886	279	4	/	/	SYM
ajcp-4886	279	5	s41580	s41580	NOUN
ajcp-4886	279	6	-	-	PUNCT
ajcp-4886	279	7	020	020	NUM
ajcp-4886	279	8	-	-	PUNCT
ajcp-4886	279	9	00326	00326	NUM
ajcp-4886	279	10	-	-	SYM
ajcp-4886	279	11	6	6	NUM
ajcp-4886	279	12	allnutt	allnutt	ADJ
ajcp-4886	279	13	,	,	PUNCT
ajcp-4886	279	14	m.	m.	NOUN
ajcp-4886	279	15	a.	a.	PROPN
ajcp-4886	279	16	,	,	PUNCT
ajcp-4886	279	17	&	&	CCONJ
ajcp-4886	279	18	matera	matera	PROPN
ajcp-4886	279	19	,	,	PUNCT
ajcp-4886	279	20	k.	k.	PROPN
ajcp-4886	279	21	m.	m.	PROPN
ajcp-4886	279	22	(	(	PUNCT
ajcp-4886	279	23	2023	2023	NUM
ajcp-4886	279	24	)	)	PUNCT
ajcp-4886	279	25	.	.	PUNCT
ajcp-4886	280	1	stabilization	stabilization	NOUN
ajcp-4886	280	2	and	and	CCONJ
ajcp-4886	280	3	reduced	reduce	VERB
ajcp-4886	280	4	cytotoxicity	cytotoxicity	NOUN
ajcp-4886	280	5	of	of	ADP
ajcp-4886	280	6	amyloid	amyloid	NOUN
ajcp-4886	280	7	beta	beta	NOUN
ajcp-4886	280	8	aggregates	aggregate	NOUN
ajcp-4886	280	9	in	in	ADP
ajcp-4886	280	10	the	the	DET
ajcp-4886	280	11	presence	presence	NOUN
ajcp-4886	280	12	of	of	ADP
ajcp-4886	280	13	catechol	catechol	NOUN
ajcp-4886	280	14	neurotransmitters	neurotransmitter	NOUN
ajcp-4886	280	15	.	.	PUNCT
ajcp-4886	281	1	neurochemical	neurochemical	ADJ
ajcp-4886	281	2	research	research	NOUN
ajcp-4886	281	3	,	,	PUNCT
ajcp-4886	281	4	49(2	49(2	NUM
ajcp-4886	281	5	)	)	PUNCT
ajcp-4886	281	6	,	,	PUNCT
ajcp-4886	281	7	379	379	NUM
ajcp-4886	281	8	-	-	SYM
ajcp-4886	281	9	387	387	NUM
ajcp-4886	281	10	.	.	PUNCT
ajcp-4886	282	1	https://doi	https://doi	NOUN
ajcp-4886	282	2	.	.	PUNCT
ajcp-4886	282	3	org/10.1007	org/10.1007	PROPN
ajcp-4886	282	4	/	/	SYM
ajcp-4886	282	5	s11064	s11064	PROPN
ajcp-4886	282	6	-	-	PUNCT
ajcp-4886	282	7	023	023	NUM
ajcp-4886	282	8	-	-	PUNCT
ajcp-4886	282	9	04036	04036	NUM
ajcp-4886	282	10	-	-	SYM
ajcp-4886	282	11	1	1	NUM
ajcp-4886	282	12	amano	amano	NOUN
ajcp-4886	282	13	,	,	PUNCT
ajcp-4886	282	14	a.	a.	PROPN
ajcp-4886	282	15	,	,	PUNCT
ajcp-4886	282	16	sanjo	sanjo	PROPN
ajcp-4886	282	17	,	,	PUNCT
ajcp-4886	282	18	n.	n.	NOUN
ajcp-4886	282	19	,	,	PUNCT
ajcp-4886	282	20	araki	araki	PROPN
ajcp-4886	282	21	,	,	PUNCT
ajcp-4886	282	22	w.	w.	PROPN
ajcp-4886	282	23	,	,	PUNCT
ajcp-4886	282	24	anraku	anraku	PROPN
ajcp-4886	282	25	,	,	PUNCT
ajcp-4886	282	26	y.	y.	PROPN
ajcp-4886	282	27	,	,	PUNCT
ajcp-4886	282	28	nakakido	nakakido	PROPN
ajcp-4886	282	29	,	,	PUNCT
ajcp-4886	282	30	m.	m.	NOUN
ajcp-4886	282	31	,	,	PUNCT
ajcp-4886	282	32	matsubara	matsubara	PROPN
ajcp-4886	282	33	,	,	PUNCT
ajcp-4886	282	34	e.	e.	PROPN
ajcp-4886	282	35	,	,	PUNCT
ajcp-4886	282	36	tomiyama	tomiyama	PROPN
ajcp-4886	282	37	,	,	PUNCT
ajcp-4886	282	38	t.	t.	PROPN
ajcp-4886	282	39	,	,	PUNCT
ajcp-4886	282	40	nagata	nagata	PROPN
ajcp-4886	282	41	,	,	PUNCT
ajcp-4886	282	42	t.	t.	PROPN
ajcp-4886	282	43	,	,	PUNCT
ajcp-4886	282	44	tsumoto	tsumoto	PROPN
ajcp-4886	282	45	,	,	PUNCT
ajcp-4886	282	46	k.	k.	PROPN
ajcp-4886	282	47	,	,	PUNCT
ajcp-4886	282	48	kataoka	kataoka	PROPN
ajcp-4886	282	49	,	,	PUNCT
ajcp-4886	282	50	k.	k.	PROPN
ajcp-4886	282	51	,	,	PUNCT
ajcp-4886	282	52	&	&	CCONJ
ajcp-4886	282	53	yokota	yokota	PROPN
ajcp-4886	282	54	,	,	PUNCT
ajcp-4886	282	55	t.	t.	PROPN
ajcp-4886	282	56	(	(	PUNCT
ajcp-4886	282	57	2023	2023	NUM
ajcp-4886	282	58	)	)	PUNCT
ajcp-4886	282	59	.	.	PUNCT
ajcp-4886	283	1	peripheral	peripheral	ADJ
ajcp-4886	283	2	administration	administration	NOUN
ajcp-4886	283	3	of	of	ADP
ajcp-4886	283	4	nanomicelle	nanomicelle	NOUN
ajcp-4886	283	5	-	-	PUNCT
ajcp-4886	283	6	encapsulated	encapsulate	VERB
ajcp-4886	283	7	anti	anti	ADJ
ajcp-4886	283	8	-	-	ADJ
ajcp-4886	283	9	aβ	aβ	ADJ
ajcp-4886	283	10	oligomer	oligomer	ADJ
ajcp-4886	283	11	fragment	fragment	NOUN
ajcp-4886	283	12	antibody	antibody	NOUN
ajcp-4886	283	13	reduces	reduce	VERB
ajcp-4886	283	14	various	various	ADJ
ajcp-4886	283	15	toxic	toxic	ADJ
ajcp-4886	283	16	aβ	aβ	DET
ajcp-4886	283	17	species	specie	NOUN
ajcp-4886	283	18	in	in	ADP
ajcp-4886	283	19	the	the	DET
ajcp-4886	283	20	brain	brain	NOUN
ajcp-4886	283	21	.	.	PUNCT
ajcp-4886	284	1	journal	journal	PROPN
ajcp-4886	284	2	of	of	ADP
ajcp-4886	284	3	nanobiotechnology	nanobiotechnology	NOUN
ajcp-4886	284	4	,	,	PUNCT
ajcp-4886	284	5	21(1	21(1	NUM
ajcp-4886	284	6	)	)	PUNCT
ajcp-4886	284	7	.	.	PUNCT
ajcp-4886	285	1	https://doi.org/10.1186/s12951-023-01772-y	https://doi.org/10.1186/s12951-023-01772-y	PROPN
ajcp-4886	285	2	amzallag	amzallag	NOUN
ajcp-4886	285	3	,	,	PUNCT
ajcp-4886	285	4	e.	e.	PROPN
ajcp-4886	285	5	,	,	PUNCT
ajcp-4886	285	6	&	&	CCONJ
ajcp-4886	285	7	hornstein	hornstein	PROPN
ajcp-4886	285	8	,	,	PUNCT
ajcp-4886	285	9	e.	e.	PROPN
ajcp-4886	285	10	(	(	PUNCT
ajcp-4886	285	11	2022	2022	NUM
ajcp-4886	285	12	)	)	PUNCT
ajcp-4886	285	13	.	.	PUNCT
ajcp-4886	286	1	crosstalk	crosstalk	VERB
ajcp-4886	286	2	between	between	ADP
ajcp-4886	286	3	biomolecular	biomolecular	ADJ
ajcp-4886	286	4	condensates	condensate	NOUN
ajcp-4886	286	5	and	and	CCONJ
ajcp-4886	286	6	proteostasis	proteostasis	NOUN
ajcp-4886	286	7	.	.	PUNCT
ajcp-4886	287	1	cells	cell	NOUN
ajcp-4886	287	2	,	,	PUNCT
ajcp-4886	287	3	11(15	11(15	NUM
ajcp-4886	287	4	)	)	PUNCT
ajcp-4886	287	5	.	.	PUNCT
ajcp-4886	288	1	https://doi.org/10.3390/cells11152415	https://doi.org/10.3390/cells11152415	NOUN
ajcp-4886	288	2	an	an	PRON
ajcp-4886	288	3	,	,	PUNCT
ajcp-4886	288	4	j.	j.	PROPN
ajcp-4886	288	5	,	,	PUNCT
ajcp-4886	288	6	kim	kim	PROPN
ajcp-4886	288	7	,	,	PUNCT
ajcp-4886	288	8	k.	k.	PROPN
ajcp-4886	288	9	,	,	PUNCT
ajcp-4886	288	10	lim	lim	PROPN
ajcp-4886	288	11	,	,	PUNCT
ajcp-4886	288	12	h.	h.	PROPN
ajcp-4886	288	13	j.	j.	PROPN
ajcp-4886	288	14	,	,	PUNCT
ajcp-4886	288	15	kim	kim	PROPN
ajcp-4886	288	16	,	,	PUNCT
ajcp-4886	288	17	h.	h.	PROPN
ajcp-4886	288	18	y.	y.	PROPN
ajcp-4886	288	19	,	,	PUNCT
ajcp-4886	288	20	shin	shin	PROPN
ajcp-4886	288	21	,	,	PUNCT
ajcp-4886	288	22	j.	j.	PROPN
ajcp-4886	288	23	,	,	PUNCT
ajcp-4886	288	24	park	park	PROPN
ajcp-4886	288	25	,	,	PUNCT
ajcp-4886	288	26	i.	i.	PROPN
ajcp-4886	288	27	,	,	PUNCT
ajcp-4886	288	28	cho	cho	PROPN
ajcp-4886	288	29	,	,	PUNCT
ajcp-4886	288	30	i.	i.	PROPN
ajcp-4886	288	31	,	,	PUNCT
ajcp-4886	288	32	kim	kim	PROPN
ajcp-4886	288	33	,	,	PUNCT
ajcp-4886	288	34	h.	h.	PROPN
ajcp-4886	288	35	y.	y.	PROPN
ajcp-4886	288	36	,	,	PUNCT
ajcp-4886	288	37	kim	kim	PROPN
ajcp-4886	288	38	,	,	PUNCT
ajcp-4886	288	39	s.	s.	PROPN
ajcp-4886	288	40	,	,	PUNCT
ajcp-4886	288	41	mclean	mclean	PROPN
ajcp-4886	288	42	,	,	PUNCT
ajcp-4886	288	43	c.	c.	PROPN
ajcp-4886	288	44	,	,	PUNCT
ajcp-4886	288	45	choi	choi	NOUN
ajcp-4886	288	46	,	,	PUNCT
ajcp-4886	288	47	k.	k.	PROPN
ajcp-4886	288	48	y.	y.	PROPN
ajcp-4886	288	49	,	,	PUNCT
ajcp-4886	288	50	kim	kim	PROPN
ajcp-4886	288	51	,	,	PUNCT
ajcp-4886	288	52	y.	y.	PROPN
ajcp-4886	288	53	,	,	PUNCT
ajcp-4886	288	54	lee	lee	PROPN
ajcp-4886	288	55	,	,	PUNCT
ajcp-4886	288	56	k.	k.	PROPN
ajcp-4886	288	57	h.	h.	PROPN
ajcp-4886	288	58	,	,	PUNCT
ajcp-4886	288	59	&	&	CCONJ
ajcp-4886	288	60	kim	kim	PROPN
ajcp-4886	288	61	,	,	PUNCT
ajcp-4886	288	62	j.	j.	PROPN
ajcp-4886	288	63	s.	s.	PROPN
ajcp-4886	288	64	(	(	PUNCT
ajcp-4886	288	65	2024	2024	NUM
ajcp-4886	288	66	)	)	PUNCT
ajcp-4886	288	67	.	.	PUNCT
ajcp-4886	289	1	early	early	ADJ
ajcp-4886	289	2	onset	onset	VERB
ajcp-4886	289	3	diagnosis	diagnosis	NOUN
ajcp-4886	289	4	in	in	ADP
ajcp-4886	289	5	alzheimer	alzheimer	PROPN
ajcp-4886	289	6	’s	’s	PART
ajcp-4886	289	7	disease	disease	NOUN
ajcp-4886	289	8	patients	patient	NOUN
ajcp-4886	289	9	via	via	ADP
ajcp-4886	289	10	amyloid	amyloid	NOUN
ajcp-4886	289	11	-	-	PUNCT
ajcp-4886	289	12	β	β	X
ajcp-4886	289	13	oligomers	oligomer	NOUN
ajcp-4886	289	14	-	-	PUNCT
ajcp-4886	289	15	sensing	sense	VERB
ajcp-4886	289	16	probe	probe	NOUN
ajcp-4886	289	17	in	in	ADP
ajcp-4886	289	18	cerebrospinal	cerebrospinal	ADJ
ajcp-4886	289	19	fluid	fluid	NOUN
ajcp-4886	289	20	.	.	PUNCT
ajcp-4886	290	1	nature	nature	NOUN
ajcp-4886	290	2	communications	communication	NOUN
ajcp-4886	290	3	,	,	PUNCT
ajcp-4886	290	4	15(1	15(1	NUM
ajcp-4886	290	5	)	)	PUNCT
ajcp-4886	290	6	.	.	PUNCT
ajcp-4886	291	1	https://doi	https://doi	PROPN
ajcp-4886	291	2	.	.	PUNCT
ajcp-4886	291	3	org/10.1038	org/10.1038	PROPN
ajcp-4886	291	4	/	/	SYM
ajcp-4886	291	5	s41467	s41467	NOUN
ajcp-4886	291	6	-	-	PUNCT
ajcp-4886	291	7	024	024	NUM
ajcp-4886	291	8	-	-	PUNCT
ajcp-4886	291	9	44818	44818	NUM
ajcp-4886	291	10	-	-	PUNCT
ajcp-4886	291	11	x	x	SYM
ajcp-4886	291	12	andrade	andrade	PROPN
ajcp-4886	291	13	,	,	PUNCT
ajcp-4886	291	14	s.	s.	PROPN
ajcp-4886	291	15	,	,	PUNCT
ajcp-4886	291	16	ramalho	ramalho	PROPN
ajcp-4886	291	17	,	,	PUNCT
ajcp-4886	291	18	m.	m.	PROPN
ajcp-4886	291	19	j.	j.	PROPN
ajcp-4886	291	20	,	,	PUNCT
ajcp-4886	291	21	loureiro	loureiro	PROPN
ajcp-4886	291	22	,	,	PUNCT
ajcp-4886	291	23	j.	j.	PROPN
ajcp-4886	291	24	a.	a.	PROPN
ajcp-4886	291	25	,	,	PUNCT
ajcp-4886	291	26	&	&	CCONJ
ajcp-4886	291	27	pereira	pereira	PROPN
ajcp-4886	291	28	,	,	PUNCT
ajcp-4886	291	29	m.	m.	PROPN
ajcp-4886	291	30	d.	d.	PROPN
ajcp-4886	291	31	c.	c.	PROPN
ajcp-4886	291	32	(	(	PUNCT
ajcp-4886	291	33	2019	2019	NUM
ajcp-4886	291	34	)	)	PUNCT
ajcp-4886	291	35	.	.	PUNCT
ajcp-4886	292	1	natural	natural	ADJ
ajcp-4886	292	2	compounds	compound	NOUN
ajcp-4886	292	3	for	for	ADP
ajcp-4886	292	4	alzheimer	alzheimer	PROPN
ajcp-4886	292	5	’s	’s	PART
ajcp-4886	292	6	disease	disease	NOUN
ajcp-4886	292	7	therapy	therapy	NOUN
ajcp-4886	292	8	:	:	PUNCT
ajcp-4886	292	9	a	a	DET
ajcp-4886	292	10	systematic	systematic	ADJ
ajcp-4886	292	11	review	review	NOUN
ajcp-4886	292	12	of	of	ADP
ajcp-4886	292	13	preclinical	preclinical	ADJ
ajcp-4886	292	14	and	and	CCONJ
ajcp-4886	292	15	clinical	clinical	ADJ
ajcp-4886	292	16	studies	study	NOUN
ajcp-4886	292	17	.	.	PUNCT
ajcp-4886	293	1	international	international	ADJ
ajcp-4886	293	2	journal	journal	NOUN
ajcp-4886	293	3	of	of	ADP
ajcp-4886	293	4	molecular	molecular	ADJ
ajcp-4886	293	5	sciences	science	NOUN
ajcp-4886	293	6	,	,	PUNCT
ajcp-4886	293	7	20(9	20(9	NUM
ajcp-4886	293	8	)	)	PUNCT
ajcp-4886	293	9	.	.	PUNCT
ajcp-4886	294	1	https://doi.org/10.3390/ijms20092313	https://doi.org/10.3390/ijms20092313	PROPN
ajcp-4886	294	2	araki	araki	PROPN
ajcp-4886	294	3	,	,	PUNCT
ajcp-4886	294	4	w.	w.	NOUN
ajcp-4886	294	5	(	(	PUNCT
ajcp-4886	294	6	2023	2023	NUM
ajcp-4886	294	7	)	)	PUNCT
ajcp-4886	294	8	.	.	PUNCT
ajcp-4886	295	1	aβ	aβ	PRON
ajcp-4886	295	2	oligomer	oligomer	ADJ
ajcp-4886	295	3	toxicity	toxicity	NOUN
ajcp-4886	295	4	-	-	PUNCT
ajcp-4886	295	5	reducing	reduce	VERB
ajcp-4886	295	6	therapy	therapy	NOUN
ajcp-4886	295	7	for	for	ADP
ajcp-4886	295	8	the	the	DET
ajcp-4886	295	9	prevention	prevention	NOUN
ajcp-4886	295	10	of	of	ADP
ajcp-4886	295	11	alzheimer	alzheimer	PROPN
ajcp-4886	295	12	’s	’s	PART
ajcp-4886	295	13	disease	disease	NOUN
ajcp-4886	295	14	:	:	PUNCT
ajcp-4886	295	15	importance	importance	NOUN
ajcp-4886	295	16	of	of	ADP
ajcp-4886	295	17	the	the	DET
ajcp-4886	295	18	nrf2	nrf2	PROPN
ajcp-4886	295	19	and	and	CCONJ
ajcp-4886	295	20	pparγ	pparγ	ADJ
ajcp-4886	295	21	pathways	pathway	NOUN
ajcp-4886	295	22	.	.	PUNCT
ajcp-4886	296	1	cells	cell	NOUN
ajcp-4886	296	2	,	,	PUNCT
ajcp-4886	296	3	12(10	12(10	NUM
ajcp-4886	296	4	)	)	PUNCT
ajcp-4886	296	5	.	.	PUNCT
ajcp-4886	297	1	https://doi.org/10.3390/cells12101386	https://doi.org/10.3390/cells12101386	PROPN
ajcp-4886	297	2	araki	araki	PROPN
ajcp-4886	297	3	,	,	PUNCT
ajcp-4886	297	4	w.	w.	PROPN
ajcp-4886	297	5	,	,	PUNCT
ajcp-4886	297	6	&	&	CCONJ
ajcp-4886	297	7	kametani	kametani	PROPN
ajcp-4886	297	8	,	,	PUNCT
ajcp-4886	297	9	f.	f.	PROPN
ajcp-4886	297	10	(	(	PUNCT
ajcp-4886	297	11	2022	2022	NUM
ajcp-4886	297	12	)	)	PUNCT
ajcp-4886	297	13	.	.	PUNCT
ajcp-4886	298	1	protection	protection	NOUN
ajcp-4886	298	2	against	against	ADP
ajcp-4886	298	3	amyloid	amyloid	NOUN
ajcp-4886	298	4	-	-	PUNCT
ajcp-4886	298	5	β	β	X
ajcp-4886	298	6	oligomer	oligomer	ADJ
ajcp-4886	298	7	neurotoxicity	neurotoxicity	NOUN
ajcp-4886	298	8	by	by	ADP
ajcp-4886	298	9	small	small	ADJ
ajcp-4886	298	10	molecules	molecule	NOUN
ajcp-4886	298	11	with	with	ADP
ajcp-4886	298	12	antioxidative	antioxidative	ADJ
ajcp-4886	298	13	properties	property	NOUN
ajcp-4886	298	14	:	:	PUNCT
ajcp-4886	298	15	potential	potential	ADJ
ajcp-4886	298	16	for	for	ADP
ajcp-4886	298	17	the	the	DET
ajcp-4886	298	18	prevention	prevention	NOUN
ajcp-4886	298	19	of	of	ADP
ajcp-4886	298	20	alzheimer	alzheimer	PROPN
ajcp-4886	298	21	’s	’s	PART
ajcp-4886	298	22	disease	disease	NOUN
ajcp-4886	298	23	dementia	dementia	NOUN
ajcp-4886	298	24	.	.	PUNCT
ajcp-4886	299	1	antioxidants	antioxidant	NOUN
ajcp-4886	299	2	,	,	PUNCT
ajcp-4886	299	3	11(1	11(1	NUM
ajcp-4886	299	4	)	)	PUNCT
ajcp-4886	299	5	.	.	PUNCT
ajcp-4886	300	1	https://doi.org/10.3390/	https://doi.org/10.3390/	PROPN
ajcp-4886	300	2	antiox11010132	antiox11010132	PROPN
ajcp-4886	300	3	bao	bao	PROPN
ajcp-4886	300	4	,	,	PUNCT
ajcp-4886	300	5	j.	j.	PROPN
ajcp-4886	300	6	,	,	PUNCT
ajcp-4886	300	7	liu	liu	PROPN
ajcp-4886	300	8	,	,	PUNCT
ajcp-4886	300	9	w.	w.	PROPN
ajcp-4886	300	10	,	,	PUNCT
ajcp-4886	300	11	zhou	zhou	PROPN
ajcp-4886	300	12	,	,	PUNCT
ajcp-4886	300	13	h.-y	h.-y	NOUN
ajcp-4886	300	14	.	.	PUNCT
ajcp-4886	300	15	,	,	PUNCT
ajcp-4886	300	16	gui	gui	PROPN
ajcp-4886	300	17	,	,	PUNCT
ajcp-4886	300	18	y.-r	y.-r	PROPN
ajcp-4886	300	19	.	.	PROPN
ajcp-4886	300	20	,	,	PUNCT
ajcp-4886	300	21	yang	yang	PROPN
ajcp-4886	300	22	,	,	PUNCT
ajcp-4886	300	23	y.-h	y.-h	PROPN
ajcp-4886	300	24	.	.	PROPN
ajcp-4886	300	25	,	,	PUNCT
ajcp-4886	300	26	wu	wu	PROPN
ajcp-4886	300	27	,	,	PUNCT
ajcp-4886	300	28	m.-j	m.-j	PROPN
ajcp-4886	300	29	.	.	PROPN
ajcp-4886	300	30	,	,	PUNCT
ajcp-4886	300	31	xiao	xiao	PROPN
ajcp-4886	300	32	,	,	PUNCT
ajcp-4886	300	33	y.-f	y.-f	PROPN
ajcp-4886	300	34	.	.	PROPN
ajcp-4886	300	35	,	,	PUNCT
ajcp-4886	300	36	shang	shang	PROPN
ajcp-4886	300	37	,	,	PUNCT
ajcp-4886	300	38	j.-t	j.-t	PROPN
ajcp-4886	300	39	.	.	PUNCT
ajcp-4886	300	40	,	,	PUNCT
ajcp-4886	300	41	long	long	ADJ
ajcp-4886	300	42	,	,	PUNCT
ajcp-4886	300	43	g.-f	g.-f	NOUN
ajcp-4886	300	44	.	.	PUNCT
ajcp-4886	300	45	,	,	PUNCT
ajcp-4886	300	46	&	&	CCONJ
ajcp-4886	300	47	shu	shu	PROPN
ajcp-4886	300	48	,	,	PUNCT
ajcp-4886	300	49	x.-j	x.-j	PROPN
ajcp-4886	300	50	.	.	PUNCT
ajcp-4886	301	1	(	(	PUNCT
ajcp-4886	301	2	2020	2020	NUM
ajcp-4886	301	3	)	)	PUNCT
ajcp-4886	301	4	.	.	PUNCT
ajcp-4886	302	1	epigallocatechin-3	epigallocatechin-3	PROPN
ajcp-4886	302	2	-	-	PUNCT
ajcp-4886	302	3	gallate	gallate	NOUN
ajcp-4886	302	4	alleviates	alleviate	VERB
ajcp-4886	302	5	cognitive	cognitive	ADJ
ajcp-4886	302	6	deficits	deficit	NOUN
ajcp-4886	302	7	in	in	ADP
ajcp-4886	302	8	app	app	PROPN
ajcp-4886	302	9	/	/	SYM
ajcp-4886	302	10	ps1	ps1	NOUN
ajcp-4886	302	11	mice	mouse	NOUN
ajcp-4886	302	12	.	.	PUNCT
ajcp-4886	303	1	current	current	ADJ
ajcp-4886	303	2	medical	medical	ADJ
ajcp-4886	303	3	science	science	NOUN
ajcp-4886	303	4	,	,	PUNCT
ajcp-4886	303	5	40(1	40(1	NOUN
ajcp-4886	303	6	)	)	PUNCT
ajcp-4886	303	7	,	,	PUNCT
ajcp-4886	303	8	18	18	NUM
ajcp-4886	303	9	-	-	SYM
ajcp-4886	303	10	27	27	NUM
ajcp-4886	303	11	.	.	PUNCT
ajcp-4886	304	1	https://doi.org/10.1007/s11596-0202142-z	https://doi.org/10.1007/s11596-0202142-z	PRON
ajcp-4886	304	2	cascella	cascella	PROPN
ajcp-4886	304	3	,	,	PUNCT
ajcp-4886	304	4	r.	r.	PROPN
ajcp-4886	304	5	,	,	PUNCT
ajcp-4886	304	6	bigi	bigi	PROPN
ajcp-4886	304	7	,	,	PUNCT
ajcp-4886	304	8	a.	a.	NOUN
ajcp-4886	304	9	,	,	PUNCT
ajcp-4886	304	10	riffert	riffert	NOUN
ajcp-4886	304	11	,	,	PUNCT
ajcp-4886	304	12	d.	d.	PROPN
ajcp-4886	304	13	g.	g.	PROPN
ajcp-4886	304	14	,	,	PUNCT
ajcp-4886	304	15	gagliani	gagliani	PROPN
ajcp-4886	304	16	,	,	PUNCT
ajcp-4886	304	17	m.	m.	PROPN
ajcp-4886	304	18	c.	c.	PROPN
ajcp-4886	304	19	,	,	PUNCT
ajcp-4886	304	20	ermini	ermini	PROPN
ajcp-4886	304	21	,	,	PUNCT
ajcp-4886	304	22	e.	e.	PROPN
ajcp-4886	304	23	,	,	PUNCT
ajcp-4886	304	24	moretti	moretti	PROPN
ajcp-4886	304	25	,	,	PUNCT
ajcp-4886	304	26	m.	m.	NOUN
ajcp-4886	304	27	,	,	PUNCT
ajcp-4886	304	28	cortese	cortese	PROPN
ajcp-4886	304	29	,	,	PUNCT
ajcp-4886	304	30	k.	k.	PROPN
ajcp-4886	304	31	,	,	PUNCT
ajcp-4886	304	32	cecchi	cecchi	NOUN
ajcp-4886	304	33	,	,	PUNCT
ajcp-4886	304	34	c.	c.	PROPN
ajcp-4886	304	35	,	,	PUNCT
ajcp-4886	304	36	&	&	CCONJ
ajcp-4886	304	37	chiti	chiti	PROPN
ajcp-4886	304	38	,	,	PUNCT
ajcp-4886	304	39	f.	f.	PROPN
ajcp-4886	304	40	(	(	PUNCT
ajcp-4886	304	41	2022	2022	NUM
ajcp-4886	304	42	)	)	PUNCT
ajcp-4886	304	43	.	.	PUNCT
ajcp-4886	305	1	a	a	DET
ajcp-4886	305	2	quantitative	quantitative	ADJ
ajcp-4886	305	3	biology	biology	NOUN
ajcp-4886	305	4	approach	approach	NOUN
ajcp-4886	305	5	correlates	correlate	VERB
ajcp-4886	305	6	neuronal	neuronal	ADJ
ajcp-4886	305	7	toxicity	toxicity	NOUN
ajcp-4886	305	8	with	with	ADP
ajcp-4886	305	9	the	the	DET
ajcp-4886	305	10	largest	large	ADJ
ajcp-4886	305	11	inclusions	inclusion	NOUN
ajcp-4886	305	12	of	of	ADP
ajcp-4886	305	13	tdp-43	tdp-43	PROPN
ajcp-4886	305	14	.	.	PUNCT
ajcp-4886	306	1	science	science	NOUN
ajcp-4886	306	2	advances	advance	NOUN
ajcp-4886	306	3	,	,	PUNCT
ajcp-4886	306	4	8(30	8(30	NUM
ajcp-4886	306	5	)	)	PUNCT
ajcp-4886	306	6	.	.	PUNCT
ajcp-4886	307	1	https://doi	https://doi	X
ajcp-4886	307	2	.	.	PUNCT
ajcp-4886	308	1	org/10.1126	org/10.1126	NOUN
ajcp-4886	308	2	/	/	SYM
ajcp-4886	308	3	sciadv.abm6376	sciadv.abm6376	PROPN
ajcp-4886	308	4	chen	chen	PROPN
ajcp-4886	308	5	,	,	PUNCT
ajcp-4886	308	6	h.	h.	PROPN
ajcp-4886	308	7	,	,	PUNCT
ajcp-4886	308	8	mcgowan	mcgowan	PROPN
ajcp-4886	308	9	,	,	PUNCT
ajcp-4886	308	10	e.	e.	PROPN
ajcp-4886	308	11	m.	m.	PROPN
ajcp-4886	308	12	,	,	PUNCT
ajcp-4886	308	13	ren	ren	PROPN
ajcp-4886	308	14	,	,	PUNCT
ajcp-4886	308	15	n.	n.	PROPN
ajcp-4886	308	16	,	,	PUNCT
ajcp-4886	308	17	lal	lal	PROPN
ajcp-4886	308	18	,	,	PUNCT
ajcp-4886	308	19	s.	s.	PROPN
ajcp-4886	308	20	,	,	PUNCT
ajcp-4886	308	21	nassif	nassif	NOUN
ajcp-4886	308	22	,	,	PUNCT
ajcp-4886	308	23	n.	n.	NOUN
ajcp-4886	308	24	,	,	PUNCT
ajcp-4886	308	25	shad	shad	NOUN
ajcp-4886	308	26	-	-	PUNCT
ajcp-4886	308	27	kaneez	kaneez	PROPN
ajcp-4886	308	28	,	,	PUNCT
ajcp-4886	308	29	f.	f.	PROPN
ajcp-4886	308	30	,	,	PUNCT
ajcp-4886	308	31	qu	qu	PROPN
ajcp-4886	308	32	,	,	PUNCT
ajcp-4886	308	33	x.	x.	PROPN
ajcp-4886	308	34	,	,	PUNCT
ajcp-4886	308	35	&	&	CCONJ
ajcp-4886	308	36	lin	lin	PROPN
ajcp-4886	308	37	,	,	PUNCT
ajcp-4886	308	38	y.	y.	PROPN
ajcp-4886	308	39	(	(	PUNCT
ajcp-4886	308	40	2018	2018	NUM
ajcp-4886	308	41	)	)	PUNCT
ajcp-4886	308	42	.	.	PUNCT
ajcp-4886	309	1	nattokinase	nattokinase	NOUN
ajcp-4886	309	2	:	:	PUNCT
ajcp-4886	309	3	a	a	DET
ajcp-4886	309	4	promising	promising	ADJ
ajcp-4886	309	5	alternative	alternative	NOUN
ajcp-4886	309	6	in	in	ADP
ajcp-4886	309	7	prevention	prevention	NOUN
ajcp-4886	309	8	and	and	CCONJ
ajcp-4886	309	9	treatment	treatment	NOUN
ajcp-4886	309	10	of	of	ADP
ajcp-4886	309	11	cardiovascular	cardiovascular	ADJ
ajcp-4886	309	12	diseases	disease	NOUN
ajcp-4886	309	13	.	.	PUNCT
ajcp-4886	310	1	biomarker	biomarker	NOUN
ajcp-4886	310	2	insights	insight	NOUN
ajcp-4886	310	3	,	,	PUNCT
ajcp-4886	310	4	13	13	NUM
ajcp-4886	310	5	.	.	PUNCT
ajcp-4886	311	1	https://doi.org/10.1177/1177271918785130	https://doi.org/10.1177/1177271918785130	PROPN
ajcp-4886	312	1	cheng	cheng	PROPN
ajcp-4886	312	2	,	,	PUNCT
ajcp-4886	312	3	y.	y.	PROPN
ajcp-4886	312	4	,	,	PUNCT
ajcp-4886	312	5	tian	tian	PROPN
ajcp-4886	312	6	,	,	PUNCT
ajcp-4886	312	7	d.-y	d.-y	PROPN
ajcp-4886	312	8	.	.	PUNCT
ajcp-4886	312	9	,	,	PUNCT
ajcp-4886	312	10	&	&	CCONJ
ajcp-4886	312	11	wang	wang	PROPN
ajcp-4886	312	12	,	,	PUNCT
ajcp-4886	312	13	y.-j	y.-j	PROPN
ajcp-4886	312	14	.	.	PUNCT
ajcp-4886	312	15	(	(	PUNCT
ajcp-4886	312	16	2020	2020	NUM
ajcp-4886	312	17	)	)	PUNCT
ajcp-4886	312	18	.	.	PUNCT
ajcp-4886	313	1	peripheral	peripheral	ADJ
ajcp-4886	313	2	clearance	clearance	NOUN
ajcp-4886	313	3	of	of	ADP
ajcp-4886	313	4	brain	brain	NOUN
ajcp-4886	313	5	-	-	PUNCT
ajcp-4886	313	6	derived	derive	VERB
ajcp-4886	313	7	aβ	aβ	NOUN
ajcp-4886	313	8	in	in	ADP
ajcp-4886	313	9	alzheimer	alzheimer	PROPN
ajcp-4886	313	10	’s	’s	PART
ajcp-4886	313	11	disease	disease	NOUN
ajcp-4886	313	12	:	:	PUNCT
ajcp-4886	313	13	pathophysiology	pathophysiology	NOUN
ajcp-4886	313	14	and	and	CCONJ
ajcp-4886	313	15	therapeutic	therapeutic	ADJ
ajcp-4886	313	16	perspectives	perspective	NOUN
ajcp-4886	313	17	.	.	PUNCT
ajcp-4886	314	1	translational	translational	ADJ
ajcp-4886	314	2	neurodegeneration	neurodegeneration	NOUN
ajcp-4886	314	3	,	,	PUNCT
ajcp-4886	314	4	9(1	9(1	NUM
ajcp-4886	314	5	)	)	PUNCT
ajcp-4886	314	6	.	.	PUNCT
ajcp-4886	315	1	https://doi	https://doi	X
ajcp-4886	315	2	.	.	PUNCT
ajcp-4886	315	3	org/10.1186	org/10.1186	PROPN
ajcp-4886	315	4	/	/	SYM
ajcp-4886	315	5	s40035	s40035	NOUN
ajcp-4886	315	6	-	-	PUNCT
ajcp-4886	315	7	020	020	NUM
ajcp-4886	315	8	-	-	PUNCT
ajcp-4886	315	9	00195	00195	NUM
ajcp-4886	315	10	-	-	SYM
ajcp-4886	315	11	1	1	NUM
ajcp-4886	315	12	cline	cline	PROPN
ajcp-4886	315	13	,	,	PUNCT
ajcp-4886	315	14	e.	e.	PROPN
ajcp-4886	315	15	n.	n.	PROPN
ajcp-4886	315	16	,	,	PUNCT
ajcp-4886	315	17	bicca	bicca	PROPN
ajcp-4886	315	18	,	,	PUNCT
ajcp-4886	315	19	m.	m.	NOUN
ajcp-4886	315	20	a.	a.	PROPN
ajcp-4886	315	21	,	,	PUNCT
ajcp-4886	315	22	viola	viola	PROPN
ajcp-4886	315	23	,	,	PUNCT
ajcp-4886	315	24	k.	k.	PROPN
ajcp-4886	315	25	l.	l.	PROPN
ajcp-4886	315	26	,	,	PUNCT
ajcp-4886	315	27	klein	klein	PROPN
ajcp-4886	315	28	,	,	PUNCT
ajcp-4886	315	29	w.	w.	PROPN
ajcp-4886	315	30	l.	l.	PROPN
ajcp-4886	315	31	,	,	PUNCT
ajcp-4886	315	32	perry	perry	PROPN
ajcp-4886	315	33	,	,	PUNCT
ajcp-4886	315	34	g.	g.	PROPN
ajcp-4886	315	35	,	,	PUNCT
ajcp-4886	315	36	avila	avila	PROPN
ajcp-4886	315	37	,	,	PUNCT
ajcp-4886	315	38	j.	j.	PROPN
ajcp-4886	315	39	,	,	PUNCT
ajcp-4886	315	40	moreira	moreira	PROPN
ajcp-4886	315	41	,	,	PUNCT
ajcp-4886	315	42	p.	p.	NOUN
ajcp-4886	315	43	i.	i.	PROPN
ajcp-4886	315	44	,	,	PUNCT
ajcp-4886	315	45	sorensen	sorensen	PROPN
ajcp-4886	315	46	,	,	PUNCT
ajcp-4886	315	47	a.	a.	NOUN
ajcp-4886	315	48	a.	a.	PROPN
ajcp-4886	315	49	,	,	PUNCT
ajcp-4886	315	50	&	&	CCONJ
ajcp-4886	315	51	tabaton	tabaton	PROPN
ajcp-4886	315	52	,	,	PUNCT
ajcp-4886	315	53	m.	m.	NOUN
ajcp-4886	315	54	(	(	PUNCT
ajcp-4886	315	55	2018	2018	NUM
ajcp-4886	315	56	)	)	PUNCT
ajcp-4886	315	57	.	.	PUNCT
ajcp-4886	316	1	the	the	DET
ajcp-4886	316	2	amyloid	amyloid	NOUN
ajcp-4886	316	3	-	-	PUNCT
ajcp-4886	316	4	β	β	X
ajcp-4886	316	5	oligomer	oligomer	ADJ
ajcp-4886	316	6	hypothesis	hypothesis	NOUN
ajcp-4886	316	7	:	:	PUNCT
ajcp-4886	316	8	beginning	begin	VERB
ajcp-4886	316	9	of	of	ADP
ajcp-4886	316	10	the	the	DET
ajcp-4886	316	11	third	third	ADJ
ajcp-4886	316	12	decade	decade	NOUN
ajcp-4886	316	13	.	.	PUNCT
ajcp-4886	317	1	journal	journal	PROPN
ajcp-4886	317	2	of	of	ADP
ajcp-4886	317	3	alzheimer	alzheimer	PROPN
ajcp-4886	317	4	’s	’s	PART
ajcp-4886	317	5	disease	disease	NOUN
ajcp-4886	317	6	,	,	PUNCT
ajcp-4886	317	7	64(s1	64(s1	NOUN
ajcp-4886	317	8	)	)	PUNCT
ajcp-4886	317	9	,	,	PUNCT
ajcp-4886	317	10	s567	s567	PROPN
ajcp-4886	317	11	-	-	SYM
ajcp-4886	317	12	s610	s610	PROPN
ajcp-4886	317	13	.	.	PUNCT
ajcp-4886	318	1	https://doi.org/10.3233/	https://doi.org/10.3233/	PROPN
ajcp-4886	318	2	jad-179941	jad-179941	NOUN
ajcp-4886	318	3	de	de	X
ajcp-4886	318	4	dios	dios	X
ajcp-4886	318	5	,	,	PUNCT
ajcp-4886	318	6	c.	c.	NOUN
ajcp-4886	318	7	,	,	PUNCT
ajcp-4886	318	8	bartolessis	bartolessis	NOUN
ajcp-4886	318	9	,	,	PUNCT
ajcp-4886	318	10	i.	i.	PROPN
ajcp-4886	318	11	,	,	PUNCT
ajcp-4886	318	12	roca	roca	PROPN
ajcp-4886	318	13	-	-	PUNCT
ajcp-4886	318	14	agujetas	agujeta	NOUN
ajcp-4886	318	15	,	,	PUNCT
ajcp-4886	318	16	v.	v.	ADV
ajcp-4886	318	17	,	,	PUNCT
ajcp-4886	318	18	barberocamps	barberocamp	NOUN
ajcp-4886	318	19	,	,	PUNCT
ajcp-4886	318	20	e.	e.	PROPN
ajcp-4886	318	21	,	,	PUNCT
ajcp-4886	318	22	mari	mari	PROPN
ajcp-4886	318	23	,	,	PUNCT
ajcp-4886	318	24	m.	m.	NOUN
ajcp-4886	318	25	,	,	PUNCT
ajcp-4886	318	26	morales	morale	NOUN
ajcp-4886	318	27	,	,	PUNCT
ajcp-4886	318	28	a.	a.	NOUN
ajcp-4886	318	29	,	,	PUNCT
ajcp-4886	318	30	&	&	CCONJ
ajcp-4886	318	31	colell	colell	PROPN
ajcp-4886	318	32	,	,	PUNCT
ajcp-4886	318	33	a.	a.	NOUN
ajcp-4886	318	34	(	(	PUNCT
ajcp-4886	318	35	2019	2019	NUM
ajcp-4886	318	36	)	)	PUNCT
ajcp-4886	318	37	.	.	PUNCT
ajcp-4886	319	1	oxidative	oxidative	ADJ
ajcp-4886	319	2	inactivation	inactivation	NOUN
ajcp-4886	319	3	of	of	ADP
ajcp-4886	319	4	amyloid	amyloid	NOUN
ajcp-4886	319	5	beta	beta	NOUN
ajcp-4886	319	6	-	-	PUNCT
ajcp-4886	319	7	degrading	degrade	VERB
ajcp-4886	319	8	proteases	protease	NOUN
ajcp-4886	319	9	by	by	ADP
ajcp-4886	319	10	cholesterol	cholesterol	NOUN
ajcp-4886	319	11	-	-	PUNCT
ajcp-4886	319	12	enhanced	enhance	VERB
ajcp-4886	319	13	mitochondrial	mitochondrial	ADJ
ajcp-4886	319	14	stress	stress	NOUN
ajcp-4886	319	15	.	.	PUNCT
ajcp-4886	320	1	redox	redox	ADJ
ajcp-4886	320	2	biology	biology	NOUN
ajcp-4886	320	3	,	,	PUNCT
ajcp-4886	320	4	26	26	NUM
ajcp-4886	320	5	.	.	PUNCT
ajcp-4886	321	1	https://doi.org/10.1016/j	https://doi.org/10.1016/j	NOUN
ajcp-4886	321	2	.	.	PUNCT
ajcp-4886	322	1	redox.2019.101283	redox.2019.101283	NOUN
ajcp-4886	322	2	derreumaux	derreumaux	VERB
ajcp-4886	322	3	,	,	PUNCT
ajcp-4886	322	4	p.	p.	PROPN
ajcp-4886	322	5	,	,	PUNCT
ajcp-4886	322	6	nguyen	nguyen	NOUN
ajcp-4886	322	7	,	,	PUNCT
ajcp-4886	322	8	p.	p.	NOUN
ajcp-4886	322	9	,	,	PUNCT
ajcp-4886	322	10	&	&	CCONJ
ajcp-4886	322	11	sterpone	sterpone	PROPN
ajcp-4886	322	12	,	,	PUNCT
ajcp-4886	322	13	f.	f.	PROPN
ajcp-4886	322	14	(	(	PUNCT
ajcp-4886	322	15	2022	2022	NUM
ajcp-4886	322	16	)	)	PUNCT
ajcp-4886	322	17	.	.	PUNCT
ajcp-4886	323	1	https://	https://	PROPN
ajcp-4886	323	2	doi.org/10.22541/au.167108799.96485165/v1	doi.org/10.22541/au.167108799.96485165/v1	PROPN
ajcp-4886	323	3	diociaiuti	diociaiuti	PROPN
ajcp-4886	323	4	,	,	PUNCT
ajcp-4886	323	5	m.	m.	NOUN
ajcp-4886	323	6	,	,	PUNCT
ajcp-4886	323	7	bonanni	bonanni	PROPN
ajcp-4886	323	8	,	,	PUNCT
ajcp-4886	323	9	r.	r.	PROPN
ajcp-4886	323	10	,	,	PUNCT
ajcp-4886	323	11	cariati	cariati	PROPN
ajcp-4886	323	12	,	,	PUNCT
ajcp-4886	323	13	i.	i.	PROPN
ajcp-4886	323	14	,	,	PUNCT
ajcp-4886	323	15	frank	frank	PROPN
ajcp-4886	323	16	,	,	PUNCT
ajcp-4886	323	17	c.	c.	PROPN
ajcp-4886	323	18	,	,	PUNCT
ajcp-4886	323	19	&	&	CCONJ
ajcp-4886	323	20	d’arcangelo	d’arcangelo	PROPN
ajcp-4886	323	21	,	,	PUNCT
ajcp-4886	323	22	g.	g.	PROPN
ajcp-4886	323	23	(	(	PUNCT
ajcp-4886	323	24	2021	2021	NUM
ajcp-4886	323	25	)	)	PUNCT
ajcp-4886	323	26	.	.	PUNCT
ajcp-4886	324	1	amyloid	amyloid	NOUN
ajcp-4886	324	2	prefibrillar	prefibrillar	ADJ
ajcp-4886	324	3	oligomers	oligomer	NOUN
ajcp-4886	324	4	:	:	PUNCT
ajcp-4886	324	5	the	the	DET
ajcp-4886	324	6	surprising	surprising	ADJ
ajcp-4886	324	7	commonalities	commonality	NOUN
ajcp-4886	324	8	in	in	ADP
ajcp-4886	324	9	their	their	PRON
ajcp-4886	324	10	structure	structure	NOUN
ajcp-4886	324	11	and	and	CCONJ
ajcp-4886	324	12	activity	activity	NOUN
ajcp-4886	324	13	.	.	PUNCT
ajcp-4886	325	1	international	international	ADJ
ajcp-4886	325	2	journal	journal	NOUN
ajcp-4886	325	3	of	of	ADP
ajcp-4886	325	4	molecular	molecular	ADJ
ajcp-4886	325	5	sciences	science	NOUN
ajcp-4886	325	6	,	,	PUNCT
ajcp-4886	325	7	22(12	22(12	NUM
ajcp-4886	325	8	)	)	PUNCT
ajcp-4886	325	9	.	.	PUNCT
ajcp-4886	326	1	https://doi.org/10.3390/	https://doi.org/10.3390/	PROPN
ajcp-4886	326	2	ijms22126435	ijms22126435	PROPN
ajcp-4886	326	3	pa	pa	PROPN
ajcp-4886	326	4	ge	ge	PROPN
ajcp-4886	326	5	25	25	NUM
ajcp-4886	326	6	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-4886	326	7	am	be	AUX
ajcp-4886	326	8	.	.	PUNCT
ajcp-4886	327	1	j.	j.	PROPN
ajcp-4886	327	2	chem	chem	PROPN
ajcp-4886	327	3	.	.	PUNCT
ajcp-4886	328	1	pharm	pharm	PROPN
ajcp-4886	328	2	.	.	PUNCT
ajcp-4886	329	1	4(1	4(1	NOUN
ajcp-4886	329	2	)	)	PUNCT
ajcp-4886	330	1	16	16	NUM
ajcp-4886	330	2	-	-	SYM
ajcp-4886	330	3	28	28	NUM
ajcp-4886	330	4	,	,	PUNCT
ajcp-4886	330	5	2025	2025	NUM
ajcp-4886	330	6	du	du	NOUN
ajcp-4886	330	7	,	,	PUNCT
ajcp-4886	330	8	h.	h.	PROPN
ajcp-4886	330	9	,	,	PUNCT
ajcp-4886	330	10	song	song	PROPN
ajcp-4886	330	11	,	,	PUNCT
ajcp-4886	330	12	j.	j.	PROPN
ajcp-4886	330	13	,	,	PUNCT
ajcp-4886	330	14	ma	ma	PROPN
ajcp-4886	330	15	,	,	PUNCT
ajcp-4886	330	16	f.	f.	PROPN
ajcp-4886	330	17	,	,	PUNCT
ajcp-4886	330	18	gao	gao	PROPN
ajcp-4886	330	19	,	,	PUNCT
ajcp-4886	330	20	h.	h.	PROPN
ajcp-4886	330	21	,	,	PUNCT
ajcp-4886	330	22	zhao	zhao	PROPN
ajcp-4886	330	23	,	,	PUNCT
ajcp-4886	330	24	x.	x.	PROPN
ajcp-4886	330	25	,	,	PUNCT
ajcp-4886	330	26	mao	mao	PROPN
ajcp-4886	330	27	,	,	PUNCT
ajcp-4886	330	28	r.	r.	PROPN
ajcp-4886	330	29	,	,	PUNCT
ajcp-4886	330	30	he	he	PRON
ajcp-4886	330	31	,	,	PUNCT
ajcp-4886	330	32	x.	x.	PROPN
ajcp-4886	330	33	,	,	PUNCT
ajcp-4886	330	34	&	&	CCONJ
ajcp-4886	330	35	yan	yan	PROPN
ajcp-4886	330	36	,	,	PUNCT
ajcp-4886	330	37	y.	y.	PROPN
ajcp-4886	330	38	(	(	PUNCT
ajcp-4886	330	39	2023	2023	NUM
ajcp-4886	330	40	)	)	PUNCT
ajcp-4886	330	41	.	.	PUNCT
ajcp-4886	331	1	novel	novel	ADJ
ajcp-4886	331	2	harmine	harmine	NOUN
ajcp-4886	331	3	derivatives	derivative	NOUN
ajcp-4886	331	4	as	as	ADP
ajcp-4886	331	5	potent	potent	ADJ
ajcp-4886	331	6	acetylcholinesterase	acetylcholinesterase	NOUN
ajcp-4886	331	7	and	and	CCONJ
ajcp-4886	331	8	amyloid	amyloid	VERB
ajcp-4886	331	9	beta	beta	NOUN
ajcp-4886	331	10	aggregation	aggregation	NOUN
ajcp-4886	331	11	dual	dual	ADJ
ajcp-4886	331	12	inhibitors	inhibitor	NOUN
ajcp-4886	331	13	for	for	ADP
ajcp-4886	331	14	management	management	NOUN
ajcp-4886	331	15	of	of	ADP
ajcp-4886	331	16	alzheimer	alzheimer	PROPN
ajcp-4886	331	17	’s	’s	PART
ajcp-4886	331	18	disease	disease	NOUN
ajcp-4886	331	19	.	.	PUNCT
ajcp-4886	332	1	journal	journal	NOUN
ajcp-4886	332	2	of	of	ADP
ajcp-4886	332	3	enzyme	enzyme	NOUN
ajcp-4886	332	4	inhibition	inhibition	NOUN
ajcp-4886	332	5	and	and	CCONJ
ajcp-4886	332	6	medicinal	medicinal	ADJ
ajcp-4886	332	7	chemistry	chemistry	NOUN
ajcp-4886	332	8	,	,	PUNCT
ajcp-4886	332	9	38(1	38(1	NUM
ajcp-4886	332	10	)	)	PUNCT
ajcp-4886	332	11	.	.	PUNCT
ajcp-4886	333	1	https://doi.org/10.1080/1	https://doi.org/10.1080/1	PROPN
ajcp-4886	333	2	4756366.2023.2281893	4756366.2023.2281893	NUM
ajcp-4886	333	3	el	el	PROPN
ajcp-4886	333	4	gaamouch	gaamouch	PROPN
ajcp-4886	333	5	,	,	PUNCT
ajcp-4886	333	6	f.	f.	PROPN
ajcp-4886	333	7	,	,	PUNCT
ajcp-4886	333	8	chen	chen	PROPN
ajcp-4886	333	9	,	,	PUNCT
ajcp-4886	333	10	f.	f.	PROPN
ajcp-4886	333	11	,	,	PUNCT
ajcp-4886	333	12	ho	ho	PROPN
ajcp-4886	333	13	,	,	PUNCT
ajcp-4886	333	14	l.	l.	PROPN
ajcp-4886	333	15	,	,	PUNCT
ajcp-4886	333	16	lin	lin	PROPN
ajcp-4886	333	17	,	,	PUNCT
ajcp-4886	333	18	h.-y	h.-y	NOUN
ajcp-4886	333	19	.	.	PUNCT
ajcp-4886	333	20	,	,	PUNCT
ajcp-4886	333	21	yuan	yuan	PROPN
ajcp-4886	333	22	,	,	PUNCT
ajcp-4886	333	23	c.	c.	PROPN
ajcp-4886	333	24	,	,	PUNCT
ajcp-4886	333	25	wong	wong	PROPN
ajcp-4886	333	26	,	,	PUNCT
ajcp-4886	333	27	j.	j.	PROPN
ajcp-4886	333	28	,	,	PUNCT
ajcp-4886	333	29	&	&	CCONJ
ajcp-4886	333	30	wang	wang	PROPN
ajcp-4886	333	31	,	,	PUNCT
ajcp-4886	333	32	j.	j.	PROPN
ajcp-4886	333	33	(	(	PUNCT
ajcp-4886	333	34	2022	2022	NUM
ajcp-4886	333	35	)	)	PUNCT
ajcp-4886	333	36	.	.	PUNCT
ajcp-4886	334	1	benefits	benefit	NOUN
ajcp-4886	334	2	of	of	ADP
ajcp-4886	334	3	dietary	dietary	ADJ
ajcp-4886	334	4	polyphenols	polyphenol	NOUN
ajcp-4886	334	5	in	in	ADP
ajcp-4886	334	6	alzheimer	alzheimer	PROPN
ajcp-4886	334	7	’s	’s	PART
ajcp-4886	334	8	disease	disease	NOUN
ajcp-4886	334	9	.	.	PUNCT
ajcp-4886	335	1	frontiers	frontier	NOUN
ajcp-4886	335	2	in	in	ADP
ajcp-4886	335	3	aging	age	VERB
ajcp-4886	335	4	neuroscience	neuroscience	NOUN
ajcp-4886	335	5	,	,	PUNCT
ajcp-4886	335	6	14	14	NUM
ajcp-4886	335	7	.	.	PUNCT
ajcp-4886	336	1	https://doi.org/10.3389/	https://doi.org/10.3389/	PROPN
ajcp-4886	336	2	fnagi.2022.1019942	fnagi.2022.1019942	PART
ajcp-4886	336	3	fish	fish	NOUN
ajcp-4886	336	4	,	,	PUNCT
ajcp-4886	336	5	p.	p.	NOUN
ajcp-4886	336	6	v.	v.	PROPN
ajcp-4886	336	7	,	,	PUNCT
ajcp-4886	336	8	steadman	steadman	PROPN
ajcp-4886	336	9	,	,	PUNCT
ajcp-4886	336	10	d.	d.	PROPN
ajcp-4886	336	11	,	,	PUNCT
ajcp-4886	336	12	bayle	bayle	PROPN
ajcp-4886	336	13	,	,	PUNCT
ajcp-4886	336	14	e.	e.	PROPN
ajcp-4886	336	15	d.	d.	PROPN
ajcp-4886	336	16	,	,	PUNCT
ajcp-4886	336	17	&	&	CCONJ
ajcp-4886	336	18	whiting	whiting	NOUN
ajcp-4886	336	19	,	,	PUNCT
ajcp-4886	336	20	p.	p.	NOUN
ajcp-4886	336	21	(	(	PUNCT
ajcp-4886	336	22	2019	2019	NUM
ajcp-4886	336	23	)	)	PUNCT
ajcp-4886	336	24	.	.	PUNCT
ajcp-4886	337	1	new	new	ADJ
ajcp-4886	337	2	approaches	approach	NOUN
ajcp-4886	337	3	for	for	ADP
ajcp-4886	337	4	the	the	DET
ajcp-4886	337	5	treatment	treatment	NOUN
ajcp-4886	337	6	of	of	ADP
ajcp-4886	337	7	alzheimer	alzheimer	PROPN
ajcp-4886	337	8	’s	’s	PART
ajcp-4886	337	9	disease	disease	NOUN
ajcp-4886	337	10	.	.	PUNCT
ajcp-4886	338	1	bioorganic	bioorganic	PROPN
ajcp-4886	338	2	&	&	CCONJ
ajcp-4886	338	3	medicinal	medicinal	ADJ
ajcp-4886	338	4	chemistry	chemistry	NOUN
ajcp-4886	338	5	letters	letter	NOUN
ajcp-4886	338	6	,	,	PUNCT
ajcp-4886	338	7	29(2	29(2	NUM
ajcp-4886	338	8	)	)	PUNCT
ajcp-4886	338	9	,	,	PUNCT
ajcp-4886	338	10	125	125	NUM
ajcp-4886	338	11	-	-	SYM
ajcp-4886	338	12	133	133	NUM
ajcp-4886	338	13	.	.	PUNCT
ajcp-4886	339	1	https://doi.org/10.1016/j	https://doi.org/10.1016/j	NOUN
ajcp-4886	339	2	.	.	PUNCT
ajcp-4886	340	1	bmcl.2018.11.034	bmcl.2018.11.034	PROPN
ajcp-4886	341	1	foley	foley	PROPN
ajcp-4886	341	2	,	,	PUNCT
ajcp-4886	341	3	a.	a.	PROPN
ajcp-4886	341	4	r.	r.	PROPN
ajcp-4886	341	5	,	,	PUNCT
ajcp-4886	341	6	lee	lee	PROPN
ajcp-4886	341	7	,	,	PUNCT
ajcp-4886	341	8	h.-w	h.-w	PROPN
ajcp-4886	341	9	.	.	PROPN
ajcp-4886	341	10	,	,	PUNCT
ajcp-4886	341	11	&	&	CCONJ
ajcp-4886	341	12	raskatov	raskatov	ADJ
ajcp-4886	341	13	,	,	PUNCT
ajcp-4886	341	14	j.	j.	PROPN
ajcp-4886	341	15	a.	a.	PROPN
ajcp-4886	341	16	(	(	PUNCT
ajcp-4886	341	17	2019	2019	NUM
ajcp-4886	341	18	)	)	PUNCT
ajcp-4886	341	19	.	.	PUNCT
ajcp-4886	342	1	a	a	DET
ajcp-4886	342	2	focused	focused	ADJ
ajcp-4886	342	3	chiral	chiral	ADJ
ajcp-4886	342	4	mutant	mutant	ADJ
ajcp-4886	342	5	library	library	NOUN
ajcp-4886	342	6	of	of	ADP
ajcp-4886	342	7	the	the	DET
ajcp-4886	342	8	amyloid	amyloid	NOUN
ajcp-4886	342	9	β	β	X
ajcp-4886	342	10	42	42	NUM
ajcp-4886	342	11	central	central	ADJ
ajcp-4886	342	12	electrostatic	electrostatic	ADJ
ajcp-4886	342	13	cluster	cluster	NOUN
ajcp-4886	342	14	as	as	ADP
ajcp-4886	342	15	a	a	DET
ajcp-4886	342	16	tool	tool	NOUN
ajcp-4886	342	17	to	to	PART
ajcp-4886	342	18	stabilize	stabilize	VERB
ajcp-4886	342	19	aggregation	aggregation	NOUN
ajcp-4886	342	20	intermediates	intermediate	NOUN
ajcp-4886	342	21	.	.	PUNCT
ajcp-4886	343	1	the	the	DET
ajcp-4886	343	2	journal	journal	NOUN
ajcp-4886	343	3	of	of	ADP
ajcp-4886	343	4	organic	organic	ADJ
ajcp-4886	343	5	chemistry	chemistry	NOUN
ajcp-4886	343	6	,	,	PUNCT
ajcp-4886	343	7	85(3	85(3	PROPN
ajcp-4886	343	8	)	)	PUNCT
ajcp-4886	343	9	,	,	PUNCT
ajcp-4886	343	10	1385	1385	NUM
ajcp-4886	343	11	-	-	SYM
ajcp-4886	343	12	1391	1391	NUM
ajcp-4886	343	13	.	.	PUNCT
ajcp-4886	344	1	https://doi.org/10.1021/	https://doi.org/10.1021/	PROPN
ajcp-4886	344	2	acs.joc.9b02312	acs.joc.9b02312	PROPN
ajcp-4886	344	3	french	french	PROPN
ajcp-4886	344	4	,	,	PUNCT
ajcp-4886	344	5	r.	r.	PROPN
ajcp-4886	344	6	l.	l.	PROPN
ajcp-4886	344	7	,	,	PUNCT
ajcp-4886	344	8	grese	grese	PROPN
ajcp-4886	344	9	,	,	PUNCT
ajcp-4886	344	10	z.	z.	PROPN
ajcp-4886	344	11	r.	r.	PROPN
ajcp-4886	344	12	,	,	PUNCT
ajcp-4886	344	13	aligireddy	aligireddy	PROPN
ajcp-4886	344	14	,	,	PUNCT
ajcp-4886	344	15	h.	h.	PROPN
ajcp-4886	344	16	,	,	PUNCT
ajcp-4886	344	17	dhavale	dhavale	PROPN
ajcp-4886	344	18	,	,	PUNCT
ajcp-4886	344	19	d.	d.	PROPN
ajcp-4886	344	20	d.	d.	PROPN
ajcp-4886	344	21	,	,	PUNCT
ajcp-4886	344	22	reeb	reeb	PROPN
ajcp-4886	344	23	,	,	PUNCT
ajcp-4886	344	24	a.	a.	NOUN
ajcp-4886	344	25	n.	n.	PROPN
ajcp-4886	344	26	,	,	PUNCT
ajcp-4886	344	27	kedia	kedia	PROPN
ajcp-4886	344	28	,	,	PUNCT
ajcp-4886	344	29	n.	n.	PROPN
ajcp-4886	344	30	,	,	PUNCT
ajcp-4886	344	31	kotzbauer	kotzbauer	PROPN
ajcp-4886	344	32	,	,	PUNCT
ajcp-4886	344	33	p.	p.	PROPN
ajcp-4886	344	34	t.	t.	PROPN
ajcp-4886	344	35	,	,	PUNCT
ajcp-4886	344	36	bieschke	bieschke	PROPN
ajcp-4886	344	37	,	,	PUNCT
ajcp-4886	344	38	j.	j.	PROPN
ajcp-4886	344	39	,	,	PUNCT
ajcp-4886	344	40	&	&	CCONJ
ajcp-4886	344	41	ayala	ayala	PROPN
ajcp-4886	344	42	,	,	PUNCT
ajcp-4886	344	43	y.	y.	PROPN
ajcp-4886	344	44	m.	m.	PROPN
ajcp-4886	344	45	(	(	PUNCT
ajcp-4886	344	46	2019	2019	NUM
ajcp-4886	344	47	)	)	PUNCT
ajcp-4886	344	48	.	.	PUNCT
ajcp-4886	345	1	detection	detection	NOUN
ajcp-4886	345	2	of	of	ADP
ajcp-4886	345	3	tar	tar	NOUN
ajcp-4886	345	4	dnabinding	dnabinding	NOUN
ajcp-4886	345	5	protein	protein	NOUN
ajcp-4886	345	6	43	43	NUM
ajcp-4886	345	7	(	(	PUNCT
ajcp-4886	345	8	tdp-43	tdp-43	NOUN
ajcp-4886	345	9	)	)	PUNCT
ajcp-4886	345	10	oligomers	oligomer	NOUN
ajcp-4886	345	11	as	as	ADP
ajcp-4886	345	12	initial	initial	ADJ
ajcp-4886	345	13	intermediate	intermediate	ADJ
ajcp-4886	345	14	species	specie	NOUN
ajcp-4886	345	15	during	during	ADP
ajcp-4886	345	16	aggregate	aggregate	ADJ
ajcp-4886	345	17	formation	formation	NOUN
ajcp-4886	345	18	.	.	PUNCT
ajcp-4886	346	1	journal	journal	NOUN
ajcp-4886	346	2	of	of	ADP
ajcp-4886	346	3	biological	biological	ADJ
ajcp-4886	346	4	chemistry	chemistry	NOUN
ajcp-4886	346	5	,	,	PUNCT
ajcp-4886	346	6	294(17	294(17	NUM
ajcp-4886	346	7	)	)	PUNCT
ajcp-4886	346	8	,	,	PUNCT
ajcp-4886	346	9	6696	6696	NUM
ajcp-4886	346	10	-	-	SYM
ajcp-4886	346	11	6709	6709	NUM
ajcp-4886	346	12	.	.	PUNCT
ajcp-4886	347	1	https://doi.org/10.1074/jbc.ra118.005889	https://doi.org/10.1074/jbc.ra118.005889	PROPN
ajcp-4886	347	2	gao	gao	PROPN
ajcp-4886	347	3	,	,	PUNCT
ajcp-4886	347	4	g.	g.	PROPN
ajcp-4886	347	5	,	,	PUNCT
ajcp-4886	347	6	zhang	zhang	PROPN
ajcp-4886	347	7	,	,	PUNCT
ajcp-4886	347	8	t.	t.	PROPN
ajcp-4886	347	9	,	,	PUNCT
ajcp-4886	347	10	zhang	zhang	PROPN
ajcp-4886	347	11	,	,	PUNCT
ajcp-4886	347	12	w.	w.	PROPN
ajcp-4886	347	13	,	,	PUNCT
ajcp-4886	347	14	luo	luo	PROPN
ajcp-4886	347	15	,	,	PUNCT
ajcp-4886	347	16	z.	z.	PROPN
ajcp-4886	347	17	,	,	PUNCT
ajcp-4886	347	18	zhang	zhang	PROPN
ajcp-4886	347	19	,	,	PUNCT
ajcp-4886	347	20	z.	z.	PROPN
ajcp-4886	347	21	,	,	PUNCT
ajcp-4886	347	22	gu	gu	PROPN
ajcp-4886	347	23	,	,	PUNCT
ajcp-4886	347	24	z.	z.	PROPN
ajcp-4886	347	25	,	,	PUNCT
ajcp-4886	347	26	yu	yu	PROPN
ajcp-4886	347	27	,	,	PUNCT
ajcp-4886	347	28	l.	l.	PROPN
ajcp-4886	347	29	,	,	PUNCT
ajcp-4886	347	30	mu	mu	PROPN
ajcp-4886	347	31	,	,	PUNCT
ajcp-4886	347	32	q.	q.	PROPN
ajcp-4886	347	33	,	,	PUNCT
ajcp-4886	347	34	&	&	CCONJ
ajcp-4886	347	35	sun	sun	PROPN
ajcp-4886	347	36	,	,	PUNCT
ajcp-4886	347	37	t.	t.	PROPN
ajcp-4886	347	38	(	(	PUNCT
ajcp-4886	347	39	2022	2022	NUM
ajcp-4886	347	40	)	)	PUNCT
ajcp-4886	347	41	.	.	PUNCT
ajcp-4886	348	1	high	high	ADJ
ajcp-4886	348	2	efficiency	efficiency	NOUN
ajcp-4886	348	3	and	and	CCONJ
ajcp-4886	348	4	related	related	ADJ
ajcp-4886	348	5	mechanism	mechanism	NOUN
ajcp-4886	348	6	of	of	ADP
ajcp-4886	348	7	au(rc	au(rc	PROPN
ajcp-4886	348	8	)	)	PUNCT
ajcp-4886	348	9	nanoclusters	nanocluster	NOUN
ajcp-4886	348	10	on	on	ADP
ajcp-4886	348	11	disaggregating	disaggregate	VERB
ajcp-4886	348	12	aβ	aβ	NOUN
ajcp-4886	348	13	fibrils	fibril	NOUN
ajcp-4886	348	14	.	.	PUNCT
ajcp-4886	349	1	journal	journal	NOUN
ajcp-4886	349	2	of	of	ADP
ajcp-4886	349	3	colloid	colloid	NOUN
ajcp-4886	349	4	and	and	CCONJ
ajcp-4886	349	5	interface	interface	NOUN
ajcp-4886	349	6	science	science	NOUN
ajcp-4886	349	7	,	,	PUNCT
ajcp-4886	349	8	621	621	NUM
ajcp-4886	349	9	,	,	PUNCT
ajcp-4886	349	10	67	67	NUM
ajcp-4886	349	11	-	-	SYM
ajcp-4886	349	12	76	76	NUM
ajcp-4886	349	13	.	.	PUNCT
ajcp-4886	350	1	https://doi.org/10.1016/j	https://doi.org/10.1016/j	NOUN
ajcp-4886	350	2	.	.	PUNCT
ajcp-4886	351	1	jcis.2022.04.085	jcis.2022.04.085	X
ajcp-4886	351	2	grasso	grasso	PROPN
ajcp-4886	351	3	,	,	PUNCT
ajcp-4886	351	4	g.	g.	PROPN
ajcp-4886	351	5	,	,	PUNCT
ajcp-4886	351	6	&	&	CCONJ
ajcp-4886	351	7	danani	danani	PROPN
ajcp-4886	351	8	,	,	PUNCT
ajcp-4886	351	9	a.	a.	NOUN
ajcp-4886	351	10	(	(	PUNCT
ajcp-4886	351	11	2020	2020	NUM
ajcp-4886	351	12	)	)	PUNCT
ajcp-4886	351	13	.	.	PUNCT
ajcp-4886	352	1	molecular	molecular	ADJ
ajcp-4886	352	2	simulations	simulation	NOUN
ajcp-4886	352	3	of	of	ADP
ajcp-4886	352	4	amyloid	amyloid	NOUN
ajcp-4886	352	5	beta	beta	NOUN
ajcp-4886	352	6	assemblies	assembly	NOUN
ajcp-4886	352	7	.	.	PUNCT
ajcp-4886	353	1	advances	advance	NOUN
ajcp-4886	353	2	in	in	ADP
ajcp-4886	353	3	physics	physics	NOUN
ajcp-4886	353	4	:	:	PUNCT
ajcp-4886	353	5	x	x	SYM
ajcp-4886	353	6	,	,	PUNCT
ajcp-4886	353	7	5(1	5(1	NUM
ajcp-4886	353	8	)	)	PUNCT
ajcp-4886	353	9	.	.	PUNCT
ajcp-4886	354	1	https://doi.org/10.1080/23746149.2020.1770627	https://doi.org/10.1080/23746149.2020.1770627	PROPN
ajcp-4886	354	2	haerianardakani	haerianardakani	PROPN
ajcp-4886	354	3	,	,	PUNCT
ajcp-4886	354	4	s.	s.	PROPN
ajcp-4886	354	5	,	,	PUNCT
ajcp-4886	354	6	kreutzer	kreutzer	NOUN
ajcp-4886	354	7	,	,	PUNCT
ajcp-4886	354	8	a.	a.	NOUN
ajcp-4886	354	9	g.	g.	PROPN
ajcp-4886	354	10	,	,	PUNCT
ajcp-4886	354	11	salveson	salveson	PROPN
ajcp-4886	354	12	,	,	PUNCT
ajcp-4886	354	13	p.	p.	PROPN
ajcp-4886	354	14	j.	j.	PROPN
ajcp-4886	354	15	,	,	PUNCT
ajcp-4886	354	16	samdin	samdin	NOUN
ajcp-4886	354	17	,	,	PUNCT
ajcp-4886	354	18	t.	t.	PROPN
ajcp-4886	354	19	d.	d.	PROPN
ajcp-4886	354	20	,	,	PUNCT
ajcp-4886	354	21	guaglianone	guaglianone	PROPN
ajcp-4886	354	22	,	,	PUNCT
ajcp-4886	354	23	g.	g.	PROPN
ajcp-4886	354	24	e.	e.	PROPN
ajcp-4886	354	25	,	,	PUNCT
ajcp-4886	354	26	&	&	CCONJ
ajcp-4886	354	27	nowick	nowick	PROPN
ajcp-4886	354	28	,	,	PUNCT
ajcp-4886	354	29	j.	j.	PROPN
ajcp-4886	354	30	s.	s.	PROPN
ajcp-4886	354	31	(	(	PUNCT
ajcp-4886	354	32	2020	2020	NUM
ajcp-4886	354	33	)	)	PUNCT
ajcp-4886	354	34	.	.	PUNCT
ajcp-4886	355	1	phenylalanine	phenylalanine	ADJ
ajcp-4886	355	2	mutation	mutation	NOUN
ajcp-4886	355	3	to	to	PART
ajcp-4886	355	4	cyclohexylalanine	cyclohexylalanine	VERB
ajcp-4886	355	5	facilitates	facilitate	VERB
ajcp-4886	355	6	triangular	triangular	NOUN
ajcp-4886	355	7	trimer	trimer	ADJ
ajcp-4886	355	8	formation	formation	NOUN
ajcp-4886	355	9	by	by	ADP
ajcp-4886	355	10	β	β	NOUN
ajcp-4886	355	11	-	-	NOUN
ajcp-4886	355	12	hairpins	hairpin	NOUN
ajcp-4886	355	13	derived	derive	VERB
ajcp-4886	355	14	from	from	ADP
ajcp-4886	355	15	aβ	aβ	PROPN
ajcp-4886	355	16	.	.	PROPN
ajcp-4886	355	17	journal	journal	PROPN
ajcp-4886	355	18	of	of	ADP
ajcp-4886	355	19	the	the	DET
ajcp-4886	355	20	american	american	PROPN
ajcp-4886	355	21	chemical	chemical	PROPN
ajcp-4886	355	22	society	society	PROPN
ajcp-4886	355	23	,	,	PUNCT
ajcp-4886	355	24	142(49	142(49	NUM
ajcp-4886	355	25	)	)	PUNCT
ajcp-4886	355	26	,	,	PUNCT
ajcp-4886	355	27	20708	20708	NUM
ajcp-4886	355	28	-	-	SYM
ajcp-4886	355	29	20716	20716	NUM
ajcp-4886	355	30	.	.	PUNCT
ajcp-4886	356	1	https://doi	https://doi	PROPN
ajcp-4886	356	2	.	.	PUNCT
ajcp-4886	356	3	org/10.1021	org/10.1021	NOUN
ajcp-4886	356	4	/	/	SYM
ajcp-4886	356	5	jacs.0c09281	jacs.0c09281	PROPN
ajcp-4886	356	6	han	han	NOUN
ajcp-4886	356	7	,	,	PUNCT
ajcp-4886	356	8	y.-l	y.-l	NOUN
ajcp-4886	356	9	.	.	PUNCT
ajcp-4886	356	10	,	,	PUNCT
ajcp-4886	356	11	yin	yin	PROPN
ajcp-4886	356	12	,	,	PUNCT
ajcp-4886	356	13	h.-h	h.-h	NOUN
ajcp-4886	356	14	.	.	PUNCT
ajcp-4886	356	15	,	,	PUNCT
ajcp-4886	356	16	li	li	PROPN
ajcp-4886	356	17	,	,	PUNCT
ajcp-4886	356	18	c.	c.	PROPN
ajcp-4886	356	19	,	,	PUNCT
ajcp-4886	356	20	du	du	PROPN
ajcp-4886	356	21	,	,	PUNCT
ajcp-4886	356	22	j.	j.	PROPN
ajcp-4886	356	23	,	,	PUNCT
ajcp-4886	356	24	he	he	PRON
ajcp-4886	356	25	,	,	PUNCT
ajcp-4886	356	26	y.	y.	PROPN
ajcp-4886	356	27	,	,	PUNCT
ajcp-4886	356	28	&	&	CCONJ
ajcp-4886	356	29	guan	guan	PROPN
ajcp-4886	356	30	,	,	PUNCT
ajcp-4886	356	31	y.x	y.x	PROPN
ajcp-4886	356	32	.	.	PROPN
ajcp-4886	356	33	(	(	PUNCT
ajcp-4886	356	34	2025	2025	NUM
ajcp-4886	356	35	)	)	PUNCT
ajcp-4886	356	36	.	.	PUNCT
ajcp-4886	357	1	discovery	discovery	NOUN
ajcp-4886	357	2	of	of	ADP
ajcp-4886	357	3	new	new	ADJ
ajcp-4886	357	4	pentapeptide	pentapeptide	NOUN
ajcp-4886	357	5	inhibitors	inhibitor	NOUN
ajcp-4886	357	6	against	against	ADP
ajcp-4886	357	7	amyloid	amyloid	NOUN
ajcp-4886	357	8	-	-	PUNCT
ajcp-4886	357	9	β	β	NOUN
ajcp-4886	357	10	aggregation	aggregation	NOUN
ajcp-4886	357	11	using	use	VERB
ajcp-4886	357	12	word2vec	word2vec	PROPN
ajcp-4886	357	13	and	and	CCONJ
ajcp-4886	357	14	molecular	molecular	ADJ
ajcp-4886	357	15	simulation	simulation	NOUN
ajcp-4886	357	16	.	.	PUNCT
ajcp-4886	358	1	acs	acs	PROPN
ajcp-4886	358	2	chemical	chemical	PROPN
ajcp-4886	358	3	neuroscience	neuroscience	NOUN
ajcp-4886	358	4	,	,	PUNCT
ajcp-4886	358	5	16(6	16(6	NUM
ajcp-4886	358	6	)	)	PUNCT
ajcp-4886	358	7	,	,	PUNCT
ajcp-4886	358	8	1055	1055	NUM
ajcp-4886	358	9	-	-	SYM
ajcp-4886	358	10	1065	1065	NUM
ajcp-4886	358	11	.	.	PUNCT
ajcp-4886	359	1	https://doi.org/10.1021/	https://doi.org/10.1021/	NOUN
ajcp-4886	359	2	acschemneuro.4c00661	acschemneuro.4c00661	PROPN
ajcp-4886	359	3	hardenberg	hardenberg	ADV
ajcp-4886	359	4	,	,	PUNCT
ajcp-4886	359	5	m.	m.	NOUN
ajcp-4886	359	6	,	,	PUNCT
ajcp-4886	359	7	horvath	horvath	PROPN
ajcp-4886	359	8	,	,	PUNCT
ajcp-4886	359	9	a.	a.	PROPN
ajcp-4886	359	10	,	,	PUNCT
ajcp-4886	359	11	ambrus	ambrus	PROPN
ajcp-4886	359	12	,	,	PUNCT
ajcp-4886	359	13	v.	v.	NOUN
ajcp-4886	359	14	,	,	PUNCT
ajcp-4886	359	15	fuxreiter	fuxreiter	NOUN
ajcp-4886	359	16	,	,	PUNCT
ajcp-4886	359	17	m.	m.	NOUN
ajcp-4886	359	18	,	,	PUNCT
ajcp-4886	359	19	&	&	CCONJ
ajcp-4886	359	20	vendruscolo	vendruscolo	PROPN
ajcp-4886	359	21	,	,	PUNCT
ajcp-4886	359	22	m.	m.	NOUN
ajcp-4886	359	23	(	(	PUNCT
ajcp-4886	359	24	2020	2020	NUM
ajcp-4886	359	25	)	)	PUNCT
ajcp-4886	359	26	.	.	PUNCT
ajcp-4886	360	1	widespread	widespread	ADJ
ajcp-4886	360	2	occurrence	occurrence	NOUN
ajcp-4886	360	3	of	of	ADP
ajcp-4886	360	4	the	the	DET
ajcp-4886	360	5	droplet	droplet	ADJ
ajcp-4886	360	6	state	state	NOUN
ajcp-4886	360	7	of	of	ADP
ajcp-4886	360	8	proteins	protein	NOUN
ajcp-4886	360	9	in	in	ADP
ajcp-4886	360	10	the	the	DET
ajcp-4886	360	11	human	human	ADJ
ajcp-4886	360	12	proteome	proteome	NOUN
ajcp-4886	360	13	.	.	PUNCT
ajcp-4886	361	1	proceedings	proceeding	NOUN
ajcp-4886	361	2	of	of	ADP
ajcp-4886	361	3	the	the	DET
ajcp-4886	361	4	national	national	PROPN
ajcp-4886	361	5	academy	academy	PROPN
ajcp-4886	361	6	of	of	ADP
ajcp-4886	361	7	sciences	sciences	PROPN
ajcp-4886	361	8	,	,	PUNCT
ajcp-4886	361	9	117(52	117(52	NUM
ajcp-4886	361	10	)	)	PUNCT
ajcp-4886	361	11	,	,	PUNCT
ajcp-4886	361	12	33254	33254	NUM
ajcp-4886	361	13	-	-	SYM
ajcp-4886	361	14	33262	33262	NUM
ajcp-4886	361	15	.	.	PUNCT
ajcp-4886	362	1	https://doi.org/10.1073/	https://doi.org/10.1073/	PROPN
ajcp-4886	362	2	pnas.2007670117	pnas.2007670117	PROPN
ajcp-4886	362	3	hector	hector	PROPN
ajcp-4886	362	4	,	,	PUNCT
ajcp-4886	362	5	a.	a.	PROPN
ajcp-4886	362	6	,	,	PUNCT
ajcp-4886	362	7	&	&	CCONJ
ajcp-4886	362	8	brouillette	brouillette	PROPN
ajcp-4886	362	9	,	,	PUNCT
ajcp-4886	362	10	j.	j.	PROPN
ajcp-4886	362	11	(	(	PUNCT
ajcp-4886	362	12	2021	2021	NUM
ajcp-4886	362	13	)	)	PUNCT
ajcp-4886	362	14	.	.	PUNCT
ajcp-4886	363	1	hyperactivity	hyperactivity	NOUN
ajcp-4886	363	2	induced	induce	VERB
ajcp-4886	363	3	by	by	ADP
ajcp-4886	363	4	soluble	soluble	ADJ
ajcp-4886	363	5	amyloid	amyloid	NOUN
ajcp-4886	363	6	-	-	PUNCT
ajcp-4886	363	7	β	β	NOUN
ajcp-4886	363	8	oligomers	oligomer	NOUN
ajcp-4886	363	9	in	in	ADP
ajcp-4886	363	10	the	the	DET
ajcp-4886	363	11	early	early	ADJ
ajcp-4886	363	12	stages	stage	NOUN
ajcp-4886	363	13	of	of	ADP
ajcp-4886	363	14	alzheimer	alzheimer	PROPN
ajcp-4886	363	15	’s	’s	PART
ajcp-4886	363	16	disease	disease	NOUN
ajcp-4886	363	17	.	.	PUNCT
ajcp-4886	364	1	frontiers	frontier	NOUN
ajcp-4886	364	2	in	in	ADP
ajcp-4886	364	3	molecular	molecular	ADJ
ajcp-4886	364	4	neuroscience	neuroscience	NOUN
ajcp-4886	364	5	,	,	PUNCT
ajcp-4886	364	6	13	13	NUM
ajcp-4886	364	7	.	.	PUNCT
ajcp-4886	365	1	https://doi.org/10.3389/fnmol.2020.600084	https://doi.org/10.3389/fnmol.2020.600084	PROPN
ajcp-4886	365	2	huang	huang	PROPN
ajcp-4886	365	3	,	,	PUNCT
ajcp-4886	365	4	y.-r	y.-r	PROPN
ajcp-4886	365	5	.	.	PROPN
ajcp-4886	365	6	,	,	PUNCT
ajcp-4886	365	7	&	&	CCONJ
ajcp-4886	365	8	liu	liu	PROPN
ajcp-4886	365	9	,	,	PUNCT
ajcp-4886	365	10	r.-t	r.-t	PROPN
ajcp-4886	365	11	.	.	PUNCT
ajcp-4886	366	1	(	(	PUNCT
ajcp-4886	366	2	2020	2020	NUM
ajcp-4886	366	3	)	)	PUNCT
ajcp-4886	366	4	.	.	PUNCT
ajcp-4886	367	1	the	the	DET
ajcp-4886	367	2	toxicity	toxicity	NOUN
ajcp-4886	367	3	and	and	CCONJ
ajcp-4886	367	4	polymorphism	polymorphism	NOUN
ajcp-4886	367	5	of	of	ADP
ajcp-4886	367	6	β	β	NOUN
ajcp-4886	367	7	-	-	ADJ
ajcp-4886	367	8	amyloid	amyloid	ADJ
ajcp-4886	367	9	oligomers	oligomer	NOUN
ajcp-4886	367	10	.	.	PUNCT
ajcp-4886	368	1	international	international	ADJ
ajcp-4886	368	2	journal	journal	NOUN
ajcp-4886	368	3	of	of	ADP
ajcp-4886	368	4	molecular	molecular	ADJ
ajcp-4886	368	5	sciences	science	NOUN
ajcp-4886	368	6	,	,	PUNCT
ajcp-4886	368	7	21(12	21(12	NUM
ajcp-4886	368	8	)	)	PUNCT
ajcp-4886	368	9	.	.	PUNCT
ajcp-4886	369	1	https://doi	https://doi	X
ajcp-4886	369	2	.	.	PUNCT
ajcp-4886	369	3	org/10.3390	org/10.3390	PROPN
ajcp-4886	369	4	/	/	SYM
ajcp-4886	369	5	ijms21124477	ijms21124477	PROPN
ajcp-4886	369	6	hughes	hughe	NOUN
ajcp-4886	369	7	,	,	PUNCT
ajcp-4886	369	8	m.	m.	PROPN
ajcp-4886	369	9	p.	p.	PROPN
ajcp-4886	369	10	,	,	PUNCT
ajcp-4886	369	11	sawaya	sawaya	PROPN
ajcp-4886	369	12	,	,	PUNCT
ajcp-4886	369	13	m.	m.	PROPN
ajcp-4886	369	14	r.	r.	PROPN
ajcp-4886	369	15	,	,	PUNCT
ajcp-4886	369	16	boyer	boyer	PROPN
ajcp-4886	369	17	,	,	PUNCT
ajcp-4886	369	18	d.	d.	PROPN
ajcp-4886	369	19	r.	r.	PROPN
ajcp-4886	369	20	,	,	PUNCT
ajcp-4886	369	21	goldschmidt	goldschmidt	PROPN
ajcp-4886	369	22	,	,	PUNCT
ajcp-4886	369	23	l.	l.	PROPN
ajcp-4886	369	24	,	,	PUNCT
ajcp-4886	369	25	rodriguez	rodriguez	PROPN
ajcp-4886	369	26	,	,	PUNCT
ajcp-4886	369	27	j.	j.	PROPN
ajcp-4886	369	28	a.	a.	PROPN
ajcp-4886	369	29	,	,	PUNCT
ajcp-4886	369	30	cascio	cascio	PROPN
ajcp-4886	369	31	,	,	PUNCT
ajcp-4886	369	32	d.	d.	PROPN
ajcp-4886	369	33	,	,	PUNCT
ajcp-4886	369	34	chong	chong	PROPN
ajcp-4886	369	35	,	,	PUNCT
ajcp-4886	369	36	l.	l.	PROPN
ajcp-4886	369	37	,	,	PUNCT
ajcp-4886	369	38	gonen	gonen	NOUN
ajcp-4886	369	39	,	,	PUNCT
ajcp-4886	369	40	t.	t.	PROPN
ajcp-4886	369	41	,	,	PUNCT
ajcp-4886	369	42	&	&	CCONJ
ajcp-4886	369	43	eisenberg	eisenberg	PROPN
ajcp-4886	369	44	,	,	PUNCT
ajcp-4886	369	45	d.	d.	PROPN
ajcp-4886	369	46	s.	s.	PROPN
ajcp-4886	369	47	(	(	PUNCT
ajcp-4886	369	48	2018	2018	NUM
ajcp-4886	369	49	)	)	PUNCT
ajcp-4886	369	50	.	.	PUNCT
ajcp-4886	370	1	atomic	atomic	ADJ
ajcp-4886	370	2	structures	structure	NOUN
ajcp-4886	370	3	of	of	ADP
ajcp-4886	370	4	lowcomplexity	lowcomplexity	NOUN
ajcp-4886	370	5	protein	protein	NOUN
ajcp-4886	370	6	segments	segment	NOUN
ajcp-4886	370	7	reveal	reveal	VERB
ajcp-4886	370	8	kinked	kinked	ADJ
ajcp-4886	370	9	β	β	NOUN
ajcp-4886	370	10	sheets	sheet	NOUN
ajcp-4886	370	11	that	that	PRON
ajcp-4886	370	12	assemble	assemble	VERB
ajcp-4886	370	13	networks	network	NOUN
ajcp-4886	370	14	.	.	PUNCT
ajcp-4886	371	1	science	science	NOUN
ajcp-4886	371	2	,	,	PUNCT
ajcp-4886	371	3	359(6376	359(6376	NUM
ajcp-4886	371	4	)	)	PUNCT
ajcp-4886	371	5	,	,	PUNCT
ajcp-4886	371	6	698	698	NUM
ajcp-4886	371	7	-	-	SYM
ajcp-4886	371	8	701	701	NUM
ajcp-4886	371	9	.	.	PUNCT
ajcp-4886	372	1	https://doi.org/10.1126/science.aan6398	https://doi.org/10.1126/science.aan6398	PROPN
ajcp-4886	372	2	huraskin	huraskin	NOUN
ajcp-4886	372	3	,	,	PUNCT
ajcp-4886	372	4	d.	d.	PROPN
ajcp-4886	372	5	,	,	PUNCT
ajcp-4886	372	6	&	&	CCONJ
ajcp-4886	372	7	horn	horn	PROPN
ajcp-4886	372	8	,	,	PUNCT
ajcp-4886	372	9	a.	a.	PROPN
ajcp-4886	372	10	h.	h.	PROPN
ajcp-4886	372	11	c.	c.	PROPN
ajcp-4886	372	12	(	(	PUNCT
ajcp-4886	372	13	2019	2019	NUM
ajcp-4886	372	14	)	)	PUNCT
ajcp-4886	372	15	.	.	PUNCT
ajcp-4886	373	1	alkali	alkali	ADJ
ajcp-4886	373	2	ion	ion	NOUN
ajcp-4886	373	3	influence	influence	NOUN
ajcp-4886	373	4	on	on	ADP
ajcp-4886	373	5	structure	structure	NOUN
ajcp-4886	373	6	and	and	CCONJ
ajcp-4886	373	7	stability	stability	NOUN
ajcp-4886	373	8	of	of	ADP
ajcp-4886	373	9	fibrillar	fibrillar	ADJ
ajcp-4886	373	10	amyloid	amyloid	NOUN
ajcp-4886	373	11	-	-	PUNCT
ajcp-4886	373	12	β	β	NOUN
ajcp-4886	373	13	oligomers	oligomer	NOUN
ajcp-4886	373	14	.	.	PUNCT
ajcp-4886	374	1	journal	journal	NOUN
ajcp-4886	374	2	of	of	ADP
ajcp-4886	374	3	molecular	molecular	ADJ
ajcp-4886	374	4	modeling	modeling	NOUN
ajcp-4886	374	5	,	,	PUNCT
ajcp-4886	374	6	25(2	25(2	NUM
ajcp-4886	374	7	)	)	PUNCT
ajcp-4886	374	8	.	.	PUNCT
ajcp-4886	375	1	https://	https://	PROPN
ajcp-4886	375	2	doi.org/10.1007/s00894-018-3920-4	doi.org/10.1007/s00894-018-3920-4	PROPN
ajcp-4886	375	3	hwang	hwang	PROPN
ajcp-4886	375	4	,	,	PUNCT
ajcp-4886	375	5	s.	s.	PROPN
ajcp-4886	375	6	s.	s.	PROPN
ajcp-4886	375	7	,	,	PUNCT
ajcp-4886	375	8	chan	chan	PROPN
ajcp-4886	375	9	,	,	PUNCT
ajcp-4886	375	10	h.	h.	PROPN
ajcp-4886	375	11	,	,	PUNCT
ajcp-4886	375	12	sorci	sorci	ADJ
ajcp-4886	375	13	,	,	PUNCT
ajcp-4886	375	14	m.	m.	NOUN
ajcp-4886	375	15	,	,	PUNCT
ajcp-4886	375	16	van	van	PROPN
ajcp-4886	375	17	deventer	deventer	PROPN
ajcp-4886	375	18	,	,	PUNCT
ajcp-4886	375	19	j.	j.	PROPN
ajcp-4886	375	20	,	,	PUNCT
ajcp-4886	375	21	wittrup	wittrup	NOUN
ajcp-4886	375	22	,	,	PUNCT
ajcp-4886	375	23	d.	d.	PROPN
ajcp-4886	375	24	,	,	PUNCT
ajcp-4886	375	25	belfort	belfort	PROPN
ajcp-4886	375	26	,	,	PUNCT
ajcp-4886	375	27	g.	g.	PROPN
ajcp-4886	375	28	,	,	PUNCT
ajcp-4886	375	29	&	&	CCONJ
ajcp-4886	375	30	walt	walt	PROPN
ajcp-4886	375	31	,	,	PUNCT
ajcp-4886	375	32	d.	d.	PROPN
ajcp-4886	375	33	(	(	PUNCT
ajcp-4886	375	34	2019	2019	NUM
ajcp-4886	375	35	)	)	PUNCT
ajcp-4886	375	36	.	.	PUNCT
ajcp-4886	376	1	detection	detection	NOUN
ajcp-4886	376	2	of	of	ADP
ajcp-4886	376	3	amyloid	amyloid	NOUN
ajcp-4886	376	4	β	β	X
ajcp-4886	376	5	oligomers	oligomer	NOUN
ajcp-4886	376	6	toward	toward	ADP
ajcp-4886	376	7	early	early	ADJ
ajcp-4886	376	8	diagnosis	diagnosis	NOUN
ajcp-4886	376	9	of	of	ADP
ajcp-4886	376	10	alzheimer	alzheimer	PROPN
ajcp-4886	376	11	’s	’s	PART
ajcp-4886	376	12	disease	disease	NOUN
ajcp-4886	376	13	.	.	PUNCT
ajcp-4886	377	1	analytical	analytical	ADJ
ajcp-4886	377	2	biochemistry	biochemistry	NOUN
ajcp-4886	377	3	,	,	PUNCT
ajcp-4886	377	4	566	566	NUM
ajcp-4886	377	5	,	,	PUNCT
ajcp-4886	377	6	40	40	NUM
ajcp-4886	377	7	-	-	SYM
ajcp-4886	377	8	45	45	NUM
ajcp-4886	377	9	.	.	PUNCT
ajcp-4886	378	1	https://doi.org/10.1016/j.ab.2018.09.011	https://doi.org/10.1016/j.ab.2018.09.011	PROPN
ajcp-4886	378	2	jang	jang	PROPN
ajcp-4886	378	3	,	,	PUNCT
ajcp-4886	378	4	c.	c.	PROPN
ajcp-4886	378	5	,	,	PUNCT
ajcp-4886	378	6	portugal	portugal	PROPN
ajcp-4886	378	7	barron	barron	PROPN
ajcp-4886	378	8	,	,	PUNCT
ajcp-4886	378	9	d.	d.	PROPN
ajcp-4886	378	10	,	,	PUNCT
ajcp-4886	378	11	duo	duo	NOUN
ajcp-4886	378	12	,	,	PUNCT
ajcp-4886	378	13	l.	l.	PROPN
ajcp-4886	378	14	,	,	PUNCT
ajcp-4886	378	15	ma	ma	PROPN
ajcp-4886	378	16	,	,	PUNCT
ajcp-4886	378	17	c.	c.	PROPN
ajcp-4886	378	18	,	,	PUNCT
ajcp-4886	378	19	seabaugh	seabaugh	NOUN
ajcp-4886	378	20	,	,	PUNCT
ajcp-4886	378	21	h.	h.	PROPN
ajcp-4886	378	22	,	,	PUNCT
ajcp-4886	378	23	&	&	CCONJ
ajcp-4886	378	24	guo	guo	PROPN
ajcp-4886	378	25	,	,	PUNCT
ajcp-4886	378	26	z.	z.	PROPN
ajcp-4886	378	27	(	(	PUNCT
ajcp-4886	378	28	2023	2023	NUM
ajcp-4886	378	29	)	)	PUNCT
ajcp-4886	378	30	.	.	PUNCT
ajcp-4886	379	1	epr	epr	PROPN
ajcp-4886	379	2	studies	study	NOUN
ajcp-4886	379	3	of	of	ADP
ajcp-4886	379	4	aβ42	aβ42	PROPN
ajcp-4886	379	5	oligomers	oligomer	NOUN
ajcp-4886	379	6	indicate	indicate	VERB
ajcp-4886	379	7	a	a	DET
ajcp-4886	379	8	parallel	parallel	NOUN
ajcp-4886	379	9	in	in	ADP
ajcp-4886	379	10	-	-	PUNCT
ajcp-4886	379	11	register	register	VERB
ajcp-4886	379	12	β	β	ADJ
ajcp-4886	379	13	-	-	ADJ
ajcp-4886	379	14	sheet	sheet	NOUN
ajcp-4886	379	15	structure	structure	NOUN
ajcp-4886	379	16	.	.	PUNCT
ajcp-4886	380	1	acs	acs	PROPN
ajcp-4886	380	2	chemical	chemical	PROPN
ajcp-4886	380	3	neuroscience	neuroscience	NOUN
ajcp-4886	380	4	,	,	PUNCT
ajcp-4886	380	5	15(1	15(1	NUM
ajcp-4886	380	6	)	)	PUNCT
ajcp-4886	380	7	,	,	PUNCT
ajcp-4886	380	8	86	86	NUM
ajcp-4886	380	9	-	-	SYM
ajcp-4886	380	10	97	97	NUM
ajcp-4886	380	11	.	.	PUNCT
ajcp-4886	381	1	https://doi	https://doi	PROPN
ajcp-4886	381	2	.	.	PUNCT
ajcp-4886	381	3	org/10.1021	org/10.1021	NOUN
ajcp-4886	381	4	/	/	SYM
ajcp-4886	381	5	acschemneuro.3c00364	acschemneuro.3c00364	PROPN
ajcp-4886	381	6	jehangir	jehangir	NOUN
ajcp-4886	381	7	,	,	PUNCT
ajcp-4886	381	8	m.	m.	NOUN
ajcp-4886	381	9	,	,	PUNCT
ajcp-4886	381	10	ali	ali	PROPN
ajcp-4886	381	11	,	,	PUNCT
ajcp-4886	381	12	r.	r.	PROPN
ajcp-4886	381	13	,	,	PUNCT
ajcp-4886	381	14	hui	hui	PROPN
ajcp-4886	381	15	,	,	PUNCT
ajcp-4886	381	16	w.	w.	PROPN
ajcp-4886	381	17	x.	x.	PROPN
ajcp-4886	381	18	,	,	PUNCT
ajcp-4886	381	19	&	&	CCONJ
ajcp-4886	381	20	wang	wang	PROPN
ajcp-4886	381	21	,	,	PUNCT
ajcp-4886	381	22	y.	y.	PROPN
ajcp-4886	381	23	(	(	PUNCT
ajcp-4886	381	24	2024	2024	NUM
ajcp-4886	381	25	)	)	PUNCT
ajcp-4886	381	26	.	.	PUNCT
ajcp-4886	382	1	an	an	DET
ajcp-4886	382	2	updated	update	VERB
ajcp-4886	382	3	review	review	NOUN
ajcp-4886	382	4	of	of	ADP
ajcp-4886	382	5	amyloid	amyloid	NOUN
ajcp-4886	382	6	beta	beta	ADJ
ajcp-4886	382	7	oligomer	oligomer	ADJ
ajcp-4886	382	8	toxicity	toxicity	NOUN
ajcp-4886	382	9	inhibition	inhibition	NOUN
ajcp-4886	382	10	and	and	CCONJ
ajcp-4886	382	11	detection	detection	NOUN
ajcp-4886	382	12	for	for	ADP
ajcp-4886	382	13	alzheimer	alzheimer	PROPN
ajcp-4886	382	14	’s	’s	PART
ajcp-4886	382	15	disease	disease	NOUN
ajcp-4886	382	16	diagnosis	diagnosis	NOUN
ajcp-4886	382	17	.	.	PUNCT
ajcp-4886	383	1	cognizance	cognizance	NOUN
ajcp-4886	383	2	journal	journal	PROPN
ajcp-4886	383	3	of	of	ADP
ajcp-4886	383	4	multidisciplinary	multidisciplinary	ADJ
ajcp-4886	383	5	studies	study	NOUN
ajcp-4886	383	6	,	,	PUNCT
ajcp-4886	383	7	4(7	4(7	NUM
ajcp-4886	383	8	)	)	PUNCT
ajcp-4886	383	9	,	,	PUNCT
ajcp-4886	383	10	164	164	NUM
ajcp-4886	383	11	-	-	SYM
ajcp-4886	383	12	186	186	NUM
ajcp-4886	383	13	.	.	PUNCT
ajcp-4886	384	1	https://doi.org/10.47760/	https://doi.org/10.47760/	PROPN
ajcp-4886	384	2	cognizance.2024.v04i07.015	cognizance.2024.v04i07.015	PROPN
ajcp-4886	384	3	kanaan	kanaan	PROPN
ajcp-4886	384	4	,	,	PUNCT
ajcp-4886	384	5	n.	n.	PROPN
ajcp-4886	384	6	m.	m.	PROPN
ajcp-4886	384	7	,	,	PUNCT
ajcp-4886	384	8	hamel	hamel	PROPN
ajcp-4886	384	9	,	,	PUNCT
ajcp-4886	384	10	c.	c.	PROPN
ajcp-4886	384	11	,	,	PUNCT
ajcp-4886	384	12	grabinski	grabinski	ADJ
ajcp-4886	384	13	,	,	PUNCT
ajcp-4886	384	14	t.	t.	PROPN
ajcp-4886	384	15	,	,	PUNCT
ajcp-4886	384	16	&	&	CCONJ
ajcp-4886	384	17	combs	combs	PROPN
ajcp-4886	384	18	,	,	PUNCT
ajcp-4886	384	19	b.	b.	PROPN
ajcp-4886	384	20	(	(	PUNCT
ajcp-4886	384	21	2020	2020	NUM
ajcp-4886	384	22	)	)	PUNCT
ajcp-4886	384	23	.	.	PUNCT
ajcp-4886	385	1	liquid	liquid	NOUN
ajcp-4886	385	2	-	-	PUNCT
ajcp-4886	385	3	liquid	liquid	NOUN
ajcp-4886	385	4	phase	phase	NOUN
ajcp-4886	385	5	separation	separation	NOUN
ajcp-4886	385	6	induces	induce	VERB
ajcp-4886	385	7	pathogenic	pathogenic	ADJ
ajcp-4886	385	8	tau	tau	PROPN
ajcp-4886	385	9	conformations	conformation	NOUN
ajcp-4886	385	10	in	in	ADP
ajcp-4886	385	11	vitro	vitro	X
ajcp-4886	385	12	.	.	PUNCT
ajcp-4886	386	1	nature	nature	NOUN
ajcp-4886	386	2	communications	communication	NOUN
ajcp-4886	386	3	,	,	PUNCT
ajcp-4886	386	4	11(1	11(1	NUM
ajcp-4886	386	5	)	)	PUNCT
ajcp-4886	386	6	.	.	PUNCT
ajcp-4886	387	1	https://doi.org/10.1038/	https://doi.org/10.1038/	PROPN
ajcp-4886	387	2	s41467	s41467	NOUN
ajcp-4886	387	3	-	-	PUNCT
ajcp-4886	387	4	020	020	NUM
ajcp-4886	387	5	-	-	PUNCT
ajcp-4886	387	6	16580	16580	NUM
ajcp-4886	387	7	-	-	PUNCT
ajcp-4886	387	8	3	3	NUM
ajcp-4886	387	9	khatua	khatua	NOUN
ajcp-4886	387	10	,	,	PUNCT
ajcp-4886	387	11	p.	p.	PROPN
ajcp-4886	387	12	,	,	PUNCT
ajcp-4886	387	13	jana	jana	PROPN
ajcp-4886	387	14	,	,	PUNCT
ajcp-4886	387	15	a.	a.	PROPN
ajcp-4886	387	16	k.	k.	PROPN
ajcp-4886	387	17	,	,	PUNCT
ajcp-4886	387	18	&	&	CCONJ
ajcp-4886	387	19	hansmann	hansmann	PROPN
ajcp-4886	387	20	,	,	PUNCT
ajcp-4886	387	21	u.	u.	PROPN
ajcp-4886	387	22	h.	h.	PROPN
ajcp-4886	387	23	e.	e.	PROPN
ajcp-4886	387	24	(	(	PUNCT
ajcp-4886	387	25	2021	2021	NUM
ajcp-4886	387	26	)	)	PUNCT
ajcp-4886	387	27	.	.	PUNCT
ajcp-4886	388	1	effect	effect	NOUN
ajcp-4886	388	2	of	of	ADP
ajcp-4886	388	3	lauric	lauric	ADJ
ajcp-4886	388	4	acid	acid	NOUN
ajcp-4886	388	5	on	on	ADP
ajcp-4886	388	6	the	the	DET
ajcp-4886	388	7	stability	stability	NOUN
ajcp-4886	388	8	of	of	ADP
ajcp-4886	388	9	aβ42	aβ42	PROPN
ajcp-4886	388	10	oligomers	oligomer	NOUN
ajcp-4886	388	11	.	.	PUNCT
ajcp-4886	389	1	acs	acs	PROPN
ajcp-4886	389	2	omega	omega	NOUN
ajcp-4886	389	3	,	,	PUNCT
ajcp-4886	389	4	6(8	6(8	NUM
ajcp-4886	389	5	)	)	PUNCT
ajcp-4886	389	6	,	,	PUNCT
ajcp-4886	389	7	5795	5795	NUM
ajcp-4886	389	8	-	-	SYM
ajcp-4886	389	9	5804	5804	NUM
ajcp-4886	389	10	.	.	PUNCT
ajcp-4886	390	1	https://doi	https://doi	PROPN
ajcp-4886	390	2	.	.	PUNCT
ajcp-4886	390	3	org/10.1021	org/10.1021	NOUN
ajcp-4886	390	4	/	/	SYM
ajcp-4886	390	5	acsomega.0c06211	acsomega.0c06211	PROPN
ajcp-4886	390	6	könig	könig	PROPN
ajcp-4886	390	7	,	,	PUNCT
ajcp-4886	390	8	a.	a.	PROPN
ajcp-4886	390	9	s.	s.	PROPN
ajcp-4886	390	10	,	,	PUNCT
ajcp-4886	390	11	rösener	rösener	PROPN
ajcp-4886	390	12	,	,	PUNCT
ajcp-4886	390	13	n.	n.	PROPN
ajcp-4886	390	14	s.	s.	PROPN
ajcp-4886	390	15	,	,	PUNCT
ajcp-4886	390	16	gremer	gremer	PROPN
ajcp-4886	390	17	,	,	PUNCT
ajcp-4886	390	18	l.	l.	PROPN
ajcp-4886	390	19	,	,	PUNCT
ajcp-4886	390	20	tusche	tusche	PROPN
ajcp-4886	390	21	,	,	PUNCT
ajcp-4886	390	22	m.	m.	NOUN
ajcp-4886	390	23	,	,	PUNCT
ajcp-4886	390	24	flender	flender	PROPN
ajcp-4886	390	25	,	,	PUNCT
ajcp-4886	390	26	d.	d.	PROPN
ajcp-4886	390	27	,	,	PUNCT
ajcp-4886	390	28	reinartz	reinartz	PROPN
ajcp-4886	390	29	,	,	PUNCT
ajcp-4886	390	30	e.	e.	PROPN
ajcp-4886	390	31	,	,	PUNCT
ajcp-4886	390	32	hoyer	hoyer	PROPN
ajcp-4886	390	33	,	,	PUNCT
ajcp-4886	390	34	w.	w.	PROPN
ajcp-4886	390	35	,	,	PUNCT
ajcp-4886	390	36	neudecker	neudecker	NOUN
ajcp-4886	390	37	,	,	PUNCT
ajcp-4886	390	38	p.	p.	NOUN
ajcp-4886	390	39	,	,	PUNCT
ajcp-4886	390	40	willbold	willbold	PROPN
ajcp-4886	390	41	,	,	PUNCT
ajcp-4886	390	42	d.	d.	PROPN
ajcp-4886	390	43	,	,	PUNCT
ajcp-4886	390	44	&	&	CCONJ
ajcp-4886	390	45	heise	heise	PROPN
ajcp-4886	390	46	,	,	PUNCT
ajcp-4886	390	47	h.	h.	PROPN
ajcp-4886	390	48	(	(	PUNCT
ajcp-4886	390	49	2021	2021	NUM
ajcp-4886	390	50	)	)	PUNCT
ajcp-4886	390	51	.	.	PUNCT
ajcp-4886	391	1	structural	structural	ADJ
ajcp-4886	391	2	details	detail	NOUN
ajcp-4886	391	3	of	of	ADP
ajcp-4886	391	4	amyloid	amyloid	NOUN
ajcp-4886	391	5	β	β	X
ajcp-4886	391	6	oligomers	oligomer	NOUN
ajcp-4886	391	7	in	in	ADP
ajcp-4886	391	8	complex	complex	ADJ
ajcp-4886	391	9	with	with	ADP
ajcp-4886	391	10	human	human	ADJ
ajcp-4886	391	11	prion	prion	NOUN
ajcp-4886	391	12	protein	protein	NOUN
ajcp-4886	391	13	as	as	SCONJ
ajcp-4886	391	14	revealed	reveal	VERB
ajcp-4886	391	15	by	by	ADP
ajcp-4886	391	16	solid	solid	ADJ
ajcp-4886	391	17	-	-	PUNCT
ajcp-4886	391	18	state	state	NOUN
ajcp-4886	391	19	mas	mas	PROPN
ajcp-4886	391	20	nmr	nmr	NOUN
ajcp-4886	391	21	spectroscopy	spectroscopy	NOUN
ajcp-4886	391	22	.	.	PUNCT
ajcp-4886	392	1	journal	journal	NOUN
ajcp-4886	392	2	of	of	ADP
ajcp-4886	392	3	biological	biological	ADJ
ajcp-4886	392	4	chemistry	chemistry	NOUN
ajcp-4886	392	5	,	,	PUNCT
ajcp-4886	392	6	296	296	NUM
ajcp-4886	392	7	.	.	PUNCT
ajcp-4886	393	1	https://doi.org/10.1016/j.jbc.2021.100499	https://doi.org/10.1016/j.jbc.2021.100499	PROPN
ajcp-4886	393	2	kubo	kubo	PROPN
ajcp-4886	393	3	,	,	PUNCT
ajcp-4886	393	4	k.	k.	PROPN
ajcp-4886	393	5	,	,	PUNCT
ajcp-4886	393	6	watanabe	watanabe	PROPN
ajcp-4886	393	7	,	,	PUNCT
ajcp-4886	393	8	h.	h.	PROPN
ajcp-4886	393	9	,	,	PUNCT
ajcp-4886	393	10	kumeta	kumeta	PROPN
ajcp-4886	393	11	,	,	PUNCT
ajcp-4886	393	12	h.	h.	PROPN
ajcp-4886	393	13	,	,	PUNCT
ajcp-4886	393	14	aizawa	aizawa	PROPN
ajcp-4886	393	15	,	,	PUNCT
ajcp-4886	393	16	t.	t.	PROPN
ajcp-4886	393	17	,	,	PUNCT
ajcp-4886	393	18	seki	seki	PROPN
ajcp-4886	393	19	,	,	PUNCT
ajcp-4886	393	20	c.	c.	PROPN
ajcp-4886	393	21	,	,	PUNCT
ajcp-4886	393	22	nakano	nakano	PROPN
ajcp-4886	393	23	,	,	PUNCT
ajcp-4886	393	24	h.	h.	PROPN
ajcp-4886	393	25	,	,	PUNCT
ajcp-4886	393	26	tokuraku	tokuraku	PROPN
ajcp-4886	393	27	,	,	PUNCT
ajcp-4886	393	28	k.	k.	PROPN
ajcp-4886	393	29	,	,	PUNCT
ajcp-4886	393	30	&	&	CCONJ
ajcp-4886	393	31	uwai	uwai	PROPN
ajcp-4886	393	32	,	,	PUNCT
ajcp-4886	393	33	k.	k.	PROPN
ajcp-4886	393	34	(	(	PUNCT
ajcp-4886	393	35	2022	2022	NUM
ajcp-4886	393	36	)	)	PUNCT
ajcp-4886	393	37	.	.	PUNCT
ajcp-4886	394	1	chemical	chemical	ADJ
ajcp-4886	394	2	analysis	analysis	NOUN
ajcp-4886	394	3	of	of	ADP
ajcp-4886	394	4	amyloid	amyloid	NOUN
ajcp-4886	394	5	β	β	NOUN
ajcp-4886	394	6	aggregation	aggregation	NOUN
ajcp-4886	394	7	inhibitors	inhibitor	NOUN
ajcp-4886	394	8	derived	derive	VERB
ajcp-4886	394	9	from	from	ADP
ajcp-4886	394	10	geranium	geranium	NOUN
ajcp-4886	394	11	thunbergii	thunbergii	NOUN
ajcp-4886	394	12	.	.	PUNCT
ajcp-4886	395	1	bioorganic	bioorganic	PROPN
ajcp-4886	395	2	&	&	CCONJ
ajcp-4886	395	3	medicinal	medicinal	ADJ
ajcp-4886	395	4	chemistry	chemistry	NOUN
ajcp-4886	395	5	,	,	PUNCT
ajcp-4886	395	6	68	68	NUM
ajcp-4886	395	7	.	.	PUNCT
ajcp-4886	396	1	https://doi.org/10.1016/j	https://doi.org/10.1016/j	NOUN
ajcp-4886	396	2	.	.	PUNCT
ajcp-4886	397	1	bmc.2022.116840	bmc.2022.116840	PROPN
ajcp-4886	397	2	kumar	kumar	PROPN
ajcp-4886	397	3	,	,	PUNCT
ajcp-4886	397	4	r.	r.	PROPN
ajcp-4886	397	5	,	,	PUNCT
ajcp-4886	397	6	das	das	PROPN
ajcp-4886	397	7	,	,	PUNCT
ajcp-4886	397	8	s.	s.	PROPN
ajcp-4886	397	9	,	,	PUNCT
ajcp-4886	397	10	mohite	mohite	PROPN
ajcp-4886	397	11	,	,	PUNCT
ajcp-4886	397	12	g.	g.	PROPN
ajcp-4886	397	13	m.	m.	PROPN
ajcp-4886	397	14	,	,	PUNCT
ajcp-4886	397	15	rout	rout	NOUN
ajcp-4886	397	16	,	,	PUNCT
ajcp-4886	397	17	s.	s.	PROPN
ajcp-4886	397	18	k.	k.	PROPN
ajcp-4886	397	19	,	,	PUNCT
ajcp-4886	397	20	halder	halder	PROPN
ajcp-4886	397	21	,	,	PUNCT
ajcp-4886	397	22	s.	s.	PROPN
ajcp-4886	397	23	,	,	PUNCT
ajcp-4886	397	24	jha	jha	PROPN
ajcp-4886	397	25	,	,	PUNCT
ajcp-4886	397	26	n.	n.	PROPN
ajcp-4886	397	27	n.	n.	PROPN
ajcp-4886	397	28	,	,	PUNCT
ajcp-4886	397	29	ray	ray	PROPN
ajcp-4886	397	30	,	,	PUNCT
ajcp-4886	397	31	s.	s.	PROPN
ajcp-4886	397	32	,	,	PUNCT
ajcp-4886	397	33	mehra	mehra	PROPN
ajcp-4886	397	34	,	,	PUNCT
ajcp-4886	397	35	s.	s.	PROPN
ajcp-4886	397	36	,	,	PUNCT
ajcp-4886	397	37	agarwal	agarwal	PROPN
ajcp-4886	397	38	,	,	PUNCT
ajcp-4886	397	39	v.	v.	PROPN
ajcp-4886	397	40	,	,	PUNCT
ajcp-4886	397	41	&	&	CCONJ
ajcp-4886	397	42	maji	maji	PROPN
ajcp-4886	397	43	,	,	PUNCT
ajcp-4886	397	44	s.	s.	PROPN
ajcp-4886	397	45	pa	pa	PROPN
ajcp-4886	397	46	ge	ge	PROPN
ajcp-4886	397	47	26	26	NUM
ajcp-4886	397	48	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-4886	397	49	am	be	AUX
ajcp-4886	397	50	.	.	PUNCT
ajcp-4886	398	1	j.	j.	PROPN
ajcp-4886	398	2	chem	chem	PROPN
ajcp-4886	398	3	.	.	PUNCT
ajcp-4886	399	1	pharm	pharm	PROPN
ajcp-4886	399	2	.	.	PUNCT
ajcp-4886	400	1	4(1	4(1	NOUN
ajcp-4886	400	2	)	)	PUNCT
ajcp-4886	401	1	16	16	NUM
ajcp-4886	401	2	-	-	SYM
ajcp-4886	401	3	28	28	NUM
ajcp-4886	401	4	,	,	PUNCT
ajcp-4886	401	5	2025	2025	NUM
ajcp-4886	401	6	k.	k.	NOUN
ajcp-4886	401	7	(	(	PUNCT
ajcp-4886	401	8	2018	2018	NUM
ajcp-4886	401	9	)	)	PUNCT
ajcp-4886	401	10	.	.	PUNCT
ajcp-4886	402	1	cytotoxic	cytotoxic	ADJ
ajcp-4886	402	2	oligomers	oligomer	NOUN
ajcp-4886	402	3	and	and	CCONJ
ajcp-4886	402	4	fibrils	fibril	NOUN
ajcp-4886	402	5	trapped	trap	VERB
ajcp-4886	402	6	in	in	ADP
ajcp-4886	402	7	a	a	DET
ajcp-4886	402	8	gel‐like	gel‐like	ADJ
ajcp-4886	402	9	state	state	NOUN
ajcp-4886	402	10	of	of	ADP
ajcp-4886	402	11	α‐synuclein	α‐synuclein	NUM
ajcp-4886	402	12	assemblies	assembly	NOUN
ajcp-4886	402	13	.	.	PUNCT
ajcp-4886	403	1	angewandte	angewandte	PROPN
ajcp-4886	403	2	chemie	chemie	PROPN
ajcp-4886	403	3	international	international	PROPN
ajcp-4886	403	4	edition	edition	PROPN
ajcp-4886	403	5	,	,	PUNCT
ajcp-4886	403	6	57(19	57(19	PROPN
ajcp-4886	403	7	)	)	PUNCT
ajcp-4886	403	8	,	,	PUNCT
ajcp-4886	403	9	52625266	52625266	NUM
ajcp-4886	403	10	.	.	PUNCT
ajcp-4886	404	1	https://doi.org/10.1002/anie.201711854	https://doi.org/10.1002/anie.201711854	PROPN
ajcp-4886	404	2	li	li	PROPN
ajcp-4886	404	3	,	,	PUNCT
ajcp-4886	404	4	c.	c.	PROPN
ajcp-4886	404	5	h.	h.	PROPN
ajcp-4886	404	6	,	,	PUNCT
ajcp-4886	404	7	coffey	coffey	PROPN
ajcp-4886	404	8	,	,	PUNCT
ajcp-4886	404	9	e.	e.	PROPN
ajcp-4886	404	10	l.	l.	PROPN
ajcp-4886	404	11	,	,	PUNCT
ajcp-4886	404	12	dall’agnese	dall’agnese	PROPN
ajcp-4886	404	13	,	,	PUNCT
ajcp-4886	404	14	a.	a.	NOUN
ajcp-4886	404	15	,	,	PUNCT
ajcp-4886	404	16	hannett	hannett	NOUN
ajcp-4886	404	17	,	,	PUNCT
ajcp-4886	404	18	n.	n.	NOUN
ajcp-4886	404	19	m.	m.	PROPN
ajcp-4886	404	20	,	,	PUNCT
ajcp-4886	404	21	tang	tang	PROPN
ajcp-4886	404	22	,	,	PUNCT
ajcp-4886	404	23	x.	x.	NOUN
ajcp-4886	404	24	,	,	PUNCT
ajcp-4886	404	25	henninger	henninger	NOUN
ajcp-4886	404	26	,	,	PUNCT
ajcp-4886	404	27	j.	j.	PROPN
ajcp-4886	404	28	e.	e.	PROPN
ajcp-4886	404	29	,	,	PUNCT
ajcp-4886	404	30	platt	platt	PROPN
ajcp-4886	404	31	,	,	PUNCT
ajcp-4886	404	32	j.	j.	PROPN
ajcp-4886	404	33	m.	m.	PROPN
ajcp-4886	404	34	,	,	PUNCT
ajcp-4886	404	35	oksuz	oksuz	NOUN
ajcp-4886	404	36	,	,	PUNCT
ajcp-4886	404	37	o.	o.	NOUN
ajcp-4886	404	38	,	,	PUNCT
ajcp-4886	404	39	zamudio	zamudio	NOUN
ajcp-4886	404	40	,	,	PUNCT
ajcp-4886	404	41	a.	a.	NOUN
ajcp-4886	404	42	v.	v.	PROPN
ajcp-4886	404	43	,	,	PUNCT
ajcp-4886	404	44	afeyan	afeyan	ADJ
ajcp-4886	404	45	,	,	PUNCT
ajcp-4886	404	46	l.	l.	PROPN
ajcp-4886	404	47	k.	k.	PROPN
ajcp-4886	404	48	,	,	PUNCT
ajcp-4886	404	49	schuijers	schuijers	PROPN
ajcp-4886	404	50	,	,	PUNCT
ajcp-4886	404	51	j.	j.	PROPN
ajcp-4886	404	52	,	,	PUNCT
ajcp-4886	404	53	liu	liu	PROPN
ajcp-4886	404	54	,	,	PUNCT
ajcp-4886	404	55	x.	x.	PROPN
ajcp-4886	404	56	s.	s.	PROPN
ajcp-4886	404	57	,	,	PUNCT
ajcp-4886	404	58	markoulaki	markoulaki	PROPN
ajcp-4886	404	59	,	,	PUNCT
ajcp-4886	404	60	s.	s.	PROPN
ajcp-4886	404	61	,	,	PUNCT
ajcp-4886	404	62	lungjangwa	lungjangwa	PROPN
ajcp-4886	404	63	,	,	PUNCT
ajcp-4886	404	64	t.	t.	PROPN
ajcp-4886	404	65	,	,	PUNCT
ajcp-4886	404	66	leroy	leroy	PROPN
ajcp-4886	404	67	,	,	PUNCT
ajcp-4886	404	68	g.	g.	PROPN
ajcp-4886	404	69	,	,	PUNCT
ajcp-4886	404	70	svoboda	svoboda	PROPN
ajcp-4886	404	71	,	,	PUNCT
ajcp-4886	404	72	d.	d.	PROPN
ajcp-4886	404	73	s.	s.	PROPN
ajcp-4886	404	74	,	,	PUNCT
ajcp-4886	404	75	wogram	wogram	PROPN
ajcp-4886	404	76	,	,	PUNCT
ajcp-4886	404	77	e.	e.	PROPN
ajcp-4886	404	78	,	,	PUNCT
ajcp-4886	404	79	lee	lee	PROPN
ajcp-4886	404	80	,	,	PUNCT
ajcp-4886	404	81	t.	t.	PROPN
ajcp-4886	404	82	i.	i.	PROPN
ajcp-4886	404	83	,	,	PUNCT
ajcp-4886	404	84	jaenisch	jaenisch	PROPN
ajcp-4886	404	85	,	,	PUNCT
ajcp-4886	404	86	r.	r.	PROPN
ajcp-4886	404	87	,	,	PUNCT
ajcp-4886	404	88	&	&	CCONJ
ajcp-4886	404	89	young	young	PROPN
ajcp-4886	404	90	,	,	PUNCT
ajcp-4886	404	91	r.	r.	PROPN
ajcp-4886	404	92	a.	a.	PROPN
ajcp-4886	404	93	(	(	PUNCT
ajcp-4886	404	94	2020	2020	NUM
ajcp-4886	404	95	)	)	PUNCT
ajcp-4886	404	96	.	.	PUNCT
ajcp-4886	405	1	mecp2	mecp2	NOUN
ajcp-4886	405	2	links	link	VERB
ajcp-4886	405	3	heterochromatin	heterochromatin	ADJ
ajcp-4886	405	4	condensates	condensate	NOUN
ajcp-4886	405	5	and	and	CCONJ
ajcp-4886	405	6	neurodevelopmental	neurodevelopmental	ADJ
ajcp-4886	405	7	disease	disease	NOUN
ajcp-4886	405	8	.	.	PUNCT
ajcp-4886	406	1	nature	nature	NOUN
ajcp-4886	406	2	,	,	PUNCT
ajcp-4886	406	3	586(7829	586(7829	NUM
ajcp-4886	406	4	)	)	PUNCT
ajcp-4886	406	5	,	,	PUNCT
ajcp-4886	406	6	440444	440444	NUM
ajcp-4886	406	7	.	.	PUNCT
ajcp-4886	407	1	https://doi.org/10.1038/s41586-020-2574-4	https://doi.org/10.1038/s41586-020-2574-4	NUM
ajcp-4886	407	2	li	li	PROPN
ajcp-4886	407	3	,	,	PUNCT
ajcp-4886	407	4	j.	j.	PROPN
ajcp-4886	407	5	,	,	PUNCT
ajcp-4886	407	6	liao	liao	PROPN
ajcp-4886	407	7	,	,	PUNCT
ajcp-4886	407	8	w.	w.	PROPN
ajcp-4886	407	9	,	,	PUNCT
ajcp-4886	407	10	huang	huang	PROPN
ajcp-4886	407	11	,	,	PUNCT
ajcp-4886	407	12	d.	d.	PROPN
ajcp-4886	407	13	,	,	PUNCT
ajcp-4886	407	14	ou	ou	PROPN
ajcp-4886	407	15	,	,	PUNCT
ajcp-4886	407	16	m.	m.	NOUN
ajcp-4886	407	17	,	,	PUNCT
ajcp-4886	407	18	chen	chen	PROPN
ajcp-4886	407	19	,	,	PUNCT
ajcp-4886	407	20	t.	t.	PROPN
ajcp-4886	407	21	,	,	PUNCT
ajcp-4886	407	22	wang	wang	PROPN
ajcp-4886	407	23	,	,	PUNCT
ajcp-4886	407	24	x.	x.	PROPN
ajcp-4886	407	25	,	,	PUNCT
ajcp-4886	407	26	zhao	zhao	PROPN
ajcp-4886	407	27	,	,	PUNCT
ajcp-4886	407	28	r.	r.	PROPN
ajcp-4886	407	29	,	,	PUNCT
ajcp-4886	407	30	zhang	zhang	PROPN
ajcp-4886	407	31	,	,	PUNCT
ajcp-4886	407	32	l.	l.	PROPN
ajcp-4886	407	33	,	,	PUNCT
ajcp-4886	407	34	mei	mei	PROPN
ajcp-4886	407	35	,	,	PUNCT
ajcp-4886	407	36	l.	l.	PROPN
ajcp-4886	407	37	,	,	PUNCT
ajcp-4886	407	38	liu	liu	PROPN
ajcp-4886	407	39	,	,	PUNCT
ajcp-4886	407	40	j.	j.	PROPN
ajcp-4886	407	41	,	,	PUNCT
ajcp-4886	407	42	&	&	CCONJ
ajcp-4886	407	43	luan	luan	PROPN
ajcp-4886	407	44	,	,	PUNCT
ajcp-4886	407	45	p.	p.	PROPN
ajcp-4886	407	46	(	(	PUNCT
ajcp-4886	407	47	2023	2023	NUM
ajcp-4886	407	48	)	)	PUNCT
ajcp-4886	407	49	.	.	PUNCT
ajcp-4886	408	1	current	current	ADJ
ajcp-4886	408	2	strategies	strategy	NOUN
ajcp-4886	408	3	of	of	ADP
ajcp-4886	408	4	detecting	detect	VERB
ajcp-4886	408	5	aβ	aβ	PRON
ajcp-4886	408	6	species	specie	NOUN
ajcp-4886	408	7	and	and	CCONJ
ajcp-4886	408	8	inhibiting	inhibit	VERB
ajcp-4886	408	9	aβ	aβ	PRON
ajcp-4886	408	10	aggregation	aggregation	NOUN
ajcp-4886	408	11	:	:	PUNCT
ajcp-4886	408	12	status	status	NOUN
ajcp-4886	408	13	and	and	CCONJ
ajcp-4886	408	14	prospects	prospect	NOUN
ajcp-4886	408	15	.	.	PUNCT
ajcp-4886	409	1	coordination	coordination	NOUN
ajcp-4886	409	2	chemistry	chemistry	NOUN
ajcp-4886	409	3	reviews	review	NOUN
ajcp-4886	409	4	,	,	PUNCT
ajcp-4886	409	5	495	495	NUM
ajcp-4886	409	6	.	.	PUNCT
ajcp-4886	410	1	https://doi	https://doi	X
ajcp-4886	410	2	.	.	PUNCT
ajcp-4886	410	3	org/10.1016	org/10.1016	PROPN
ajcp-4886	410	4	/	/	SYM
ajcp-4886	410	5	j.ccr.2023.215375	j.ccr.2023.215375	PROPN
ajcp-4886	410	6	limbocker	limbocker	NOUN
ajcp-4886	410	7	,	,	PUNCT
ajcp-4886	410	8	r.	r.	PROPN
ajcp-4886	410	9	,	,	PUNCT
ajcp-4886	410	10	chia	chia	PROPN
ajcp-4886	410	11	,	,	PUNCT
ajcp-4886	410	12	s.	s.	PROPN
ajcp-4886	410	13	,	,	PUNCT
ajcp-4886	410	14	ruggeri	ruggeri	PROPN
ajcp-4886	410	15	,	,	PUNCT
ajcp-4886	410	16	f.	f.	PROPN
ajcp-4886	410	17	s.	s.	PROPN
ajcp-4886	410	18	,	,	PUNCT
ajcp-4886	410	19	perni	perni	PROPN
ajcp-4886	410	20	,	,	PUNCT
ajcp-4886	410	21	m.	m.	NOUN
ajcp-4886	410	22	,	,	PUNCT
ajcp-4886	410	23	cascella	cascella	PROPN
ajcp-4886	410	24	,	,	PUNCT
ajcp-4886	410	25	r.	r.	PROPN
ajcp-4886	410	26	,	,	PUNCT
ajcp-4886	410	27	heller	heller	NOUN
ajcp-4886	410	28	,	,	PUNCT
ajcp-4886	410	29	g.	g.	PROPN
ajcp-4886	410	30	t.	t.	PROPN
ajcp-4886	410	31	,	,	PUNCT
ajcp-4886	410	32	meisl	meisl	PROPN
ajcp-4886	410	33	,	,	PUNCT
ajcp-4886	410	34	g.	g.	PROPN
ajcp-4886	410	35	,	,	PUNCT
ajcp-4886	410	36	mannini	mannini	PROPN
ajcp-4886	410	37	,	,	PUNCT
ajcp-4886	410	38	b.	b.	PROPN
ajcp-4886	410	39	,	,	PUNCT
ajcp-4886	410	40	habchi	habchi	PROPN
ajcp-4886	410	41	,	,	PUNCT
ajcp-4886	410	42	j.	j.	PROPN
ajcp-4886	410	43	,	,	PUNCT
ajcp-4886	410	44	michaels	michaels	PROPN
ajcp-4886	410	45	,	,	PUNCT
ajcp-4886	410	46	t.	t.	PROPN
ajcp-4886	410	47	c.	c.	PROPN
ajcp-4886	410	48	t.	t.	PROPN
ajcp-4886	410	49	,	,	PUNCT
ajcp-4886	410	50	challa	challa	PROPN
ajcp-4886	410	51	,	,	PUNCT
ajcp-4886	410	52	p.	p.	PROPN
ajcp-4886	410	53	k.	k.	PROPN
ajcp-4886	410	54	,	,	PUNCT
ajcp-4886	410	55	ahn	ahn	PROPN
ajcp-4886	410	56	,	,	PUNCT
ajcp-4886	410	57	m.	m.	NOUN
ajcp-4886	410	58	,	,	PUNCT
ajcp-4886	410	59	casford	casford	PROPN
ajcp-4886	410	60	,	,	PUNCT
ajcp-4886	410	61	s.	s.	PROPN
ajcp-4886	410	62	t.	t.	PROPN
ajcp-4886	410	63	,	,	PUNCT
ajcp-4886	410	64	fernando	fernando	PROPN
ajcp-4886	410	65	,	,	PUNCT
ajcp-4886	410	66	n.	n.	PROPN
ajcp-4886	410	67	,	,	PUNCT
ajcp-4886	410	68	xu	xu	PROPN
ajcp-4886	410	69	,	,	PUNCT
ajcp-4886	410	70	c.	c.	PROPN
ajcp-4886	410	71	k.	k.	PROPN
ajcp-4886	410	72	,	,	PUNCT
ajcp-4886	410	73	kloss	kloss	PROPN
ajcp-4886	410	74	,	,	PUNCT
ajcp-4886	410	75	n.	n.	PROPN
ajcp-4886	410	76	d.	d.	PROPN
ajcp-4886	410	77	,	,	PUNCT
ajcp-4886	410	78	cohen	cohen	PROPN
ajcp-4886	410	79	,	,	PUNCT
ajcp-4886	410	80	s.	s.	PROPN
ajcp-4886	410	81	i.	i.	PROPN
ajcp-4886	410	82	a.	a.	PROPN
ajcp-4886	410	83	,	,	PUNCT
ajcp-4886	410	84	kumita	kumita	PROPN
ajcp-4886	410	85	,	,	PUNCT
ajcp-4886	410	86	j.	j.	PROPN
ajcp-4886	410	87	r.	r.	PROPN
ajcp-4886	410	88	,	,	PUNCT
ajcp-4886	410	89	cecchi	cecchi	NOUN
ajcp-4886	410	90	,	,	PUNCT
ajcp-4886	410	91	c.	c.	PROPN
ajcp-4886	410	92	,	,	PUNCT
ajcp-4886	410	93	zasloff	zasloff	NOUN
ajcp-4886	410	94	,	,	PUNCT
ajcp-4886	410	95	m.	m.	NOUN
ajcp-4886	410	96	,	,	PUNCT
ajcp-4886	410	97	linse	linse	PROPN
ajcp-4886	410	98	,	,	PUNCT
ajcp-4886	410	99	s.	s.	PROPN
ajcp-4886	410	100	,	,	PUNCT
ajcp-4886	410	101	knowles	knowles	PROPN
ajcp-4886	410	102	,	,	PUNCT
ajcp-4886	410	103	t.	t.	PROPN
ajcp-4886	410	104	p.	p.	PROPN
ajcp-4886	410	105	j.	j.	PROPN
ajcp-4886	410	106	,	,	PUNCT
ajcp-4886	410	107	chiti	chiti	PROPN
ajcp-4886	410	108	,	,	PUNCT
ajcp-4886	410	109	f.	f.	PROPN
ajcp-4886	410	110	,	,	PUNCT
ajcp-4886	410	111	vendruscolo	vendruscolo	PROPN
ajcp-4886	410	112	,	,	PUNCT
ajcp-4886	410	113	m.	m.	NOUN
ajcp-4886	410	114	,	,	PUNCT
ajcp-4886	410	115	&	&	CCONJ
ajcp-4886	410	116	dobson	dobson	PROPN
ajcp-4886	410	117	,	,	PUNCT
ajcp-4886	410	118	c.	c.	PROPN
ajcp-4886	410	119	m.	m.	NOUN
ajcp-4886	410	120	(	(	PUNCT
ajcp-4886	410	121	2019	2019	NUM
ajcp-4886	410	122	)	)	PUNCT
ajcp-4886	410	123	.	.	PUNCT
ajcp-4886	411	1	trodusquemine	trodusquemine	PROPN
ajcp-4886	411	2	enhances	enhance	VERB
ajcp-4886	411	3	aβ42	aβ42	PROPN
ajcp-4886	411	4	aggregation	aggregation	NOUN
ajcp-4886	411	5	but	but	CCONJ
ajcp-4886	411	6	suppresses	suppress	VERB
ajcp-4886	411	7	its	its	PRON
ajcp-4886	411	8	toxicity	toxicity	NOUN
ajcp-4886	411	9	by	by	ADP
ajcp-4886	411	10	displacing	displace	VERB
ajcp-4886	411	11	oligomers	oligomer	NOUN
ajcp-4886	411	12	from	from	ADP
ajcp-4886	411	13	cell	cell	NOUN
ajcp-4886	411	14	membranes	membrane	NOUN
ajcp-4886	411	15	.	.	PUNCT
ajcp-4886	412	1	nature	nature	NOUN
ajcp-4886	412	2	communications	communication	NOUN
ajcp-4886	412	3	,	,	PUNCT
ajcp-4886	412	4	10(1	10(1	NUM
ajcp-4886	412	5	)	)	PUNCT
ajcp-4886	412	6	.	.	PUNCT
ajcp-4886	413	1	https://doi.org/10.1038/	https://doi.org/10.1038/	PROPN
ajcp-4886	413	2	s41467	s41467	NOUN
ajcp-4886	413	3	-	-	PUNCT
ajcp-4886	413	4	018	018	NUM
ajcp-4886	413	5	-	-	PUNCT
ajcp-4886	413	6	07699	07699	NUM
ajcp-4886	413	7	-	-	SYM
ajcp-4886	413	8	5	5	NUM
ajcp-4886	413	9	liu	liu	PROPN
ajcp-4886	413	10	,	,	PUNCT
ajcp-4886	413	11	h.	h.	PROPN
ajcp-4886	413	12	,	,	PUNCT
ajcp-4886	413	13	zhao	zhao	PROPN
ajcp-4886	413	14	,	,	PUNCT
ajcp-4886	413	15	x.	x.	PROPN
ajcp-4886	413	16	,	,	PUNCT
ajcp-4886	413	17	chen	chen	PROPN
ajcp-4886	413	18	,	,	PUNCT
ajcp-4886	413	19	j.	j.	PROPN
ajcp-4886	413	20	,	,	PUNCT
ajcp-4886	413	21	win	win	PROPN
ajcp-4886	413	22	,	,	PUNCT
ajcp-4886	413	23	y.	y.	PROPN
ajcp-4886	413	24	y.	y.	PROPN
ajcp-4886	413	25	,	,	PUNCT
ajcp-4886	413	26	&	&	CCONJ
ajcp-4886	413	27	cai	cai	PROPN
ajcp-4886	413	28	,	,	PUNCT
ajcp-4886	413	29	j.	j.	PROPN
ajcp-4886	413	30	(	(	PUNCT
ajcp-4886	413	31	2025	2025	NUM
ajcp-4886	413	32	)	)	PUNCT
ajcp-4886	413	33	.	.	PUNCT
ajcp-4886	414	1	unnatural	unnatural	ADJ
ajcp-4886	414	2	foldamers	foldamer	NOUN
ajcp-4886	414	3	as	as	ADP
ajcp-4886	414	4	inhibitors	inhibitor	NOUN
ajcp-4886	414	5	of	of	ADP
ajcp-4886	414	6	aβ	aβ	PRON
ajcp-4886	414	7	aggregation	aggregation	NOUN
ajcp-4886	414	8	via	via	ADP
ajcp-4886	414	9	stabilizing	stabilize	VERB
ajcp-4886	414	10	the	the	DET
ajcp-4886	414	11	aβ	aβ	NOUN
ajcp-4886	414	12	helix	helix	NOUN
ajcp-4886	414	13	.	.	PUNCT
ajcp-4886	415	1	chemical	chemical	NOUN
ajcp-4886	415	2	communications	communication	NOUN
ajcp-4886	415	3	,	,	PUNCT
ajcp-4886	415	4	61(24	61(24	NUM
ajcp-4886	415	5	)	)	PUNCT
ajcp-4886	415	6	,	,	PUNCT
ajcp-4886	415	7	4586	4586	NUM
ajcp-4886	415	8	-	-	SYM
ajcp-4886	415	9	4594	4594	NUM
ajcp-4886	415	10	.	.	PUNCT
ajcp-4886	416	1	https://doi.org/10.1039/	https://doi.org/10.1039/	PROPN
ajcp-4886	416	2	d4cc05280c	d4cc05280c	PROPN
ajcp-4886	416	3	loeffler	loeffler	NOUN
ajcp-4886	416	4	,	,	PUNCT
ajcp-4886	416	5	d.	d.	PROPN
ajcp-4886	416	6	a.	a.	PROPN
ajcp-4886	416	7	(	(	PUNCT
ajcp-4886	416	8	2023	2023	NUM
ajcp-4886	416	9	)	)	PUNCT
ajcp-4886	416	10	.	.	PUNCT
ajcp-4886	417	1	experimental	experimental	ADJ
ajcp-4886	417	2	approaches	approach	NOUN
ajcp-4886	417	3	for	for	ADP
ajcp-4886	417	4	altering	alter	VERB
ajcp-4886	417	5	the	the	DET
ajcp-4886	417	6	expression	expression	NOUN
ajcp-4886	417	7	of	of	ADP
ajcp-4886	417	8	abeta‐degrading	abeta‐degrade	VERB
ajcp-4886	417	9	enzymes	enzyme	NOUN
ajcp-4886	417	10	.	.	PUNCT
ajcp-4886	418	1	journal	journal	NOUN
ajcp-4886	418	2	of	of	ADP
ajcp-4886	418	3	neurochemistry	neurochemistry	NOUN
ajcp-4886	418	4	,	,	PUNCT
ajcp-4886	418	5	164(6	164(6	NUM
ajcp-4886	418	6	)	)	PUNCT
ajcp-4886	418	7	,	,	PUNCT
ajcp-4886	418	8	725	725	PROPN
ajcp-4886	418	9	-	-	SYM
ajcp-4886	418	10	763	763	NUM
ajcp-4886	418	11	.	.	PUNCT
ajcp-4886	419	1	https://doi	https://doi	PROPN
ajcp-4886	419	2	.	.	PUNCT
ajcp-4886	419	3	org/10.1111	org/10.1111	PROPN
ajcp-4886	419	4	/	/	SYM
ajcp-4886	419	5	jnc.15762	jnc.15762	NUM
ajcp-4886	419	6	luo	luo	PROPN
ajcp-4886	419	7	,	,	PUNCT
ajcp-4886	419	8	f.	f.	PROPN
ajcp-4886	419	9	,	,	PUNCT
ajcp-4886	419	10	gui	gui	PROPN
ajcp-4886	419	11	,	,	PUNCT
ajcp-4886	419	12	x.	x.	PROPN
ajcp-4886	419	13	,	,	PUNCT
ajcp-4886	419	14	zhou	zhou	PROPN
ajcp-4886	419	15	,	,	PUNCT
ajcp-4886	419	16	h.	h.	PROPN
ajcp-4886	419	17	,	,	PUNCT
ajcp-4886	419	18	gu	gu	PROPN
ajcp-4886	419	19	,	,	PUNCT
ajcp-4886	419	20	j.	j.	PROPN
ajcp-4886	419	21	,	,	PUNCT
ajcp-4886	419	22	li	li	PROPN
ajcp-4886	419	23	,	,	PUNCT
ajcp-4886	419	24	y.	y.	PROPN
ajcp-4886	419	25	,	,	PUNCT
ajcp-4886	419	26	liu	liu	PROPN
ajcp-4886	419	27	,	,	PUNCT
ajcp-4886	419	28	x.	x.	PROPN
ajcp-4886	419	29	,	,	PUNCT
ajcp-4886	419	30	zhao	zhao	PROPN
ajcp-4886	419	31	,	,	PUNCT
ajcp-4886	419	32	m.	m.	NOUN
ajcp-4886	419	33	,	,	PUNCT
ajcp-4886	419	34	li	li	PROPN
ajcp-4886	419	35	,	,	PUNCT
ajcp-4886	419	36	d.	d.	PROPN
ajcp-4886	419	37	,	,	PUNCT
ajcp-4886	419	38	li	li	PROPN
ajcp-4886	419	39	,	,	PUNCT
ajcp-4886	419	40	x.	x.	PROPN
ajcp-4886	419	41	,	,	PUNCT
ajcp-4886	419	42	&	&	CCONJ
ajcp-4886	419	43	liu	liu	PROPN
ajcp-4886	419	44	,	,	PUNCT
ajcp-4886	419	45	c.	c.	PROPN
ajcp-4886	419	46	(	(	PUNCT
ajcp-4886	419	47	2018	2018	NUM
ajcp-4886	419	48	)	)	PUNCT
ajcp-4886	419	49	.	.	PUNCT
ajcp-4886	420	1	atomic	atomic	ADJ
ajcp-4886	420	2	structures	structure	NOUN
ajcp-4886	420	3	of	of	ADP
ajcp-4886	420	4	fus	fus	PROPN
ajcp-4886	420	5	lc	lc	PROPN
ajcp-4886	420	6	domain	domain	NOUN
ajcp-4886	420	7	segments	segment	NOUN
ajcp-4886	420	8	reveal	reveal	VERB
ajcp-4886	420	9	bases	basis	NOUN
ajcp-4886	420	10	for	for	ADP
ajcp-4886	420	11	reversible	reversible	ADJ
ajcp-4886	420	12	amyloid	amyloid	NOUN
ajcp-4886	420	13	fibril	fibril	ADJ
ajcp-4886	420	14	formation	formation	NOUN
ajcp-4886	420	15	.	.	PUNCT
ajcp-4886	421	1	nature	nature	NOUN
ajcp-4886	421	2	structural	structural	ADJ
ajcp-4886	421	3	&	&	CCONJ
ajcp-4886	421	4	molecular	molecular	ADJ
ajcp-4886	421	5	biology	biology	NOUN
ajcp-4886	421	6	,	,	PUNCT
ajcp-4886	421	7	25(4	25(4	NOUN
ajcp-4886	421	8	)	)	PUNCT
ajcp-4886	421	9	,	,	PUNCT
ajcp-4886	421	10	341	341	NUM
ajcp-4886	421	11	-	-	SYM
ajcp-4886	421	12	346	346	NUM
ajcp-4886	421	13	.	.	PUNCT
ajcp-4886	422	1	https://doi.org/10.1038/	https://doi.org/10.1038/	NOUN
ajcp-4886	422	2	s41594	s41594	PROPN
ajcp-4886	422	3	-	-	PUNCT
ajcp-4886	422	4	018	018	NUM
ajcp-4886	422	5	-	-	PUNCT
ajcp-4886	422	6	0050	0050	NUM
ajcp-4886	422	7	-	-	PUNCT
ajcp-4886	422	8	8	8	NUM
ajcp-4886	422	9	madhu	madhu	NOUN
ajcp-4886	422	10	,	,	PUNCT
ajcp-4886	422	11	p.	p.	NOUN
ajcp-4886	422	12	,	,	PUNCT
ajcp-4886	422	13	&	&	CCONJ
ajcp-4886	422	14	mukhopadhyay	mukhopadhyay	PROPN
ajcp-4886	422	15	,	,	PUNCT
ajcp-4886	422	16	s.	s.	PROPN
ajcp-4886	422	17	(	(	PUNCT
ajcp-4886	422	18	2021	2021	NUM
ajcp-4886	422	19	)	)	PUNCT
ajcp-4886	422	20	.	.	PUNCT
ajcp-4886	423	1	distinct	distinct	ADJ
ajcp-4886	423	2	types	type	NOUN
ajcp-4886	423	3	of	of	ADP
ajcp-4886	423	4	amyloid‐β	amyloid‐β	ADJ
ajcp-4886	423	5	oligomers	oligomer	NOUN
ajcp-4886	423	6	displaying	display	VERB
ajcp-4886	423	7	diverse	diverse	ADJ
ajcp-4886	423	8	neurotoxicity	neurotoxicity	NOUN
ajcp-4886	423	9	mechanisms	mechanism	NOUN
ajcp-4886	423	10	in	in	ADP
ajcp-4886	423	11	alzheimer	alzheimer	PROPN
ajcp-4886	423	12	’s	’s	PART
ajcp-4886	423	13	disease	disease	NOUN
ajcp-4886	423	14	.	.	PUNCT
ajcp-4886	424	1	journal	journal	NOUN
ajcp-4886	424	2	of	of	ADP
ajcp-4886	424	3	cellular	cellular	ADJ
ajcp-4886	424	4	biochemistry	biochemistry	NOUN
ajcp-4886	424	5	,	,	PUNCT
ajcp-4886	424	6	122(11	122(11	NUM
ajcp-4886	424	7	)	)	PUNCT
ajcp-4886	424	8	,	,	PUNCT
ajcp-4886	424	9	1594	1594	NUM
ajcp-4886	424	10	-	-	SYM
ajcp-4886	424	11	1608	1608	NUM
ajcp-4886	424	12	.	.	PUNCT
ajcp-4886	425	1	https://doi	https://doi	PROPN
ajcp-4886	425	2	.	.	PUNCT
ajcp-4886	425	3	org/10.1002	org/10.1002	PROPN
ajcp-4886	425	4	/	/	SYM
ajcp-4886	425	5	jcb.30141	jcb.30141	ADJ
ajcp-4886	425	6	mantile	mantile	NOUN
ajcp-4886	425	7	,	,	PUNCT
ajcp-4886	425	8	f.	f.	PROPN
ajcp-4886	425	9	,	,	PUNCT
ajcp-4886	425	10	&	&	CCONJ
ajcp-4886	425	11	prisco	prisco	PROPN
ajcp-4886	425	12	,	,	PUNCT
ajcp-4886	425	13	a.	a.	PROPN
ajcp-4886	425	14	(	(	PUNCT
ajcp-4886	425	15	2020	2020	NUM
ajcp-4886	425	16	)	)	PUNCT
ajcp-4886	425	17	.	.	PUNCT
ajcp-4886	426	1	vaccination	vaccination	NOUN
ajcp-4886	426	2	against	against	ADP
ajcp-4886	426	3	β	β	NOUN
ajcp-4886	426	4	-	-	NOUN
ajcp-4886	426	5	amyloid	amyloid	NOUN
ajcp-4886	426	6	as	as	ADP
ajcp-4886	426	7	a	a	DET
ajcp-4886	426	8	strategy	strategy	NOUN
ajcp-4886	426	9	for	for	ADP
ajcp-4886	426	10	the	the	DET
ajcp-4886	426	11	prevention	prevention	NOUN
ajcp-4886	426	12	of	of	ADP
ajcp-4886	426	13	alzheimer	alzheimer	PROPN
ajcp-4886	426	14	’s	’s	PART
ajcp-4886	426	15	disease	disease	NOUN
ajcp-4886	426	16	.	.	PUNCT
ajcp-4886	427	1	biology	biology	NOUN
ajcp-4886	427	2	,	,	PUNCT
ajcp-4886	427	3	9(12	9(12	NUM
ajcp-4886	427	4	)	)	PUNCT
ajcp-4886	427	5	.	.	PUNCT
ajcp-4886	428	1	https://doi	https://doi	X
ajcp-4886	428	2	.	.	PUNCT
ajcp-4886	428	3	org/10.3390	org/10.3390	PROPN
ajcp-4886	428	4	/	/	SYM
ajcp-4886	428	5	biology9120425	biology9120425	PROPN
ajcp-4886	428	6	martinez	martinez	PROPN
ajcp-4886	428	7	pomier	pomier	PROPN
ajcp-4886	428	8	,	,	PUNCT
ajcp-4886	428	9	k.	k.	PROPN
ajcp-4886	428	10	,	,	PUNCT
ajcp-4886	428	11	ahmed	ahmed	PROPN
ajcp-4886	428	12	,	,	PUNCT
ajcp-4886	428	13	r.	r.	PROPN
ajcp-4886	428	14	,	,	PUNCT
ajcp-4886	428	15	&	&	CCONJ
ajcp-4886	428	16	melacini	melacini	PROPN
ajcp-4886	428	17	,	,	PUNCT
ajcp-4886	428	18	g.	g.	PROPN
ajcp-4886	428	19	(	(	PUNCT
ajcp-4886	428	20	2020	2020	NUM
ajcp-4886	428	21	)	)	PUNCT
ajcp-4886	428	22	.	.	PUNCT
ajcp-4886	429	1	catechins	catechin	NOUN
ajcp-4886	429	2	as	as	ADP
ajcp-4886	429	3	tools	tool	NOUN
ajcp-4886	429	4	to	to	PART
ajcp-4886	429	5	understand	understand	VERB
ajcp-4886	429	6	the	the	DET
ajcp-4886	429	7	molecular	molecular	ADJ
ajcp-4886	429	8	basis	basis	NOUN
ajcp-4886	429	9	of	of	ADP
ajcp-4886	429	10	neurodegeneration	neurodegeneration	NOUN
ajcp-4886	429	11	.	.	PUNCT
ajcp-4886	430	1	molecules	molecule	NOUN
ajcp-4886	430	2	,	,	PUNCT
ajcp-4886	430	3	25(16	25(16	NOUN
ajcp-4886	430	4	)	)	PUNCT
ajcp-4886	430	5	.	.	PUNCT
ajcp-4886	431	1	https://doi	https://doi	X
ajcp-4886	431	2	.	.	PUNCT
ajcp-4886	431	3	org/10.3390	org/10.3390	PROPN
ajcp-4886	431	4	/	/	SYM
ajcp-4886	431	5	molecules25163571	molecules25163571	PROPN
ajcp-4886	431	6	matsushima	matsushima	PROPN
ajcp-4886	431	7	,	,	PUNCT
ajcp-4886	431	8	y.	y.	PROPN
ajcp-4886	431	9	,	,	PUNCT
ajcp-4886	431	10	irie	irie	PROPN
ajcp-4886	431	11	,	,	PUNCT
ajcp-4886	431	12	y.	y.	PROPN
ajcp-4886	431	13	,	,	PUNCT
ajcp-4886	431	14	kageyama	kageyama	PROPN
ajcp-4886	431	15	,	,	PUNCT
ajcp-4886	431	16	y.	y.	PROPN
ajcp-4886	431	17	,	,	PUNCT
ajcp-4886	431	18	bellier	bellier	NOUN
ajcp-4886	431	19	,	,	PUNCT
ajcp-4886	431	20	j.	j.	PROPN
ajcp-4886	431	21	p.	p.	PROPN
ajcp-4886	431	22	,	,	PUNCT
ajcp-4886	431	23	tooyama	tooyama	NOUN
ajcp-4886	431	24	,	,	PUNCT
ajcp-4886	431	25	i.	i.	NOUN
ajcp-4886	431	26	,	,	PUNCT
ajcp-4886	431	27	maki	maki	PROPN
ajcp-4886	431	28	,	,	PUNCT
ajcp-4886	431	29	t.	t.	PROPN
ajcp-4886	431	30	,	,	PUNCT
ajcp-4886	431	31	kume	kume	PROPN
ajcp-4886	431	32	,	,	PUNCT
ajcp-4886	431	33	t.	t.	PROPN
ajcp-4886	431	34	,	,	PUNCT
ajcp-4886	431	35	yanagita	yanagita	PROPN
ajcp-4886	431	36	,	,	PUNCT
ajcp-4886	431	37	r.	r.	PROPN
ajcp-4886	431	38	c.	c.	PROPN
ajcp-4886	431	39	,	,	PUNCT
ajcp-4886	431	40	&	&	CCONJ
ajcp-4886	431	41	irie	irie	PROPN
ajcp-4886	431	42	,	,	PUNCT
ajcp-4886	431	43	k.	k.	PROPN
ajcp-4886	431	44	(	(	PUNCT
ajcp-4886	431	45	2022	2022	NUM
ajcp-4886	431	46	)	)	PUNCT
ajcp-4886	431	47	.	.	PUNCT
ajcp-4886	432	1	structure	structure	NOUN
ajcp-4886	432	2	optimization	optimization	NOUN
ajcp-4886	432	3	of	of	ADP
ajcp-4886	432	4	the	the	DET
ajcp-4886	432	5	toxic	toxic	ADJ
ajcp-4886	432	6	conformation	conformation	NOUN
ajcp-4886	432	7	model	model	NOUN
ajcp-4886	432	8	of	of	ADP
ajcp-4886	432	9	amyloid	amyloid	NOUN
ajcp-4886	432	10	β42	β42	NOUN
ajcp-4886	432	11	by	by	ADP
ajcp-4886	432	12	intramolecular	intramolecular	ADJ
ajcp-4886	432	13	disulfide	disulfide	NOUN
ajcp-4886	432	14	bond	bond	NOUN
ajcp-4886	432	15	formation	formation	NOUN
ajcp-4886	432	16	.	.	PUNCT
ajcp-4886	433	1	chembiochem	chembiochem	PROPN
ajcp-4886	433	2	,	,	PUNCT
ajcp-4886	433	3	23(8	23(8	NUM
ajcp-4886	433	4	)	)	PUNCT
ajcp-4886	433	5	.	.	PUNCT
ajcp-4886	434	1	https://doi.org/10.1002/	https://doi.org/10.1002/	PROPN
ajcp-4886	434	2	cbic.202200029	cbic.202200029	PROPN
ajcp-4886	434	3	matuszyk	matuszyk	NOUN
ajcp-4886	434	4	,	,	PUNCT
ajcp-4886	434	5	m.	m.	NOUN
ajcp-4886	434	6	m.	m.	NOUN
ajcp-4886	434	7	,	,	PUNCT
ajcp-4886	434	8	garwood	garwood	PROPN
ajcp-4886	434	9	,	,	PUNCT
ajcp-4886	434	10	c.	c.	PROPN
ajcp-4886	434	11	j.	j.	PROPN
ajcp-4886	434	12	,	,	PUNCT
ajcp-4886	434	13	ferraiuolo	ferraiuolo	PROPN
ajcp-4886	434	14	,	,	PUNCT
ajcp-4886	434	15	l.	l.	PROPN
ajcp-4886	434	16	,	,	PUNCT
ajcp-4886	434	17	simpson	simpson	PROPN
ajcp-4886	434	18	,	,	PUNCT
ajcp-4886	434	19	j.	j.	PROPN
ajcp-4886	434	20	e.	e.	PROPN
ajcp-4886	434	21	,	,	PUNCT
ajcp-4886	434	22	staniforth	staniforth	PROPN
ajcp-4886	434	23	,	,	PUNCT
ajcp-4886	434	24	r.	r.	PROPN
ajcp-4886	434	25	a.	a.	PROPN
ajcp-4886	434	26	,	,	PUNCT
ajcp-4886	434	27	&	&	CCONJ
ajcp-4886	434	28	wharton	wharton	PROPN
ajcp-4886	434	29	,	,	PUNCT
ajcp-4886	434	30	s.	s.	PROPN
ajcp-4886	434	31	b.	b.	PROPN
ajcp-4886	434	32	(	(	PUNCT
ajcp-4886	434	33	2021	2021	NUM
ajcp-4886	434	34	)	)	PUNCT
ajcp-4886	434	35	.	.	PUNCT
ajcp-4886	435	1	biological	biological	ADJ
ajcp-4886	435	2	and	and	CCONJ
ajcp-4886	435	3	methodological	methodological	ADJ
ajcp-4886	435	4	complexities	complexity	NOUN
ajcp-4886	435	5	of	of	ADP
ajcp-4886	435	6	beta‐	beta‐	NOUN
ajcp-4886	435	7	amyloid	amyloid	NOUN
ajcp-4886	435	8	peptide	peptide	NOUN
ajcp-4886	435	9	:	:	PUNCT
ajcp-4886	435	10	implications	implication	NOUN
ajcp-4886	435	11	for	for	ADP
ajcp-4886	435	12	alzheimer	alzheimer	PROPN
ajcp-4886	435	13	’s	’s	PART
ajcp-4886	435	14	disease	disease	NOUN
ajcp-4886	435	15	research	research	NOUN
ajcp-4886	435	16	.	.	PUNCT
ajcp-4886	436	1	journal	journal	PROPN
ajcp-4886	436	2	of	of	ADP
ajcp-4886	436	3	neurochemistry	neurochemistry	PROPN
ajcp-4886	436	4	,	,	PUNCT
ajcp-4886	436	5	160(4	160(4	NUM
ajcp-4886	436	6	)	)	PUNCT
ajcp-4886	436	7	,	,	PUNCT
ajcp-4886	436	8	434	434	NUM
ajcp-4886	436	9	-	-	SYM
ajcp-4886	436	10	453	453	NUM
ajcp-4886	436	11	.	.	PUNCT
ajcp-4886	437	1	https://doi.org/10.1111/jnc.15538	https://doi.org/10.1111/jnc.15538	VERB
ajcp-4886	437	2	mohammed	mohammed	PROPN
ajcp-4886	437	3	,	,	PUNCT
ajcp-4886	437	4	a.	a.	NOUN
ajcp-4886	437	5	a.	a.	PROPN
ajcp-4886	437	6	,	,	PUNCT
ajcp-4886	437	7	barale	barale	NOUN
ajcp-4886	437	8	,	,	PUNCT
ajcp-4886	437	9	s.	s.	PROPN
ajcp-4886	437	10	s.	s.	PROPN
ajcp-4886	437	11	,	,	PUNCT
ajcp-4886	437	12	kamble	kamble	PROPN
ajcp-4886	437	13	,	,	PUNCT
ajcp-4886	437	14	s.	s.	PROPN
ajcp-4886	437	15	a.	a.	PROPN
ajcp-4886	437	16	,	,	PUNCT
ajcp-4886	437	17	paymal	paymal	PROPN
ajcp-4886	437	18	,	,	PUNCT
ajcp-4886	437	19	s.	s.	PROPN
ajcp-4886	437	20	b.	b.	PROPN
ajcp-4886	437	21	,	,	PUNCT
ajcp-4886	437	22	&	&	CCONJ
ajcp-4886	437	23	sonawane	sonawane	PROPN
ajcp-4886	437	24	,	,	PUNCT
ajcp-4886	437	25	k.	k.	PROPN
ajcp-4886	437	26	d.	d.	PROPN
ajcp-4886	437	27	(	(	PUNCT
ajcp-4886	437	28	2023	2023	NUM
ajcp-4886	437	29	)	)	PUNCT
ajcp-4886	437	30	.	.	PUNCT
ajcp-4886	438	1	molecular	molecular	ADJ
ajcp-4886	438	2	insights	insight	NOUN
ajcp-4886	438	3	into	into	ADP
ajcp-4886	438	4	the	the	DET
ajcp-4886	438	5	inhibition	inhibition	NOUN
ajcp-4886	438	6	of	of	ADP
ajcp-4886	438	7	early	early	ADJ
ajcp-4886	438	8	stages	stage	NOUN
ajcp-4886	438	9	of	of	ADP
ajcp-4886	438	10	aβ	aβ	PRON
ajcp-4886	438	11	peptide	peptide	NOUN
ajcp-4886	438	12	aggregation	aggregation	NOUN
ajcp-4886	438	13	and	and	CCONJ
ajcp-4886	438	14	destabilization	destabilization	NOUN
ajcp-4886	438	15	of	of	ADP
ajcp-4886	438	16	alzheimer	alzheimer	PROPN
ajcp-4886	438	17	’s	’s	PART
ajcp-4886	438	18	aβ	aβ	NOUN
ajcp-4886	438	19	protofibril	protofibril	ADJ
ajcp-4886	438	20	by	by	ADP
ajcp-4886	438	21	dipeptide	dipeptide	NOUN
ajcp-4886	438	22	d	d	PROPN
ajcp-4886	438	23	-	-	PUNCT
ajcp-4886	438	24	trp	trp	PROPN
ajcp-4886	438	25	-	-	PUNCT
ajcp-4886	438	26	aib	aib	PROPN
ajcp-4886	438	27	:	:	PUNCT
ajcp-4886	438	28	a	a	DET
ajcp-4886	438	29	molecular	molecular	ADJ
ajcp-4886	438	30	modelling	modelling	NOUN
ajcp-4886	438	31	approach	approach	NOUN
ajcp-4886	438	32	.	.	PUNCT
ajcp-4886	439	1	international	international	ADJ
ajcp-4886	439	2	journal	journal	NOUN
ajcp-4886	439	3	of	of	ADP
ajcp-4886	439	4	biological	biological	ADJ
ajcp-4886	439	5	macromolecules	macromolecule	NOUN
ajcp-4886	439	6	,	,	PUNCT
ajcp-4886	439	7	242	242	NUM
ajcp-4886	439	8	.	.	PUNCT
ajcp-4886	440	1	https://doi.org/10.1016/j	https://doi.org/10.1016/j	NOUN
ajcp-4886	440	2	.	.	PUNCT
ajcp-4886	441	1	ijbiomac.2023.124880	ijbiomac.2023.124880	ADJ
ajcp-4886	441	2	mokra	mokra	NOUN
ajcp-4886	441	3	,	,	PUNCT
ajcp-4886	441	4	d.	d.	PROPN
ajcp-4886	441	5	,	,	PUNCT
ajcp-4886	441	6	joskova	joskova	PROPN
ajcp-4886	441	7	,	,	PUNCT
ajcp-4886	441	8	m.	m.	NOUN
ajcp-4886	441	9	,	,	PUNCT
ajcp-4886	441	10	&	&	CCONJ
ajcp-4886	441	11	mokry	mokry	PROPN
ajcp-4886	441	12	,	,	PUNCT
ajcp-4886	441	13	j.	j.	PROPN
ajcp-4886	441	14	(	(	PUNCT
ajcp-4886	441	15	2022	2022	NUM
ajcp-4886	441	16	)	)	PUNCT
ajcp-4886	441	17	.	.	PUNCT
ajcp-4886	442	1	therapeutic	therapeutic	ADJ
ajcp-4886	442	2	effects	effect	NOUN
ajcp-4886	442	3	of	of	ADP
ajcp-4886	442	4	green	green	ADJ
ajcp-4886	442	5	tea	tea	NOUN
ajcp-4886	442	6	polyphenol	polyphenol	NOUN
ajcp-4886	442	7	(	(	PUNCT
ajcp-4886	442	8	‒)-epigallocatechin-3	‒)-epigallocatechin-3	NOUN
ajcp-4886	442	9	-	-	PUNCT
ajcp-4886	442	10	gallate	gallate	NOUN
ajcp-4886	442	11	(	(	PUNCT
ajcp-4886	442	12	egcg	egcg	NOUN
ajcp-4886	442	13	)	)	PUNCT
ajcp-4886	442	14	in	in	ADP
ajcp-4886	442	15	relation	relation	NOUN
ajcp-4886	442	16	to	to	ADP
ajcp-4886	442	17	molecular	molecular	ADJ
ajcp-4886	442	18	pathways	pathway	NOUN
ajcp-4886	442	19	controlling	control	VERB
ajcp-4886	442	20	inflammation	inflammation	NOUN
ajcp-4886	442	21	,	,	PUNCT
ajcp-4886	442	22	oxidative	oxidative	ADJ
ajcp-4886	442	23	stress	stress	NOUN
ajcp-4886	442	24	,	,	PUNCT
ajcp-4886	442	25	and	and	CCONJ
ajcp-4886	442	26	apoptosis	apoptosis	NOUN
ajcp-4886	442	27	.	.	PUNCT
ajcp-4886	443	1	international	international	ADJ
ajcp-4886	443	2	journal	journal	NOUN
ajcp-4886	443	3	of	of	ADP
ajcp-4886	443	4	molecular	molecular	ADJ
ajcp-4886	443	5	sciences	science	NOUN
ajcp-4886	443	6	,	,	PUNCT
ajcp-4886	443	7	24(1	24(1	NUM
ajcp-4886	443	8	)	)	PUNCT
ajcp-4886	443	9	.	.	PUNCT
ajcp-4886	444	1	https://doi.org/10.3390/	https://doi.org/10.3390/	PROPN
ajcp-4886	444	2	ijms24010340	ijms24010340	PROPN
ajcp-4886	444	3	momma	momma	NOUN
ajcp-4886	444	4	,	,	PUNCT
ajcp-4886	444	5	y.	y.	PROPN
ajcp-4886	444	6	,	,	PUNCT
ajcp-4886	444	7	tsuji	tsuji	PROPN
ajcp-4886	444	8	,	,	PUNCT
ajcp-4886	444	9	m.	m.	NOUN
ajcp-4886	444	10	,	,	PUNCT
ajcp-4886	444	11	oguchi	oguchi	INTJ
ajcp-4886	444	12	,	,	PUNCT
ajcp-4886	444	13	t.	t.	PROPN
ajcp-4886	444	14	,	,	PUNCT
ajcp-4886	444	15	ohashi	ohashi	PROPN
ajcp-4886	444	16	,	,	PUNCT
ajcp-4886	444	17	h.	h.	PROPN
ajcp-4886	444	18	,	,	PUNCT
ajcp-4886	444	19	nohara	nohara	PROPN
ajcp-4886	444	20	,	,	PUNCT
ajcp-4886	444	21	t.	t.	PROPN
ajcp-4886	444	22	,	,	PUNCT
ajcp-4886	444	23	ito	ito	PROPN
ajcp-4886	444	24	,	,	PUNCT
ajcp-4886	444	25	n.	n.	PROPN
ajcp-4886	444	26	,	,	PUNCT
ajcp-4886	444	27	yamamoto	yamamoto	PROPN
ajcp-4886	444	28	,	,	PUNCT
ajcp-4886	444	29	k.	k.	PROPN
ajcp-4886	444	30	,	,	PUNCT
ajcp-4886	444	31	nagata	nagata	PROPN
ajcp-4886	444	32	,	,	PUNCT
ajcp-4886	444	33	m.	m.	NOUN
ajcp-4886	444	34	,	,	PUNCT
ajcp-4886	444	35	kimura	kimura	NOUN
ajcp-4886	444	36	,	,	PUNCT
ajcp-4886	444	37	a.	a.	NOUN
ajcp-4886	444	38	m.	m.	NOUN
ajcp-4886	444	39	,	,	PUNCT
ajcp-4886	444	40	nakamura	nakamura	PROPN
ajcp-4886	444	41	,	,	PUNCT
ajcp-4886	444	42	s.	s.	PROPN
ajcp-4886	444	43	,	,	PUNCT
ajcp-4886	444	44	kiuchi	kiuchi	PROPN
ajcp-4886	444	45	,	,	PUNCT
ajcp-4886	444	46	y.	y.	PROPN
ajcp-4886	444	47	,	,	PUNCT
ajcp-4886	444	48	&	&	CCONJ
ajcp-4886	444	49	ono	ono	PROPN
ajcp-4886	444	50	,	,	PUNCT
ajcp-4886	444	51	k.	k.	PROPN
ajcp-4886	444	52	(	(	PUNCT
ajcp-4886	444	53	2023	2023	NUM
ajcp-4886	444	54	)	)	PUNCT
ajcp-4886	444	55	.	.	PUNCT
ajcp-4886	445	1	the	the	DET
ajcp-4886	445	2	curcumin	curcumin	NOUN
ajcp-4886	445	3	derivative	derivative	PROPN
ajcp-4886	445	4	gt863	gt863	PROPN
ajcp-4886	445	5	protects	protect	VERB
ajcp-4886	445	6	cell	cell	NOUN
ajcp-4886	445	7	membranes	membrane	NOUN
ajcp-4886	445	8	in	in	ADP
ajcp-4886	445	9	cytotoxicity	cytotoxicity	NOUN
ajcp-4886	445	10	by	by	ADP
ajcp-4886	445	11	aβ	aβ	DET
ajcp-4886	445	12	oligomers	oligomer	NOUN
ajcp-4886	445	13	.	.	PUNCT
ajcp-4886	446	1	international	international	ADJ
ajcp-4886	446	2	journal	journal	NOUN
ajcp-4886	446	3	of	of	ADP
ajcp-4886	446	4	molecular	molecular	ADJ
ajcp-4886	446	5	sciences	science	NOUN
ajcp-4886	446	6	,	,	PUNCT
ajcp-4886	446	7	24(4	24(4	NUM
ajcp-4886	446	8	)	)	PUNCT
ajcp-4886	446	9	.	.	PUNCT
ajcp-4886	447	1	https://doi.org/10.3390/	https://doi.org/10.3390/	PROPN
ajcp-4886	447	2	ijms24043089	ijms24043089	PROPN
ajcp-4886	447	3	moracci	moracci	PROPN
ajcp-4886	447	4	,	,	PUNCT
ajcp-4886	447	5	l.	l.	PROPN
ajcp-4886	447	6	,	,	PUNCT
ajcp-4886	447	7	crotti	crotti	PROPN
ajcp-4886	447	8	,	,	PUNCT
ajcp-4886	447	9	s.	s.	PROPN
ajcp-4886	447	10	,	,	PUNCT
ajcp-4886	447	11	traldi	traldi	NOUN
ajcp-4886	447	12	,	,	PUNCT
ajcp-4886	447	13	p.	p.	NOUN
ajcp-4886	447	14	,	,	PUNCT
ajcp-4886	447	15	agostini	agostini	PROPN
ajcp-4886	447	16	,	,	PUNCT
ajcp-4886	447	17	m.	m.	NOUN
ajcp-4886	447	18	,	,	PUNCT
ajcp-4886	447	19	cosma	cosma	PROPN
ajcp-4886	447	20	,	,	PUNCT
ajcp-4886	447	21	c.	c.	PROPN
ajcp-4886	447	22	,	,	PUNCT
ajcp-4886	447	23	&	&	CCONJ
ajcp-4886	447	24	lapolla	lapolla	PROPN
ajcp-4886	447	25	,	,	PUNCT
ajcp-4886	447	26	a.	a.	NOUN
ajcp-4886	447	27	(	(	PUNCT
ajcp-4886	447	28	2021	2021	NUM
ajcp-4886	447	29	)	)	PUNCT
ajcp-4886	447	30	.	.	PUNCT
ajcp-4886	448	1	role	role	NOUN
ajcp-4886	448	2	of	of	ADP
ajcp-4886	448	3	mass	mass	ADJ
ajcp-4886	448	4	spectrometry	spectrometry	NOUN
ajcp-4886	448	5	in	in	ADP
ajcp-4886	448	6	the	the	DET
ajcp-4886	448	7	study	study	NOUN
ajcp-4886	448	8	of	of	ADP
ajcp-4886	448	9	interactions	interaction	NOUN
ajcp-4886	448	10	between	between	ADP
ajcp-4886	448	11	amylin	amylin	NOUN
ajcp-4886	448	12	and	and	CCONJ
ajcp-4886	448	13	metal	metal	NOUN
ajcp-4886	448	14	ions	ion	NOUN
ajcp-4886	448	15	.	.	PUNCT
ajcp-4886	449	1	mass	mass	ADJ
ajcp-4886	449	2	spectrometry	spectrometry	NOUN
ajcp-4886	449	3	reviews	review	NOUN
ajcp-4886	449	4	,	,	PUNCT
ajcp-4886	449	5	42(3	42(3	NUM
ajcp-4886	449	6	)	)	PUNCT
ajcp-4886	449	7	,	,	PUNCT
ajcp-4886	449	8	984	984	NUM
ajcp-4886	449	9	-	-	SYM
ajcp-4886	449	10	1007	1007	NUM
ajcp-4886	449	11	.	.	PUNCT
ajcp-4886	450	1	https://doi.org/10.1002/mas.21732	https://doi.org/10.1002/mas.21732	PROPN
ajcp-4886	450	2	mroczko	mroczko	PROPN
ajcp-4886	450	3	,	,	PUNCT
ajcp-4886	450	4	b.	b.	PROPN
ajcp-4886	450	5	,	,	PUNCT
ajcp-4886	450	6	groblewska	groblewska	PROPN
ajcp-4886	450	7	,	,	PUNCT
ajcp-4886	450	8	m.	m.	NOUN
ajcp-4886	450	9	,	,	PUNCT
ajcp-4886	450	10	litman	litman	NOUN
ajcp-4886	450	11	-	-	PUNCT
ajcp-4886	450	12	zawadzka	zawadzka	PROPN
ajcp-4886	450	13	,	,	PUNCT
ajcp-4886	450	14	a.	a.	NOUN
ajcp-4886	450	15	,	,	PUNCT
ajcp-4886	450	16	kornhuber	kornhuber	PROPN
ajcp-4886	450	17	,	,	PUNCT
ajcp-4886	450	18	j.	j.	PROPN
ajcp-4886	450	19	,	,	PUNCT
ajcp-4886	450	20	&	&	CCONJ
ajcp-4886	450	21	lewczuk	lewczuk	PROPN
ajcp-4886	450	22	,	,	PUNCT
ajcp-4886	450	23	p.	p.	NOUN
ajcp-4886	450	24	(	(	PUNCT
ajcp-4886	450	25	2017	2017	NUM
ajcp-4886	450	26	)	)	PUNCT
ajcp-4886	450	27	.	.	PUNCT
ajcp-4886	451	1	amyloid	amyloid	NOUN
ajcp-4886	451	2	β	β	X
ajcp-4886	451	3	oligomers	oligomer	NOUN
ajcp-4886	451	4	(	(	PUNCT
ajcp-4886	451	5	aβos	aβos	PROPN
ajcp-4886	451	6	)	)	PUNCT
ajcp-4886	451	7	in	in	ADP
ajcp-4886	451	8	alzheimer	alzheimer	PROPN
ajcp-4886	451	9	’s	’s	PART
ajcp-4886	451	10	disease	disease	NOUN
ajcp-4886	451	11	.	.	PUNCT
ajcp-4886	452	1	journal	journal	PROPN
ajcp-4886	452	2	of	of	ADP
ajcp-4886	452	3	neural	neural	ADJ
ajcp-4886	452	4	transmission	transmission	NOUN
ajcp-4886	452	5	,	,	PUNCT
ajcp-4886	452	6	125(2	125(2	NUM
ajcp-4886	452	7	)	)	PUNCT
ajcp-4886	452	8	,	,	PUNCT
ajcp-4886	452	9	177	177	NUM
ajcp-4886	452	10	-	-	SYM
ajcp-4886	452	11	191	191	NUM
ajcp-4886	452	12	.	.	PUNCT
ajcp-4886	453	1	https://doi	https://doi	NOUN
ajcp-4886	453	2	.	.	PUNCT
ajcp-4886	453	3	org/10.1007	org/10.1007	PROPN
ajcp-4886	453	4	/	/	SYM
ajcp-4886	453	5	s00702	s00702	PROPN
ajcp-4886	453	6	-	-	PUNCT
ajcp-4886	453	7	017	017	NUM
ajcp-4886	453	8	-	-	PUNCT
ajcp-4886	453	9	1820	1820	NUM
ajcp-4886	453	10	-	-	PUNCT
ajcp-4886	453	11	x	x	SYM
ajcp-4886	453	12	muhammad	muhammad	PROPN
ajcp-4886	453	13	,	,	PUNCT
ajcp-4886	453	14	j.	j.	PROPN
ajcp-4886	453	15	,	,	PUNCT
ajcp-4886	453	16	xiaohui	xiaohui	PROPN
ajcp-4886	453	17	,	,	PUNCT
ajcp-4886	453	18	w.	w.	PROPN
ajcp-4886	453	19	,	,	PUNCT
ajcp-4886	453	20	kashif	kashif	PROPN
ajcp-4886	453	21	,	,	PUNCT
ajcp-4886	453	22	k.	k.	PROPN
ajcp-4886	453	23	,	,	PUNCT
ajcp-4886	453	24	umar	umar	PROPN
ajcp-4886	453	25	,	,	PUNCT
ajcp-4886	453	26	a.	a.	PROPN
ajcp-4886	453	27	,	,	PUNCT
ajcp-4886	453	28	&	&	CCONJ
ajcp-4886	453	29	ke	ke	PROPN
ajcp-4886	453	30	,	,	PUNCT
ajcp-4886	453	31	z.	z.	PROPN
ajcp-4886	453	32	(	(	PUNCT
ajcp-4886	453	33	2024	2024	NUM
ajcp-4886	453	34	)	)	PUNCT
ajcp-4886	453	35	.	.	PUNCT
ajcp-4886	454	1	chemical	chemical	NOUN
ajcp-4886	454	2	regulation	regulation	NOUN
ajcp-4886	454	3	of	of	ADP
ajcp-4886	454	4	tau	tau	PROPN
ajcp-4886	454	5	oligomers	oligomer	NOUN
ajcp-4886	454	6	in	in	ADP
ajcp-4886	454	7	phase	phase	NOUN
ajcp-4886	454	8	separation	separation	NOUN
ajcp-4886	454	9	in	in	ADP
ajcp-4886	454	10	alzheimer	alzheimer	PROPN
ajcp-4886	454	11	’s	’s	PART
ajcp-4886	454	12	disease	disease	NOUN
ajcp-4886	454	13	.	.	PUNCT
ajcp-4886	455	1	world	world	PROPN
ajcp-4886	455	2	journal	journal	PROPN
ajcp-4886	455	3	of	of	ADP
ajcp-4886	455	4	biology	biology	NOUN
ajcp-4886	455	5	pharmacy	pharmacy	NOUN
ajcp-4886	455	6	and	and	CCONJ
ajcp-4886	455	7	health	health	NOUN
ajcp-4886	455	8	sciences	science	NOUN
ajcp-4886	455	9	,	,	PUNCT
ajcp-4886	455	10	19(2	19(2	NUM
ajcp-4886	455	11	)	)	PUNCT
ajcp-4886	455	12	,	,	PUNCT
ajcp-4886	455	13	380	380	NUM
ajcp-4886	455	14	-	-	SYM
ajcp-4886	455	15	390	390	NUM
ajcp-4886	455	16	.	.	PUNCT
ajcp-4886	456	1	https://doi.org/10.30574/wjbphs.2024.19.2.0534	https://doi.org/10.30574/wjbphs.2024.19.2.0534	NUM
ajcp-4886	456	2	muhammad	muhammad	PROPN
ajcp-4886	456	3	,	,	PUNCT
ajcp-4886	456	4	j.	j.	PROPN
ajcp-4886	456	5	,	,	PUNCT
ajcp-4886	456	6	xiaohui	xiaohui	PROPN
ajcp-4886	456	7	,	,	PUNCT
ajcp-4886	456	8	w.	w.	PROPN
ajcp-4886	456	9	,	,	PUNCT
ajcp-4886	456	10	ye	ye	PROPN
ajcp-4886	456	11	,	,	PUNCT
ajcp-4886	456	12	z.	z.	PROPN
ajcp-4886	456	13	,	,	PUNCT
ajcp-4886	456	14	umar	umar	PROPN
ajcp-4886	456	15	,	,	PUNCT
ajcp-4886	456	16	a.	a.	PROPN
ajcp-4886	456	17	,	,	PUNCT
ajcp-4886	456	18	kashif	kashif	PROPN
ajcp-4886	456	19	,	,	PUNCT
ajcp-4886	456	20	k.	k.	PROPN
ajcp-4886	456	21	,	,	PUNCT
ajcp-4886	456	22	&	&	CCONJ
ajcp-4886	456	23	wang	wang	PROPN
ajcp-4886	456	24	,	,	PUNCT
ajcp-4886	456	25	c.	c.	PROPN
ajcp-4886	456	26	(	(	PUNCT
ajcp-4886	456	27	2024	2024	NUM
ajcp-4886	456	28	)	)	PUNCT
ajcp-4886	456	29	.	.	PUNCT
ajcp-4886	457	1	inhibition	inhibition	NOUN
ajcp-4886	457	2	of	of	ADP
ajcp-4886	457	3	amyloid	amyloid	NOUN
ajcp-4886	457	4	beta	beta	NOUN
ajcp-4886	457	5	oligomer	oligomer	NOUN
ajcp-4886	457	6	,	,	PUNCT
ajcp-4886	457	7	fibrils	fibril	NOUN
ajcp-4886	457	8	,	,	PUNCT
ajcp-4886	457	9	and	and	CCONJ
ajcp-4886	457	10	peptide	peptide	NOUN
ajcp-4886	457	11	using	use	VERB
ajcp-4886	457	12	nanoparticles	nanoparticle	NOUN
ajcp-4886	457	13	to	to	PART
ajcp-4886	457	14	disrupt	disrupt	VERB
ajcp-4886	457	15	alzheimer	alzheimer	PROPN
ajcp-4886	457	16	’s	’s	PART
ajcp-4886	457	17	pathogenesis	pathogenesis	NOUN
ajcp-4886	457	18	.	.	PUNCT
ajcp-4886	458	1	world	world	PROPN
ajcp-4886	458	2	journal	journal	PROPN
ajcp-4886	458	3	of	of	ADP
ajcp-4886	458	4	advanced	advanced	ADJ
ajcp-4886	458	5	research	research	NOUN
ajcp-4886	458	6	and	and	CCONJ
ajcp-4886	458	7	reviews	review	NOUN
ajcp-4886	458	8	,	,	PUNCT
ajcp-4886	458	9	23(2	23(2	NUM
ajcp-4886	458	10	)	)	PUNCT
ajcp-4886	458	11	,	,	PUNCT
ajcp-4886	458	12	343	343	NUM
ajcp-4886	458	13	-	-	SYM
ajcp-4886	458	14	357	357	NUM
ajcp-4886	458	15	.	.	PUNCT
ajcp-4886	459	1	https://	https://	PROPN
ajcp-4886	459	2	doi.org/10.30574/wjarr.2024.23.2.2349	doi.org/10.30574/wjarr.2024.23.2.2349	PROPN
ajcp-4886	459	3	ono	ono	PROPN
ajcp-4886	459	4	,	,	PUNCT
ajcp-4886	459	5	k.	k.	PROPN
ajcp-4886	459	6	,	,	PUNCT
ajcp-4886	459	7	&	&	CCONJ
ajcp-4886	459	8	tsuji	tsuji	PROPN
ajcp-4886	459	9	,	,	PUNCT
ajcp-4886	459	10	m.	m.	NOUN
ajcp-4886	459	11	(	(	PUNCT
ajcp-4886	459	12	2020	2020	NUM
ajcp-4886	459	13	)	)	PUNCT
ajcp-4886	459	14	.	.	PUNCT
ajcp-4886	460	1	protofibrils	protofibril	NOUN
ajcp-4886	460	2	of	of	ADP
ajcp-4886	460	3	amyloid	amyloid	NOUN
ajcp-4886	460	4	-	-	PUNCT
ajcp-4886	460	5	β	β	NOUN
ajcp-4886	460	6	are	be	AUX
ajcp-4886	460	7	important	important	ADJ
ajcp-4886	460	8	targets	target	NOUN
ajcp-4886	460	9	of	of	ADP
ajcp-4886	460	10	a	a	DET
ajcp-4886	460	11	disease	disease	NOUN
ajcp-4886	460	12	-	-	PUNCT
ajcp-4886	460	13	modifying	modify	VERB
ajcp-4886	460	14	approach	approach	NOUN
ajcp-4886	460	15	for	for	ADP
ajcp-4886	460	16	alzheimer	alzheimer	PROPN
ajcp-4886	460	17	’s	’s	PART
ajcp-4886	460	18	disease	disease	NOUN
ajcp-4886	460	19	.	.	PUNCT
ajcp-4886	461	1	international	international	ADJ
ajcp-4886	461	2	journal	journal	PROPN
ajcp-4886	461	3	pa	pa	PROPN
ajcp-4886	461	4	ge	ge	PROPN
ajcp-4886	461	5	27	27	NUM
ajcp-4886	461	6	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-4886	461	7	am	be	AUX
ajcp-4886	461	8	.	.	PUNCT
ajcp-4886	462	1	j.	j.	PROPN
ajcp-4886	462	2	chem	chem	PROPN
ajcp-4886	462	3	.	.	PUNCT
ajcp-4886	463	1	pharm	pharm	PROPN
ajcp-4886	463	2	.	.	PUNCT
ajcp-4886	464	1	4(1	4(1	NOUN
ajcp-4886	464	2	)	)	PUNCT
ajcp-4886	465	1	16	16	NUM
ajcp-4886	465	2	-	-	SYM
ajcp-4886	465	3	28	28	NUM
ajcp-4886	465	4	,	,	PUNCT
ajcp-4886	465	5	2025	2025	NUM
ajcp-4886	465	6	of	of	ADP
ajcp-4886	465	7	molecular	molecular	ADJ
ajcp-4886	465	8	sciences	science	NOUN
ajcp-4886	465	9	,	,	PUNCT
ajcp-4886	465	10	21(3	21(3	NUM
ajcp-4886	465	11	)	)	PUNCT
ajcp-4886	465	12	.	.	PUNCT
ajcp-4886	466	1	https://doi.org/10.3390/	https://doi.org/10.3390/	PROPN
ajcp-4886	466	2	ijms21030952	ijms21030952	PROPN
ajcp-4886	466	3	pagano	pagano	PROPN
ajcp-4886	466	4	,	,	PUNCT
ajcp-4886	466	5	k.	k.	PROPN
ajcp-4886	466	6	,	,	PUNCT
ajcp-4886	466	7	tomaselli	tomaselli	PROPN
ajcp-4886	466	8	,	,	PUNCT
ajcp-4886	466	9	s.	s.	PROPN
ajcp-4886	466	10	,	,	PUNCT
ajcp-4886	466	11	molinari	molinari	PROPN
ajcp-4886	466	12	,	,	PUNCT
ajcp-4886	466	13	h.	h.	PROPN
ajcp-4886	466	14	,	,	PUNCT
ajcp-4886	466	15	&	&	CCONJ
ajcp-4886	466	16	ragona	ragona	PROPN
ajcp-4886	466	17	,	,	PUNCT
ajcp-4886	466	18	l.	l.	PROPN
ajcp-4886	466	19	(	(	PUNCT
ajcp-4886	466	20	2020	2020	NUM
ajcp-4886	466	21	)	)	PUNCT
ajcp-4886	466	22	.	.	PUNCT
ajcp-4886	467	1	natural	natural	ADJ
ajcp-4886	467	2	compounds	compound	NOUN
ajcp-4886	467	3	as	as	ADP
ajcp-4886	467	4	inhibitors	inhibitor	NOUN
ajcp-4886	467	5	of	of	ADP
ajcp-4886	467	6	aβ	aβ	PRON
ajcp-4886	467	7	peptide	peptide	NOUN
ajcp-4886	467	8	aggregation	aggregation	NOUN
ajcp-4886	467	9	:	:	PUNCT
ajcp-4886	467	10	chemical	chemical	NOUN
ajcp-4886	467	11	requirements	requirement	NOUN
ajcp-4886	467	12	and	and	CCONJ
ajcp-4886	467	13	molecular	molecular	ADJ
ajcp-4886	467	14	mechanisms	mechanism	NOUN
ajcp-4886	467	15	.	.	PUNCT
ajcp-4886	468	1	frontiers	frontier	NOUN
ajcp-4886	468	2	in	in	ADP
ajcp-4886	468	3	neuroscience	neuroscience	NOUN
ajcp-4886	468	4	,	,	PUNCT
ajcp-4886	468	5	14	14	NUM
ajcp-4886	468	6	.	.	PUNCT
ajcp-4886	469	1	https://doi.org/10.3389/fnins.2020.619667	https://doi.org/10.3389/fnins.2020.619667	PROPN
ajcp-4886	469	2	panza	panza	PROPN
ajcp-4886	469	3	,	,	PUNCT
ajcp-4886	469	4	f.	f.	PROPN
ajcp-4886	469	5	,	,	PUNCT
ajcp-4886	469	6	dibello	dibello	PROPN
ajcp-4886	469	7	,	,	PUNCT
ajcp-4886	469	8	v.	v.	PROPN
ajcp-4886	469	9	,	,	PUNCT
ajcp-4886	469	10	sardone	sardone	PROPN
ajcp-4886	469	11	,	,	PUNCT
ajcp-4886	469	12	r.	r.	PROPN
ajcp-4886	469	13	,	,	PUNCT
ajcp-4886	469	14	zupo	zupo	NOUN
ajcp-4886	469	15	,	,	PUNCT
ajcp-4886	469	16	r.	r.	PROPN
ajcp-4886	469	17	,	,	PUNCT
ajcp-4886	469	18	castellana	castellana	PROPN
ajcp-4886	469	19	,	,	PUNCT
ajcp-4886	469	20	f.	f.	PROPN
ajcp-4886	469	21	,	,	PUNCT
ajcp-4886	469	22	leccisotti	leccisotti	PROPN
ajcp-4886	469	23	,	,	PUNCT
ajcp-4886	469	24	i.	i.	PROPN
ajcp-4886	469	25	,	,	PUNCT
ajcp-4886	469	26	moretti	moretti	PROPN
ajcp-4886	469	27	,	,	PUNCT
ajcp-4886	469	28	m.	m.	PROPN
ajcp-4886	469	29	c.	c.	PROPN
ajcp-4886	469	30	,	,	PUNCT
ajcp-4886	469	31	altamura	altamura	NOUN
ajcp-4886	469	32	,	,	PUNCT
ajcp-4886	469	33	m.	m.	NOUN
ajcp-4886	469	34	,	,	PUNCT
ajcp-4886	469	35	bellomo	bellomo	PROPN
ajcp-4886	469	36	,	,	PUNCT
ajcp-4886	469	37	a.	a.	PROPN
ajcp-4886	469	38	,	,	PUNCT
ajcp-4886	469	39	daniele	daniele	PROPN
ajcp-4886	469	40	,	,	PUNCT
ajcp-4886	469	41	a.	a.	NOUN
ajcp-4886	469	42	,	,	PUNCT
ajcp-4886	469	43	solfrizzi	solfrizzi	PROPN
ajcp-4886	469	44	,	,	PUNCT
ajcp-4886	469	45	v.	v.	ADV
ajcp-4886	469	46	,	,	PUNCT
ajcp-4886	469	47	resta	resta	PROPN
ajcp-4886	469	48	,	,	PUNCT
ajcp-4886	469	49	e.	e.	PROPN
ajcp-4886	469	50	,	,	PUNCT
ajcp-4886	469	51	&	&	CCONJ
ajcp-4886	469	52	lozupone	lozupone	NOUN
ajcp-4886	469	53	,	,	PUNCT
ajcp-4886	469	54	m.	m.	NOUN
ajcp-4886	469	55	(	(	PUNCT
ajcp-4886	469	56	2025	2025	NUM
ajcp-4886	469	57	)	)	PUNCT
ajcp-4886	469	58	.	.	PUNCT
ajcp-4886	470	1	successes	success	NOUN
ajcp-4886	470	2	and	and	CCONJ
ajcp-4886	470	3	failures	failure	NOUN
ajcp-4886	470	4	:	:	PUNCT
ajcp-4886	470	5	the	the	DET
ajcp-4886	470	6	latest	late	ADJ
ajcp-4886	470	7	advances	advance	NOUN
ajcp-4886	470	8	in	in	ADP
ajcp-4886	470	9	the	the	DET
ajcp-4886	470	10	clinical	clinical	ADJ
ajcp-4886	470	11	development	development	NOUN
ajcp-4886	470	12	of	of	ADP
ajcp-4886	470	13	amyloid	amyloid	NOUN
ajcp-4886	470	14	–	–	PUNCT
ajcp-4886	470	15	β	β	X
ajcp-4886	470	16	–	–	PUNCT
ajcp-4886	470	17	targeting	target	VERB
ajcp-4886	470	18	monoclonal	monoclonal	NOUN
ajcp-4886	470	19	antibodies	antibody	NOUN
ajcp-4886	470	20	for	for	ADP
ajcp-4886	470	21	treating	treat	VERB
ajcp-4886	470	22	alzheimer	alzheimer	PROPN
ajcp-4886	470	23	’s	’s	PART
ajcp-4886	470	24	disease	disease	NOUN
ajcp-4886	470	25	.	.	PUNCT
ajcp-4886	471	1	expert	expert	ADJ
ajcp-4886	471	2	opinion	opinion	NOUN
ajcp-4886	471	3	on	on	ADP
ajcp-4886	471	4	biological	biological	ADJ
ajcp-4886	471	5	therapy	therapy	NOUN
ajcp-4886	471	6	,	,	PUNCT
ajcp-4886	471	7	25(3	25(3	NUM
ajcp-4886	471	8	)	)	PUNCT
ajcp-4886	471	9	,	,	PUNCT
ajcp-4886	471	10	275283	275283	NUM
ajcp-4886	471	11	.	.	PUNCT
ajcp-4886	472	1	https://doi.org/10.1080/14712598.2025.24639	https://doi.org/10.1080/14712598.2025.24639	PROPN
ajcp-4886	472	2	63	63	NUM
ajcp-4886	472	3	peng	peng	PROPN
ajcp-4886	472	4	,	,	PUNCT
ajcp-4886	472	5	c.	c.	PROPN
ajcp-4886	472	6	,	,	PUNCT
ajcp-4886	472	7	wang	wang	PROPN
ajcp-4886	472	8	,	,	PUNCT
ajcp-4886	472	9	x.	x.	PROPN
ajcp-4886	472	10	,	,	PUNCT
ajcp-4886	472	11	li	li	PROPN
ajcp-4886	472	12	,	,	PUNCT
ajcp-4886	472	13	y.	y.	PROPN
ajcp-4886	472	14	,	,	PUNCT
ajcp-4886	472	15	li	li	PROPN
ajcp-4886	472	16	,	,	PUNCT
ajcp-4886	472	17	h.-w	h.-w	PROPN
ajcp-4886	472	18	.	.	PROPN
ajcp-4886	472	19	,	,	PUNCT
ajcp-4886	472	20	&	&	CCONJ
ajcp-4886	472	21	wong	wong	PROPN
ajcp-4886	472	22	,	,	PUNCT
ajcp-4886	472	23	m.	m.	PROPN
ajcp-4886	472	24	s.	s.	PROPN
ajcp-4886	472	25	(	(	PUNCT
ajcp-4886	472	26	2019	2019	NUM
ajcp-4886	472	27	)	)	PUNCT
ajcp-4886	472	28	.	.	PUNCT
ajcp-4886	473	1	versatile	versatile	ADJ
ajcp-4886	473	2	fluorescent	fluorescent	ADJ
ajcp-4886	473	3	probes	probe	NOUN
ajcp-4886	473	4	for	for	ADP
ajcp-4886	473	5	near	near	ADV
ajcp-4886	473	6	-	-	PUNCT
ajcp-4886	473	7	infrared	infrared	ADJ
ajcp-4886	473	8	imaging	imaging	NOUN
ajcp-4886	473	9	of	of	ADP
ajcp-4886	473	10	amyloid	amyloid	NOUN
ajcp-4886	473	11	-	-	PUNCT
ajcp-4886	473	12	β	β	NOUN
ajcp-4886	473	13	species	specie	NOUN
ajcp-4886	473	14	in	in	ADP
ajcp-4886	473	15	alzheimer	alzheimer	PROPN
ajcp-4886	473	16	’s	’s	PART
ajcp-4886	473	17	disease	disease	PROPN
ajcp-4886	473	18	mouse	mouse	PROPN
ajcp-4886	473	19	model	model	NOUN
ajcp-4886	473	20	.	.	PUNCT
ajcp-4886	474	1	journal	journal	NOUN
ajcp-4886	474	2	of	of	ADP
ajcp-4886	474	3	materials	material	NOUN
ajcp-4886	474	4	chemistry	chemistry	NOUN
ajcp-4886	474	5	b	b	NOUN
ajcp-4886	474	6	,	,	PUNCT
ajcp-4886	474	7	7(12	7(12	NUM
ajcp-4886	474	8	)	)	PUNCT
ajcp-4886	474	9	,	,	PUNCT
ajcp-4886	474	10	1986	1986	NUM
ajcp-4886	474	11	-	-	SYM
ajcp-4886	474	12	1995	1995	NUM
ajcp-4886	474	13	.	.	PUNCT
ajcp-4886	475	1	https://doi.org/10.1039/c9tb00161a	https://doi.org/10.1039/c9tb00161a	X
ajcp-4886	475	2	penke	penke	PROPN
ajcp-4886	475	3	,	,	PUNCT
ajcp-4886	475	4	b.	b.	PROPN
ajcp-4886	475	5	,	,	PUNCT
ajcp-4886	475	6	szűcs	szűcs	PROPN
ajcp-4886	475	7	,	,	PUNCT
ajcp-4886	475	8	m.	m.	NOUN
ajcp-4886	475	9	,	,	PUNCT
ajcp-4886	475	10	&	&	CCONJ
ajcp-4886	475	11	bogár	bogár	PROPN
ajcp-4886	475	12	,	,	PUNCT
ajcp-4886	475	13	f.	f.	PROPN
ajcp-4886	475	14	(	(	PUNCT
ajcp-4886	475	15	2020	2020	NUM
ajcp-4886	475	16	)	)	PUNCT
ajcp-4886	475	17	.	.	PUNCT
ajcp-4886	476	1	oligomerization	oligomerization	NOUN
ajcp-4886	476	2	and	and	CCONJ
ajcp-4886	476	3	conformational	conformational	ADJ
ajcp-4886	476	4	change	change	NOUN
ajcp-4886	476	5	turn	turn	VERB
ajcp-4886	476	6	monomeric	monomeric	ADJ
ajcp-4886	476	7	β	β	NOUN
ajcp-4886	476	8	-	-	NOUN
ajcp-4886	476	9	amyloid	amyloid	NOUN
ajcp-4886	476	10	and	and	CCONJ
ajcp-4886	476	11	tau	tau	PROPN
ajcp-4886	476	12	proteins	protein	NOUN
ajcp-4886	476	13	toxic	toxic	ADJ
ajcp-4886	476	14	:	:	PUNCT
ajcp-4886	476	15	their	their	PRON
ajcp-4886	476	16	role	role	NOUN
ajcp-4886	476	17	in	in	ADP
ajcp-4886	476	18	alzheimer	alzheimer	PROPN
ajcp-4886	476	19	’s	’s	PART
ajcp-4886	476	20	pathogenesis	pathogenesis	NOUN
ajcp-4886	476	21	.	.	PUNCT
ajcp-4886	477	1	molecules	molecule	NOUN
ajcp-4886	477	2	,	,	PUNCT
ajcp-4886	477	3	25(7	25(7	NUM
ajcp-4886	477	4	)	)	PUNCT
ajcp-4886	477	5	.	.	PUNCT
ajcp-4886	478	1	https://	https://	PROPN
ajcp-4886	478	2	doi.org/10.3390/molecules25071659	doi.org/10.3390/molecules25071659	PROPN
ajcp-4886	478	3	phan	phan	PROPN
ajcp-4886	478	4	,	,	PUNCT
ajcp-4886	478	5	h.	h.	PROPN
ajcp-4886	478	6	t.	t.	PROPN
ajcp-4886	478	7	t.	t.	PROPN
ajcp-4886	478	8	,	,	PUNCT
ajcp-4886	478	9	samarat	samarat	PROPN
ajcp-4886	478	10	,	,	PUNCT
ajcp-4886	478	11	k.	k.	PROPN
ajcp-4886	478	12	,	,	PUNCT
ajcp-4886	478	13	takamura	takamura	NOUN
ajcp-4886	478	14	,	,	PUNCT
ajcp-4886	478	15	y.	y.	PROPN
ajcp-4886	478	16	,	,	PUNCT
ajcp-4886	478	17	azooussou	azooussou	PROPN
ajcp-4886	478	18	,	,	PUNCT
ajcp-4886	478	19	a.	a.	PROPN
ajcp-4886	478	20	f.	f.	PROPN
ajcp-4886	478	21	,	,	PUNCT
ajcp-4886	478	22	nakazono	nakazono	PROPN
ajcp-4886	478	23	,	,	PUNCT
ajcp-4886	478	24	y.	y.	PROPN
ajcp-4886	478	25	,	,	PUNCT
ajcp-4886	478	26	&	&	CCONJ
ajcp-4886	478	27	vestergaard	vestergaard	ADJ
ajcp-4886	478	28	,	,	PUNCT
ajcp-4886	478	29	m.	m.	PROPN
ajcp-4886	478	30	d.	d.	PROPN
ajcp-4886	478	31	c.	c.	PROPN
ajcp-4886	478	32	(	(	PUNCT
ajcp-4886	478	33	2019	2019	NUM
ajcp-4886	478	34	)	)	PUNCT
ajcp-4886	478	35	.	.	PUNCT
ajcp-4886	479	1	polyphenols	polyphenol	NOUN
ajcp-4886	479	2	modulate	modulate	VERB
ajcp-4886	479	3	alzheimer	alzheimer	PROPN
ajcp-4886	479	4	’s	’s	PART
ajcp-4886	479	5	amyloid	amyloid	NOUN
ajcp-4886	479	6	beta	beta	NOUN
ajcp-4886	479	7	aggregation	aggregation	NOUN
ajcp-4886	479	8	in	in	ADP
ajcp-4886	479	9	a	a	DET
ajcp-4886	479	10	structure	structure	NOUN
ajcp-4886	479	11	-	-	PUNCT
ajcp-4886	479	12	dependent	dependent	ADJ
ajcp-4886	479	13	manner	manner	NOUN
ajcp-4886	479	14	.	.	PUNCT
ajcp-4886	480	1	nutrients	nutrient	NOUN
ajcp-4886	480	2	,	,	PUNCT
ajcp-4886	480	3	11(4	11(4	NUM
ajcp-4886	480	4	)	)	PUNCT
ajcp-4886	480	5	.	.	PUNCT
ajcp-4886	481	1	https://doi.org/10.3390/	https://doi.org/10.3390/	PROPN
ajcp-4886	481	2	nu11040756	nu11040756	PROPN
ajcp-4886	481	3	rana	rana	PROPN
ajcp-4886	481	4	,	,	PUNCT
ajcp-4886	481	5	m.	m.	NOUN
ajcp-4886	481	6	,	,	PUNCT
ajcp-4886	481	7	&	&	CCONJ
ajcp-4886	481	8	sharma	sharma	PROPN
ajcp-4886	481	9	,	,	PUNCT
ajcp-4886	481	10	a.	a.	PROPN
ajcp-4886	481	11	k.	k.	PROPN
ajcp-4886	481	12	(	(	PUNCT
ajcp-4886	481	13	2019	2019	NUM
ajcp-4886	481	14	)	)	PUNCT
ajcp-4886	481	15	.	.	PUNCT
ajcp-4886	482	1	cu	cu	PROPN
ajcp-4886	482	2	and	and	CCONJ
ajcp-4886	482	3	zn	zn	NOUN
ajcp-4886	482	4	interactions	interaction	NOUN
ajcp-4886	482	5	with	with	ADP
ajcp-4886	482	6	aβ	aβ	NOUN
ajcp-4886	482	7	peptides	peptide	NOUN
ajcp-4886	482	8	:	:	PUNCT
ajcp-4886	482	9	consequence	consequence	NOUN
ajcp-4886	482	10	of	of	ADP
ajcp-4886	482	11	coordination	coordination	NOUN
ajcp-4886	482	12	on	on	ADP
ajcp-4886	482	13	aggregation	aggregation	NOUN
ajcp-4886	482	14	and	and	CCONJ
ajcp-4886	482	15	formation	formation	NOUN
ajcp-4886	482	16	of	of	ADP
ajcp-4886	482	17	neurotoxic	neurotoxic	ADJ
ajcp-4886	482	18	soluble	soluble	ADJ
ajcp-4886	482	19	aβ	aβ	NOUN
ajcp-4886	482	20	oligomers	oligomer	NOUN
ajcp-4886	482	21	.	.	PUNCT
ajcp-4886	483	1	metallomics	metallomic	NOUN
ajcp-4886	483	2	,	,	PUNCT
ajcp-4886	483	3	11(1	11(1	NUM
ajcp-4886	483	4	)	)	PUNCT
ajcp-4886	483	5	,	,	PUNCT
ajcp-4886	483	6	64	64	NUM
ajcp-4886	483	7	-	-	SYM
ajcp-4886	483	8	84	84	NUM
ajcp-4886	483	9	.	.	PUNCT
ajcp-4886	484	1	https://doi	https://doi	X
ajcp-4886	484	2	.	.	PUNCT
ajcp-4886	485	1	org/10.1039	org/10.1039	NOUN
ajcp-4886	485	2	/	/	SYM
ajcp-4886	485	3	c8mt00203	c8mt00203	PROPN
ajcp-4886	485	4	g	g	NOUN
ajcp-4886	485	5	rostami	rostami	NOUN
ajcp-4886	485	6	,	,	PUNCT
ajcp-4886	485	7	j.	j.	PROPN
ajcp-4886	485	8	,	,	PUNCT
ajcp-4886	485	9	mothes	mothe	NOUN
ajcp-4886	485	10	,	,	PUNCT
ajcp-4886	485	11	t.	t.	PROPN
ajcp-4886	485	12	,	,	PUNCT
ajcp-4886	485	13	kolahdouzan	kolahdouzan	PROPN
ajcp-4886	485	14	,	,	PUNCT
ajcp-4886	485	15	m.	m.	NOUN
ajcp-4886	485	16	,	,	PUNCT
ajcp-4886	485	17	eriksson	eriksson	PROPN
ajcp-4886	485	18	,	,	PUNCT
ajcp-4886	485	19	o.	o.	PROPN
ajcp-4886	485	20	,	,	PUNCT
ajcp-4886	485	21	moslem	moslem	PROPN
ajcp-4886	485	22	,	,	PUNCT
ajcp-4886	485	23	m.	m.	NOUN
ajcp-4886	485	24	,	,	PUNCT
ajcp-4886	485	25	bergström	bergström	NOUN
ajcp-4886	485	26	,	,	PUNCT
ajcp-4886	485	27	j.	j.	PROPN
ajcp-4886	485	28	,	,	PUNCT
ajcp-4886	485	29	ingelsson	ingelsson	PROPN
ajcp-4886	485	30	,	,	PUNCT
ajcp-4886	485	31	m.	m.	NOUN
ajcp-4886	485	32	,	,	PUNCT
ajcp-4886	485	33	o’callaghan	o’callaghan	PROPN
ajcp-4886	485	34	,	,	PUNCT
ajcp-4886	485	35	p.	p.	PROPN
ajcp-4886	485	36	,	,	PUNCT
ajcp-4886	485	37	healy	healy	PROPN
ajcp-4886	485	38	,	,	PUNCT
ajcp-4886	485	39	l.	l.	PROPN
ajcp-4886	485	40	m.	m.	PROPN
ajcp-4886	485	41	,	,	PUNCT
ajcp-4886	485	42	falk	falk	NOUN
ajcp-4886	485	43	,	,	PUNCT
ajcp-4886	485	44	a.	a.	PROPN
ajcp-4886	485	45	,	,	PUNCT
ajcp-4886	485	46	&	&	CCONJ
ajcp-4886	485	47	erlandsson	erlandsson	PROPN
ajcp-4886	485	48	,	,	PUNCT
ajcp-4886	485	49	a.	a.	NOUN
ajcp-4886	485	50	(	(	PUNCT
ajcp-4886	485	51	2021	2021	NUM
ajcp-4886	485	52	)	)	PUNCT
ajcp-4886	485	53	.	.	PUNCT
ajcp-4886	486	1	crosstalk	crosstalk	VERB
ajcp-4886	486	2	between	between	ADP
ajcp-4886	486	3	astrocytes	astrocyte	NOUN
ajcp-4886	486	4	and	and	CCONJ
ajcp-4886	486	5	microglia	microglia	ADJ
ajcp-4886	486	6	results	result	NOUN
ajcp-4886	486	7	in	in	ADP
ajcp-4886	486	8	increased	increase	VERB
ajcp-4886	486	9	degradation	degradation	NOUN
ajcp-4886	486	10	of	of	ADP
ajcp-4886	486	11	α	α	NOUN
ajcp-4886	486	12	-	-	PUNCT
ajcp-4886	486	13	synuclein	synuclein	NOUN
ajcp-4886	486	14	and	and	CCONJ
ajcp-4886	486	15	amyloid	amyloid	NOUN
ajcp-4886	486	16	-	-	PUNCT
ajcp-4886	486	17	β	β	NOUN
ajcp-4886	486	18	aggregates	aggregate	NOUN
ajcp-4886	486	19	.	.	PUNCT
ajcp-4886	487	1	journal	journal	NOUN
ajcp-4886	487	2	of	of	ADP
ajcp-4886	487	3	neuroinflammation	neuroinflammation	NOUN
ajcp-4886	487	4	,	,	PUNCT
ajcp-4886	487	5	18(1	18(1	NUM
ajcp-4886	487	6	)	)	PUNCT
ajcp-4886	487	7	.	.	PUNCT
ajcp-4886	488	1	https://doi.org/10.1186/s12974-021-02158-3	https://doi.org/10.1186/s12974-021-02158-3	PROPN
ajcp-4886	488	2	russ	russ	PROPN
ajcp-4886	488	3	,	,	PUNCT
ajcp-4886	488	4	h.	h.	PROPN
ajcp-4886	488	5	,	,	PUNCT
ajcp-4886	488	6	mazzanti	mazzanti	PROPN
ajcp-4886	488	7	,	,	PUNCT
ajcp-4886	488	8	m.	m.	NOUN
ajcp-4886	488	9	,	,	PUNCT
ajcp-4886	488	10	parsons	parson	NOUN
ajcp-4886	488	11	,	,	PUNCT
ajcp-4886	488	12	c.	c.	PROPN
ajcp-4886	488	13	,	,	PUNCT
ajcp-4886	488	14	riemann	riemann	PROPN
ajcp-4886	488	15	,	,	PUNCT
ajcp-4886	488	16	k.	k.	PROPN
ajcp-4886	488	17	,	,	PUNCT
ajcp-4886	488	18	gebauer	gebauer	PROPN
ajcp-4886	488	19	,	,	PUNCT
ajcp-4886	488	20	a.	a.	PROPN
ajcp-4886	488	21	,	,	PUNCT
ajcp-4886	488	22	&	&	CCONJ
ajcp-4886	488	23	rammes	ramme	NOUN
ajcp-4886	488	24	,	,	PUNCT
ajcp-4886	488	25	g.	g.	PROPN
ajcp-4886	488	26	(	(	PUNCT
ajcp-4886	488	27	2022	2022	NUM
ajcp-4886	488	28	)	)	PUNCT
ajcp-4886	488	29	.	.	PUNCT
ajcp-4886	489	1	the	the	DET
ajcp-4886	489	2	small	small	ADJ
ajcp-4886	489	3	molecule	molecule	NOUN
ajcp-4886	489	4	gal-201	gal-201	VERB
ajcp-4886	489	5	efficiently	efficiently	ADV
ajcp-4886	489	6	detoxifies	detoxifie	NOUN
ajcp-4886	489	7	soluble	soluble	ADJ
ajcp-4886	489	8	amyloid	amyloid	NOUN
ajcp-4886	489	9	β	β	X
ajcp-4886	489	10	oligomers	oligomer	NOUN
ajcp-4886	489	11	:	:	PUNCT
ajcp-4886	489	12	new	new	ADJ
ajcp-4886	489	13	approach	approach	NOUN
ajcp-4886	489	14	towards	towards	ADP
ajcp-4886	489	15	oral	oral	ADJ
ajcp-4886	489	16	disease	disease	NOUN
ajcp-4886	489	17	-	-	PUNCT
ajcp-4886	489	18	modifying	modify	VERB
ajcp-4886	489	19	treatment	treatment	NOUN
ajcp-4886	489	20	of	of	ADP
ajcp-4886	489	21	alzheimer	alzheimer	PROPN
ajcp-4886	489	22	’s	’s	PART
ajcp-4886	489	23	disease	disease	NOUN
ajcp-4886	489	24	.	.	PUNCT
ajcp-4886	490	1	international	international	ADJ
ajcp-4886	490	2	journal	journal	NOUN
ajcp-4886	490	3	of	of	ADP
ajcp-4886	490	4	molecular	molecular	ADJ
ajcp-4886	490	5	sciences	science	NOUN
ajcp-4886	490	6	,	,	PUNCT
ajcp-4886	490	7	23(10	23(10	NUM
ajcp-4886	490	8	)	)	PUNCT
ajcp-4886	490	9	.	.	PUNCT
ajcp-4886	491	1	https://doi.org/10.3390/ijms23105794	https://doi.org/10.3390/ijms23105794	PROPN
ajcp-4886	491	2	saha	saha	PROPN
ajcp-4886	491	3	,	,	PUNCT
ajcp-4886	491	4	d.	d.	PROPN
ajcp-4886	491	5	,	,	PUNCT
ajcp-4886	491	6	&	&	CCONJ
ajcp-4886	491	7	jana	jana	PROPN
ajcp-4886	491	8	,	,	PUNCT
ajcp-4886	491	9	b.	b.	PROPN
ajcp-4886	491	10	(	(	PUNCT
ajcp-4886	491	11	2022	2022	NUM
ajcp-4886	491	12	)	)	PUNCT
ajcp-4886	491	13	.	.	PUNCT
ajcp-4886	492	1	identifying	identify	VERB
ajcp-4886	492	2	the	the	DET
ajcp-4886	492	3	template	template	NOUN
ajcp-4886	492	4	for	for	ADP
ajcp-4886	492	5	oligomer	oligomer	ADJ
ajcp-4886	492	6	to	to	PART
ajcp-4886	492	7	fibril	fibril	VERB
ajcp-4886	492	8	conversion	conversion	NOUN
ajcp-4886	492	9	for	for	ADP
ajcp-4886	492	10	amyloid‐β	amyloid‐β	NOUN
ajcp-4886	492	11	(	(	PUNCT
ajcp-4886	492	12	1‐42	1‐42	NUM
ajcp-4886	492	13	)	)	PUNCT
ajcp-4886	492	14	oligomers	oligomer	NOUN
ajcp-4886	492	15	using	use	VERB
ajcp-4886	492	16	hamiltonian	hamiltonian	ADJ
ajcp-4886	492	17	replica	replica	NOUN
ajcp-4886	492	18	exchange	exchange	NOUN
ajcp-4886	492	19	molecular	molecular	ADJ
ajcp-4886	492	20	dynamics	dynamic	NOUN
ajcp-4886	492	21	.	.	PUNCT
ajcp-4886	493	1	chemphyschem	chemphyschem	NOUN
ajcp-4886	493	2	,	,	PUNCT
ajcp-4886	493	3	23(24	23(24	PROPN
ajcp-4886	493	4	)	)	PUNCT
ajcp-4886	493	5	.	.	PUNCT
ajcp-4886	494	1	https://	https://	PROPN
ajcp-4886	494	2	doi.org/10.1002/cphc.202200393	doi.org/10.1002/cphc.202200393	PROPN
ajcp-4886	494	3	sahoo	sahoo	PROPN
ajcp-4886	494	4	,	,	PUNCT
ajcp-4886	494	5	b.	b.	PROPN
ajcp-4886	494	6	r.	r.	PROPN
ajcp-4886	494	7	,	,	PUNCT
ajcp-4886	494	8	panda	panda	NOUN
ajcp-4886	494	9	,	,	PUNCT
ajcp-4886	494	10	p.	p.	PROPN
ajcp-4886	494	11	k.	k.	PROPN
ajcp-4886	494	12	,	,	PUNCT
ajcp-4886	494	13	liang	liang	PROPN
ajcp-4886	494	14	,	,	PUNCT
ajcp-4886	494	15	w.	w.	PROPN
ajcp-4886	494	16	,	,	PUNCT
ajcp-4886	494	17	tang	tang	PROPN
ajcp-4886	494	18	,	,	PUNCT
ajcp-4886	494	19	w.-j	w.-j	PROPN
ajcp-4886	494	20	.	.	PROPN
ajcp-4886	494	21	,	,	PUNCT
ajcp-4886	494	22	ahuja	ahuja	PROPN
ajcp-4886	494	23	,	,	PUNCT
ajcp-4886	494	24	r.	r.	PROPN
ajcp-4886	494	25	,	,	PUNCT
ajcp-4886	494	26	&	&	CCONJ
ajcp-4886	494	27	ramamoorthy	ramamoorthy	ADJ
ajcp-4886	494	28	,	,	PUNCT
ajcp-4886	494	29	a.	a.	NOUN
ajcp-4886	494	30	(	(	PUNCT
ajcp-4886	494	31	2021	2021	NUM
ajcp-4886	494	32	)	)	PUNCT
ajcp-4886	494	33	.	.	PUNCT
ajcp-4886	495	1	degradation	degradation	NOUN
ajcp-4886	495	2	of	of	ADP
ajcp-4886	495	3	alzheimer	alzheimer	PROPN
ajcp-4886	495	4	’s	’s	PART
ajcp-4886	495	5	amyloid	amyloid	NOUN
ajcp-4886	495	6	-	-	PUNCT
ajcp-4886	495	7	β	β	NOUN
ajcp-4886	495	8	by	by	ADP
ajcp-4886	495	9	a	a	DET
ajcp-4886	495	10	catalytically	catalytically	ADV
ajcp-4886	495	11	inactive	inactive	ADJ
ajcp-4886	495	12	insulin	insulin	NOUN
ajcp-4886	495	13	-	-	PUNCT
ajcp-4886	495	14	degrading	degrade	VERB
ajcp-4886	495	15	enzyme	enzyme	NOUN
ajcp-4886	495	16	.	.	PUNCT
ajcp-4886	496	1	journal	journal	NOUN
ajcp-4886	496	2	of	of	ADP
ajcp-4886	496	3	molecular	molecular	ADJ
ajcp-4886	496	4	biology	biology	NOUN
ajcp-4886	496	5	,	,	PUNCT
ajcp-4886	496	6	433(13	433(13	NUM
ajcp-4886	496	7	)	)	PUNCT
ajcp-4886	496	8	.	.	PUNCT
ajcp-4886	497	1	https://doi.org/10.1016/j.jmb.2021.166993	https://doi.org/10.1016/j.jmb.2021.166993	PROPN
ajcp-4886	497	2	savastano	savastano	NOUN
ajcp-4886	497	3	,	,	PUNCT
ajcp-4886	497	4	a.	a.	PROPN
ajcp-4886	497	5	,	,	PUNCT
ajcp-4886	497	6	flores	flores	PROPN
ajcp-4886	497	7	,	,	PUNCT
ajcp-4886	497	8	d.	d.	PROPN
ajcp-4886	497	9	,	,	PUNCT
ajcp-4886	497	10	kadavath	kadavath	PROPN
ajcp-4886	497	11	,	,	PUNCT
ajcp-4886	497	12	h.	h.	PROPN
ajcp-4886	497	13	,	,	PUNCT
ajcp-4886	497	14	biernat	biernat	PROPN
ajcp-4886	497	15	,	,	PUNCT
ajcp-4886	497	16	j.	j.	PROPN
ajcp-4886	497	17	,	,	PUNCT
ajcp-4886	497	18	mandelkow	mandelkow	PROPN
ajcp-4886	497	19	,	,	PUNCT
ajcp-4886	497	20	e.	e.	PROPN
ajcp-4886	497	21	,	,	PUNCT
ajcp-4886	497	22	&	&	CCONJ
ajcp-4886	497	23	zweckstetter	zweckstetter	PROPN
ajcp-4886	497	24	,	,	PUNCT
ajcp-4886	497	25	m.	m.	NOUN
ajcp-4886	497	26	(	(	PUNCT
ajcp-4886	497	27	2020	2020	NUM
ajcp-4886	497	28	)	)	PUNCT
ajcp-4886	497	29	.	.	PUNCT
ajcp-4886	498	1	disease‐	disease‐	PRON
ajcp-4886	498	2	associated	associate	VERB
ajcp-4886	498	3	tau	tau	PROPN
ajcp-4886	498	4	phosphorylation	phosphorylation	NOUN
ajcp-4886	498	5	hinders	hinder	VERB
ajcp-4886	498	6	tubulin	tubulin	NOUN
ajcp-4886	498	7	assembly	assembly	NOUN
ajcp-4886	498	8	within	within	ADP
ajcp-4886	498	9	tau	tau	PROPN
ajcp-4886	498	10	condensates	condensate	NOUN
ajcp-4886	498	11	.	.	PUNCT
ajcp-4886	499	1	angewandte	angewandte	PROPN
ajcp-4886	499	2	chemie	chemie	PROPN
ajcp-4886	499	3	international	international	PROPN
ajcp-4886	499	4	edition	edition	PROPN
ajcp-4886	499	5	,	,	PUNCT
ajcp-4886	499	6	60(2	60(2	NUM
ajcp-4886	499	7	)	)	PUNCT
ajcp-4886	499	8	,	,	PUNCT
ajcp-4886	499	9	726	726	NUM
ajcp-4886	499	10	-	-	SYM
ajcp-4886	499	11	730	730	NUM
ajcp-4886	499	12	.	.	PUNCT
ajcp-4886	500	1	https://	https://	PROPN
ajcp-4886	500	2	doi.org/10.1002/anie.202011157	doi.org/10.1002/anie.202011157	NOUN
ajcp-4886	500	3	sehar	sehar	PROPN
ajcp-4886	500	4	,	,	PUNCT
ajcp-4886	500	5	u.	u.	PROPN
ajcp-4886	500	6	,	,	PUNCT
ajcp-4886	500	7	rawat	rawat	PROPN
ajcp-4886	500	8	,	,	PUNCT
ajcp-4886	500	9	p.	p.	PROPN
ajcp-4886	500	10	,	,	PUNCT
ajcp-4886	500	11	reddy	reddy	PROPN
ajcp-4886	500	12	,	,	PUNCT
ajcp-4886	500	13	a.	a.	NOUN
ajcp-4886	500	14	p.	p.	PROPN
ajcp-4886	500	15	,	,	PUNCT
ajcp-4886	500	16	kopel	kopel	PROPN
ajcp-4886	500	17	,	,	PUNCT
ajcp-4886	500	18	j.	j.	PROPN
ajcp-4886	500	19	,	,	PUNCT
ajcp-4886	500	20	&	&	CCONJ
ajcp-4886	500	21	reddy	reddy	PROPN
ajcp-4886	500	22	,	,	PUNCT
ajcp-4886	500	23	p.	p.	NOUN
ajcp-4886	500	24	h.	h.	PROPN
ajcp-4886	501	1	(	(	PUNCT
ajcp-4886	501	2	2022	2022	NUM
ajcp-4886	501	3	)	)	PUNCT
ajcp-4886	501	4	.	.	PUNCT
ajcp-4886	502	1	amyloid	amyloid	NOUN
ajcp-4886	502	2	beta	beta	NOUN
ajcp-4886	502	3	in	in	ADP
ajcp-4886	502	4	aging	aging	NOUN
ajcp-4886	502	5	and	and	CCONJ
ajcp-4886	502	6	alzheimer	alzheimer	PROPN
ajcp-4886	502	7	’s	’s	PART
ajcp-4886	502	8	disease	disease	NOUN
ajcp-4886	502	9	.	.	PUNCT
ajcp-4886	503	1	international	international	ADJ
ajcp-4886	503	2	journal	journal	NOUN
ajcp-4886	503	3	of	of	ADP
ajcp-4886	503	4	molecular	molecular	ADJ
ajcp-4886	503	5	sciences	science	NOUN
ajcp-4886	503	6	,	,	PUNCT
ajcp-4886	503	7	23(21	23(21	NUM
ajcp-4886	503	8	)	)	PUNCT
ajcp-4886	503	9	.	.	PUNCT
ajcp-4886	504	1	https://doi.org/10.3390/ijms232112924	https://doi.org/10.3390/ijms232112924	PROPN
ajcp-4886	504	2	senapati	senapati	PROPN
ajcp-4886	504	3	,	,	PUNCT
ajcp-4886	504	4	s.	s.	PROPN
ajcp-4886	504	5	,	,	PUNCT
ajcp-4886	504	6	secchi	secchi	PROPN
ajcp-4886	504	7	,	,	PUNCT
ajcp-4886	504	8	v.	v.	PROPN
ajcp-4886	504	9	,	,	PUNCT
ajcp-4886	504	10	cova	cova	PROPN
ajcp-4886	504	11	,	,	PUNCT
ajcp-4886	504	12	f.	f.	PROPN
ajcp-4886	504	13	,	,	PUNCT
ajcp-4886	504	14	richman	richman	PROPN
ajcp-4886	504	15	,	,	PUNCT
ajcp-4886	504	16	m.	m.	NOUN
ajcp-4886	504	17	,	,	PUNCT
ajcp-4886	504	18	villa	villa	PROPN
ajcp-4886	504	19	,	,	PUNCT
ajcp-4886	504	20	i.	i.	PROPN
ajcp-4886	504	21	,	,	PUNCT
ajcp-4886	504	22	yehuda	yehuda	PROPN
ajcp-4886	504	23	,	,	PUNCT
ajcp-4886	504	24	r.	r.	PROPN
ajcp-4886	504	25	,	,	PUNCT
ajcp-4886	504	26	shenberger	shenberger	NOUN
ajcp-4886	504	27	,	,	PUNCT
ajcp-4886	504	28	y.	y.	PROPN
ajcp-4886	504	29	,	,	PUNCT
ajcp-4886	504	30	campione	campione	NOUN
ajcp-4886	504	31	,	,	PUNCT
ajcp-4886	504	32	m.	m.	NOUN
ajcp-4886	504	33	,	,	PUNCT
ajcp-4886	504	34	rahimipour	rahimipour	NOUN
ajcp-4886	504	35	,	,	PUNCT
ajcp-4886	504	36	s.	s.	PROPN
ajcp-4886	504	37	,	,	PUNCT
ajcp-4886	504	38	&	&	CCONJ
ajcp-4886	504	39	monguzzi	monguzzi	PROPN
ajcp-4886	504	40	,	,	PUNCT
ajcp-4886	504	41	a.	a.	NOUN
ajcp-4886	504	42	(	(	PUNCT
ajcp-4886	504	43	2023	2023	NUM
ajcp-4886	504	44	)	)	PUNCT
ajcp-4886	504	45	.	.	PUNCT
ajcp-4886	505	1	noninvasive	noninvasive	ADJ
ajcp-4886	505	2	treatment	treatment	NOUN
ajcp-4886	505	3	of	of	ADP
ajcp-4886	505	4	alzheimer	alzheimer	PROPN
ajcp-4886	505	5	’s	’s	PART
ajcp-4886	505	6	disease	disease	NOUN
ajcp-4886	505	7	with	with	ADP
ajcp-4886	505	8	scintillating	scintillating	ADJ
ajcp-4886	505	9	nanotubes	nanotube	NOUN
ajcp-4886	505	10	.	.	PUNCT
ajcp-4886	506	1	advanced	advanced	ADJ
ajcp-4886	506	2	healthcare	healthcare	NOUN
ajcp-4886	506	3	materials	material	NOUN
ajcp-4886	506	4	,	,	PUNCT
ajcp-4886	506	5	12(32	12(32	NUM
ajcp-4886	506	6	)	)	PUNCT
ajcp-4886	506	7	.	.	PUNCT
ajcp-4886	507	1	https://doi.org/10.1002/adhm.202301527	https://doi.org/10.1002/adhm.202301527	PROPN
ajcp-4886	507	2	sharari	sharari	PROPN
ajcp-4886	507	3	,	,	PUNCT
ajcp-4886	507	4	s.	s.	PROPN
ajcp-4886	507	5	,	,	PUNCT
ajcp-4886	507	6	vaikath	vaikath	NOUN
ajcp-4886	507	7	,	,	PUNCT
ajcp-4886	507	8	n.	n.	PROPN
ajcp-4886	507	9	n.	n.	PROPN
ajcp-4886	507	10	,	,	PUNCT
ajcp-4886	507	11	tsakou	tsakou	PROPN
ajcp-4886	507	12	,	,	PUNCT
ajcp-4886	507	13	m.	m.	NOUN
ajcp-4886	507	14	,	,	PUNCT
ajcp-4886	507	15	ghanem	ghanem	PROPN
ajcp-4886	507	16	,	,	PUNCT
ajcp-4886	507	17	s.	s.	PROPN
ajcp-4886	507	18	s.	s.	PROPN
ajcp-4886	507	19	,	,	PUNCT
ajcp-4886	507	20	&	&	CCONJ
ajcp-4886	507	21	vekrellis	vekrellis	PROPN
ajcp-4886	507	22	,	,	PUNCT
ajcp-4886	507	23	k.	k.	PROPN
ajcp-4886	507	24	(	(	PUNCT
ajcp-4886	507	25	2023	2023	NUM
ajcp-4886	507	26	)	)	PUNCT
ajcp-4886	507	27	.	.	PUNCT
ajcp-4886	508	1	screening	screen	VERB
ajcp-4886	508	2	for	for	ADP
ajcp-4886	508	3	novel	novel	ADJ
ajcp-4886	508	4	inhibitors	inhibitor	NOUN
ajcp-4886	508	5	of	of	ADP
ajcp-4886	508	6	amyloid	amyloid	NOUN
ajcp-4886	508	7	beta	beta	NOUN
ajcp-4886	508	8	aggregation	aggregation	NOUN
ajcp-4886	508	9	and	and	CCONJ
ajcp-4886	508	10	toxicity	toxicity	NOUN
ajcp-4886	508	11	as	as	ADP
ajcp-4886	508	12	potential	potential	ADJ
ajcp-4886	508	13	drugs	drug	NOUN
ajcp-4886	508	14	for	for	ADP
ajcp-4886	508	15	alzheimer	alzheimer	PROPN
ajcp-4886	508	16	’s	’s	PART
ajcp-4886	508	17	disease	disease	NOUN
ajcp-4886	508	18	.	.	PUNCT
ajcp-4886	509	1	international	international	ADJ
ajcp-4886	509	2	journal	journal	NOUN
ajcp-4886	509	3	of	of	ADP
ajcp-4886	509	4	molecular	molecular	ADJ
ajcp-4886	509	5	sciences	science	NOUN
ajcp-4886	509	6	,	,	PUNCT
ajcp-4886	509	7	24(14	24(14	NOUN
ajcp-4886	509	8	)	)	PUNCT
ajcp-4886	509	9	.	.	PUNCT
ajcp-4886	510	1	https://doi.org/10.3390/	https://doi.org/10.3390/	PROPN
ajcp-4886	510	2	ijms241411326	ijms241411326	PROPN
ajcp-4886	510	3	shin	shin	NOUN
ajcp-4886	510	4	,	,	PUNCT
ajcp-4886	510	5	y.	y.	PROPN
ajcp-4886	510	6	,	,	PUNCT
ajcp-4886	510	7	berry	berry	PROPN
ajcp-4886	510	8	,	,	PUNCT
ajcp-4886	510	9	j.	j.	PROPN
ajcp-4886	510	10	,	,	PUNCT
ajcp-4886	510	11	pannucci	pannucci	PROPN
ajcp-4886	510	12	,	,	PUNCT
ajcp-4886	510	13	n.	n.	NOUN
ajcp-4886	510	14	,	,	PUNCT
ajcp-4886	510	15	haataja	haataja	PROPN
ajcp-4886	510	16	,	,	PUNCT
ajcp-4886	510	17	m.	m.	NOUN
ajcp-4886	510	18	p.	p.	PROPN
ajcp-4886	510	19	,	,	PUNCT
ajcp-4886	510	20	toettcher	toettcher	PROPN
ajcp-4886	510	21	,	,	PUNCT
ajcp-4886	510	22	j.	j.	PROPN
ajcp-4886	510	23	e.	e.	PROPN
ajcp-4886	510	24	,	,	PUNCT
ajcp-4886	510	25	&	&	CCONJ
ajcp-4886	510	26	brangwynne	brangwynne	PROPN
ajcp-4886	510	27	,	,	PUNCT
ajcp-4886	510	28	c.	c.	PROPN
ajcp-4886	510	29	p.	p.	PROPN
ajcp-4886	510	30	(	(	PUNCT
ajcp-4886	510	31	2017	2017	NUM
ajcp-4886	510	32	)	)	PUNCT
ajcp-4886	510	33	.	.	PUNCT
ajcp-4886	511	1	spatiotemporal	spatiotemporal	ADJ
ajcp-4886	511	2	control	control	NOUN
ajcp-4886	511	3	of	of	ADP
ajcp-4886	511	4	intracellular	intracellular	ADJ
ajcp-4886	511	5	phase	phase	NOUN
ajcp-4886	511	6	transitions	transition	NOUN
ajcp-4886	511	7	using	use	VERB
ajcp-4886	511	8	light	light	ADJ
ajcp-4886	511	9	-	-	PUNCT
ajcp-4886	511	10	activated	activate	VERB
ajcp-4886	511	11	optodroplets	optodroplet	NOUN
ajcp-4886	511	12	.	.	PUNCT
ajcp-4886	512	1	cell	cell	NOUN
ajcp-4886	512	2	,	,	PUNCT
ajcp-4886	512	3	168(1	168(1	NUM
ajcp-4886	512	4	-	-	SYM
ajcp-4886	512	5	2	2	NUM
ajcp-4886	512	6	)	)	PUNCT
ajcp-4886	512	7	,	,	PUNCT
ajcp-4886	512	8	159171.e114	159171.e114	NUM
ajcp-4886	512	9	.	.	PUNCT
ajcp-4886	513	1	https://doi.org/10.1016/j.cell.2016.11.054	https://doi.org/10.1016/j.cell.2016.11.054	ADJ
ajcp-4886	513	2	sikanyika	sikanyika	NOUN
ajcp-4886	513	3	,	,	PUNCT
ajcp-4886	513	4	n.	n.	PROPN
ajcp-4886	513	5	l.	l.	PROPN
ajcp-4886	513	6	,	,	PUNCT
ajcp-4886	513	7	parkington	parkington	PROPN
ajcp-4886	513	8	,	,	PUNCT
ajcp-4886	513	9	h.	h.	PROPN
ajcp-4886	513	10	c.	c.	PROPN
ajcp-4886	513	11	,	,	PUNCT
ajcp-4886	513	12	smith	smith	PROPN
ajcp-4886	513	13	,	,	PUNCT
ajcp-4886	513	14	a.	a.	NOUN
ajcp-4886	513	15	i.	i.	PROPN
ajcp-4886	513	16	,	,	PUNCT
ajcp-4886	513	17	&	&	CCONJ
ajcp-4886	513	18	kuruppu	kuruppu	PROPN
ajcp-4886	513	19	,	,	PUNCT
ajcp-4886	513	20	s.	s.	PROPN
ajcp-4886	513	21	(	(	PUNCT
ajcp-4886	513	22	2019	2019	NUM
ajcp-4886	513	23	)	)	PUNCT
ajcp-4886	513	24	.	.	PUNCT
ajcp-4886	514	1	powering	power	VERB
ajcp-4886	514	2	amyloid	amyloid	NOUN
ajcp-4886	514	3	beta	beta	ADJ
ajcp-4886	514	4	degrading	degrade	VERB
ajcp-4886	514	5	enzymes	enzyme	NOUN
ajcp-4886	514	6	:	:	PUNCT
ajcp-4886	514	7	a	a	DET
ajcp-4886	514	8	possible	possible	ADJ
ajcp-4886	514	9	therapy	therapy	NOUN
ajcp-4886	514	10	for	for	ADP
ajcp-4886	514	11	alzheimer	alzheimer	PROPN
ajcp-4886	514	12	’s	’s	PART
ajcp-4886	514	13	disease	disease	NOUN
ajcp-4886	514	14	.	.	PUNCT
ajcp-4886	515	1	neurochemical	neurochemical	ADJ
ajcp-4886	515	2	research	research	NOUN
ajcp-4886	515	3	,	,	PUNCT
ajcp-4886	515	4	44(6	44(6	NOUN
ajcp-4886	515	5	)	)	PUNCT
ajcp-4886	515	6	,	,	PUNCT
ajcp-4886	515	7	1289	1289	NUM
ajcp-4886	515	8	-	-	SYM
ajcp-4886	515	9	1296	1296	NUM
ajcp-4886	515	10	.	.	PUNCT
ajcp-4886	516	1	https://doi.org/10.1007/s11064-01902756-x	https://doi.org/10.1007/s11064-01902756-x	PROPN
ajcp-4886	516	2	song	song	NOUN
ajcp-4886	516	3	,	,	PUNCT
ajcp-4886	516	4	c.	c.	PROPN
ajcp-4886	516	5	,	,	PUNCT
ajcp-4886	516	6	shi	shi	PROPN
ajcp-4886	516	7	,	,	PUNCT
ajcp-4886	516	8	j.	j.	PROPN
ajcp-4886	516	9	,	,	PUNCT
ajcp-4886	516	10	zhang	zhang	PROPN
ajcp-4886	516	11	,	,	PUNCT
ajcp-4886	516	12	p.	p.	PROPN
ajcp-4886	516	13	,	,	PUNCT
ajcp-4886	516	14	zhang	zhang	PROPN
ajcp-4886	516	15	,	,	PUNCT
ajcp-4886	516	16	y.	y.	PROPN
ajcp-4886	516	17	,	,	PUNCT
ajcp-4886	516	18	xu	xu	PROPN
ajcp-4886	516	19	,	,	PUNCT
ajcp-4886	516	20	j.	j.	PROPN
ajcp-4886	516	21	,	,	PUNCT
ajcp-4886	516	22	zhao	zhao	PROPN
ajcp-4886	516	23	,	,	PUNCT
ajcp-4886	516	24	l.	l.	PROPN
ajcp-4886	516	25	,	,	PUNCT
ajcp-4886	516	26	zhang	zhang	PROPN
ajcp-4886	516	27	,	,	PUNCT
ajcp-4886	516	28	r.	r.	PROPN
ajcp-4886	516	29	,	,	PUNCT
ajcp-4886	516	30	wang	wang	PROPN
ajcp-4886	516	31	,	,	PUNCT
ajcp-4886	516	32	h.	h.	PROPN
ajcp-4886	516	33	,	,	PUNCT
ajcp-4886	516	34	&	&	CCONJ
ajcp-4886	516	35	chen	chen	PROPN
ajcp-4886	516	36	,	,	PUNCT
ajcp-4886	516	37	h.	h.	PROPN
ajcp-4886	516	38	(	(	PUNCT
ajcp-4886	516	39	2022	2022	NUM
ajcp-4886	516	40	)	)	PUNCT
ajcp-4886	516	41	.	.	PUNCT
ajcp-4886	517	1	immunotherapy	immunotherapy	NOUN
ajcp-4886	517	2	for	for	ADP
ajcp-4886	517	3	alzheimer	alzheimer	PROPN
ajcp-4886	517	4	’s	’s	PART
ajcp-4886	517	5	disease	disease	NOUN
ajcp-4886	517	6	:	:	PUNCT
ajcp-4886	517	7	targeting	target	VERB
ajcp-4886	517	8	β	β	NOUN
ajcp-4886	517	9	-	-	NOUN
ajcp-4886	517	10	amyloid	amyloid	NOUN
ajcp-4886	517	11	and	and	CCONJ
ajcp-4886	517	12	beyond	beyond	ADP
ajcp-4886	517	13	.	.	PUNCT
ajcp-4886	518	1	translational	translational	ADJ
ajcp-4886	518	2	neurodegeneration	neurodegeneration	NOUN
ajcp-4886	518	3	,	,	PUNCT
ajcp-4886	518	4	11(1	11(1	NUM
ajcp-4886	518	5	)	)	PUNCT
ajcp-4886	518	6	.	.	PUNCT
ajcp-4886	519	1	https://doi.org/10.1186/s40035-022-00292-3	https://doi.org/10.1186/s40035-022-00292-3	NUM
ajcp-4886	519	2	stanković	stanković	PROPN
ajcp-4886	519	3	,	,	PUNCT
ajcp-4886	519	4	i.	i.	NOUN
ajcp-4886	519	5	m.	m.	PROPN
ajcp-4886	519	6	,	,	PUNCT
ajcp-4886	519	7	niu	niu	PROPN
ajcp-4886	519	8	,	,	PUNCT
ajcp-4886	519	9	s.	s.	PROPN
ajcp-4886	519	10	,	,	PUNCT
ajcp-4886	519	11	hall	hall	PROPN
ajcp-4886	519	12	,	,	PUNCT
ajcp-4886	519	13	m.	m.	PROPN
ajcp-4886	519	14	b.	b.	PROPN
ajcp-4886	519	15	,	,	PUNCT
ajcp-4886	519	16	&	&	CCONJ
ajcp-4886	519	17	zarić	zarić	PROPN
ajcp-4886	519	18	,	,	PUNCT
ajcp-4886	519	19	s.	s.	PROPN
ajcp-4886	519	20	d.	d.	PROPN
ajcp-4886	519	21	(	(	PUNCT
ajcp-4886	519	22	2020	2020	NUM
ajcp-4886	519	23	)	)	PUNCT
ajcp-4886	519	24	.	.	PUNCT
ajcp-4886	520	1	role	role	NOUN
ajcp-4886	520	2	of	of	ADP
ajcp-4886	520	3	aromatic	aromatic	ADJ
ajcp-4886	520	4	amino	amino	NOUN
ajcp-4886	520	5	acids	acid	NOUN
ajcp-4886	520	6	in	in	ADP
ajcp-4886	520	7	amyloid	amyloid	NOUN
ajcp-4886	520	8	self	self	NOUN
ajcp-4886	520	9	-	-	PUNCT
ajcp-4886	520	10	assembly	assembly	NOUN
ajcp-4886	520	11	.	.	PUNCT
ajcp-4886	521	1	international	international	ADJ
ajcp-4886	521	2	journal	journal	NOUN
ajcp-4886	521	3	of	of	ADP
ajcp-4886	521	4	biological	biological	ADJ
ajcp-4886	521	5	macromolecules	macromolecule	NOUN
ajcp-4886	521	6	,	,	PUNCT
ajcp-4886	521	7	156	156	NUM
ajcp-4886	521	8	,	,	PUNCT
ajcp-4886	521	9	949959	949959	NUM
ajcp-4886	521	10	.	.	PUNCT
ajcp-4886	522	1	https://doi.org/10.1016/j.ijbiomac.2020.03.064	https://doi.org/10.1016/j.ijbiomac.2020.03.064	NOUN
ajcp-4886	522	2	sternke	sternke	NOUN
ajcp-4886	522	3	-	-	PUNCT
ajcp-4886	522	4	hoffmann	hoffmann	PROPN
ajcp-4886	522	5	,	,	PUNCT
ajcp-4886	522	6	r.	r.	PROPN
ajcp-4886	522	7	,	,	PUNCT
ajcp-4886	522	8	peduzzo	peduzzo	PROPN
ajcp-4886	522	9	,	,	PUNCT
ajcp-4886	522	10	a.	a.	NOUN
ajcp-4886	522	11	,	,	PUNCT
ajcp-4886	522	12	bolakhrif	bolakhrif	PROPN
ajcp-4886	522	13	,	,	PUNCT
ajcp-4886	522	14	n.	n.	NOUN
ajcp-4886	522	15	,	,	PUNCT
ajcp-4886	522	16	haas	haas	PROPN
ajcp-4886	522	17	,	,	PUNCT
ajcp-4886	522	18	r.	r.	PROPN
ajcp-4886	522	19	,	,	PUNCT
ajcp-4886	522	20	&	&	CCONJ
ajcp-4886	522	21	buell	buell	PROPN
ajcp-4886	522	22	,	,	PUNCT
ajcp-4886	522	23	a.	a.	PROPN
ajcp-4886	522	24	k.	k.	PROPN
ajcp-4886	522	25	(	(	PUNCT
ajcp-4886	522	26	2020	2020	NUM
ajcp-4886	522	27	)	)	PUNCT
ajcp-4886	522	28	.	.	PUNCT
ajcp-4886	523	1	the	the	DET
ajcp-4886	523	2	aggregation	aggregation	NOUN
ajcp-4886	523	3	conditions	condition	NOUN
ajcp-4886	523	4	define	define	VERB
ajcp-4886	523	5	whether	whether	SCONJ
ajcp-4886	523	6	egcg	egcg	NOUN
ajcp-4886	523	7	is	be	AUX
ajcp-4886	523	8	an	an	DET
ajcp-4886	523	9	inhibitor	inhibitor	NOUN
ajcp-4886	523	10	or	or	CCONJ
ajcp-4886	523	11	enhancer	enhancer	NOUN
ajcp-4886	523	12	of	of	ADP
ajcp-4886	523	13	α	α	NOUN
ajcp-4886	523	14	-	-	PUNCT
ajcp-4886	523	15	synuclein	synuclein	NOUN
ajcp-4886	523	16	amyloid	amyloid	NOUN
ajcp-4886	523	17	fibril	fibril	ADJ
ajcp-4886	523	18	formation	formation	NOUN
ajcp-4886	523	19	.	.	PUNCT
ajcp-4886	524	1	international	international	ADJ
ajcp-4886	524	2	journal	journal	NOUN
ajcp-4886	524	3	of	of	ADP
ajcp-4886	524	4	molecular	molecular	ADJ
ajcp-4886	524	5	sciences	science	NOUN
ajcp-4886	524	6	,	,	PUNCT
ajcp-4886	524	7	21(6	21(6	NUM
ajcp-4886	524	8	)	)	PUNCT
ajcp-4886	524	9	.	.	PUNCT
ajcp-4886	525	1	https://	https://	PROPN
ajcp-4886	525	2	doi.org/10.3390/ijms21061995	doi.org/10.3390/ijms21061995	PROPN
ajcp-4886	525	3	taylor	taylor	PROPN
ajcp-4886	525	4	,	,	PUNCT
ajcp-4886	525	5	a.	a.	PROPN
ajcp-4886	525	6	i.	i.	PROPN
ajcp-4886	525	7	p.	p.	PROPN
ajcp-4886	525	8	,	,	PUNCT
ajcp-4886	525	9	&	&	CCONJ
ajcp-4886	525	10	staniforth	staniforth	PROPN
ajcp-4886	525	11	,	,	PUNCT
ajcp-4886	525	12	r.	r.	PROPN
ajcp-4886	525	13	a.	a.	PROPN
ajcp-4886	525	14	(	(	PUNCT
ajcp-4886	525	15	2022	2022	NUM
ajcp-4886	525	16	)	)	PUNCT
ajcp-4886	525	17	.	.	PUNCT
ajcp-4886	526	1	general	general	ADJ
ajcp-4886	526	2	principles	principle	NOUN
ajcp-4886	526	3	underpinning	underpin	VERB
ajcp-4886	526	4	amyloid	amyloid	NOUN
ajcp-4886	526	5	structure	structure	NOUN
ajcp-4886	526	6	.	.	PUNCT
ajcp-4886	527	1	frontiers	frontier	NOUN
ajcp-4886	527	2	in	in	ADP
ajcp-4886	527	3	neuroscience	neuroscience	NOUN
ajcp-4886	527	4	,	,	PUNCT
ajcp-4886	527	5	16	16	NUM
ajcp-4886	527	6	.	.	PUNCT
ajcp-4886	528	1	https://doi.org/10.3389/	https://doi.org/10.3389/	PROPN
ajcp-4886	528	2	fnins.2022.878869	fnins.2022.878869	ADJ
ajcp-4886	528	3	thapliyal	thapliyal	NOUN
ajcp-4886	528	4	,	,	PUNCT
ajcp-4886	528	5	s.	s.	PROPN
ajcp-4886	528	6	,	,	PUNCT
ajcp-4886	528	7	singh	singh	PROPN
ajcp-4886	528	8	,	,	PUNCT
ajcp-4886	528	9	t.	t.	PROPN
ajcp-4886	528	10	,	,	PUNCT
ajcp-4886	528	11	handu	handu	NOUN
ajcp-4886	528	12	,	,	PUNCT
ajcp-4886	528	13	s.	s.	PROPN
ajcp-4886	528	14	,	,	PUNCT
ajcp-4886	528	15	bisht	bisht	PROPN
ajcp-4886	528	16	,	,	PUNCT
ajcp-4886	528	17	m.	m.	NOUN
ajcp-4886	528	18	,	,	PUNCT
ajcp-4886	528	19	kumari	kumari	PROPN
ajcp-4886	528	20	,	,	PUNCT
ajcp-4886	528	21	p.	p.	PROPN
ajcp-4886	528	22	,	,	PUNCT
ajcp-4886	528	23	arya	arya	NOUN
ajcp-4886	528	24	,	,	PUNCT
ajcp-4886	528	25	p.	p.	PROPN
ajcp-4886	528	26	,	,	PUNCT
ajcp-4886	528	27	srivastava	srivastava	PROPN
ajcp-4886	528	28	,	,	PUNCT
ajcp-4886	528	29	p.	p.	PROPN
ajcp-4886	528	30	,	,	PUNCT
ajcp-4886	528	31	&	&	CCONJ
ajcp-4886	528	32	gandham	gandham	PROPN
ajcp-4886	528	33	,	,	PUNCT
ajcp-4886	528	34	r.	r.	PROPN
ajcp-4886	528	35	(	(	PUNCT
ajcp-4886	528	36	2021	2021	NUM
ajcp-4886	528	37	)	)	PUNCT
ajcp-4886	528	38	.	.	PUNCT
ajcp-4886	529	1	a	a	DET
ajcp-4886	529	2	review	review	NOUN
ajcp-4886	529	3	on	on	ADP
ajcp-4886	529	4	potential	potential	ADJ
ajcp-4886	529	5	footprints	footprint	NOUN
ajcp-4886	529	6	of	of	ADP
ajcp-4886	529	7	ferulic	ferulic	ADJ
ajcp-4886	529	8	acid	acid	NOUN
ajcp-4886	529	9	for	for	ADP
ajcp-4886	529	10	pa	pa	PROPN
ajcp-4886	529	11	ge	ge	PROPN
ajcp-4886	529	12	28	28	NUM
ajcp-4886	529	13	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-4886	529	14	am	be	AUX
ajcp-4886	529	15	.	.	PUNCT
ajcp-4886	530	1	j.	j.	PROPN
ajcp-4886	530	2	chem	chem	PROPN
ajcp-4886	530	3	.	.	PUNCT
ajcp-4886	531	1	pharm	pharm	PROPN
ajcp-4886	531	2	.	.	PUNCT
ajcp-4886	532	1	4(1	4(1	NOUN
ajcp-4886	532	2	)	)	PUNCT
ajcp-4886	533	1	16	16	NUM
ajcp-4886	533	2	-	-	SYM
ajcp-4886	533	3	28	28	NUM
ajcp-4886	533	4	,	,	PUNCT
ajcp-4886	533	5	2025	2025	NUM
ajcp-4886	533	6	treatment	treatment	NOUN
ajcp-4886	533	7	of	of	ADP
ajcp-4886	533	8	neurological	neurological	ADJ
ajcp-4886	533	9	disorders	disorder	NOUN
ajcp-4886	533	10	.	.	PUNCT
ajcp-4886	534	1	neurochemical	neurochemical	ADJ
ajcp-4886	534	2	research	research	NOUN
ajcp-4886	534	3	,	,	PUNCT
ajcp-4886	534	4	46(5	46(5	NOUN
ajcp-4886	534	5	)	)	PUNCT
ajcp-4886	534	6	,	,	PUNCT
ajcp-4886	534	7	1043	1043	NUM
ajcp-4886	534	8	-	-	SYM
ajcp-4886	534	9	1057	1057	NUM
ajcp-4886	534	10	.	.	PUNCT
ajcp-4886	535	1	https://doi.org/10.1007/	https://doi.org/10.1007/	PROPN
ajcp-4886	535	2	s11064	s11064	PROPN
ajcp-4886	535	3	-	-	PUNCT
ajcp-4886	535	4	021	021	NUM
ajcp-4886	535	5	-	-	PUNCT
ajcp-4886	535	6	03257	03257	NUM
ajcp-4886	535	7	-	-	PUNCT
ajcp-4886	535	8	6	6	NUM
ajcp-4886	535	9	tzioras	tziora	NOUN
ajcp-4886	535	10	,	,	PUNCT
ajcp-4886	535	11	m.	m.	NOUN
ajcp-4886	535	12	,	,	PUNCT
ajcp-4886	535	13	mcgeachan	mcgeachan	PROPN
ajcp-4886	535	14	,	,	PUNCT
ajcp-4886	535	15	r.	r.	PROPN
ajcp-4886	535	16	i.	i.	PROPN
ajcp-4886	535	17	,	,	PUNCT
ajcp-4886	535	18	durrant	durrant	PROPN
ajcp-4886	535	19	,	,	PUNCT
ajcp-4886	535	20	c.	c.	PROPN
ajcp-4886	535	21	s.	s.	PROPN
ajcp-4886	535	22	,	,	PUNCT
ajcp-4886	535	23	&	&	CCONJ
ajcp-4886	535	24	spires	spires	PROPN
ajcp-4886	535	25	-	-	PUNCT
ajcp-4886	535	26	jones	jones	PROPN
ajcp-4886	535	27	,	,	PUNCT
ajcp-4886	535	28	t.	t.	PROPN
ajcp-4886	535	29	l.	l.	PROPN
ajcp-4886	535	30	(	(	PUNCT
ajcp-4886	535	31	2022	2022	NUM
ajcp-4886	535	32	)	)	PUNCT
ajcp-4886	535	33	.	.	PUNCT
ajcp-4886	536	1	synaptic	synaptic	ADJ
ajcp-4886	536	2	degeneration	degeneration	NOUN
ajcp-4886	536	3	in	in	ADP
ajcp-4886	536	4	alzheimer	alzheimer	PROPN
ajcp-4886	536	5	disease	disease	PROPN
ajcp-4886	536	6	.	.	PUNCT
ajcp-4886	537	1	nature	nature	NOUN
ajcp-4886	537	2	reviews	review	NOUN
ajcp-4886	537	3	neurology	neurology	NOUN
ajcp-4886	537	4	,	,	PUNCT
ajcp-4886	537	5	19(1	19(1	NUM
ajcp-4886	537	6	)	)	PUNCT
ajcp-4886	537	7	,	,	PUNCT
ajcp-4886	537	8	1938	1938	NUM
ajcp-4886	537	9	.	.	PUNCT
ajcp-4886	538	1	https://doi.org/10.1038/s41582-022-00749-z	https://doi.org/10.1038/s41582-022-00749-z	PROPN
ajcp-4886	538	2	uddin	uddin	PROPN
ajcp-4886	538	3	,	,	PUNCT
ajcp-4886	538	4	m.	m.	NOUN
ajcp-4886	538	5	s.	s.	PROPN
ajcp-4886	538	6	,	,	PUNCT
ajcp-4886	538	7	al	al	PROPN
ajcp-4886	538	8	mamun	mamun	PROPN
ajcp-4886	538	9	,	,	PUNCT
ajcp-4886	538	10	a.	a.	PROPN
ajcp-4886	538	11	,	,	PUNCT
ajcp-4886	538	12	kabir	kabir	PROPN
ajcp-4886	538	13	,	,	PUNCT
ajcp-4886	538	14	m.	m.	NOUN
ajcp-4886	538	15	t.	t.	PROPN
ajcp-4886	538	16	,	,	PUNCT
ajcp-4886	538	17	ashraf	ashraf	PROPN
ajcp-4886	538	18	,	,	PUNCT
ajcp-4886	538	19	g.	g.	PROPN
ajcp-4886	538	20	m.	m.	PROPN
ajcp-4886	538	21	,	,	PUNCT
ajcp-4886	538	22	bin	bin	PROPN
ajcp-4886	538	23	-	-	PUNCT
ajcp-4886	538	24	jumah	jumah	PROPN
ajcp-4886	538	25	,	,	PUNCT
ajcp-4886	538	26	m.	m.	NOUN
ajcp-4886	538	27	n.	n.	PROPN
ajcp-4886	538	28	,	,	PUNCT
ajcp-4886	538	29	&	&	CCONJ
ajcp-4886	538	30	abdel	abdel	PROPN
ajcp-4886	538	31	-	-	PUNCT
ajcp-4886	538	32	daim	daim	PROPN
ajcp-4886	538	33	,	,	PUNCT
ajcp-4886	538	34	m.	m.	NOUN
ajcp-4886	538	35	m.	m.	NOUN
ajcp-4886	538	36	(	(	PUNCT
ajcp-4886	538	37	2020	2020	NUM
ajcp-4886	538	38	)	)	PUNCT
ajcp-4886	538	39	.	.	PUNCT
ajcp-4886	539	1	multi	multi	ADJ
ajcp-4886	539	2	-	-	ADJ
ajcp-4886	539	3	target	target	ADJ
ajcp-4886	539	4	drug	drug	NOUN
ajcp-4886	539	5	candidates	candidate	NOUN
ajcp-4886	539	6	for	for	ADP
ajcp-4886	539	7	multifactorial	multifactorial	ADJ
ajcp-4886	539	8	alzheimer	alzheimer	PROPN
ajcp-4886	539	9	’s	’s	PART
ajcp-4886	539	10	disease	disease	NOUN
ajcp-4886	539	11	:	:	PUNCT
ajcp-4886	539	12	ache	ache	NOUN
ajcp-4886	539	13	and	and	CCONJ
ajcp-4886	539	14	nmdar	nmdar	ADV
ajcp-4886	539	15	as	as	ADP
ajcp-4886	539	16	molecular	molecular	ADJ
ajcp-4886	539	17	targets	target	NOUN
ajcp-4886	539	18	.	.	PUNCT
ajcp-4886	540	1	molecular	molecular	ADJ
ajcp-4886	540	2	neurobiology	neurobiology	NOUN
ajcp-4886	540	3	,	,	PUNCT
ajcp-4886	540	4	58(1	58(1	NUM
ajcp-4886	540	5	)	)	PUNCT
ajcp-4886	540	6	,	,	PUNCT
ajcp-4886	540	7	281303	281303	NUM
ajcp-4886	540	8	.	.	PUNCT
ajcp-4886	541	1	https://doi.org/10.1007/s12035-020-02116-9	https://doi.org/10.1007/s12035-020-02116-9	PRON
ajcp-4886	541	2	viola	viola	PROPN
ajcp-4886	541	3	,	,	PUNCT
ajcp-4886	541	4	k.	k.	PROPN
ajcp-4886	541	5	l.	l.	PROPN
ajcp-4886	541	6	,	,	PUNCT
ajcp-4886	541	7	&	&	CCONJ
ajcp-4886	541	8	klein	klein	PROPN
ajcp-4886	541	9	,	,	PUNCT
ajcp-4886	541	10	w.	w.	PROPN
ajcp-4886	541	11	l.	l.	PROPN
ajcp-4886	541	12	(	(	PUNCT
ajcp-4886	541	13	2015	2015	NUM
ajcp-4886	541	14	)	)	PUNCT
ajcp-4886	541	15	.	.	PUNCT
ajcp-4886	542	1	amyloid	amyloid	NOUN
ajcp-4886	542	2	β	β	X
ajcp-4886	542	3	oligomers	oligomer	NOUN
ajcp-4886	542	4	in	in	ADP
ajcp-4886	542	5	alzheimer	alzheimer	PROPN
ajcp-4886	542	6	’s	’s	PART
ajcp-4886	542	7	disease	disease	NOUN
ajcp-4886	542	8	pathogenesis	pathogenesis	NOUN
ajcp-4886	542	9	,	,	PUNCT
ajcp-4886	542	10	treatment	treatment	NOUN
ajcp-4886	542	11	,	,	PUNCT
ajcp-4886	542	12	and	and	CCONJ
ajcp-4886	542	13	diagnosis	diagnosis	NOUN
ajcp-4886	542	14	.	.	PUNCT
ajcp-4886	543	1	acta	acta	PROPN
ajcp-4886	543	2	neuropathologica	neuropathologica	PROPN
ajcp-4886	543	3	,	,	PUNCT
ajcp-4886	543	4	129(2	129(2	NUM
ajcp-4886	543	5	)	)	PUNCT
ajcp-4886	543	6	,	,	PUNCT
ajcp-4886	543	7	183	183	NUM
ajcp-4886	543	8	-	-	SYM
ajcp-4886	543	9	206	206	NUM
ajcp-4886	543	10	.	.	PUNCT
ajcp-4886	544	1	https://doi.org/10.1007/s00401-015-1386-3	https://doi.org/10.1007/s00401-015-1386-3	PROPN
ajcp-4886	544	2	volynsky	volynsky	NOUN
ajcp-4886	544	3	,	,	PUNCT
ajcp-4886	544	4	p.	p.	PROPN
ajcp-4886	544	5	e.	e.	PROPN
ajcp-4886	544	6	,	,	PUNCT
ajcp-4886	544	7	urban	urban	ADJ
ajcp-4886	544	8	,	,	PUNCT
ajcp-4886	544	9	a.	a.	PROPN
ajcp-4886	544	10	s.	s.	PROPN
ajcp-4886	544	11	,	,	PUNCT
ajcp-4886	544	12	pavlov	pavlov	PROPN
ajcp-4886	544	13	,	,	PUNCT
ajcp-4886	544	14	k.	k.	PROPN
ajcp-4886	545	1	v.	v.	PROPN
ajcp-4886	545	2	,	,	PUNCT
ajcp-4886	545	3	bershatsky	bershatsky	PROPN
ajcp-4886	545	4	,	,	PUNCT
ajcp-4886	545	5	y.	y.	PROPN
ajcp-4886	545	6	v.	v.	PROPN
ajcp-4886	545	7	,	,	PUNCT
ajcp-4886	545	8	bocharova	bocharova	PROPN
ajcp-4886	545	9	,	,	PUNCT
ajcp-4886	545	10	o.	o.	PROPN
ajcp-4886	545	11	v.	v.	PROPN
ajcp-4886	545	12	,	,	PUNCT
ajcp-4886	545	13	kryuchkova	kryuchkova	PROPN
ajcp-4886	545	14	,	,	PUNCT
ajcp-4886	545	15	a.	a.	PROPN
ajcp-4886	545	16	k.	k.	PROPN
ajcp-4886	545	17	,	,	PUNCT
ajcp-4886	545	18	zlobina	zlobina	PROPN
ajcp-4886	545	19	,	,	PUNCT
ajcp-4886	545	20	v.	v.	PROPN
ajcp-4886	545	21	v.	v.	ADV
ajcp-4886	545	22	,	,	PUNCT
ajcp-4886	545	23	gavrilenkova	gavrilenkova	PROPN
ajcp-4886	545	24	,	,	PUNCT
ajcp-4886	545	25	a.	a.	NOUN
ajcp-4886	545	26	a.	a.	PROPN
ajcp-4886	545	27	,	,	PUNCT
ajcp-4886	545	28	dolotova	dolotova	PROPN
ajcp-4886	545	29	,	,	PUNCT
ajcp-4886	545	30	s.	s.	PROPN
ajcp-4886	545	31	m.	m.	PROPN
ajcp-4886	545	32	,	,	PUNCT
ajcp-4886	545	33	kamynina	kamynina	PROPN
ajcp-4886	545	34	,	,	PUNCT
ajcp-4886	545	35	a.	a.	PROPN
ajcp-4886	545	36	v.	v.	PROPN
ajcp-4886	545	37	,	,	PUNCT
ajcp-4886	545	38	zangieva	zangieva	PROPN
ajcp-4886	545	39	,	,	PUNCT
ajcp-4886	545	40	o.	o.	PROPN
ajcp-4886	545	41	t.	t.	PROPN
ajcp-4886	545	42	,	,	PUNCT
ajcp-4886	545	43	taldaev	taldaev	PROPN
ajcp-4886	545	44	,	,	PUNCT
ajcp-4886	545	45	a.	a.	NOUN
ajcp-4886	545	46	,	,	PUNCT
ajcp-4886	545	47	batishchev	batishchev	PROPN
ajcp-4886	545	48	,	,	PUNCT
ajcp-4886	545	49	o.	o.	PROPN
ajcp-4886	545	50	v.	v.	PROPN
ajcp-4886	545	51	,	,	PUNCT
ajcp-4886	545	52	okhrimenko	okhrimenko	ADJ
ajcp-4886	545	53	,	,	PUNCT
ajcp-4886	545	54	i.	i.	PROPN
ajcp-4886	545	55	s.	s.	PROPN
ajcp-4886	545	56	,	,	PUNCT
ajcp-4886	545	57	rakitina	rakitina	NOUN
ajcp-4886	545	58	,	,	PUNCT
ajcp-4886	545	59	t.	t.	PROPN
ajcp-4886	545	60	v.	v.	PROPN
ajcp-4886	545	61	,	,	PUNCT
ajcp-4886	545	62	efremov	efremov	ADJ
ajcp-4886	545	63	,	,	PUNCT
ajcp-4886	545	64	r.	r.	PROPN
ajcp-4886	545	65	g.	g.	PROPN
ajcp-4886	545	66	,	,	PUNCT
ajcp-4886	545	67	&	&	CCONJ
ajcp-4886	545	68	bocharov	bocharov	PROPN
ajcp-4886	545	69	,	,	PUNCT
ajcp-4886	545	70	e.	e.	PROPN
ajcp-4886	545	71	v.	v.	PROPN
ajcp-4886	545	72	(	(	PUNCT
ajcp-4886	545	73	2025	2025	NUM
ajcp-4886	545	74	)	)	PUNCT
ajcp-4886	545	75	.	.	PUNCT
ajcp-4886	546	1	diverse	diverse	ADJ
ajcp-4886	546	2	interactions	interaction	NOUN
ajcp-4886	546	3	of	of	ADP
ajcp-4886	546	4	sterols	sterol	NOUN
ajcp-4886	546	5	with	with	ADP
ajcp-4886	546	6	amyloid	amyloid	NOUN
ajcp-4886	546	7	precursor	precursor	NOUN
ajcp-4886	546	8	protein	protein	NOUN
ajcp-4886	546	9	transmembrane	transmembrane	NOUN
ajcp-4886	546	10	domain	domain	NOUN
ajcp-4886	546	11	can	can	AUX
ajcp-4886	546	12	shift	shift	VERB
ajcp-4886	546	13	distribution	distribution	NOUN
ajcp-4886	546	14	between	between	ADP
ajcp-4886	546	15	alternative	alternative	ADJ
ajcp-4886	546	16	amyloid	amyloid	NOUN
ajcp-4886	546	17	-	-	PUNCT
ajcp-4886	546	18	β	β	NOUN
ajcp-4886	546	19	production	production	NOUN
ajcp-4886	546	20	cascades	cascade	NOUN
ajcp-4886	546	21	in	in	ADP
ajcp-4886	546	22	manner	manner	NOUN
ajcp-4886	546	23	dependent	dependent	ADJ
ajcp-4886	546	24	on	on	ADP
ajcp-4886	546	25	local	local	ADJ
ajcp-4886	546	26	lipid	lipid	NOUN
ajcp-4886	546	27	environment	environment	NOUN
ajcp-4886	546	28	.	.	PUNCT
ajcp-4886	547	1	international	international	ADJ
ajcp-4886	547	2	journal	journal	NOUN
ajcp-4886	547	3	of	of	ADP
ajcp-4886	547	4	molecular	molecular	ADJ
ajcp-4886	547	5	sciences	science	NOUN
ajcp-4886	547	6	,	,	PUNCT
ajcp-4886	547	7	26(2	26(2	NUM
ajcp-4886	547	8	)	)	PUNCT
ajcp-4886	547	9	.	.	PUNCT
ajcp-4886	548	1	https://	https://	PROPN
ajcp-4886	548	2	doi.org/10.3390/ijms26020553	doi.org/10.3390/ijms26020553	PROPN
ajcp-4886	548	3	wang	wang	PROPN
ajcp-4886	548	4	,	,	PUNCT
ajcp-4886	548	5	c.	c.	PROPN
ajcp-4886	548	6	,	,	PUNCT
ajcp-4886	548	7	wang	wang	PROPN
ajcp-4886	548	8	,	,	PUNCT
ajcp-4886	548	9	x.	x.	PROPN
ajcp-4886	548	10	,	,	PUNCT
ajcp-4886	548	11	chan	chan	PROPN
ajcp-4886	548	12	,	,	PUNCT
ajcp-4886	548	13	h.	h.	PROPN
ajcp-4886	548	14	n.	n.	PROPN
ajcp-4886	548	15	,	,	PUNCT
ajcp-4886	548	16	liu	liu	PROPN
ajcp-4886	548	17	,	,	PUNCT
ajcp-4886	548	18	g.	g.	PROPN
ajcp-4886	548	19	,	,	PUNCT
ajcp-4886	548	20	wang	wang	PROPN
ajcp-4886	548	21	,	,	PUNCT
ajcp-4886	548	22	z.	z.	PROPN
ajcp-4886	548	23	,	,	PUNCT
ajcp-4886	548	24	li	li	PROPN
ajcp-4886	548	25	,	,	PUNCT
ajcp-4886	548	26	h.	h.	PROPN
ajcp-4886	548	27	w.	w.	PROPN
ajcp-4886	548	28	,	,	PUNCT
ajcp-4886	548	29	&	&	CCONJ
ajcp-4886	548	30	wong	wong	PROPN
ajcp-4886	548	31	,	,	PUNCT
ajcp-4886	548	32	m.	m.	PROPN
ajcp-4886	548	33	s.	s.	PROPN
ajcp-4886	548	34	(	(	PUNCT
ajcp-4886	548	35	2020	2020	NUM
ajcp-4886	548	36	)	)	PUNCT
ajcp-4886	548	37	.	.	PUNCT
ajcp-4886	549	1	amyloid‐β	amyloid‐β	PROPN
ajcp-4886	549	2	oligomer‐	oligomer‐	PROPN
ajcp-4886	549	3	targeted	target	VERB
ajcp-4886	549	4	gadolinium‐based	gadolinium‐base	VERB
ajcp-4886	549	5	nir	nir	ADJ
ajcp-4886	549	6	/	/	SYM
ajcp-4886	550	1	mr	mr	PROPN
ajcp-4886	550	2	dual‐modal	dual‐modal	PROPN
ajcp-4886	550	3	theranostic	theranostic	ADJ
ajcp-4886	550	4	nanoprobe	nanoprobe	NOUN
ajcp-4886	550	5	for	for	ADP
ajcp-4886	550	6	alzheimer	alzheimer	PROPN
ajcp-4886	550	7	’s	’s	PART
ajcp-4886	550	8	disease	disease	NOUN
ajcp-4886	550	9	.	.	PUNCT
ajcp-4886	551	1	advanced	advanced	ADJ
ajcp-4886	551	2	functional	functional	ADJ
ajcp-4886	551	3	materials	material	NOUN
ajcp-4886	551	4	,	,	PUNCT
ajcp-4886	551	5	30(16	30(16	NOUN
ajcp-4886	551	6	)	)	PUNCT
ajcp-4886	551	7	.	.	PUNCT
ajcp-4886	552	1	https://doi	https://doi	PROPN
ajcp-4886	552	2	.	.	PUNCT
ajcp-4886	553	1	org/10.1002	org/10.1002	PROPN
ajcp-4886	553	2	/	/	SYM
ajcp-4886	553	3	adfm.201909529	adfm.201909529	NUM
ajcp-4886	553	4	wegmann	wegmann	NOUN
ajcp-4886	553	5	,	,	PUNCT
ajcp-4886	553	6	s.	s.	PROPN
ajcp-4886	553	7	,	,	PUNCT
ajcp-4886	553	8	eftekharzadeh	eftekharzadeh	PROPN
ajcp-4886	553	9	,	,	PUNCT
ajcp-4886	553	10	b.	b.	PROPN
ajcp-4886	553	11	,	,	PUNCT
ajcp-4886	553	12	tepper	tepper	PROPN
ajcp-4886	553	13	,	,	PUNCT
ajcp-4886	553	14	k.	k.	PROPN
ajcp-4886	553	15	,	,	PUNCT
ajcp-4886	553	16	zoltowska	zoltowska	PROPN
ajcp-4886	553	17	,	,	PUNCT
ajcp-4886	553	18	k.	k.	PROPN
ajcp-4886	553	19	m.	m.	PROPN
ajcp-4886	553	20	,	,	PUNCT
ajcp-4886	553	21	bennett	bennett	PROPN
ajcp-4886	553	22	,	,	PUNCT
ajcp-4886	553	23	r.	r.	PROPN
ajcp-4886	553	24	e.	e.	PROPN
ajcp-4886	553	25	,	,	PUNCT
ajcp-4886	553	26	dujardin	dujardin	PROPN
ajcp-4886	553	27	,	,	PUNCT
ajcp-4886	553	28	s.	s.	PROPN
ajcp-4886	553	29	,	,	PUNCT
ajcp-4886	553	30	laskowski	laskowski	NOUN
ajcp-4886	553	31	,	,	PUNCT
ajcp-4886	553	32	p.	p.	PROPN
ajcp-4886	553	33	r.	r.	PROPN
ajcp-4886	553	34	,	,	PUNCT
ajcp-4886	553	35	mackenzie	mackenzie	PROPN
ajcp-4886	553	36	,	,	PUNCT
ajcp-4886	553	37	d.	d.	PROPN
ajcp-4886	553	38	,	,	PUNCT
ajcp-4886	553	39	kamath	kamath	PROPN
ajcp-4886	553	40	,	,	PUNCT
ajcp-4886	553	41	t.	t.	PROPN
ajcp-4886	553	42	,	,	PUNCT
ajcp-4886	553	43	commins	commin	NOUN
ajcp-4886	553	44	,	,	PUNCT
ajcp-4886	553	45	c.	c.	NOUN
ajcp-4886	553	46	,	,	PUNCT
ajcp-4886	553	47	vanderburg	vanderburg	NOUN
ajcp-4886	553	48	,	,	PUNCT
ajcp-4886	553	49	c.	c.	PROPN
ajcp-4886	553	50	,	,	PUNCT
ajcp-4886	553	51	roe	roe	PROPN
ajcp-4886	553	52	,	,	PUNCT
ajcp-4886	553	53	a.	a.	PROPN
ajcp-4886	553	54	d.	d.	PROPN
ajcp-4886	553	55	,	,	PUNCT
ajcp-4886	553	56	fan	fan	PROPN
ajcp-4886	553	57	,	,	PUNCT
ajcp-4886	553	58	z.	z.	PROPN
ajcp-4886	553	59	,	,	PUNCT
ajcp-4886	553	60	molliex	molliex	ADJ
ajcp-4886	553	61	,	,	PUNCT
ajcp-4886	553	62	a.	a.	NOUN
ajcp-4886	553	63	m.	m.	NOUN
ajcp-4886	553	64	,	,	PUNCT
ajcp-4886	553	65	hernandez‐vega	hernandez‐vega	PROPN
ajcp-4886	553	66	,	,	PUNCT
ajcp-4886	553	67	a.	a.	NOUN
ajcp-4886	553	68	,	,	PUNCT
ajcp-4886	553	69	muller	muller	PROPN
ajcp-4886	553	70	,	,	PUNCT
ajcp-4886	553	71	d.	d.	PROPN
ajcp-4886	553	72	,	,	PUNCT
ajcp-4886	553	73	hyman	hyman	PROPN
ajcp-4886	553	74	,	,	PUNCT
ajcp-4886	553	75	a.	a.	NOUN
ajcp-4886	553	76	a.	a.	PROPN
ajcp-4886	553	77	,	,	PUNCT
ajcp-4886	553	78	mandelkow	mandelkow	PROPN
ajcp-4886	553	79	,	,	PUNCT
ajcp-4886	553	80	e.	e.	PROPN
ajcp-4886	553	81	,	,	PUNCT
ajcp-4886	553	82	taylor	taylor	PROPN
ajcp-4886	553	83	,	,	PUNCT
ajcp-4886	553	84	j.	j.	PROPN
ajcp-4886	553	85	p.	p.	PROPN
ajcp-4886	553	86	,	,	PUNCT
ajcp-4886	553	87	&	&	CCONJ
ajcp-4886	553	88	hyman	hyman	PROPN
ajcp-4886	553	89	,	,	PUNCT
ajcp-4886	553	90	b.	b.	PROPN
ajcp-4886	553	91	t.	t.	PROPN
ajcp-4886	553	92	(	(	PUNCT
ajcp-4886	553	93	2018	2018	NUM
ajcp-4886	553	94	)	)	PUNCT
ajcp-4886	553	95	.	.	PUNCT
ajcp-4886	554	1	tau	tau	PROPN
ajcp-4886	554	2	protein	protein	NOUN
ajcp-4886	554	3	liquid	liquid	NOUN
ajcp-4886	554	4	–	–	PUNCT
ajcp-4886	554	5	liquid	liquid	ADJ
ajcp-4886	554	6	phase	phase	NOUN
ajcp-4886	554	7	separation	separation	NOUN
ajcp-4886	554	8	can	can	AUX
ajcp-4886	554	9	initiate	initiate	VERB
ajcp-4886	554	10	tau	tau	PROPN
ajcp-4886	554	11	aggregation	aggregation	NOUN
ajcp-4886	554	12	.	.	PUNCT
ajcp-4886	555	1	the	the	DET
ajcp-4886	555	2	embo	embo	PROPN
ajcp-4886	555	3	journal	journal	NOUN
ajcp-4886	555	4	,	,	PUNCT
ajcp-4886	555	5	37(7	37(7	NUM
ajcp-4886	555	6	)	)	PUNCT
ajcp-4886	555	7	.	.	PUNCT
ajcp-4886	556	1	https://	https://	PROPN
ajcp-4886	556	2	doi.org/10.15252/embj.201798049	doi.org/10.15252/embj.201798049	PROPN
ajcp-4886	556	3	wu	wu	PROPN
ajcp-4886	556	4	,	,	PUNCT
ajcp-4886	556	5	y.	y.	PROPN
ajcp-4886	556	6	,	,	PUNCT
ajcp-4886	556	7	guo	guo	PROPN
ajcp-4886	556	8	,	,	PUNCT
ajcp-4886	556	9	s.	s.	PROPN
ajcp-4886	556	10	,	,	PUNCT
ajcp-4886	556	11	wang	wang	PROPN
ajcp-4886	556	12	,	,	PUNCT
ajcp-4886	556	13	k.	k.	PROPN
ajcp-4886	556	14	,	,	PUNCT
ajcp-4886	556	15	&	&	CCONJ
ajcp-4886	556	16	kang	kang	PROPN
ajcp-4886	556	17	,	,	PUNCT
ajcp-4886	556	18	j.	j.	PROPN
ajcp-4886	556	19	(	(	PUNCT
ajcp-4886	556	20	2023	2023	NUM
ajcp-4886	556	21	)	)	PUNCT
ajcp-4886	556	22	.	.	PUNCT
ajcp-4886	557	1	the	the	DET
ajcp-4886	557	2	interaction	interaction	NOUN
ajcp-4886	557	3	of	of	ADP
ajcp-4886	557	4	peptide	peptide	ADJ
ajcp-4886	557	5	inhibitors	inhibitor	NOUN
ajcp-4886	557	6	and	and	CCONJ
ajcp-4886	557	7	aβ	aβ	DET
ajcp-4886	557	8	protein	protein	NOUN
ajcp-4886	557	9	:	:	PUNCT
ajcp-4886	557	10	binding	bind	VERB
ajcp-4886	557	11	mode	mode	NOUN
ajcp-4886	557	12	analysis	analysis	NOUN
ajcp-4886	557	13	,	,	PUNCT
ajcp-4886	557	14	inhibition	inhibition	NOUN
ajcp-4886	557	15	of	of	ADP
ajcp-4886	557	16	the	the	DET
ajcp-4886	557	17	formation	formation	NOUN
ajcp-4886	557	18	of	of	ADP
ajcp-4886	557	19	aβ	aβ	DET
ajcp-4886	557	20	aggregates	aggregate	NOUN
ajcp-4886	557	21	,	,	PUNCT
ajcp-4886	557	22	and	and	CCONJ
ajcp-4886	557	23	then	then	ADV
ajcp-4886	557	24	exert	exert	VERB
ajcp-4886	557	25	neuroprotective	neuroprotective	ADJ
ajcp-4886	557	26	effects	effect	NOUN
ajcp-4886	557	27	.	.	PUNCT
ajcp-4886	558	1	frontiers	frontier	NOUN
ajcp-4886	558	2	in	in	ADP
ajcp-4886	558	3	aging	age	VERB
ajcp-4886	558	4	neuroscience	neuroscience	NOUN
ajcp-4886	558	5	,	,	PUNCT
ajcp-4886	558	6	15	15	NUM
ajcp-4886	558	7	.	.	PUNCT
ajcp-4886	559	1	https://doi	https://doi	PROPN
ajcp-4886	559	2	.	.	PUNCT
ajcp-4886	559	3	org/10.3389	org/10.3389	PROPN
ajcp-4886	559	4	/	/	SYM
ajcp-4886	559	5	fnagi.2023.1139418	fnagi.2023.1139418	PROPN
ajcp-4886	559	6	yang	yang	PROPN
ajcp-4886	559	7	,	,	PUNCT
ajcp-4886	559	8	d.	d.	PROPN
ajcp-4886	559	9	,	,	PUNCT
ajcp-4886	559	10	zhu	zhu	PROPN
ajcp-4886	559	11	,	,	PUNCT
ajcp-4886	559	12	w.	w.	PROPN
ajcp-4886	559	13	,	,	PUNCT
ajcp-4886	559	14	wang	wang	PROPN
ajcp-4886	559	15	,	,	PUNCT
ajcp-4886	559	16	y.	y.	PROPN
ajcp-4886	559	17	,	,	PUNCT
ajcp-4886	559	18	tan	tan	PROPN
ajcp-4886	559	19	,	,	PUNCT
ajcp-4886	559	20	f.	f.	PROPN
ajcp-4886	559	21	,	,	PUNCT
ajcp-4886	559	22	ma	ma	PROPN
ajcp-4886	559	23	,	,	PUNCT
ajcp-4886	559	24	z.	z.	PROPN
ajcp-4886	559	25	,	,	PUNCT
ajcp-4886	559	26	gao	gao	PROPN
ajcp-4886	559	27	,	,	PUNCT
ajcp-4886	559	28	j.	j.	PROPN
ajcp-4886	559	29	,	,	PUNCT
ajcp-4886	559	30	&	&	CCONJ
ajcp-4886	559	31	lin	lin	PROPN
ajcp-4886	559	32	,	,	PUNCT
ajcp-4886	559	33	x.	x.	NOUN
ajcp-4886	559	34	(	(	PUNCT
ajcp-4886	559	35	2020	2020	NUM
ajcp-4886	559	36	)	)	PUNCT
ajcp-4886	559	37	.	.	PUNCT
ajcp-4886	560	1	selection	selection	NOUN
ajcp-4886	560	2	of	of	ADP
ajcp-4886	560	3	mutant	mutant	ADJ
ajcp-4886	560	4	µplasmin	µplasmin	NOUN
ajcp-4886	560	5	for	for	ADP
ajcp-4886	560	6	amyloid	amyloid	NOUN
ajcp-4886	560	7	-	-	PUNCT
ajcp-4886	560	8	β	β	NOUN
ajcp-4886	560	9	cleavage	cleavage	NOUN
ajcp-4886	560	10	in	in	ADP
ajcp-4886	560	11	vivo	vivo	NOUN
ajcp-4886	560	12	.	.	PUNCT
ajcp-4886	561	1	scientific	scientific	ADJ
ajcp-4886	561	2	reports	report	NOUN
ajcp-4886	561	3	,	,	PUNCT
ajcp-4886	561	4	10(1	10(1	NUM
ajcp-4886	561	5	)	)	PUNCT
ajcp-4886	561	6	.	.	PUNCT
ajcp-4886	562	1	https://doi.org/10.1038/s41598-020-69079-8	https://doi.org/10.1038/s41598-020-69079-8	PROPN
ajcp-4886	562	2	zbinden	zbinden	NOUN
ajcp-4886	562	3	,	,	PUNCT
ajcp-4886	562	4	a.	a.	NOUN
ajcp-4886	562	5	,	,	PUNCT
ajcp-4886	562	6	pérez	pérez	NOUN
ajcp-4886	562	7	-	-	PUNCT
ajcp-4886	562	8	berlanga	berlanga	NOUN
ajcp-4886	562	9	,	,	PUNCT
ajcp-4886	562	10	m.	m.	NOUN
ajcp-4886	562	11	,	,	PUNCT
ajcp-4886	562	12	de	de	X
ajcp-4886	562	13	rossi	rossi	PROPN
ajcp-4886	562	14	,	,	PUNCT
ajcp-4886	562	15	p.	p.	PROPN
ajcp-4886	562	16	,	,	PUNCT
ajcp-4886	562	17	&	&	CCONJ
ajcp-4886	562	18	polymenidou	polymenidou	NOUN
ajcp-4886	562	19	,	,	PUNCT
ajcp-4886	562	20	m.	m.	NOUN
ajcp-4886	562	21	(	(	PUNCT
ajcp-4886	562	22	2020	2020	NUM
ajcp-4886	562	23	)	)	PUNCT
ajcp-4886	562	24	.	.	PUNCT
ajcp-4886	563	1	phase	phase	NOUN
ajcp-4886	563	2	separation	separation	NOUN
ajcp-4886	563	3	and	and	CCONJ
ajcp-4886	563	4	neurodegenerative	neurodegenerative	ADJ
ajcp-4886	563	5	diseases	disease	NOUN
ajcp-4886	563	6	:	:	PUNCT
ajcp-4886	563	7	a	a	DET
ajcp-4886	563	8	disturbance	disturbance	NOUN
ajcp-4886	563	9	in	in	ADP
ajcp-4886	563	10	the	the	DET
ajcp-4886	563	11	force	force	NOUN
ajcp-4886	563	12	.	.	PUNCT
ajcp-4886	564	1	developmental	developmental	ADJ
ajcp-4886	564	2	cell	cell	NOUN
ajcp-4886	564	3	,	,	PUNCT
ajcp-4886	564	4	55(1	55(1	NOUN
ajcp-4886	564	5	)	)	PUNCT
ajcp-4886	564	6	,	,	PUNCT
ajcp-4886	564	7	45	45	NUM
ajcp-4886	564	8	-	-	SYM
ajcp-4886	564	9	68	68	NUM
ajcp-4886	564	10	.	.	PUNCT
ajcp-4886	565	1	https://doi	https://doi	X
ajcp-4886	565	2	.	.	PUNCT
ajcp-4886	566	1	org/10.1016	org/10.1016	PROPN
ajcp-4886	566	2	/	/	SYM
ajcp-4886	566	3	j.devcel.2020.09.014	j.devcel.2020.09.014	PROPN
ajcp-4886	566	4	zeng	zeng	PROPN
ajcp-4886	566	5	,	,	PUNCT
ajcp-4886	566	6	m.	m.	PROPN
ajcp-4886	566	7	,	,	PUNCT
ajcp-4886	566	8	shang	shang	PROPN
ajcp-4886	566	9	,	,	PUNCT
ajcp-4886	566	10	y.	y.	PROPN
ajcp-4886	566	11	,	,	PUNCT
ajcp-4886	566	12	araki	araki	PROPN
ajcp-4886	566	13	,	,	PUNCT
ajcp-4886	566	14	y.	y.	PROPN
ajcp-4886	566	15	,	,	PUNCT
ajcp-4886	566	16	guo	guo	PROPN
ajcp-4886	566	17	,	,	PUNCT
ajcp-4886	566	18	t.	t.	PROPN
ajcp-4886	566	19	,	,	PUNCT
ajcp-4886	566	20	huganir	huganir	PROPN
ajcp-4886	566	21	,	,	PUNCT
ajcp-4886	566	22	r.	r.	PROPN
ajcp-4886	566	23	l.	l.	PROPN
ajcp-4886	566	24	,	,	PUNCT
ajcp-4886	566	25	&	&	CCONJ
ajcp-4886	566	26	zhang	zhang	PROPN
ajcp-4886	566	27	,	,	PUNCT
ajcp-4886	566	28	m.	m.	NOUN
ajcp-4886	566	29	(	(	PUNCT
ajcp-4886	566	30	2016	2016	NUM
ajcp-4886	566	31	)	)	PUNCT
ajcp-4886	566	32	.	.	PUNCT
ajcp-4886	567	1	phase	phase	NOUN
ajcp-4886	567	2	transition	transition	NOUN
ajcp-4886	567	3	in	in	ADP
ajcp-4886	567	4	postsynaptic	postsynaptic	ADJ
ajcp-4886	567	5	densities	density	NOUN
ajcp-4886	567	6	underlies	underlie	VERB
ajcp-4886	567	7	formation	formation	NOUN
ajcp-4886	567	8	of	of	ADP
ajcp-4886	567	9	synaptic	synaptic	ADJ
ajcp-4886	567	10	complexes	complex	NOUN
ajcp-4886	567	11	and	and	CCONJ
ajcp-4886	567	12	synaptic	synaptic	ADJ
ajcp-4886	567	13	plasticity	plasticity	NOUN
ajcp-4886	567	14	.	.	PUNCT
ajcp-4886	568	1	cell	cell	NOUN
ajcp-4886	568	2	,	,	PUNCT
ajcp-4886	568	3	166(5	166(5	NUM
ajcp-4886	568	4	)	)	PUNCT
ajcp-4886	568	5	,	,	PUNCT
ajcp-4886	568	6	1163	1163	NUM
ajcp-4886	568	7	-	-	SYM
ajcp-4886	568	8	1175.e1112	1175.e1112	NUM
ajcp-4886	568	9	.	.	PUNCT
ajcp-4886	569	1	https://doi.org/10.1016/j.cell.2016.07.008	https://doi.org/10.1016/j.cell.2016.07.008	NOUN
ajcp-4886	569	2	žerovnik	žerovnik	VERB
ajcp-4886	569	3	,	,	PUNCT
ajcp-4886	569	4	e.	e.	PROPN
ajcp-4886	569	5	,	,	PUNCT
ajcp-4886	569	6	&	&	CCONJ
ajcp-4886	569	7	venko	venko	PROPN
ajcp-4886	569	8	,	,	PUNCT
ajcp-4886	569	9	k.	k.	PROPN
ajcp-4886	569	10	(	(	PUNCT
ajcp-4886	569	11	2023	2023	NUM
ajcp-4886	569	12	)	)	PUNCT
ajcp-4886	569	13	.	.	PUNCT
ajcp-4886	570	1	protein	protein	NOUN
ajcp-4886	570	2	condensates	condensate	NOUN
ajcp-4886	570	3	and	and	CCONJ
ajcp-4886	570	4	protein	protein	NOUN
ajcp-4886	570	5	aggregates	aggregate	NOUN
ajcp-4886	570	6	:	:	PUNCT
ajcp-4886	570	7	in	in	ADP
ajcp-4886	570	8	vitro	vitro	X
ajcp-4886	570	9	,	,	PUNCT
ajcp-4886	570	10	in	in	ADP
ajcp-4886	570	11	the	the	DET
ajcp-4886	570	12	cell	cell	NOUN
ajcp-4886	570	13	,	,	PUNCT
ajcp-4886	570	14	and	and	CCONJ
ajcp-4886	570	15	in	in	ADP
ajcp-4886	570	16	silico	silico	NOUN
ajcp-4886	570	17	.	.	PUNCT
ajcp-4886	571	1	frontiers	frontier	NOUN
ajcp-4886	571	2	in	in	ADP
ajcp-4886	571	3	bioscience	bioscience	NOUN
ajcp-4886	571	4	-	-	PUNCT
ajcp-4886	571	5	landmark	landmark	NOUN
ajcp-4886	571	6	,	,	PUNCT
ajcp-4886	571	7	28(8	28(8	NUM
ajcp-4886	571	8	)	)	PUNCT
ajcp-4886	571	9	.	.	PUNCT
ajcp-4886	572	1	https://	https://	PROPN
ajcp-4886	572	2	doi.org/10.31083/j.fbl2808183	doi.org/10.31083/j.fbl2808183	PROPN
ajcp-4886	572	3	zhang	zhang	PROPN
ajcp-4886	572	4	,	,	PUNCT
ajcp-4886	572	5	w.	w.	PROPN
ajcp-4886	572	6	,	,	PUNCT
ajcp-4886	572	7	gao	gao	PROPN
ajcp-4886	572	8	,	,	PUNCT
ajcp-4886	572	9	g.	g.	PROPN
ajcp-4886	572	10	,	,	PUNCT
ajcp-4886	572	11	ma	ma	PROPN
ajcp-4886	572	12	,	,	PUNCT
ajcp-4886	572	13	z.	z.	PROPN
ajcp-4886	572	14	,	,	PUNCT
ajcp-4886	572	15	luo	luo	PROPN
ajcp-4886	572	16	,	,	PUNCT
ajcp-4886	572	17	z.	z.	PROPN
ajcp-4886	572	18	,	,	PUNCT
ajcp-4886	572	19	he	he	PRON
ajcp-4886	572	20	,	,	PUNCT
ajcp-4886	572	21	m.	m.	NOUN
ajcp-4886	572	22	,	,	PUNCT
ajcp-4886	572	23	&	&	CCONJ
ajcp-4886	572	24	sun	sun	PROPN
ajcp-4886	572	25	,	,	PUNCT
ajcp-4886	572	26	t.	t.	PROPN
ajcp-4886	572	27	(	(	PUNCT
ajcp-4886	572	28	2020	2020	NUM
ajcp-4886	572	29	)	)	PUNCT
ajcp-4886	572	30	.	.	PUNCT
ajcp-4886	573	1	au23(cr)14	au23(cr)14	NOUN
ajcp-4886	574	1	nanocluster	nanocluster	PROPN
ajcp-4886	574	2	restores	restore	VERB
ajcp-4886	574	3	fibril	fibril	ADJ
ajcp-4886	574	4	aβ	aβ	PROPN
ajcp-4886	574	5	’s	’s	ADV
ajcp-4886	574	6	unfolded	unfold	VERB
ajcp-4886	574	7	state	state	NOUN
ajcp-4886	574	8	with	with	ADP
ajcp-4886	574	9	abolished	abolish	VERB
ajcp-4886	574	10	cytotoxicity	cytotoxicity	NOUN
ajcp-4886	574	11	and	and	CCONJ
ajcp-4886	574	12	dissolves	dissolve	VERB
ajcp-4886	574	13	endogenous	endogenous	ADJ
ajcp-4886	574	14	aβ	aβ	DET
ajcp-4886	574	15	plaques	plaque	NOUN
ajcp-4886	574	16	.	.	PUNCT
ajcp-4886	575	1	national	national	PROPN
ajcp-4886	575	2	science	science	PROPN
ajcp-4886	575	3	review	review	PROPN
ajcp-4886	575	4	,	,	PUNCT
ajcp-4886	575	5	7(4	7(4	NUM
ajcp-4886	575	6	)	)	PUNCT
ajcp-4886	575	7	,	,	PUNCT
ajcp-4886	575	8	763	763	NUM
ajcp-4886	575	9	-	-	SYM
ajcp-4886	575	10	774	774	NUM
ajcp-4886	575	11	.	.	PUNCT
ajcp-4886	576	1	https://doi.org/10.1093/nsr/	https://doi.org/10.1093/nsr/	NUM
ajcp-4886	576	2	nwz215	nwz215	PROPN
ajcp-4886	576	3	zhou	zhou	PROPN
ajcp-4886	576	4	,	,	PUNCT
ajcp-4886	576	5	x.	x.	NOUN
ajcp-4886	576	6	,	,	PUNCT
ajcp-4886	576	7	venigalla	venigalla	PROPN
ajcp-4886	576	8	,	,	PUNCT
ajcp-4886	576	9	m.	m.	NOUN
ajcp-4886	576	10	,	,	PUNCT
ajcp-4886	576	11	raju	raju	PROPN
ajcp-4886	576	12	,	,	PUNCT
ajcp-4886	576	13	r.	r.	PROPN
ajcp-4886	576	14	,	,	PUNCT
ajcp-4886	576	15	&	&	CCONJ
ajcp-4886	576	16	münch	münch	PROPN
ajcp-4886	576	17	,	,	PUNCT
ajcp-4886	576	18	g.	g.	PROPN
ajcp-4886	576	19	(	(	PUNCT
ajcp-4886	576	20	2022	2022	NUM
ajcp-4886	576	21	)	)	PUNCT
ajcp-4886	576	22	.	.	PUNCT
ajcp-4886	577	1	pharmacological	pharmacological	ADJ
ajcp-4886	577	2	considerations	consideration	NOUN
ajcp-4886	577	3	for	for	ADP
ajcp-4886	577	4	treating	treat	VERB
ajcp-4886	577	5	neuroinflammation	neuroinflammation	NOUN
ajcp-4886	577	6	with	with	ADP
ajcp-4886	577	7	curcumin	curcumin	NOUN
ajcp-4886	577	8	in	in	ADP
ajcp-4886	577	9	alzheimer	alzheimer	PROPN
ajcp-4886	577	10	’s	’s	PART
ajcp-4886	577	11	disease	disease	NOUN
ajcp-4886	577	12	.	.	PUNCT
ajcp-4886	578	1	journal	journal	PROPN
ajcp-4886	578	2	of	of	ADP
ajcp-4886	578	3	neural	neural	ADJ
ajcp-4886	578	4	transmission	transmission	NOUN
ajcp-4886	578	5	,	,	PUNCT
ajcp-4886	578	6	129(5	129(5	NUM
ajcp-4886	578	7	-	-	SYM
ajcp-4886	578	8	6	6	NUM
ajcp-4886	578	9	)	)	PUNCT
ajcp-4886	578	10	,	,	PUNCT
ajcp-4886	578	11	755771	755771	NUM
ajcp-4886	578	12	.	.	PUNCT
ajcp-4886	579	1	https://doi.org/10.1007/s00702-022-02480-x	https://doi.org/10.1007/s00702-022-02480-x	PROPN
ajcp-4886	579	2	żukowska	żukowska	PROPN
ajcp-4886	579	3	,	,	PUNCT
ajcp-4886	579	4	j.	j.	PROPN
ajcp-4886	579	5	,	,	PUNCT
ajcp-4886	579	6	moss	moss	NOUN
ajcp-4886	579	7	,	,	PUNCT
ajcp-4886	579	8	s.	s.	PROPN
ajcp-4886	579	9	j.	j.	PROPN
ajcp-4886	579	10	,	,	PUNCT
ajcp-4886	579	11	subramanian	subramanian	PROPN
ajcp-4886	579	12	,	,	PUNCT
ajcp-4886	579	13	v.	v.	PROPN
ajcp-4886	579	14	,	,	PUNCT
ajcp-4886	579	15	&	&	CCONJ
ajcp-4886	579	16	acharya	acharya	PROPN
ajcp-4886	579	17	,	,	PUNCT
ajcp-4886	579	18	k.	k.	PROPN
ajcp-4886	579	19	r.	r.	PROPN
ajcp-4886	579	20	(	(	PUNCT
ajcp-4886	579	21	2023	2023	NUM
ajcp-4886	579	22	)	)	PUNCT
ajcp-4886	579	23	.	.	PUNCT
ajcp-4886	580	1	molecular	molecular	ADJ
ajcp-4886	580	2	basis	basis	NOUN
ajcp-4886	580	3	of	of	ADP
ajcp-4886	580	4	selective	selective	ADJ
ajcp-4886	580	5	amyloid‐β	amyloid‐β	ADJ
ajcp-4886	580	6	degrading	degrading	ADJ
ajcp-4886	580	7	enzymes	enzyme	NOUN
ajcp-4886	580	8	in	in	ADP
ajcp-4886	580	9	alzheimer	alzheimer	PROPN
ajcp-4886	580	10	’s	’s	PART
ajcp-4886	580	11	disease	disease	NOUN
ajcp-4886	580	12	.	.	PUNCT
ajcp-4886	581	1	the	the	DET
ajcp-4886	581	2	febs	febs	NOUN
ajcp-4886	581	3	journal	journal	PROPN
ajcp-4886	581	4	,	,	PUNCT
ajcp-4886	581	5	291(14	291(14	NUM
ajcp-4886	581	6	)	)	PUNCT
ajcp-4886	581	7	,	,	PUNCT
ajcp-4886	581	8	2999	2999	NUM
ajcp-4886	581	9	-	-	SYM
ajcp-4886	581	10	3029	3029	NUM
ajcp-4886	581	11	.	.	PUNCT
ajcp-4886	582	1	https://doi.org/10.1111/	https://doi.org/10.1111/	PROPN
ajcp-4886	582	2	febs.16939	febs.16939	PROPN